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Abstract 
Congenital myasthenic syndromes (CMS) are a group of rare, inherited disorders 
characterised by impaired function of the neuromuscular junction (NMJ). This is due 
to defects in one of the many proteins associated with the NMJ. Patients with CMS 
present with fatigable skeletal muscle weakness that can vary in age of onset, 
severity and muscles affected. In 3 patients with CMS, missense mutations in a gene 
encoding an unconventional myosin protein, not previously linked to neuromuscular 
diseases, MYO9A, were identified as likely causing their disorder. Therefore, the aim 
of this project was to determine whether MYO9A is playing a role at the NMJ and 
how loss or defective function of this protein may impact signal transmission. This 
question was addressed using a range of models, including patient fibroblasts 
converted into neurons, morpholino and CRISPR/Cas9-mediated knockdown 
zebrafish and a knockout mouse model.  
Investigation of the NSC-34 cells led to the finding that the cytoskeleton was affected 
in the absence of MYO9A, and this impacted on the dynamics of intracellular vesicles 
and endo/exocytosis. Secretome analysis revealed a downregulation of agrin 
secretion in MYO9A deficient cells, a protein important for the development and 
function of the NMJ.  
Analysis of NMJs in MYO9A-depleted zebrafish and mice revealed changes in 
morphology, including smaller nerve terminals and area of endplates. Due to the 
suitability of zebrafish for drug screening, fish were treated with a synthetic agrin 
compound. This rescued a number of the defective features identified in the 
knockdown fish, thus providing a potential mode of action for this form of CMS and 
an avenue for patient treatment. This study highlights a role for MYO9A at the NMJ, 
the first unconventional myosin motor protein associated with a neuromuscular 
disease, thus opening a new avenue of proteins and pathways that may be relevant 
for a range of disorders.  
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Chapter 1. Introduction 
The main aim of this project was to determine whether Myosin IXa (MYO9A) 
contributes to the development and integrity of the neuromuscular junction (NMJ). 
Pathological mechanisms that may lead to manifestation of a Congenital Myasthenic 
Syndrome (CMS) phenotype in patients lacking the functional protein were 
determined, and thus potential therapeutic targets for new treatments identified.  
1.1  The motor nervous system 
The cell bodies of skeletal motor neurons reside in the ventral spinal cord, where 
they receive descending inputs from the brain and direct inputs from the sensory 
nervous system in order to guide and control all movements of the body. This 
includes tonic action to maintain posture and position, as well as voluntary 
movement. The axons of motor neurons exit the spinal cord during prenatal 
development and travel to their target tissue (muscle for the somatic motor system) 
where they often branch profusely and innervate multiple muscle fibres. Initially 
mammalian muscle fibres are contacted by multiple axons, however, during a 
process of competition this is reduced to a single axon per fibre (Tapia et al., 2012). 
A motor neuron and its associated muscle fibres are collectively referred to as a 
motor unit, as shown in Figure 1.1. During movement, motor units are recruited 
according to size, with progressively larger motor units recruited as the desired force 
of muscle contraction increases (Mendell, 2005).  
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Figure 1.1. Structure of the motor system. Schematic diagram showing a 
myelinated motor neuron axon originating in the ventral spinal cord, and extending 
towards a target muscle where it branches and innervates a number of muscle fibres. 
The collective muscle fibres, neuromuscular junctions and motor axon are termed the 
motor unit. Individual muscle fibre types can be detected using antibodies against 
specific isoforms of myosin heavy chain (MyHC): MyHC I = Type I, blue, MyHC IIa = 
Type IIa, red, MyHC IIb = Type IIb, green and MyHC IIx = Type IIx, not shown. NMJs 
can be visualised using fluorophore-bound α-bungarotoxin (aBTx) to bind 
acetylcholine receptors (AChRs, green) and antibodies against neurofilament and 
synaptophysin for the presynaptic axon and terminal (red), respectively.  
 
Skeletal muscles are composed of many individual fibres that contain repeating 
functional units (sarcomeres) made up of actin and myosin, necessary for muscle 
contraction. During development, myoblasts fuse to form multinucleated muscle 
fibres, with nuclei located in the centre of the fibre. As muscle matures, the nuclei 
migrate to the cell periphery, and thus internal nuclei can be a marker of regenerating 
fibres or disease (Folker and Baylies, 2013). Fibres are classified according to their 
rate of contraction (fast or slow) and the main method for adenosine triphosphate 
(ATP) production (glycolysis or oxidative phosphorylation). Fibres are classed as: 
Type I (slow, oxidative), Type IIa (fast, oxidative), Type IIx (fast, glycolytic) or Type IIb 
(fast, glycolytic, not expressed in human), and they can be identified by the 
expression of different MyHC isoforms, as shown in Figure 1.1 (Schiaffino and 
Reggiani, 2011). Muscles are made up of varying combinations of muscle fibre types 
which convey different functional properties.  
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Muscle fibre architecture is relatively conserved among vertebrates, even at the level 
of zebrafish in which fast and slow fibres are present, albeit at different proportions 
(van Raamsdonk et al., 1978). While muscles in mammals contain different fibre 
types throughout, in zebrafish a vast collection of fast twitch muscles fibres is 
surrounded by a single layer of superficial slow twitch fibres to allow for fast, darting 
movements to take place (van Raamsdonk et al., 1978). Zebrafish also have motor 
units that are recruited according to the movement required. However, muscle fibres 
are co-innervated by primary motor neurons with large amplitude outputs, recruited 
for fast, short bursts of movement, and multiple secondary motor neurons with lower 
amplitude signals that coordinate slow swimming (Wang and Brehm, 2017, Luna et 
al., 2015). Thus graded muscle responses in zebrafish can be achieved by the same 
motor unit, depending on the neural input activated, thus expanding on the 
recruitment of increased muscle fibres and larger units observed in mammals. The 
connection between the nerve and muscles in these motor units is termed the NMJ 
(Figure 1.1). 
1.2 Neuromuscular junction 
1.2.1 Signal transmission at the NMJ 
The NMJ is the site of signal transmission between a motor axon terminal and its 
target muscle fibre. It is a highly specialised cholinergic tripartite synapse, consisting 
of the motor axon and muscle fibre, as well as a terminal Schwann cell which 
surrounds the junction. Initiation of an action potential at the axon hillock adjacent to 
the motor neuron cell body is caused by descending input from the central nervous 
system (CNS) or reflex pathway from the sensory nervous system. The action 
potential is transmitted down the axon which is ensheathed in myelin, produced by 
Schwann cells, to allow for salutatory conduction to occur (Figure 1.2, step 1). Arrival 
at the nerve terminal of an action potential leads to membrane depolarisation and 
subsequent activation of voltage-gated calcium channels (Figure 1.2, step 2). There 
is an influx of calcium ions that stimulate the fusion of vesicles docked at the 
presynaptic terminal with the membrane thus releasing their contents into the 
synaptic cleft (Figure 1.2, step 3). These vesicles contain acetylcholine (ACh), the 
main neurotransmitter released at the NMJ. ACh is synthesised in the nerve terminal 
from acetyl coenzyme A and choline, mediated by the enzyme choline acetyl-
transferase (ChAT). Availability of choline is a rate limiting step for this process. It is 
recycled after breakdown of ACh by acetylcholinesterase (AChE) in the synaptic 
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cleft, and is taken back into the nerve terminal (Figure 1.2, step 8). After synthesis of 
ACh, the neurotransmitter is packaged into synaptic vesicles by vesicular ACh 
transporter (VaChT), forming individual ‘quantum’ of transmitter (Taylor and Brown, 
1999). Vesicles are transported to the active zone of the nerve terminal, which is the 
specialised release site. Docking and priming vesicles is a complex process, 
involving a number of macromolecules at the active zone that interact with the vesicle 
to manoeuvre it into the site of release, as described in detail by the McMahan 
laboratory (Harlow et al., 2013, Jung et al., 2018). Action potential-mediated influx of 
calcium is detected by synaptotagmin which triggers the fast, synchronous fusion of 
these vesicles to the presynaptic membrane (Brose et al., 1992). This process is 
thought to be modulated by the active zone protein Bassoon, which has been shown 
to co-localise with P/Q type (adult subtype) voltage-sensitive calcium channels at the 
release sites of vesicles (Nishimune et al., 2012). Exocytosis involves a number of 
proteins associated with the soluble N-ethylmaleimide-sensitive fusion protein 
attachment protein receptors (SNARE) complex, including syntaxin 1A and SNAP-25. 
Vesicle-SNARE proteins interact with target-SNAREs on the nerve membrane to 
initiate release of ACh from the vesicle and into the synaptic cleft. The number of 
vesicles released after each action potential is termed the ‘quantal content’ (QC), and 
this tends to increase in line with terminal area (Slater, 2017).  
Nicotinic ACh receptors (AChR) are situated on the postsynaptic muscle fibre 
opposed to the release sites of the nerve terminal to minimise diffusion distance 
(Fagerlund and Eriksson, 2009). AChRs are anchored in place with a complex 
arrangement of cytoskeletal components within the cell. Binding of ACh to AChRs 
leads to the influx of cations into the muscle cell, causing depolarisation (Figure 1.2, 
step 4/5). Spontaneous release of quanta of neurotransmitter occurs even at rest, 
and causes miniature endplate potentials (mEPPs) to occur. These small events are 
graded postsynaptic potentials and they are not sufficient to cause an action 
potential. Following arrival of a presynaptic action potential and subsequent release 
of ACh into the cleft, there is a larger postsynaptic depolarisation termed the endplate 
potential (EPP). If sufficient depolarisation occurs and reaches threshold, an action 
potential is initiated that propagates along the muscle fibre membrane, causing an 
increase in intracellular calcium and contraction mediated by a network of actin and 
myosin filaments (Figure 1.2, step 6/7, Fagerlund and Eriksson, 2009). ACh is rapidly 
broken down in the cleft by AChE which terminates its action on the muscle fibre 
(Figure 1.2, step 8). AChE is situated in the synaptic basal lamina, which contains 
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numerous proteins important for cell adhesion and neuromuscular signalling such as 
collagens, laminin and agrin. 
Figure 1.2. Signal transmission at the Neuromuscular Junction:  1) An action 
potential propagates down the motor axon, reaching the nerve terminal where it 
depolarises the membrane. 2) Voltage gated calcium channels open and there is an 
influx of Ca2+ into the cell. 3) An increase in intracellular Ca2+ initiates fusion of 
vesicles docked at active zones with the membrane and release of acetylcholine into 
the synaptic cleft. 4) Acetylcholine diffuses across the cleft and binds to acetylcholine 
receptors causing a change in pore configuration. 5) Na+ passes through the AChR 
into the postsynaptic muscle cell causing depolarisation of the muscle membrane. 6) 
Voltage-gated Na+ channels open and there is a further influx of ions and leading to 
the generation of an action potential. 7) The action potential propagates across the 
muscle membrane leading to muscle fibre contraction (contractile unit shown). 8) The 
effect of acetylcholine is short-lived as upon detaching from AChRs it is rapidly 
broken down by acetylcholinesterase in the synaptic cleft and one of its substrates; 
choline, is recycled back into the nerve terminal. 
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1.2.2 Development of the NMJ 
The main aim of NMJ development is to form a highly efficient and reliable synapse 
which successfully converts action potentials from the nerve terminal into muscle 
contractions. This is achieved by complex developmental processes to create a 
number of pre and postsynaptic specialisations that optimise function and can adapt 
to physiological stress. These specialisations act to enforce a robust safety factor for 
signal transmission. The safety factor has been defined as ‘the amount of transmitter 
released per nerve impulse being greater than that required to trigger an action 
potential in the muscle fibre’ (Wood and Slater, 2001).  
The features important for safety factor maintenance include a number of structures 
that can be viewed at the ultrastructural level, as indicated in the electron 
micrographs of Figure 1.3, such as a concentration of vesicles at the nerve terminal, 
a synaptic cleft containing a basal lamina to anchor a number of important proteins, 
postsynaptic folds which increase the surface area of the endplate, and an 
enrichment of receptors, ion channels and structural proteins at the postsynapse 
represented as dense material on the electron micrographs.  
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Figure 1.3. Electron micrographs of NMJs from zebrafish, mouse and human. 
Presynaptic nerve terminals are highlighted in blue and part of the postsynaptic 
muscle fibre is highlighted in red. Synaptic vesicles can be observed in each case, an 
example of which is outlined in orange, as well as clear postsynaptic folds in mouse 
(B) and human (C), as well as potential folds in zebrafish (A), indicated with red 
arrows. Mitochondria can also be observed (yellow M) and examples of postsynaptic 
densities lining the folds are shown in green. Images modified from: (Helmprobst et 
al., 2015, Issop et al., 2018, Slater, 2017). 
Zebrafish NMJs, as studied in this project, have also been visualized using electron 
microscopy (Figure 1.3A). This revealed the presence of extensive synaptic vesicles, 
presynaptic mitochondria, cytoskeletal components, endosomal structures and 
vesicles docked at the active zone, connected with filamentous structures that have 
also been described in mammals (Jung et al., 2018, Helmprobst et al., 2015, Bruses, 
2011, Westerfield et al., 1990). At 30 hours post fertilisation (hpf) the presynaptic 
terminal in zebrafish is large and the synaptic cleft is not well defined, however, by 3 
days post fertilisation (dpf) a dense basal lamina structure can be identified and 
terminals are smaller and well-defined (Drapeau et al., 2001). The synaptic cleft is 
around 65nm wide in 4-8 dpf zebrafish, falling within the range of 50-100nm found in 
human junctions (Helmprobst et al., 2015, Slater, 2017). An as yet unclear feature of 
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zebrafish NMJs is the extent of post-junctional folding, which is extensive in human 
and mouse NMJs. Furthermore, terminal size and QC holds a positive correlation for 
most vertebrates, with humans having small terminal sizes and small QCs (20-30), 
whereas vertebrates such as frogs have large terminals and correspondingly large 
QCs (over 100) (Slater, 2015). However, in zebrafish measurements of QC and 
overall terminal size have not been performed in parallel, and thus whether they 
observe a similar trend is not known. Despite these differences, the gross 
morphology of zebrafish NMJs is similar to human and the relative ease in which the 
junctions can be studied and manipulated make them useful models for studying 
human NMJ diseases, especially those that affect early development.  
Much of the current understanding regarding structure and function of NMJs 
originates from research that has been performed in the mouse, due to the 
accessibility and availability of tissue, as well as the multitude of murine disease 
models now available. As mammals they have a closer NMJ structure to humans 
than zebrafish, bearing more obvious postsynaptic specialisations and clearly defined 
AChR clusters forming individual endplates (Figure 1.3B). There remain some 
differences however, in features such as postsynaptic junctional fold lengths which 
are much longer in humans, terminal size which is smaller in humans and the QC of 
motor synapses is also smaller in humans than in mice (20-30 in humans vs 50-100 
in mouse, Slater, 2015). Overall, however, the process of cholinergic signalling and 
the main structural components of zebrafish and mouse NMJs are similar to those 
found in humans and allow comprehensive analysis to be performed which would not 
otherwise be achievable. The development of such features is discussed in 
subsequent sections.  
1.2.2.1 AChR cluster formation 
Development of the NMJ begins prenatally in humans, mice and zebrafish. In mice 
and zebrafish, NMJ development has been observed to start with a process termed 
‘pre-patterning’, in which aneural AChR clusters form over the surface of myotubes in 
a distinct position along the midline of the muscle and in the absence of any neural 
input (Yang et al., 2001). While muscles have an intrinsic capacity to form these 
AChR clusters, further specialisations and mature synapse formation require nervous 
input. Contact from motor neurons leads to the incorporation of aneural AChR 
clusters to form neural clusters and thus an immature synapse is formed. The 
purpose of aneural clusters in pre-patterning has been questioned due to the ability 
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of zebrafish to establish AChR clusters after developing on a muscle-specific kinase 
(MuSK)-null background, thus in the absence of aneural receptors (Jing et al., 2009). 
Furthermore, some NMJs in zebrafish form where aneural clusters were situated, 
whereas others form on previously unoccupied regions of muscle (Panzer et al., 
2005). Nevertheless, in the presence of aneural receptor clusters subsequent release 
of ACh from the nerve terminal leads to the dispersal of surrounding AChRs and a 
concentration of receptors just at the NMJ. Localised synthesis of new AChRs also 
contributes to the receptor density (Sanes and Lichtman, 2001). Mature AChR 
clusters form directly opposite the ACh-releasing synaptic boutons of the innervating 
axon. These receptor clusters can be visualised by using a fluorophore-bound 
neurotoxin: aBTx, which can bind to AChRs (Anderson and Cohen, 1974). In 
humans, use of such tools reveals NMJs with multiple, distinct, round clusters of 
AChRs colocalising with terminal boutons. The presynaptic boutons are usually 
stained with antibodies against synaptophysin in mice and synaptic vesicle protein 2 
(SV2) in fish (Panzer et al., 2005, Colasante et al., 1993). Whereas in mice these 
clusters are less distinct and merge to form a characteristic ‘pretzel’ configuration 
(Figure 1.4). Fish NMJs are less condensed, with long interconnected boutons 
forming across the muscle fibre, which is reflected in the spatial distribution of AChR 
clusters (Slater, 2017). NMJs can grow with developing muscle during postnatal life, 
achieved by the insertion of new AChRs to maintain a consistent receptor density 
(Slater, 1982, Balice-Gordon et al., 1990).  
10 
 
 
Figure 1.4. Mouse and zebrafish NMJs.  Example of characteristic mouse pretzel 
shaped NMJs (10 months old) and zebrafish (5 dpf) NMJs, white box shows enlarged 
region. Presynapse stained with antibodies against SV2 (red) in zebrafish and 
synaptophysin with neurofilament (red) in mice. Postsynaptic acetylcholine receptors 
are stained with aBTx (green). Mouse scale bar = 25µm, zebrafish = 10µm.  
Perhaps one of the most important events in NMJ development is the release of 
neural agrin, which acts to mediate these clustering events. Agrin is a heparin 
proteoglycan located in the synaptic basal lamina after it has been released from the 
nerve. Originally isolated from the electric organ of Torpedo Californica (Godfrey et 
al., 1984), agrin was later found to be present in the nerves, muscles and Schwann 
cells of mammals (Magill-Solc and McMahan, 1988), however, it has been 
demonstrated that neural agrin is 1000-fold more adept at inducing AChR clusters 
than muscle agrin (Gesemann et al., 1995). This key difference has been attributed 
to the secreted, neural isoform of agrin having an extra 8, 11 or 19 amino acid insert 
at a 3’ splice site termed the z-site (Ruegg and Bixby, 1998, Tintignac et al., 2015). 
The receptor for agrin is Low Density Lipoprotein Receptor Related Protein 4 (LRP4), 
found on the muscle membrane in dimers (Kim et al., 2008). LRP4 is bound by 
MuSK, also present in dimers, and binding of agrin to this complex begins a cascade 
of events starting with MuSK self-phosphorylation and recruitment of Downstream of 
Tyrosine Kinase 7 (DOK7) and leading to the stable incorporation of AChRs (Inoue et 
al., 2009, Okada et al., 2006, Zhang et al., 2011, Bergamin et al., 2010). This 
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process is very important for NMJ development as mice lacking agrin are not viable 
and die at birth due to defective NMJ formation (although the presence of aneural 
receptor clusters is not affected) (Gautam et al., 1996, Lin et al., 2001). MuSK also 
affects other downstream pathways including the accumulation of rapsyn, which has 
been shown to cluster AChRs and other NMJ proteins important for synapse 
function. Concurrently, rapsyn deficient mice have AChRs that are spread out over 
the muscle fibre rather than concentrated in clusters (Gautam et al., 1995). Zebrafish 
also express these key proteins, including LRP4, MuSK, agrin and AChR subunits, 
and loss of such factors in the fish also affects signal transmission, NMJ structure 
and movement abilities (Kim et al., 2007, Remedio et al., 2016, Zhang and Granato, 
2000, Zhang et al., 2004, Zhang et al., 2001, Park et al., 2014). While development 
of appropriate AChR clusters is a crucial part of NMJ formation, there are numerous 
other specialisations that take place to complete maturation of the synapse. 
1.2.2.2 Innervation of NMJ and presynaptic specialisations 
After establishment of the mature innervation pattern, further optimisation of the 
functional apparatus is required to produce an efficient and reliable synapse, as 
outlined in Figure 1.5. In the presynaptic nerve terminal active zones form, which are 
sites optimised for vesicular release of ACh with concentrated presence of exocytotic 
machinery (Jung et al., 2018). Nerves also start to release agrin and ACh to 
modulate AChR clustering as described above. There are likely to be many secreted 
proteins important for cross-talk at the NMJ and co-maturation of pre and 
postsynaptic regions. Another such group of identified factors is the Wnt family, 
which have demonstrated importance for concentration of presynaptic vesicles and 
maintenance of appropriate terminal size. In addition, blocking Wnt secretion is 
associated with reduced postsynaptic folds. This effect results collectively in impaired 
neurotransmission in mice (Shen et al., 2018). Similarly, Wnt signalling also plays a 
role in development of zebrafish NMJs, as Wnt11r is important for AChR pre-
patterning and guidance of growth cones to the appropriate muscle region, thus 
affecting both the pre and postsynapse (Jing et al., 2009). 
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Figure 1.5. Formation and maturation of the neuromuscular junction:  A) Motor 
axons extend from the ventral spinal cord and branch to form many small varicosities 
that lie in proximity to the muscle fibre. Many axons may innervate a single immature 
NMJ at this stage in development, competing for sole occupation. On the muscle 
fibre there are aneural AChRs formed in a pre-patterning process. B) Axons are 
eliminated during development until only one innervates each muscle fibre, and there 
is only one NMJ per fibre. Membranous invaginations are also formed to vastly 
expand the surface area of the muscle endplate and aneaural AChRs are 
incorporated to form neural clusters in response to the release of neural agrin. The 
NMJ at this stage takes on an oval conformation that gradually becomes more 
complex during development. C) The release of ACh from the presynapse causes 
the dispersal of surrounding aneural AChRs that have not been incorporated. The 
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presynaptic apparatus also segregates into distinct active zones, from which ACh is 
released, and endocytotic zones. On the postsynaptic membrane the AChRs and 
voltage-gated Na+ channels segregate to the peaks and troughs of the invaginations 
respectively, to minimise the diffusion distance for ACh from the active zones. The 
AChRs also demonstrate an alteration in their subunit conformation, replacing the γ 
subunit for ε, thus forming the adult receptor. During development there is perforation 
of the AChR clusters, as well as an insertion of new and extrasynaptic receptors that 
lead to the formation of a pretzel-like postsynaptic structure (in mice). After birth there 
is also myelination of the motor axons to allow for fast salutatory conduction and 
terminal Schwann cells encapsulate the nerve terminal providing metabolic support 
and signalling interactions. Kranocytes also localise to the NMJ, capping the synapse 
in postnatal development. 
Maturation of the NMJ is not complete at birth and continues into early postnatal life, 
with a series of pre- and postsynaptic changes mediated by numerous factors which 
facilitate the development of movement. In mice, the innervation pattern of muscle 
fibres by motor axons alters during early postnatal development, but is complete 
before birth in humans. Initially there is a rich neural innervation of fibres (Figure 
1.5A), followed by significant elimination of axons during a highly dynamic phase of 
competition that takes place until only one axon per muscle fibre remains, allowing 
for very specific control of muscles (Gan and Lichtman, 1998, Walsh and Lichtman, 
2003). While the NMJ is a cholinergic synapse, recent research has also implicated a 
role for glutamatergic signalling in the elimination of excess axons, as blockade of 
glutamate slowed elimination and application of exogenous N-methyl-D-aspartate 
accelerated the elimination process (Personius et al., 2016). During this stage of 
maturation it can be observed that the alignment between pre- and postsynaptic 
apparatus is not perfect, motor axons often project beyond AChR clusters. However, 
following the pruning process the nerve terminal and postsynaptic region are 
precisely apposed. The colocalisation of pre and postsynaptic areas can be 
measured to determine whether any defects in this process have occurred, as 
misalignment may result in less ACh binding AChRs, thus affecting postsynaptic 
depolarisation.  
Myelination of motor axons by Schwann cells also occurs in early life, facilitating fast 
salutatory conduction of action potentials. Appearance of terminal Schwann cells is 
also important for the external environment of the NMJ, with interaction of many 
growth factors and signalling molecules, muscle fibres and nerves taking place 
(Figure 1.5C). A fourth cell type is also present at the NMJ, the kranocytes, which 
cover the terminals during postnatal development and are reactive to physiological 
changes within the neuromuscular system, such as paralysis (Court et al., 2008).   
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 Further changes to the NMJ occur, with the nerve terminal separating into distinct 
compartments. The endocytic regions alternate with active sites to allow alignment of 
ACh releasing regions with receptor rich domains on the crests of folds in the 
postsynaptic NMJ, which enhances synaptic transmission (Figure 1.5C, Matthews-
Bellinger and Salpeter, 1983). The molecular events responsible for these 
presynaptic maturation steps are not fully understood, however there have been a 
number of important factors identified. For example, loss of the main subunit present 
in all synaptic laminins (laminin β2) leads to defective synaptic vesicle clustering, less 
active zones, a reduction in QC, as well as invasion of terminal Schwann cell 
processes into the cleft, thus less efficient synaptic signalling (Noakes et al., 1995, 
Knight et al., 2003). 
1.2.2.3 Postsynaptic specialisations 
As discussed above, the postsynapse forms folds to extend the surface area of the 
endplate, thus increasing the amount of membrane in contact with the synaptic 
region. AChRs become localised at the top of junctional crests. This places the 
receptors as close to the active zones as possible thus reducing the diffusion 
distance for ACh across the synaptic cleft (Figure 1.5B). There is also segregation in 
the folds between AChRs and voltage-gated Na+ channels, the latter of which 
become localised to the junctional troughs (Figure 1.5C, Flucher and Daniels, 1989). 
This has been suggested to provide a route for signal amplification between nerve 
and muscle, which could explain, for example, why folds are extensive in human 
NMJs that have relatively small QCs (Slater, 2017). The folds are thus crucial 
determinants for the safety factor, which could be affected by a reduction in folding, 
AChR number or localisation, or concentration of Na+ channels, therefore preventing 
depolarisation from reaching action potential threshold.  
Further specialisations to the postsynapse include changes in AChR subunit 
composition during synaptic maturation, with the γ-subunit being replaced by the ε-
subunit to form the adult receptor (from α2βγδ to α2βδε, Figure 1.5C, Mishina et al., 
1986). The change in receptor configuration leads to shorter burst durations but an 
accompanying increase in Na+, K+, and Ca2+ conductance (Mishina et al., 1986, 
Villarroel and Sakmann, 1996). Zebrafish express the same AChR subunits as 
mammals in their most abundant muscle type, fast muscle. However, on slow 
muscles it has been postulated that zebrafish express an AChR receptor lacking both 
ε and γ subunits, containing only α,β and δ (Mongeon et al., 2011). Finally, a recent 
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role for rapsyn as an E3 ligase has been reported, which confers the ability of this 
protein to increase AChR subunit neddylation at the NMJ (Li et al., 2016). This was 
found to stimulate AChR clustering and could be further activated by agrin, thus 
expanding on the known roles of rapsyn and possible mechanisms by which AChR 
stability is mediated. While it is clear a number of important changes occur during 
development to form NMJs, many of these pathways are also crucial for the 
continued function of this synapse in adult muscle.  
1.2.3 Maintenance of the NMJ 
Signal transmission at the NMJ is required throughout life for all actions requiring 
movement of skeletal muscle, therefore maintenance of this synapse after 
development and maturation is important. During development, AChRs are inserted 
into the endplate membrane after which they are endocytosed and either targeted for 
degradation and replacement by a new receptor, or recycled back to the surface. In 
newly formed synapses this process is rapid, with AChR half-life only around 1 day. 
In adult synapses this extends significantly to around 10 days, highlighting the 
increased stability of endplate AChRs in vertebrates following development (Bruneau 
et al., 2005, Cohen et al., 1990, Yampolsky et al., 2010, Burden, 1977). The purpose 
for prolonged AChR half-lives has not been fully elucidated, however, it has been 
suggested that the process of receptor internalisation itself acts as a means to 
degrade defective AChRs and insert new, fully functional receptors (Yampolsky et al., 
2010). Thus any defects in receptor endocytosis, degradation or recycling may affect 
the density of AChRs and proportion of functional receptors at the postsynapse. 
Proteins implicated in maintaining balance of inserted/recycling/degrading receptors 
include those that interact with the cytoskeleton such as Myosin Va, important for 
recycling of AChRs back to the surface (Roder et al., 2008), and rapsyn which plays 
a crucial role in AChR stability (Gervasio et al., 2007). Microtubule Actin Crosslinking 
Factor 1 (MACF1) has also recently been shown to regulate postnatal AChR cluster 
size in mice, through interaction with the cytoskeleton and rapsyn (Oury et al., 2019). 
The action of neural agrin is also necessary for the longer-term stability of AChRs in 
adult synapses, as well as its role in forming receptor aggregations during 
development (Bezakova et al., 2001, Samuel et al., 2012). Similarly, Agrin’s receptor 
LRP4 is required for NMJ maintenance as knockout from adult mice leads to 
shortening of junctional folds and less synaptic vesicles, with a corresponding 
reduction in mEPP frequency and amplitude (Barik et al., 2014). Another component 
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of the agrin-LRP4 pathway is MuSK, and similarly removal of MuSK from the 
postnatal synapse leads to loss of AChRs, thus highlighting the continued importance 
for these proteins throughout life (Hesser et al., 2006). 
As well as the contribution of proteins known to be important for NMJ development in 
maintenance of this synapse, such as agrin and LRP4, a number of other proteins 
may be involved in NMJ stability in the adult. For example, in the laminin family of 
proteins laminin β2 is critically important for presynaptic maturation and absence of 
laminin α5 delays differentiation of the NMJ but its loss does not affect the adult 
synapse (Nishimune et al., 2012, Noakes et al., 1995). On the other hand, laminin α4 
has been shown to have minor effects on developing NMJs but is important for 
maintaining presynaptic morphology in adult mice (Samuel et al., 2012). Overall, the 
continued presence, and involvement of new proteins toward the maintenance of 
NMJ structure and function is required throughout life. 
Further to these classical pathways involved in NMJ development and maintenance, 
recent data has drawn on observations from the early 1900’s that sympathetic 
innervation is also present at the NMJ. Presynaptic vesicle release, muscle 
contraction force and AChR levels were all found to be modulated by sympathetic 
innervation, thus highlighting the complexity of NMJ development and function (Khan 
et al., 2016, Rodrigues et al., 2019). Close association of NMJs with sympathetic 
neurons has been demonstrated and this increases during postnatal development 
(Straka et al., 2018). Furthermore, β-2 adrenoceptors partially colocalise with AChRs 
(Khan et al., 2016). Activation of these adrenoceptors by sympathetic innervation, or 
application of agonists, causes an elevation of cyclic adenosine monophosphate and 
a downstream increase in AChR expression at the NMJ (Khan et al., 2016, Legay 
and Mei, 2017). Therefore, it is apparent that not only innervation from motor neurons 
is important for functioning of the NMJ. The inherent complexity of NMJ development 
and maintenance exposes numerous areas in which dysfunction may lead to 
disease.  
1.3 Disorders of the NMJ  
The safety factor of the NMJ allows signalling to occur reliably as physiological 
conditions and demands change. This ensures that neural signalling results in a 
muscle contraction for that motor unit when required, even during periods of intense 
exercise. The complex nature of NMJ development and maintenance contributes to 
the formation of this safety factor, thus defects in any of a number of proteins 
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involved in this process may affect its efficacy. The safety factor of mammalian NMJs 
is estimated to be between 2 and 10, indicating that there is at least twice as much 
neurotransmitter released than required to stimulate a postsynaptic response (Wood 
and Slater, 2001). Despite this flexibility, an impairment in any part of the pathway 
between the action potential arriving at the nerve terminal and postsynaptic muscle 
contraction that reduces the safety factor to below this threshold can affect efficiency 
of signal transduction and thus cause disease.  
Disorders of the NMJ can be caused through genetics, autoimmune diseases or 
through influence of environmental factors such as toxins. Toxins that affect the NMJ 
include aBTx, present in snake venom, which binds to the α subunit of the AChR. 
The relatively irreversible binding of this toxin prevents signalling and leads to 
paralysis of the muscle (Furman, 2018). However, the use of aBTx bound to a 
fluorophore is also a valuable tool for the study of NMJs by providing a reliable label 
for the postsynaptic AChRs as demonstrated in Figure 1.4. Impaired signalling at the 
NMJ also occurs due to disease, termed the Myasthenic syndromes. These are a 
group of disorders that manifest with fatigable weakness of the skeletal muscles. 
Myasthenias are most commonly autoimmune (Myasthenia Gravis), in which patients 
acquire antibodies against key components of the NMJ such as AChRs or MuSK 
(Meriggioli and Sanders, 2009). A rare class of genetically determined myasthenias 
also occurs, termed CMS. CMS are caused by mutations in genes encoding proteins 
that act to maintain this safety factor and conduct successful NMJ signalling, of which 
there are now over 30 reported proteins implicated in the disease (Finsterer, 2019, 
Rodriguez Cruz et al., 2018).  
Other diseases that are not considered primarily disorders of the NMJ can also 
demonstrate impairment of the safety factor as part of their pathology. These include 
the much more common neurological disorders such as amyotrophic lateral sclerosis 
(ALS), whereby defective NMJs have been found early in disease progression with 
features such as reduced synaptic vesicle populations (Cappello and Francolini, 
2017). Diseases primarily characterised by myopathic changes can also show 
impaired NMJ signalling, including Muscular Dystrophies. For example, mouse 
muscular dystrophy models (mdx and mdx/utrn-/-) exhibit smaller mEPPs and NMJ 
fragmentation, with a compensatory increase in QC (van der Pijl et al., 2016). 
Therefore, understanding more about the structural and functional components that 
are important in the maintenance of the safety factor and thus ability to perform 
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voluntary muscle movements will have widespread implications for a number of 
diseases.  
1.3.1 Congenital Myasthenic Syndromes 
Patients with CMS present with a heterogeneous set of phenotypes, largely 
dependent on the genetic basis underlying that individual’s disorder. The disease is 
characterised by fatigable skeletal muscle weakness (and sparing of smooth/cardiac 
muscles), however, even this feature can vary considerably in the muscle affected 
and severity of weakness. Commonly affected muscles include the proximal and 
distal limb muscles, bulbar muscles involved in eating and speaking, ocular muscles 
for eye movements and the respiratory muscles. An effect on the respiratory muscles 
can cause potentially life threatening episodes of apnoea requiring hospitilisation and 
ventilation (McMacken et al., 2018b). Age of onset can be as early as in utero, 
manifesting as reduced foetal movements, or mild adult onset of symptoms and 
anywhere in between, although onset is usually in early childhood (average age 3.6 
years Jagtap et al., 2013). Patients may also have other atypical phenotypes such as 
CNS abnormalities, epilepsy or neuropathy (Finsterer, 2019, Rodriguez Cruz et al., 
2018). 
1.3.1.1 Clinical diagnosis 
A clinical diagnosis of CMS can be suspected based on the presence of muscle 
weakness, family history of CMS, absence of auto-antibodies for NMJ components 
and electrophysiological investigations. These include repetitive nerve stimulation 
and single fibre electromyography (EMG). Repetitive nerve stimulation is a technique 
in which supramaximal electrical stimulation of a motor neuron is performed to elicit a 
reliable postsynaptic response in the target muscle, a compound muscle action 
potential (CMAP). The safety factor of the NMJ ensures a consistent CMAP 
amplitude in healthy muscle. Therefore, in diseases such as CMS where the safety 
factor is impaired, the amplitude of the CMAP can vary (Pitt, 2018). This can depend 
on the location of the defect, although clear distinction between pre and postsynaptic 
CMS is not always possible. For example, in cases of postsynaptic protein 
involvement in disease, a decrease in CMAP amplitude can be observed and this is 
generally considered pathological if the decrement is over 10%. Conversely, in 
presynaptic CMS there can be a smaller initial CMAP amplitude, followed by an 
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increment when stimulation frequency increases due to increased terminal calcium 
levels (McMacken et al., 2018b). 
Single-fibre EMG records from fibres within the same motor unit and allows the 
difference in latency from stimulation to muscle fibre action potential to be observed. 
Variation in latency is termed jitter and in disorders such as CMS there can be 
increased jitter or impulse blocking (in which no action potential is elicited) due to 
impairment of signal transmission from the nerve to muscle (Howard, 2013). 
1.3.1.2 Genetic diagnosis 
After a clinical diagnosis of CMS is made, a genetic diagnosis is important for 
understanding which treatments may be applicable for a patient. The phenotypic 
profile of the patient may provide strong evidence suggesting mutations in a specific 
established CMS gene, allowing single genes to be sequenced for mutations. For 
example, if a patient presents with only typical NMJ-associated phenotypes and has 
ophthalmoplegia, then the most common cause of CMS is due to mutations in the 
Cholinergic Receptor Nicotinic Epsilon Subunit (CHRNE) gene encoding the AChR Ɛ 
subunit (Rodriguez Cruz et al., 2018). In the case where screening known genes is 
not successful or there are no clear phenotypic clues, whole exome or genome 
sequencing can be undertaken to identify novel mutations in known genes, or 
potentially new candidate genes for CMS (for example; Azuma et al., 2017, Cossins 
et al., 2013, Logan et al., 2015, O'Connor et al., 2016). This approach is particularly 
useful when genetic data from parents is also available for analysis.  
1.3.1.3 Treatment approaches 
Treatment approaches for CMS vary depending on the nature of the NMJ 
dysfunction, however, a few options are available that can reduce symptoms in a 
number of patients (Figure 1.6, Thompson et al., 2019). In general, AChE inhibitors, 
which prolong the presence of ACh at the synaptic cleft, can show benefit if the 
defective protein is part of the glycosylation network but not part of the LRP4/MuSK 
pathway. This family of drugs is often administered along with 3,4-Diaminopyridine 
(DAP) which blocks presynaptic potassium channels thus increasing intracellular 
calcium and subsequent ACh secretion (Wirtz et al., 2010). Therefore, this drug often 
shows efficacy in disorders resulting in less stimulation of the AChRs (including 
presynaptic CMS, Engel, 2007). Sympathomimetic drugs, including the β-2 
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adrenoceptor agonist Salbutamol, have also shown beneficial effects in CMS patients 
such as those with mutations in Dok7, CHRNE and MuSK (Finsterer, 2019). The 
reason sympathomimetic drugs can provide symptomatic improvement to patients is 
as yet unknown, although recent efforts have been made to uncover more about the 
action of these drugs at the NMJ. These include in vitro analysis of C2C12 cells 
demonstrating an increase in AChR cluster number after salbutamol treatment, 
improvement in zebrafish AChR clustering and motility and beneficial effects to the 
postsynapse in a CMS mouse model (Clausen et al., 2018, McMacken et al., 2018a, 
McMacken et al., 2019). AChR open channel blockers, such as Fluoxetine, have 
variable effects but tend to provide improvements in slow-channel syndrome 
(characterised by prolonged acetylcholine receptor ion channel activation) cases. 
Although such compounds can have serious side effects including severe 
hypotension and serotonergic crisis (Chaouch et al., 2012).  
 While a number of treatments can be used for CMS, they show variable efficacy and 
sometimes detrimental effects in different subtypes, as well the presence of a 
number of associated side-effects (Engel et al., 2015). Therefore, there is a pressing 
requirement for greater understanding of the genetic defects involved in NMJ 
transmission disorders, pathways of action and specific effects on the various 
components of the NMJ, in order to develop more targeted treatments for patients.  
1.3.1.4 CMS genes 
To date 33 genes have been reported to cause CMS, each encoding proteins that 
provide structural or functional support to the safety factor of the NMJ (Finsterer, 
2019). Proteins are generally classified as presynaptic, synaptic, postsynaptic or part 
of the glycosylation pathway, as outlined in Figure 1.6.  
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Figure 1.6. Localisation of proteins implicated in CMS at the NMJ.  Schematic of 
pre, synaptic and postsynaptic NMJ displaying localisation and general pathway of 
reported CMS genes, including the ubiquitously expressed glycosylation proteins. 
Commonly used classes of drug used to treat CMS are also shown, along with their 
site of action. The presence of β-2 adrenoceptors and site of agonist action has not 
been confirmed. Red = antagonist/blocker, green = agonist.  
The first identified genetic cause of CMS were mutations in the CHRNE gene 
encoding for the AChR Ɛ subunit (Gomez and Gammack, 1995, Ohno et al., 1995). 
To this day, defective AChR subunit proteins remain the cause of the most prevalent 
subtypes of CMS, and genes encoding proteins involved in clustering AChRs and 
postsynaptic specialisations are also commonly identified with mutations in CMS 
patients such as DOK7 and RAPSN (Finsterer, 2019). Therefore, the majority of CMS 
cases are caused by proteins affecting AChR signal transmission at the postsynapse. 
The most prevalent presynaptic CMS subtype is that due to mutations in CHAT, 
which is the gene encoding for the enzyme (ChAT) responsible for ACh synthesis in 
the nerve. Other presynaptic genes encode for proteins implicated in ACh vesicle 
release, which would clearly affect the safety factor of the NMJ by reducing release 
probability or dynamics (Finsterer, 2019). Within the last decade, mutations in genes 
encoding ubiquitously expressed glycosylation proteins have been identified and 
research is ongoing to uncover how proteins with widespread expression manifest 
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with a primarily neuromuscular pathology (Belaya et al., 2012, Cossins et al., 2013, 
Selcen et al., 2014, Senderek et al., 2011). Recently, a number of cytoskeletal and 
structural proteins have also been identified with involvement in CMS, including 
MYO9A, MACF1, PLEC, COL13A1 and PREPL, highlighting that proteins not directly 
involved in the transmission of ACh from nerve to muscle may be important (Oury et 
al., 2019, O'Connor et al., 2016, Logan et al., 2015, Regal et al., 2014, Selcen et al., 
2011). An association network of the proteins currently identified as defective in CMS 
patients is shown in Figure 1.7. Proteins are linked according to evidence suggesting 
they work toward a common function (rather than physical interaction), as predicted 
by STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) analysis 
(Szklarczyk et al., 2019). Groups of proteins that cluster together are highlighted and 
form the subsets often used to define CMS: ACh synthesis and release, postsynaptic 
specialisations, postsynaptic transmission and glycosylation. A number of proteins do 
not fall directly within one of these clusters, but are nevertheless important for 
pathology as the genetic causes for this group of diseases expands.  
 
Figure 1.7. Interaction network of proteins implicated in CMS.  Proteins that have 
found to be defective CMS are shown in an association network. Line thickness 
represents confidence that two proteins work toward a similar function (rather than a 
physical interaction). Clusters in red represent proteins implicated in ACh synthesis 
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and release, those in blue are involved in postsynaptic specialisations, yellow 
proteins are involved in postsynaptic transmission and glycosylation-related proteins 
are highlighted in green. Data based on text mining, databases, gene fusion, co-
expression, co-occurrence, experimental evidence and gene neighborhood data as 
outlined on STRING v11.0 (https://string-db.org, last accessed 29.03.2019). 
Despite the advent and increasing use of genetic techniques such as whole exome 
and whole genome sequencing, between 20-40% of CMS patients remain without a 
genetic diagnosis indicating there are still further novel causative genes to be 
identified (Thompson et al., 2019). By expanding the protein association network to 
include closely related proteins, further insight may be gained regarding potential 
candidate proteins playing roles in NMJ physiology or disease. In Figure 1.8, proteins 
predicted to influence the same function as the reported CMS proteins are shown. 
This highlights a number of presynaptic components that may be implicated in ACh 
synthesis and release. Roles for ubiquitously expressed or extracellular proteins are 
being increasingly recognised as important for CMS, and highlighting this, a number 
of glycosylation and extracellular matrix proteins were also identified. As the genetic 
landscape for CMS expands, it remains important to investigate novel genes using in 
vitro and in vivo models to assist in assigning causality to genetic defects and 
understanding more about the pathways involved in the disease.  
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Figure 1.8. Association network of proteins implicated in CMS, including 
interacting proteins. STRING diagram showing clustering of CMS proteins with 
interacting proteins included. Line thickness represents confidence that two proteins 
work toward a similar function (rather than a physical interaction). Red dashed circles 
encompass proteins not previously associated with CMS and are listed in the table 
under the heading of the CMS protein cluster they fall within.  
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1.4 Models used to investigate CMS 
Investigation of rare diseases such as CMS are greatly facilitated by the advent of in 
vitro and in vivo models. These can be used for investigating molecular mechanisms, 
modelling patient mutations, functional analysis of movement and NMJ signalling, as 
well as for trialing drug treatments and novel therapeutic strategies. 
1.4.1 Cell models for CMS 
A multitude of cell models have been used in CMS research, usually to analyse the 
effect of a particular patient mutation on protein function. The cell models used in 
studies of CMS proteins are shown in Figure 1.9. The vast majority of in vitro analysis 
related to CMS is undertaken using the immortal human embryonic kidney cell line 
HEK293, likely due to the ease of culturing and transfection of these cells making 
them amenable to screening of multiple patient mutations. Most of the studies using 
HEK293 cells performed analysis of AChR kinetics, thus demonstrating the benefit of 
these cells if mutations in genes are expected to affect AChR function. A number of 
studies also utilised C2C12 cells, an immortilised mouse skeletal muscle cell line. 
The C2C12 cells are initially myoblasts which can be differentiated into 
multinucleated myotubes over a period of 5-7 days. The myotubes express the 
subunits of AChRs and can be stimulated by agrin to form clusters along the surface 
of the myotubes (Ferns et al., 1996). Therefore, C2C12 cells are particularly suited to 
analysis of AChR clustering dynamics, which was assessed in 5 of the 7 publications 
identified. Surprisingly, only 4 studies used neuronal cell-lines, while 7 used the 
fibroblast-like cell-line: COS. However, the majority of experiments involving COS 
cells were performed to analyse protein expression and improper splicing due to 
patient mutations, rather than NMJ-specific functions or pathways.  
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Figure 1.9. Cell models used for studying CMS genes. Graph depicts the number 
of studies that have used each cell type for study of molecular function of identified 
CMS genes. Some studies used more than one cell type thus are included in multiple 
categories, total study number is 38. Only studies explicitly studying the role of the 
protein in the context of CMS were included. Cell-lines from human sources are 
denoted with an asterisk.  
Analysis of cells from patients can be useful as further genetic manipulation is not 
required and expression of the variants of interest are present on the genetic 
background of the patient. However, patient cells are often unavailable. Only 3 
publications noted the use of patient cells, however, proteomic analysis revealed that 
myoblasts/myotubes of humans express almost all of the CMS-related proteins, 
including all of the AChR subunits and postsynaptic specialisation-associated 
proteins (O'Connor et al., 2018b). As the use of direct conversion protocols becomes 
more widespread, the use of patient cells may increase. Obtaining fibroblasts from 
patients is the least invasive procedure commonly performed for sample collection, 
but fibroblasts are likely not the ideal model for an NMJ disorder. If they were 
converted into myoblasts or induced neuronal progenitor cells (iNPCs), then they 
would be more functionally relevant and would expand the possibilities for performing 
in vitro experiments (Wakao et al., 2017, Meyer et al., 2015). Cell models are 
valuable for analysing effects of patient mutations on protein expression and ion 
channel kinetics, and models related to muscle or nerve have further benefits due to 
the ability to assess integrity of pathways important for NMJ development such as 
neurite extension in nerves or AChR clustering in muscles.
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1.4.2  Zebrafish models of CMS  
In order to understand more about the contribution of CMS-related proteins to the 
functioning of the NMJ, and how defective proteins may cause the disease, animal 
models are required. Multisystem models, rather than cells, are particularly important 
for studying CMS disease mechanisms as patients present with a range of 
phenotypes that affect not only different muscles but also other tissues. Furthermore, 
a number of CMS-related proteins are expressed ubiquitously, and using animal 
models may shed light on the selective NMJ pathology related to many of these 
proteins. In vivo studies are also useful in designing and testing novel therapeutic 
strategies and preparing preclinical data that may support future clinical trials in 
patients.  
There are a number of invertebrate models that have been used to assess proteins 
associated with CMS, such as Caenorhabditis elegans (C.elegans) and Drosophila 
melanogaster. For example, an LRP4-null Drosophila model revealed a decrease in 
excitatory synapse number and disruption of active zone structure, and a MuSK-
deletion C.elegans mutant showed mislocalised AChR subunits, disrupted channel 
currents and impaired localisation of cholinergic synaptic vesicles (Francis et al., 
2005, Mosca et al., 2017, O'Connor et al., 2018b). Use of such models offers many 
benefits, including their small size, ability to screen many animals rapidly and access 
to the complete lineage of developing cells in C.elegans, allowing cells to be traced 
through development. Furthermore, many of the proteins involved in molecular 
events at the NMJ, such as transmitter release machinery, are conserved 
(Ackermann et al., 2015).  
Vertebrates are more commonly used to generate disease models for the NMJ, as 
they are evolutionarily closer to humans, have cholinergic synapses and those such 
as zebrafish share many of the benefits observed for invertebrate systems. Zebrafish 
produce around 200 embryos per pairing (Wilson, 2012), allowing large numbers of 
fish to be studied. Embryonic development occurs externally in a chorion and 
zebrafish remain optically transparent in early life allowing gross morphological 
features to be observed. This includes features such as muscle somite structure and 
developing neurons and receptor clusters if fluorescent probes are used. Genetic 
manipulation techniques in zebrafish are now well developed, including the use of 
transient morpholino(MO)-mediated knockdowns to reduced expression of a protein 
from the transcriptional level, or CRISPR/Cas9 (Clustered regularly interspaced short 
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palindromic repeats/CRISPR associated protein 9) to induce genomic deletions or 
insertions at desired target points (Hwang et al., 2013). Zebrafish also perform a 
stereotyped set of movements at different time points in development and maturation 
of nerve and muscle systems are well documented, with many of the same proteins 
involved as found in humans. Another benefit to using zebrafish for NMJ studies is 
the ability to perform paired nerve-muscle recordings, in which the cell body of a 
primary motor neuron can be patch clamped, along with a muscle cell innervated by 
that neuron (Wen and Brehm, 2005). This provides a powerful system in which to 
record effects of different genetic manipulations or drug treatments on NMJ 
signalling. One main difference when considering the use of zebrafish as models for 
genetic disease is the genome duplication event that teleosts underwent (Meyer and 
Schartl, 1999). As a result, zebrafish often express more than one orthologue for 
human genes, and whether they have acquired different functions or have genetic 
redundancy is unclear. While 70% of human genes have a zebrafish orthologue, it 
has been reported that 82% of human disease genes are accounted for in the 
zebrafish genome (Howe et al., 2013), and from a search of the Zebrafish 
Information Network database (https://zfin.org/) it can be seen that all CMS-
associated genes identified to date have at least one orthologue.  
The main zebrafish models of CMS are shown in Table 1-1. To date, 14 of the 33 
CMS genes have associated zebrafish models that have been used to delineate their 
role at the NMJ. Others may be available that do not refer to the NMJ. CMS 
manifests as fatigable muscle weakness in patients, and this can affect the ability to 
perform motor tasks. In corroboration with this 71% of the models generated also 
reveal movement defects. Of the remaining 31%, motility wasn’t reported for 4 
models and was found to be unaffected in only one, highlighting the ability to induce 
measurable movement changes in zebrafish due to impairments in CMS-related 
proteins. Tail shape and muscle integrity is affected in less than half of the fish, which 
corroborates with the majority of patients not displaying myopathic features. Almost 
all zebrafish that were assessed for pre or postsynaptic defects exhibited 
abnormalities, supporting the use of this model for studying such effects. Some of the 
ubiquitously expressed proteins, such as GMPPB and SLC25A1, also influence other 
tissues such as the CNS and heart. Overall, a number of zebrafish models have 
been generated that successfully replicate a number of important components of the 
patient disease phenotype, and these allow further experiments including drug 
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screens or use of electrophysiology to functionally analyse effects on the NMJ to be 
performed.  
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Table 1-1. Zebrafish models of CMS. Zebrafish with mutations in genes implicated in CMS, or targeted for knockdown with 
morpholinos (MO). Genotype is included, and phenotypes correspond to homozygotes when mutant lines are used. Motility refers to 
any abnormalities in movement reported from chorion movements in early development, through to swimming. Tail shape, if 
affected, refers to presence of curved tails. Impaired motor neuron extension and branching, as well as any AChR clustering defects 
(prepatterned or synaptic) are included, along with effects on muscle integrity and somite size. Other phenotypes include presence 
of cardiac/hindbrain oedemas, eye size, brain abnormalities and sensory defects. Red boxes = affected, green = unaffected and 
white = not reported. *unptbr307, unptbo81, unptbt187, unptbb72, unptbr160, unptdp253, unpte314b and unpp31CD.  
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1.4.3 Mouse models of CMS 
Mammalian models of human diseases are also important, as the pathways involved 
in developing and maintaining the NMJ are evolutionarily closer to human than those 
in fish. Perfect phenocopies of human diseases in mouse models are still unlikely to 
be achieved due to variations in protein function or genetic redundancy between 
species, as well as differences in protein homology as outlined in Table 1-2. 
However, use of mice overcomes the problem of gene duplications present in the 
zebrafish and thus increases the chance of genes encoding for proteins that have 
similar functions. Furthermore, mouse CMS-related proteins have a higher sequence 
homology with human than those found in zebrafish, with 64% of the mouse models 
analysed in Table 1-2 demonstrating over 90% sequence similarity.  
 
Table 1-2. Protein homologies of limb-girdle CMS proteins for mouse and 
zebrafish as compared with human using the NCBI protein BLAST tool. 
Percentage sequence cover and identity is shown, as well as the human isoform the 
sequence matched with and the Uniprot accession number of the corresponding 
zebrafish/mouse protein. Modified from O’Connor et al (2018b). 
Mice are also able to perform more complex behvioural tasks than fish, which can be 
important when assessing features such as fatigable weakness or muscle strength in 
functional tests. A number of electrophysiological tests can also be performed in 
mice, which is of particular importance as morphologically disrupted NMJs may not 
significantly affect signal transmission, and vice versa. The tests that are often 
performed include EMG, which is an in vivo test whereby CMAPs can be recorded 
following nervous stimulation, as sometimes used in CMS patients for diagnosis. Due 
to the nature of the test it can be performed at repeated points to monitor disease 
progression or response to treatments. Ex vivo nerve-muscle preparations can also 
be subject to physiological analysis, allowing measurement of mEPPs and EPPs 
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which provides the ability to make estimates of QC, and thus whether a nerve is 
releasing appropriate amounts of ACh (Webster, 2018). Finally, when testing novel 
therapeutics, mammalian preclinical models must be used (McElvany, 2009), thus 
generating robust animal models at an early stage of the research process is 
desirable so that phenotypes can be well characterised and appropriate outcome 
measures generated.   
There are a large number of mouse models that have been developed for the study 
of CMS-associated genes as shown in Table 1-3. Only 10 of the 33 genes do not 
have a corresponding mouse model published in relation to effects on the NMJ or as 
a CMS disease model (there may be models generated for other purposes). A 
number of these models have been well-characterised, comprising morphological 
analysis of NMJs, electrophysiology to assess synapse function and behvioural tests, 
rendering them useful for future drug testing studies.  
Gene Mouse model Gene Mouse model 
AGRN  LRP4  
ALG14  MACF1  
ALG2  MUNC13–1  
CHAT  MUSK  
CHRNA1  MYO9A  
CHRNB1  PLEC1  
CHRND  PREPL  
CHRNE  RAPSN  
CHRNG  RPH3A  
COL13A1  SCN4A  
COLQ  SLC18A3  
DOK7  SLC25A1  
DPAGT1  SLC5A7  
GFPT1  SNAP25  
GMPPB  SYT2  
LAMA5  VAMP1  
LAMB2    
Table 1-3. Mouse models developed for the in vivo analysis of the 33 currently 
recognised CMS genes.Only models in which the NMJ has been analysed are 
included. 
For example, a mouse model of slow channel myasthenia has been generated in 
which the human AChR εL221F mutation is expressed on an AChRε-null background 
(Webster et al., 2013). This mouse successfully recapitulates many of the patient 
symptoms, such as fatigable muscle weakness as demonstrated using the inverted 
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screen test (where latency to fall is assessed in mice hanging from a wire mesh). The 
patient mutation in vitro causes prolonged AChR channel opening, thus ex vivo 
nerve-muscle preparations were used to analyse the time course of endplate 
currents, revealing they were similarly prolonged in the mouse model. In vivo EMG 
was also performed, which showed the presence of increased jitter and decrement of 
CMAPs after a train of stimuli beyond that observed in mice harbouring a wildtype 
copy of the AChRε subunit. This is also observed in patients. Another phenotypic 
similarity with patients was observed in morphological analysis of the NMJs, 
revealing evidence of fragmentation and of degeneration of the postsynaptic folds. 
The characterisation of this model provided a basis for performing tests using 
another CMS drug, ephedrine, that had not previously been tested in humans with 
this subtype of the disease (Webster et al., 2013). 
Overall, a combined approach utilising both in vitro and in vivo models of disease, 
coupled with analysis of patient material or performance of electrophysiological tests 
in patients, is likely to yield the most robust information. This would allow molecular 
targets and pathways to be studied at the cellular level, as well as determining the 
effect of specific genetic manipulations at the level of the NMJ and in whole systems, 
thus forming the basis for testing novel therapeutic strategies.  
1.5 MYO9A-CMS 
1.5.1 Clinical presentation of MYO9A-CMS patients 
The finding that a number of ubiquitously expressed proteins can cause impaired 
function of the NMJ leading to CMS has expanded the search for novel causative 
genes encoding proteins that may play other roles out with the NMJ. In 2016, 
mutations in three patients from two unrelated families were identified in an 
unconventional myosin gene; MYO9A (O'Connor et al., 2016). This is a ubiquitously 
expressed gene that encodes for a protein classed as an actin-based molecular 
motor, as part of a large family of unconventional myosin proteins. Mutations were 
identified using whole exome sequencing analysis on a cohort of genetically 
undiagnosed CMS patients, as part of my MSci research project. The variants in 
MYO9A were first identified in patient 1, who was of German origin and was the first 
daughter of healthy non-consanguineous parents (Figure 1.11A). After finding these 
variants, the remaining genetically unsolved cohort were analysed for the presence 
of any variants in MYO9A and two siblings that had consanguineous parents of 
Kurdish origin were identified (Figure 1.11B,C).  
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Figure 1.10. MYO9A-CMS patient pedigrees. A. Pedigree for patient 1 (arrow 
head), including age at last clinical update and compound heterozygous amino-acid 
changes in MYO9A. The mother, father and unaffected sister all carried one variant. 
B. Pedigree for patients 2 and 3 (arrow heads), including age at last clinical update 
and homozygous amino-acid changes in MYO9A. Parents are first degree cousins 
and both carry the variant in heterozygous form. They had 4 deceased children who 
died within the first year of life due to CMS-like symptoms but no diagnosis was 
made. UD = undiagnosed but symptomatic (light red), y.o = years old, hom = 
homozygous, het = heterozygous, red = CMS diagnosis. C. Patients 2 and 3, 
indicating presence of bilateral ptosis and ophthalmoplegia; with asymmetric upward 
deviation of gaze (left eye) in the male patient. Photo from O’Connor et al (2016). 
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Patient 1 presented with a variety of typical CMS symptoms, including proximal and 
distal skeletal muscle weakness, difficulties with swallowing, ptosis (drooping of the 
eyelids), episodic apnoea and respiratory failure. Other forms of CMS that display 
episodic apnoea include CHAT, RAPSN, SLC5A7, fast channel syndrome and 
SLC18A3 (McMacken et al., 2018b). These symptoms manifested at the neonatal 
stage and up until the last update at age 4 years, when the patient still relied on 
feeding with a percutaneous endoscopic gastrostomy. To confirm the diagnosis of 
suspected CMS, single fibre EMG was performed on the orbicularis oculi muscle. 
This revealed the presence of abnormal jitter, with 4 abnormal pairs recorded at an 
average jitter of 75µs, compared to 39.8-54.6µs (95% confidence intervals) reported 
in orbicularis oculi muscle recordings from healthy 10 year olds (Selvan, 2011). When 
testing another site of the orbicularis oculi muscle, despite increasing stimulation 
intensity, unstable potentials were identified. However, testing was ceased due to 
distress of the infant. As increased jitter can also be a sign of reinnervation (Selvan, 
2011), concentric EMG recordings were also performed, revealing normal action 
potential configurations and no evidence of denervation, thus supporting a CMS 
diagnosis.  
Magnetic resonance imaging of the brain did not reveal any pathological findings, 
although there may be a slight cognitive delay (not objectively tested). Metabolic 
testing to rule out other disorders such as muscular dystrophy were negative, 
covering acylcarnitines in blood, amino acids in serum, creatine kinase and organic 
acids in urine. The patient exhibited improvements in motor and respiratory function 
in response to a combination of an anticholinesterase (pyridostigmine) and 3,4-DAP, 
which are also often effective in CHAT, PREPL, RAPSN and fast channel 
syndromes, as well as sometimes in agrin-CMS (Engel, 2018).  
Patients 2 and 3 also had early symptom onset as they presented in the prenatal 
period with reduced foetal movements. The parents had previously lost 4 children in 
the first year of life due to severe CMS-like symptoms. Bilateral ptosis was present 
from birth in patient 2, and further manifestations appeared after 2 months in the form 
of generalised hypotonia and difficulty with swallowing. Reaching motor milestones 
was delayed, with head control only obtained at 12 months, sitting at 3 years and 
walking with support by 5 years of age, which was the age of last update. Further 
ocular phenotypes were also present with symmetric multivectorial nystagmus, left 
eye up-gaze deviation and ophthalmoplegia. Presence of learning difficulties was 
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found and the ability to speak had not yet been obtained. Treatment with 3,4-DAP 
and fluoxetine led to respiratory crises, which also occurred during respiratory 
infection, however improvements were obtained by treatment with pyridostigmine. A 
diagnosis of CMS was made after single fibre EMG results indicated the presence of 
increased jitter. 
The older sibling, patient 3, was 11 years old at the time of last update. Symptom 
onset was also early, with bilateral ptosis apparent within the first week after birth, 
followed by development of generalised hypotonia, difficulties swallowing and 
controlling head and torso. By 12 months of age patient 3 could sit and at 18 months 
head control was obtained, followed by the ability to walk unassisted by 30 months. 
Nystagmus, symmetric ophthalmoplegia and oculomotor apraxia with head tilt were 
also present. Episodes of respiratory crises also occurred for this patient in periods of 
respiratory infection. Pryidostigmine treatment improved management of ptosis, 
swallowing, chewing and breathing in this patient, and in the younger sibling. Brain 
magnetic resonance imaging did not reveal any abnormalities in patient 3, nor did 
metabolic testing including creatine kinase in serum, organic acids in urine and 
amino acids in serum. Repetitive nerve stimulation of the right ala nasi muscle 
revealed a 22% decrement, supporting the diagnosis of CMS.   
1.5.2 MYO9A patient mutations 
The variants identified in these three patients were all missense changes in the tail 
domain of the MYO9A protein, shown in Figure 1.13. Patient 1 has compound 
heterozygous mutations affecting protein residues: p.R1517H and p.R2283H 
(rs149046541 and rs142345927, respectively). In both positions an arginine amino 
acid is exchanged for a histidine, which is exchanging a positively charged amino 
acid for a neutral one, and due to the unique chemical properties of histidine it does 
not generally substitute well. Corroborating this, polyphen prediction software 
predicts p.R1517H to be damaging, and this variant has a minor allele frequency of 
0.09% in the ExAC database (a database of 60,706 individuals exomes) not 
appearing in homozygosity in any subjects (Lek et al., 2016). This variant resides 
within exon 25 of the main transcript (NM_006901) in a highly conserved region of 
MYO9A (Figure 1.12). This exon is within the tail region, specifically in a coiled-coil 
domain that is situated between an IQ motif and a C1 zinc-binding domain.  
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Figure 1.11. Conservation of MYO9A exons in different species.  The top 
sequence in dark blue, denoted by MYO9A, indicates the full isoform of the human 
protein. Exons of interest are highlighted in green, demonstrating their presence 
throughout the species shown, except lamprey. Data generated from UCSC genome 
browser (Kent et al., 2002).  
On the other hand, p.R2283H is predicted to be benign using polyphen prediction 
software, although appears damaging using MutationTaster (O'Connor et al., 2016, 
Schwarz et al., 2014). P.R2283H has a minor allele frequency of 0.2% in the ExAC 
database, with 2 homozygotes reported. In the main MYO9A transcript, p.R2283H is 
situated in exon 40 in a relatively well-conserved region. This is also in the tail region 
of MYO9A, towards the c-terminus and adjacent to the Rho-GTPase domain. It is 
hypothesised that p.R2283H, due to its benign predicted effect and relatively high 
minor allele frequency for a rare disease (predicted to occur in homozygosity for 4 in 
1,000,000 people), has a rather mild effect on the patient phenotype and only when 
expressed in conjunction with the rarer p.R1517H is there a sufficiently detrimental 
effect on protein function. 
Patients 2 and 3 had homozygous missense variants in MYO9A: p.D1698G 
(rs150726107). This variant had a minor allele frequency of 0.06% in the ExAC 
database, with no presence of homozygosity. Parents were both heterozygous for 
the variant. Exchange of a negatively charged, fairly well conserved aspartate for a 
small amino acid residue glycine, is predicted to alter splicing of the MYO9A (Desmet 
et al., 2009). The variant is positioned within exon 26 of the main transcript, which is 
also located between the IQ motif and protein kinase C domain.  
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Overall, these variants were identified as the likely cause for CMS in these three 
patients, after considering the rest of the exome data available for each case. The 
mutations found in these patients could be altering the structure and function of the 
MYO9A protein, which will be discussed in subsequent sections.  
1.5.3 Family of Unconventional Myosins 
MYO9A is an unconventional myosin protein. Myosin proteins are a diverse group of 
actin-based molecular motors, present in almost all eukaryotic cells. They are 
involved in a multitude of cellular functions including muscle contraction, cell motility, 
intracellular trafficking, endo- and exocytosis and alterations in cell morphology 
(Batters and Veigel, 2016). Humans have around 40 genes encoding myosins which 
can be divided into 12 distinct subfamilies depending on their specific protein 
domains (Foth et al., 2006). These include the muscle-specific or conventional 
myosin; myosin II, which is part of the contractile apparatus of muscle cells. The rest 
of the family constitute the unconventional myosins, a group of myosin motors that 
have the ability to interact with actin and perform a variety of functions. Myosins all 
have a catalytic domain of approximately 80 kDa in their N-terminal head region 
responsible for the hydrolysis of ATP and binding of actin, termed the myosin motor 
domain (Batters and Veigel, 2016). This confers the ability of myosins to bind actin 
and processively move along filaments. Each class of myosin also possesses a neck 
region of varying lengths, containing different numbers of IQ motifs, from 1 in myosin 
XVI to 6 in myosin IX (Patel et al., 2001, Gorman et al., 1999). This region undergoes 
small conformational changes which affect the motor domain, with the length of the 
neck determining how much force can be generated by the head (Batters and Veigel, 
2016). Each class has a distinct tail region containing different domains which confer 
the unique functions of each myosin subset, such as ability to anchor the myosin to 
cellular compartments or select cargo (Krendel and Mooseker, 2005). Two sets of 
myosins; myosin III and IX, are able to act as motorised signalling molecules due to 
the expression of domains with enzymatic activities (Bahler, 2000). The diseases that 
have been associated with unconventional myosins so far are listed in Table 1-4, 
highlighting the diversity in function and expression of this protein family.  
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Unconventional Myosin 
subtype Disease association OMIM identifier 
Ie Glomerulosclerosis 601479 
IIIa  Deafness 606808 
Va Griscelli syndrome 160777 
Vb Microvillus inclusion disease 606540 
VI Deafness 600970 
VIIa Deafness, Usher Syndrome 276903 
IXa Congenital Myasthenic Syndrome  604875 
XVa Deafness 602666 
Table 1-4. Diseases associated with unconventional myosins as reported on 
the OMIM database.  Unconventional myosin subtype, disease and OMIM identifier 
included. 
With relevance to the NMJ, only two unconventional myosins have been directly 
implicated in having a role at this synapse, including the identification of MYO9A as 
potentially causative for a subset of CMS (O'Connor et al., 2016). Myosin Va has also 
been demonstrated to play a role at the NMJ in mice, where a subsynaptic 
enrichment of Myosin Va and protein kinase A was found to positively correlate with 
AChR stability in the dystrophic mdx mouse model (Roder et al., 2008, Roder et al., 
2012). A number of myosins have been shown to play roles in the nervous system in 
general, with functions in neuronal migration, outgrowth, morphogenesis and axonal 
transport (Brown and Bridgman, 2004). Of potential relevance to the NMJ, several 
myosins have also been shown to partake in endo- and exocytotic mechanisms, as 
well as vesicle trafficking in both nerves and other tissues. For example, Myosin X 
provides a link between the extracellular matrix receptors; integrins, and the 
necessary cytoskeletal rearrangements that precede axonal elongation in 
development or following injury in spinal sensory and motor neurons (Plantman et al., 
2013). This group of myosins also transports netrin-1 receptors to the peripheral tip 
of neurites where interactions are important for axonal guidance (Zhu et al., 2007). 
Myosin VI associates with cortical actin which lies beneath the plasma membrane, 
and is thought to be the only unconventional myosin to move toward the minus end 
(rather than plus end) of actin filaments and thus is likely to play a role in endocytosis 
(Wells et al., 1999). During secretion from cells actin filaments undergo local 
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reorganisation to facilitate the process. Myosins Ic, Ie, II, Va and VI have been 
implicated in these final stages of secretion, commonly described as approach, 
docking, priming and fusion of vesicles (Bond et al., 2011). If an unconventional 
myosin were to play a similar role at the NMJ it may affect the ability of the synapse 
to respond to guidance cues, changes in environment, internalisation of ligand-bound 
receptors and in secretion of proteins from the cell.  
1.5.4 MYO9 proteins 
1.5.4.1 Protein structure 
There are 2 class 9 myosin proteins expressed in humans; MYO9A (chromosome 15, 
Figure 1.13) and MYO9B (chromosome 19). Both myosins follow the same basic 
structural composition as other unconventional myosins, containing a force 
generating motor domain in the head region which binds actin and hydrolyses ATP. 
This is preceded by an extension that has similarities to a Ras-association domain, 
however it has been shown not to bind Ras in both MYO9A and MYO9B (Chieregatti 
et al., 1998, Kalhammer et al., 1997). Unique to this subset of myosins is the 
presence of a large 100-200 amino acid insertion in the head domain, termed loop 2. 
This extension contains an IQ motif for binding calmodulin and has been shown to 
bind actin, allowing this single-headed motor protein to move processively along actin 
filaments (Elfrink et al., 2014, Saczko-Brack et al., 2016). A further 6 IQ motifs for 
MYO9A and 4 motifs for MYO9B are present in the neck domain, which can also bind 
calmodulin. Activity of MYO9B has been shown to be responsive to calcium due to 
the conformational changes induced by a switch from calcium-free calmodulin to 
calcium-calmodulin, which inhibit its ATPase activity (Liao et al., 2010) and recently, 
the ability of MYO9A to bind calcium-calmodulin has also been demonstrated (Li et 
al., 2017). Both class IX myosins have an extended tail region that contains an 
atypical C1 domain for which the function is not yet known (typical C1 domains bind 
diacylglycerol) and a Rho-GTPase activating protein (GAP) domain (Gorman et al., 
1999, Bahler et al., 2011). The tail region of MYO9A is longer than MYO9B, 
containing a sequence predicted to adopt a coiled-coil structure and two alternatively 
spliced regions (Chieregatti et al., 1998), resulting in a 293 kDa protein for MYO9A 
as opposed to 243 kDa for MYO9B. The Rho-GAP domains were found to stimulate 
the GTPase activity of Rho but not Rac (Post et al., 1998, Chieregatti et al., 1998). 
MYO9A is predicted to possess 20 different protein isoforms that differ in 5’ and 3’ 
truncations, as well as absence of 16 cassette exons. Of these splice variants only 4 
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include the tail region bearing the patient mutations, and 2 of these contain all of the 
identified domains (Thierry-Mieg and Thierry-Mieg, 2006). Tissue specific expression 
of these different isoforms may provide an explanation for the NMJ-specific 
phenotype of the patients.  
 
Figure 1.12. Structure of MYO9A. Diagram of MYO9A protein domains identified, 
including the head region Ras-associating domain and myosin motor domain that 
contains an extension at loop 2 with an IQ motif. The neck region consists of 6 IQ 
motifs for binding of calmodulin. The tail region of MYO9A has 3 sequences 
predicted to adopt a coiled-coil conformation, as well as an atypical C1 domain and 
Rho-Gap domain. The location of the 3 MYO9A-CMS patient mutations are noted: 
patient 1 in purple, compound heterozygous, patients 2 and 3 in green, homozygous. 
The location of reported mutations in an arthrogryposis patient (Bayram et al., 2016) 
are also included (blue, compound heterozygous), and homozygous mutations in a 
foetal akinesia patient shown in red (Maddirevula et al., 2019). Modified from: 
O’Connor et al (2016). 
MYO9A RNA is expressed ubiquitously, with highest levels present in the testis and 
peripheral nerves, and to a lesser extent in the muscle and brain (GTEx, 
https://gtexportal.org/home/gene/MYO9A, last accessed 26.03.19, Chieregatti et al., 
1998). As there are a number of different isoforms, expression of specific exons that 
contain patient mutations were also analysed, revealing that exons 25 (p.R1517H) 
and 26 (p.D1698G) are predominantly expressed in the testis, nerve, oesophagus 
muscle and arteries. Exon 40, in which the p.R2283H variant resides, is expressed in 
the brain, muscles and many other tissues. Considering protein expression levels 
using the Human Protein Atlas resource, the level of expression is similar across all 
aforementioned tissues, with the RNA enrichment in the testis absent at the protein 
level (Uhlen et al., 2015). MYO9B on the other hand is expressed to a higher extent 
in endocrine tissues, immune cells, muscle, testis and many other tissues at both the 
protein and RNA level (GTEx, https://gtexportal.org/home/gene/MYO9B, last 
accessed 26.03.19, Uhlen et al., 2015, Chieregatti et al., 1998). 
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The human class IX myosin canonical protein sequences are only 57% similar, which 
includes only 71% coverage of MYO9A, thus highlighting the likely differing roles of 
the two proteins within this class. Human MYO9A compared to the mouse homolog 
displays an 88% similarity, covering 100% of the sequence. Zebrafish also display a 
high degree of homology with human MYO9A, with Myo9aa 63% similar covering 
100% of the sequence, and Myo9ab 62% similar covering 82% of the sequence  
(https://blast.ncbi.nlm.nih.gov/Blast.cgi, last accessed 26.03.19). Overall MYO9A is 
well conserved, including within the species relevant to this project.  
1.5.4.2 Protein function 
Consistent with the identification of an active RhoGAP domain in MYO9A, analysis of 
the MYO9A interactome as generated by the STRING database reveals associations 
of this unconventional myosin with a range of Rho family proteins (Figure 1.13). This 
includes RhoA, with which MYO9A has been shown to interact with in numerous 
studies by negatively regulating its activity (Abouhamed et al., 2009, Omelchenko 
and Hall, 2012).  
 
Figure 1.13. String association network for MYO9A. Human MYO9A and 
associated proteins are shown, linked with lines representing confidence of 
interaction. Interactions do not necessitate binding but suggest the two proteins work 
towards the same function, based on experimental evidence, databases, text mining, 
co-expression, neighbourhood, gene fusion and co-occurrence data, performed using 
the STRING database (Szklarczyk et al., 2019).  
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Human MYO9A was originally cloned by Gorman et al (1999), performed because it 
was in a region identified to contain a gene causing the disease Bardet-Biedl 
syndrome. Despite this, MYO9A variants have never been identified in patients with 
this disease. The previous year, Myr 7, the rat MYO9A homolog, was identified as a 
protein similar in structure to Myr 5 (MYO9B). Initial analysis revealed Myr 7/MYO9A 
could activate RhoA, but not Rac1 and only partially CDC42 GTPase activities in vitro 
(Chieregatti et al., 1998). These first observations, coupled with expression studies 
identifying the protein within the brain, lead to the hypothesis that MYO9A may be 
important for regulating Rho activity in neurons. It was not until 10 years later that 
further research emerged suggesting a role for this unconventional myosin protein in 
brain ependymal epithelial cells that line the ventricles, due to its absence causing 
hydrocephalus in a mouse model (Table 1-5). This was attributed to altered epithelial 
cell morphology and cell junctions, but could be attenuated by blocking the Rho-
associated protein kinase (ROCK) pathway, a downstream target for RhoA 
(Abouhamed et al., 2009). Therefore, this demonstrated for the first time in vivo that 
MYO9A activity has functional consequences for the RhoA pathway.  
Mouse 
genotype 
Tissue 
affected 
Phenotype PMID 
Myo9a-/- Kidney Bilateral renal disease, polyuria and low molecular 
weight proteinuria 
26136556 
Myo9a-/- Brain 
(ventricles) 
Severe hydrocephalus with stenosis, closure of the 
ventral caudal 3rd ventricle and the aqueduct 
19828736 
Myo9a+/- Brain 
(hippocampus) 
Impairment of long term potentiation, synaptic 
transmission and cognitive function 
26834556 
Myo9a-/- Gross 
phenotype 
Abnormal gait and small size 19828736 
Table 1-5. Phenotypes associated with depletion of MYO9A in mice. Table 
shows genotype of mice (homozygous or heterozygous knockout) along with 
associated phenotypes and main tissue investigated. Pubmed IDs are provided 
(PMID).  
The downstream network of RhoA includes a number of proteins with diverse 
functions. However, one of the main roles is in modulation of the actin cytoskeleton, 
as well as some microtubule and intermediate filament interactions (Jaffe and Hall, 
2005). Through these functions, Rho GTPases such as MYO9A are particularly 
important for cell migration, polarity, movement and junction formation. This is 
exemplified by reports highlighting that an absence of MYO9A from bronchial 
epithelial cells leads to cell scattering based on a loss of local actin cytoskeleton 
organisation and inability of cells to form new adhesions. The binding of actin 
filaments could be reinstated by expression of the motor domain in the head, 
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whereas rescue of cell junction formation required the RhoGAP domain (Omelchenko 
and Hall, 2012). In further support for a role for MYO9A in regulating RhoA-
dependent processes, it has been reported that MYO9A contains a PDZ-binding 
motif at the c-terminus (p.2540-2550), allowing binding of a viral PDZ-containing 
protein that brings MYO9A and RhoA into close association allowing MYO9A-
mediated inactivation of RhoA. This leads to altered actin cytoskeleton dynamics and 
allows viral spread between cells (Handa et al., 2013). In two studies performed to 
identify genes that may contribute to desirable features in farmed animals there was 
a suggested contribution of MYO9A to abdominal fatness in chickens and muscle 
mass in pigs. However, no functional work was performed to support these findings 
and thus mechanisms of action are unclear (Zhang et al., 2012, Liu et al., 2018). 
As described, actin dynamics and other unconventional myosins have been shown to 
play important roles in vesicle secretion from cells. Corroborating this, MYO9A in 
mouse was shown to localise to cortical actin in kidney tubule cells, where its loss 
affected endocytosis of ligand bound receptors from the cell surface (Thelen et al., 
2015). A previously unreported effect on diaphanous-related formin 1 was also 
identified, a Rho effector protein that modulates the cytoskeleton and thus is likely a 
downstream target of the MYO9A/RhoA pathway. 
Almost 20 years after initial predictions that MYO9A would play a role in neurons, 2 
studies reported effects of MYO9A in the CNS and PNS. The first of these was by 
Folci et al (2016), demonstrating an association of MYO9A with the postsynaptic 
density of hippocampal neurons from rat, where it binds to the GluA2 subunit of the 
alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR). 
Heterozygous knockout of MYO9A from mice impacted on long term potentiation and 
performance in cognitive tasks as outlined in Table 1-5. While mechanisms for such 
an effect were not investigated, it was hypothesised that MYO9A affects AMPAR 
endocytosis and trafficking through both RhoA-mediated and myosin motor-mediated 
pathways. As a result, its loss leads to a surface build-up of AMPARs and affects 
synaptic plasticity. The second such study to implicate a role for MYO9A in neurons 
was based on our observations that 3 patients with CMS harboured variants in 
MYO9A that segregated with the disease, and found MYO9A to localise at the NMJ 
in mouse, and loss of the protein to impact on NMJ development in zebrafish 
(O'Connor et al., 2016). Another disease, arthrogryposis, has also been associated 
with MYO9A mutations, in which compound heterozygous missense variants were 
45 
 
identified in one patient (Bayram et al., 2016). Association of a gene with both 
arthrogryposis and CMS has occurred previously, as there are overlapping 
phenotypes. For example, reduced foetal movements due to prenatal NMJ 
transmission defects sometimes present in CMS and can lead to joint contracture 
(arthrogryposis) formation (Brownlow et al., 2001, Vajsar et al., 1995). A homozygous 
nonsense mutation in MYO9A was recently reported in an autozygosity study for a 
foetal akinesia patient, linking in with the report of arthrogryposis, and also with the 
hydrocephalus phenotype observed in MYO9A KO mice (Maddirevula et al., 2019). 
The mutation was positioned in the motor domain, the same region in which one of 
the arthrogryposis variants was located, and thus may explain the severity of the 
patient’s phenotype due to the likely truncation of the protein near the n-terminus. 
Reflecting this observation, the motor domain of MYO9A has been shown to play an 
important novel role delineated in vitro, in which MYO9A crosslinks actin filaments to 
form polar structures that may provide support for localised RhoGAP activity, as well 
as involvement in cell polarity and migration (Saczko-Brack et al., 2016). Further 
defects due to a role of this myosin in cytoskeleton regulation has been highlighted 
by the identification of MYO9A gene dysregulation in monosomy blastocysts (in 
which a chromosome is absent, chromosome 15 in this case). Decreased expression 
of MYO9A was hypothesised to affect implantation of monosomy blastocysts in 
pregnancy due to roles in cytoskeleton modulation and cell junction formation, 
although no functional data was obtained (McCallie et al., 2016).  
With regards to clinical effects of RhoA pathway modulation due to MYO9A, the 
presence of ANXA2-MYO9A gene fusions were reported to significantly worsen the 
prognosis of diffuse gastric cancer patients. The gene fusion product maintained the 
RhoGAP domain of MYO9A and caused its overexpression, subsequently reducing 
the activity of active RhoA in cells (Yang et al., 2018). Hum-7 is the C.elegans 
homolog of MYO9A/B. Although it only has approximately 20% protein homology with 
its human counterparts, it contains the main domains. Depletion of Hum-7 increased 
embryonic lethality, corroborating previous studies suggesting roles for MYO9A in 
early development (Bayram et al., 2016, Maddirevula et al., 2019, McCallie et al., 
2016, O'Connor et al., 2016). Further supporting the role of MYO9A in nervous 
development, Hum-7, was also found to affect postembryonic axon guidance, 
causing axon migration defects when knocked down (Wallace et al., 2018).  
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Overall, a number of recent studies have built on the suggested roles for MYO9A in 
neuronal function but also broadly in cytoskeletal structure and RhoA pathway 
modulation. However, the precise role of MYO9A at the NMJ remains to be 
established. Furthermore, whether such a role is due to interactions with the 
cytoskeleton and RhoA pathway in particular is not known, or if there is involvement 
of other pathways. A mechanism by which dysfunction of MYO9A could disrupt the 
safety factor of the NMJ and lead to impaired signalling resulting in CMS also 
requires investigation. These questions will be addressed within this thesis, with a 
particular focus on the roles of MYO9A in morphology and function of the NMJ.  
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1.6  Aims 
The main aim of this project was to determine whether MYO9A contributes to the 
development and integrity of the NMJ. Pathological mechanisms that may lead to 
manifestation of a CMS phenotype in patients lacking the functional protein will be 
determined, and thus potential therapeutic targets for new treatments identified. It is 
hypothesised that defects in MYO9A cause a presynaptic CMS, due to interactions 
with the cytoskeleton and RhoA pathway within motor neurons. Each chapter will 
address a specific aim to investigate this hypothesis.  
Chapter 3: 
To generate a range of in vitro and in vivo models appropriate for studying the role of 
MYO9A at the NMJ, including patient-derived neuronal progenitor cells and 
knockdown zebrafish.  
Chapter 4: 
To perform observations of NMJ development in zebrafish, coupled with behavioural 
testing to assess whether loss of MYO9A affects motor activity and/or synapse 
morphology. This was accompanied by assessment of patient nerve cells and 
morphology of adult NMJs in a MYO9A knockout mouse.  
Chapter 5: 
To assess the effects of MYO9A-depletion or patient mutation on the cytoskeleton 
and vesicular transport, using cell models as well as zebrafish and mouse tissue.  
To determine whether any defects observed were mediated by the interaction of 
MYO9A with the RhoA/ROCK pathway. 
ROCK inhibitor treatment was trialed in vitro and in vivo and effects on vesicular 
transport and NMJ development studied.  
Chapter 6: 
To determine whether loss of MYO9A affects secretion from a nerve cell model, 
using secretomics. 
Identified factors of relevance to the NMJ guided selection and application of novel 
compounds using the most appropriate model to test for therapeutic potential. 
Screening of a novel compound was performed including morphological analysis of 
NMJs and effects on motor behaviours.  
48 
 
Chapter 2. Materials and Methods 
2.1 Solutions and buffers 
A list of solutions and buffers used in this project is shown below in alphabetical 
order. 
Coomassie Brilliant Blue dye  NSC-34 cell growth medium 
1% Coomassie DMEM 
40% ETOH 10% FBS 
50% distilled water 100 units/ml penicillin/streptomycin 
10% acetic acid 3 µg/ml puromycin  
Destaining buffer 1 1xPBS 
47.7% water 1x PBS tablet 
10% acetic acid 500ml distilled water 
40% ETOH 1xPBST 
2.3% glycerine 1x PBS tablet 
Destaining buffer 2 500ml distilled water 
82.8% water 0.1% Tween 20 
5% acetic acid 4% PFA in PBS 
10% ETOH 1xPBS 
2.3% glycerine NaOH pellets  
E3 medium 4% PFA 
5mM NaCl pH adjusted to 7.4   
0.17mM KCl Secretomics lysis buffer 
0.33mM MgSO4 50 mM TrisHCl pH 7.8 
0.33mM CaCl2  150 mM NaCl 
0.01% methylene blue 1% SDS 
Fibroblast growth medium 1 protease cOmplete mini tablet  
DMEM 1 phosphatase inhibitor PhosSTOP tablet 
15% FBS SH-SY5Y cell growth medium 
FM-Dye staining solution 1:1 DMEM:Ham's F12 
5μg/ml FM-Dye 10% FBS 
HBSS TAE buffer 
Freezing medium 40mM Tris base 
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30% FBS 20mM acetic acid 
60% DMEM  1mM EDTA 
10% dimethylsulfoxide 1xTBS 
Immunofluorescence blocking buffer 50 mM Tris-Cl, pH 7.5 
1x PBS 150 mM NaCl 
4% BSA Made up in distilled water 
0.1% Tween 20 1xTBS-T 
Immunofluorescence blocking buffer 
for zebrafish 
1xTBS 
0.1% Tween 20 
1x PBS 1xTransfer buffer  
5% horse serum 25 mM Tris 
0.1% Tween 20 192 mM glycine 
LB media 20% methanol 
10 mg/ml Bacto-tryptone Made up in distilled water 
5 mg/ml yeast extract  1xTris-Glycine running buffer  
10 mg/ml NaCl  25 mM Tris 
2% w/v dextrose (pH 7.4)  192 mM glycine 
LB plates 0.1% SDS 
LB media  Made up in distilled water 
15 g/l agar Western blot blocking buffer 
Lysis buffer 5% BSA 
RIPA buffer 1xTBS 
Protease cOmplete mini tablet (1 
tablet/10ml) 
 
Neuroinduction media  
1:1 DMEM:F-12 with 1% GlutaMAX  
1x N2 supplement (from 100x stock)  
1x B27 supplement (from 50x stock)  
10ng/ml Recombinant Human Leukemia 
Inhibitory Factor 
 
3µM CHIR 99021  
2µM SB431542  
Neurodifferentiation media  
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1:1 DMEM:F-12 with 1% GlutaMAX  
1x N2 supplement (from 100x stock)  
1x B27 supplement (from 50x stock)  
300ng/ml cAMP  
200µM Vitamin C  
10ng/ml BDNF  
10ng/ml GDNF  
2.2 Standard molecular biology techniques 
2.2.1 DNA extraction  
The ‘Hot Shot’ method of DNA extraction was utilised for obtaining genomic DNA 
(gDNA) from zebrafish embryos (maximum 20 per reaction), adult zebrafish fin clips 
(<2mm) and mouse tails (<2mm). Lysis reagent (50mM NaOH) was added to each 
sample until submerged (approx. 50µl for embryos and fin clips and 100µl tail tips). 
Samples were incubated at 95⁰C for 15 mins, with regular vortexing. After cooling 
samples to 4⁰C, 1M Tris-HCL (pH8) neutralisation buffer was applied at a volume of 
one tenth of the lysis reagent. After mixing, samples were centrifuged at 13000g and 
stored at -20⁰C until use.   
2.2.2 RNA extraction  
To prepare cells in culture for RNA extraction, cells (<1x105) were washed 3x in ice-
cold phosphate buffered saline (PBS) and scraped into PBS before centrifuging at 
250g at 4⁰C. Following removal of supernatant, pellets were homogenised by 
vortexing in lysis buffer and RNA extracted using a Qiagen RNeasy Mini Kit 
according to the manufacturer’s instructions.  
To isolate RNA from zebrafish embryos, a combination of TRIzol and Qiagen RNeasy 
Mini Kit methods was used. Approximately 30 embryos were incubated in 250µl of 
TRIzol reagent (Invitrogen) and homogenised using a Tissue Rupture, followed by a 
5 min incubation at room temperature. Chloroform (50µl, Sigma Aldrich) was added 
to the lysed samples before centrifuging at 12000g for 15 mins at 4⁰C. The upper 
aqueous phase was placed in a new microcentrifuge tube and combined at a ratio of 
1:1 with 70% ethanol. The combined solution was then applied to an RNeasy spin 
column and the Qiagen RNeasy Mini Kit instructions followed.  
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Samples were incubated at -80⁰C until required, after which purity and 
concentrations were determined using a NanoDrop 2000 (ThermoFisher Scientific). 
RNA was considered pure if the 260/280 ratio of absorbance was approximately 2, 
and 260/230 ratio of absorbance between 2 and 2.2.    
2.2.3 Reverse transcription cDNA synthesis 
Reverse transcription was performed using the Applied Biosciences High Capacity 
cDNA reverse transcription kit, according to manufacturer’s instructions. Briefly, a 2x 
master mix was prepared including 2µl 10x reverse transcription buffer, 0.8µl 25x 
dNTP mix (100mM), 2µl 10x reverse transcription random primers, 1µl Multiscribe 
reverse transcriptase, 4.2µl nuclease-free water, per reaction. The master mix was 
combined with the RNA sample (<2µg) at a 1:1 ratio and subject to thermal cycling 
for 10 mins at 25⁰C, 120 mins at 37⁰C and 5 mins at 85⁰C, before storing at 4⁰C.  
2.2.4 Polymerase chain reaction  
HotStarTaq DNA polymerase kit (Qiagen) was used to perform polymerase chain 
reactions (PCRs). The final concentration of components in each reaction mix was as 
follows; 1x PCR buffer, 200µM of each dNTP, 0.1µM forward and reverse primers, 
2.5 units HotStarTaq DNA polymerase, 8.825µl distilled water and 1µl DNA, to a total 
volume of 15µl. Reactions were then subject to thermal cycling, as shown in Table 
2-1. 
Step Temperature (⁰C) Time (mins) Cycles 
Initial activation 95 15 1 
Denaturation 95 1 25-40 (40 used 
only for zebrafish 
reactions) 
Annealing Variable 0.5  
Extension 72 1  
Final Extension 72 10 1 
Storage 4 ∞  
Table 2-1. Thermal cycling conditions used for PCR reactions with HotStarTaq 
DNA polymerase. 
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Gradient PCRs were performed for each new primer set to determine the most 
effective annealing temperature. Primers shown in Table 2-2. 
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Primer Species Application Sequence (5’-3’) 
Annealing 
temperature 
(°C) 
myo9aa 
exon 2 
Fwd 
Zebrafish Sequencing ACTATCTACTGCCCTGTCGC 56 
myo9aa 
exon 2 
Rev 
Zebrafish Sequencing GGTAGTCCTCGCTGCTGAAG 56 
myo9aa 
exon 2b 
Fwd 
Zebrafish Sequencing TGACTTGCAACCACATCTGC 56 
myo9aa 
exon 2b 
Rev 
Zebrafish Sequencing AGGTTATCGATCGGCTGCAG 56 
myo9ab 
exon 1 
Fwd 
Zebrafish Sequencing TCACACTTCTCCTACTCGCG 56 
myo9ab 
exon 1 
Rev 
Zebrafish Sequencing TGGCGAAGTTGATGCAGAAC 56 
myo9ab 
exon 12 
Fwd 
Zebrafish Sequencing CCGTTGTGTGTTTCTCCAGG 56 
myo9ab 
exon 12 
Rev 
Zebrafish Sequencing TCCTCTAGATCTGCCAGTTCC 56 
R1517 
Fwd 
Human Sequencing 
AGAAGGTATCACTGCTCAGG
A 
55 
R1517 
Rev 
Human Sequencing GCCACCAAACACTCTCCAAT 55 
D1698G 
Fwd 
Human Sequencing AGAGAGGGAAATGCTAGGCC 56 
D1698G 
Rev 
Human Sequencing CGCTGTGATGTCTCTCTTTGG 56 
R2283H 
Fwd 
Human Sequencing GACACCACTGACCCACTACA 57 
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R2283H 
Rev 
Human Sequencing GGCAACCGAACTACAACAGG 57 
S1971L 
Fwd 
Human Sequencing TCTGGAAAAGACGATGAGGC 55 
S1971L 
Rev 
Human Sequencing GGGATGCTATATTGGGTGGC 55 
MYO9A 
start 
Human Sequencing AGCTGCTGAGGTGATTGAGT / 
MYO9A 
mid 
Human Sequencing TTCCTCTGCTCACTTACCCC / 
MYO9A 
end 
Human Sequencing GCAAGTCTGAACCTTCCAGC / 
S1971L 
Fwd 
Human Mutagenesis 
GATGAATATATGAATGAATTC
AAGACTTTAGATTGCACAGCC
ACAAAGGTGCC 
63 
S1971L 
Rev 
Human Mutagenesis 
GTTTTTGGCACCTTTGTGGCT
GTGCAATCTAAAGTCTTGAAT
TCATTCATATATTCATC 
63 
R1517 
Fwd 
Human Mutagenesis 
GAATGAAAAAGAGATGATGG
AACAGATTCACCAGCAAACA
GATATTTTAGAGAAGGAGC 
63 
R1517 
Rev 
Human Mutagenesis 
GCTCCTTCTCTAAAATATCTG
TTTGCTGGTGAATCTGTTCCA
TCATCTCTTTTTCATTC 
63 
D1698G 
Fwd 
Human Mutagenesis 
CAGTAAAAATCCTCAACTCCA
TAAAGAAGGTGAACCAGCAT
GGAAACCTGTGAAGTTAGCT
G 
63 
D1698G 
Rev 
Human Mutagenesis 
CAGCTAACTTCACAGGTTTCC
ATGCTGGTTCACCTTCTTTAT
GGAGTTGAGGATTTTTACTG 
63 
R2283H 
Fwd 
Human Mutagenesis 
GATTCGTAGATCAATGGGAA
AGGGGCATATTCGTCGAGGA
AACTATCCAGGTC 
63 
R2283H 
Rev 
Human Mutagenesis 
GACCTGGATAGTTTCCTCGA
CGAATATGCCCCTTTCCCATT
GATCTACGAATC 
63 
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Myo9a 
Fwd 1 
Mouse Genotyping GCAGCTAGAGCCGTGAGTC 58 
Myo9a 
Rev 
Mouse Genotyping TCAGCATCCACATGATGACTC 58 
Myo9a 
Fwd 2 
Mouse Genotyping 
ATGTTTGCATGTGTGCAGTG
C 
58 
Table 2-2. Primers used in PCRs and sequencing for human, mouse and 
zebrafish. Application, sequence and annealing temperature included, except when 
primers used only for sequencing. 
2.2.5 Agarose gel electrophoresis  
Agarose gels were poured at a concentration of 1-4% (w/v) agarose (NBS 
Biologicals, Low EEO) in 1 x TAE buffer (40mM Tris base, 20mM acetic acid and 
1mM EDTA) depending on the predicted size of the product. SafeView DNA dye 
(NBS Biologicals) was added to the gel at a ratio of 1:10 for visualisation of DNA 
fragments. Samples were combined with 6x blue/orange loading dye and loaded onto 
the gel submerged in 1x TAE buffer, along with a 100 base pair (bp) DNA ladder 
(Promega), and ran for 30-45 mins at 90 V. Gels were imaged using a GelDoc-It 
imager.   
2.2.6 DNA sequencing  
For sequencing of DNA, PCRs were performed as described in Section 2.1.4 and 
purified using ExoSAP-IT (Applied Biosystems). ExoSAP-IT was added at a ratio of 
5:2 with the PCR reaction and incubated at 37⁰C for 15 mins, followed by 15 mins at 
80⁰C. Purified samples (1ng/µl), along with 2µl primer for sequencing (10µM), were 
sent to Eurofins Genomics (Germany).  
2.2.7 Quantitative RT-PCR 
Quantitative reverse transcriptase PCR (qRT-PCR) was performed on cDNA using 
either PowerSYBR green master mix (Applied Biosystems) or iTaq Universal SYBR 
Green supermix (Bio-Rad).  
Optimisation of annealing temperature was performed for each primer set using 
standard gradient PCR, primers shown in Table 2-3. Annealing temperature 
optimisation for COL1A1, COL3A1, PAX6, SOX1, SOX2, NES and GAPDH primers 
was performed by the laboratory of Professor Rita Horvath. Appropriate cDNA 
concentration and reaction efficiency for each primer set (excluding those listed 
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above) was determined by carrying out a qRT-PCR dilution calibration curve on serial 
dilutions of stock cDNA.  
Primer Species Sequence 5’-3’ 
Annealing 
temperature 
(°C) 
COL1A1 Fwd Human GATTCCCTGGACCTAAAGGTGC 58 
COL1A1 Rev Human AGCCTCTCCATCTTTGCCAGCA 58 
COL3A1 Fwd Human CCCTGGATCTCCAGGATA 58 
COL3A1 Rev Human GTCCGGGTCTACCTGATT 58 
PAX6 Fwd Human GTGTCCAACGGATGTGTGAG 58 
PAX6 Rev Human CTAGCCAGGTTGCGAAGAAC 58 
SOX1 Fwd Human GAGTGGAAGGTCATGTCCGAGG 58 
SOX1 Rev Human CCTTCTTGAGCAGCGTCTTGGT 58 
SOX2 Fwd Human GCTACAGCATGATGCAGGACCA 58 
SOX2 Rev Human TCTGCGAGCTGGTCATGGAGTT 58 
NES Fwd Human TCAAGATGTCCCTCAGCCTGGA 58 
NES Rev Human AAGCTGAGGGAAGTCTTGGAGC 58 
GAPDH Fwd  Human GTCTCCTCTGACTTCAACAGCG 58 
GAPDH Rev Human ACCACCCTGTTGCTGTAGCCAA 58 
TBP Fwd Human TATAATCCCAAGCGGTTTGC 58 
TBP Rev Human GCTGGAAAACCCAACTTCTG 58 
MYO9A Fwd Human AAGGCCTCAAGTACTGGTCC 58 
MYO9A Rev Human TCAGTGCATCGTGATTTCAGG 58 
Myo9a Fwd Mouse ATTCTGAGCCGGATTGCTT 60 
Myo9a Rev Mouse TGTCTTCGTGTCTTGGGAAG 60 
Pgk1 Fwd Mouse GGAGCGGGTCGTGATGA 60 
Pgk1 Rev Mouse GCCTTGATCCTTTGGTTGTTTG 60 
Table 2-3. Primers for qRT-PCR, including species, sequence and annealing 
temperature.  
Reactions using PowerSYBR green master mix contained: 1x Power SYBR Green 
PCR Master Mix, 500nM forward/reverse primers, cDNA (variable), nuclease-free 
water (up to final volume of 20µl). ITaq universal SYBR Green reactions were 
composed of: 1x iTaq Universal SYBR Green Supermix, 750nM forward/reverse 
primer, cDNA (variable), nuclease-free water (up to final volume of 20µl).  
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A CFX96 Touch Real Time detection system (BioRad) was used to perform thermal 
cycling for the qRT-PCRs (Table 2-4). Melt curves were analysed and qRT-PCR 
products also subject to gel electrophoresis to confirm the presence of a single 
amplicon. Data analysis was performed in CFX Manager software, or manually using 
Excel, applying the delta Ct method.   
  
Power SYBR 
Green 
ITaq universal 
SYBR Green 
 
Step Temperature (⁰C) Time (mins) Cycles 
Enzyme 
activation 
95 10 3 1 
Denaturation 95 0.15 0.10 40 
Annealing/Ex-
tension 
Variable 1 1  
Melt Curve 
65-95 with 0.5 
increments 
0.03/step 0.03/step 1 
Table 2-4. Thermal cycling conditions for PowerSYBR Green and iTaq universal 
SYBR Green reaction mixes for qRT-PCR.  
2.2.8 Production of single guide RNAs for CRISPR/Cas9-mediated genome 
editing 
This protocol was modified from Varshney et al (2016). Single guide RNAs (sgRNAs) 
for generating CRISPR/Cas9-mediated knockdown zebrafish were designed using 
CRISPR scan (http://www.crisprscan.org/, date last accessed February 20, 2019, 
Moreno-Mateos et al., 2015). Targets were picked that had the highest CRISPRscan 
score (efficiency score) and no off target effects predicted (Table 2-5). DNA 
oligonucleotides that included the target region and surrounding T7 promoter 
sequence and tail sequence were then ordered from Eurofins Genomics, along with a 
universal bottom strand ultramer 
(5′AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATT
TTAACTTGCTATTTCTAGCTCTAAAAC-3′). Primers were designed to flank the 
surrounding region of the gene for confirmation of knockdown and also ordered from 
Eurofins Genomics (Table 2-2).  
58 
 
Gene Target site 
sequence 
Promoter + sgRNA + 
universal primer sequence 
Off-
targets 
CRISPRscan 
efficacy 
score 
myo9
aa 
AGGAGTTCGGT
GGGGAGGAGTG
G 
taatacgactcactataGGGAGT
TCGGTGGGGAGGAGgtttta
gagctagaa 
0 79 
myo9
aa 
GCGCTGGACGG
GATAATCGGTGG 
taatacgactcactataGGGCTG
GACGGGATAATCGGgtttta
gagctagaa 
0 77 
myo9
ab 
GTGTTTCAGATC
CTGTCCATTGG 
taatacgactcactataGGGTTT
CAGATCCTGTCCATgttttag
agctagaa 
0 69 
myo9
ab 
AGTGCAGACTTG
GAGCCCAGCGG 
taatacgactcactataGGTGCA
GACTTGGAGCCCAGgtttta
gagctagaa 
0 78 
Tyr GGACTGGAGGA
CTTCTGGGG 
taatacgactcactataGGACTG
GAGGACTTCTGGGGgtttta
gagctagaa 
0 69 
Table 2-5. sgRNA sequences used for CRISPR/Cas9-mediated gene 
modification in zebrafish. Sequence of target site and target site including promoter 
and universal binding sequence are shown. Off targets refers to other areas of the 
genome the sgRNA may bind. The higher the CRISPRscan score (out of 100), the 
higher the predicted efficacy of that sgRNA.  
The sgRNA sequence oligo and universal bottom strand were annealed using the 
reaction mix described in Table 2-6 and reaction performed in a thermocycler 
according to steps in Table 2-7.  
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Component 1x Volume (µl) 
5x My Taq Buffer 5 
gRNA target oligo (100µM) 2 
Universal strand ultramer (100µM) 2 
My Taq DNA polymerase 0.2 
Nuclease free water 15.8 
Total volume 25 
Table 2-6. Annealing reaction for sgRNA oligo and universal bottom strand. 
Temperature (°C) Time (mins) 
95 5 
89 0.25 
83 0.25 
77 0.25 
71 0.25 
65 0.25 
59 0.25 
53 0.25 
50 10 
72 10 
4 ∞ 
Table 2-7. Thermocycler program for annealing of sgRNA and universal bottom 
strand. 
A Qiagen PCR purification kit was then used to purify samples according to 
manufacturer’s instructions. The purified product was used as a template for the 
MEGAshortscript T7 kit (Invitrogen), set up as shown in Table 2-8, with 8 reactions 
per sgRNA sequence. This was incubated overnight at 37⁰C. The following day, 1µl 
of TURBO DNase was added to each reaction and incubated at 37⁰C for 15 mins.  
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Component 1x volume (µl) 
T7 10x reaction buffer 2 
T7 ATP solution 2 
T7 CTP solution 2 
T7 GTP solution 2 
T7 UTP solution 2 
Template DNA 8 
T7 Enzyme mix 2 
Total volume 20 
Table 2-8. MEGAshortscript T7 reaction mixture.  
The 8 reactions per sgRNA were pooled to increase yield and RNase-free water 
added to a final volume of 800µl. The pooled samples were then added to a Mirvana 
spin column (mirVana miRNA isolation kit, ThermoFisher Scientific) and subject to 
washes to purify the RNA according to manufacturer’s instructions. RNA was eluted 
in 30µl of RNase-free water and concentration/purity assessed using a Nanodrop 
2000 (ThermoFisher Scientific), aliquots were stored at -80⁰C.  
Prior to injection into zebrafish embryos, the sgRNA and Cas9 reaction mix was 
prepared as outlined in Table 2-9, and heated to 37⁰C for 5 mins to improve 
knockdown efficiency as described by Burger et al (2016). 
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Component 1x volume (µl) 
10x Cas9 Buffer (0.2M HEPES, 1M 
NaCl, 50mM MgCl2, 1mM EDTA) 
1 
EnGen Cas9 NLS Protein (20µM, NEB, 
MO646T) 
3.58 
RNA  3000ng - variable 
2M KCL 1.5 
0.5% Phenol red 1 
RNase-free water Up to 10 
Total volume 10 
Table 2-9. Reaction mixture for zebrafish injection with sgRNA and Cas9 
protein. 
2.3 Tissue culture  
2.3.1 Maintenance of cultured cells 
Cells were maintained at 37⁰C in 5% CO2 to subconfluence. Fibroblasts were 
cultured in Dulbecco’s modified Eagle medium (DMEM, Gibco), supplemented with 
15% fetal bovine serum (FBS, Gibco). NSC-34 cells (control and MYO9A knockdown 
(KD)) were cultured in DMEM with 10% FBS, 100 units/ml penicillin/streptomycin 
(Gibco) and 3 µg/ml puromycin (Gibco) to maintain selective pressure. SH-SY5Y cells 
were maintained in 1:1 DMEM:Ham's F12 (Gibco), supplemented with 10% FBS.  
Cells were sub-cultured when reaching 90-100% confluence by washing with PBS 
followed with application of Trypsin-EDTA (0.05%, Gibco), for 5 mins at 37⁰C. In the 
case of SH-SY5Y cells, medium was also centrifuged at 250g to collect cells in 
suspension. Dissociation was ceased by addition of 4x volume of DMEM + 10% FBS 
and cells subject to centrifugation at 250g. The resulting cell pellet was re-suspended 
in its respective growth medium and plated as required. 
Freezing of cells was performed at an early (<5) passage for each cell-type used. 
Cells were cultured in T75 flasks until 80% confluent, before Trypsin-mediated 
dissociation was performed as described. Cell pellets were resuspended in 10ml 
freezing medium, composed of 30% FBS, 60% DMEM and 10% dimethylsulfoxide. 
Vials containing 1ml (10 per flask) were transferred to a ThermoFisher Scientific Mr 
Frosty with 100% isopropyl alcohol in a -80°C freezer, to ensure slow cooling. Long-
term stocks of cells were transferred to liquid nitrogen storage after 3 days at -80°C.  
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Thawing of cells was performed rapidly at 37°C before plating in a T25 flask with 
growth medium. After allowing cells to adhere for 6 hours, medium was changed to 
new growth medium to remove the dimethylsulfoxide present in freezing medium.  
2.3.2 shRNA transfection of NSC-34 cells 
Generation, optimisation and transfection of shRNAs for MYO9A knockdown from 
NSC-34 cells was performed during my Masters project (O’Connor, 2015, University 
of Glasgow). A new control shRNA knockdown line was generated during this 
project, using the commercially available control shRNA, expressed within a plasmid 
containing a puromycin resistance gene (Santa Cruz Biotechnology, 108060). 
Transfection of the control shRNA was performed using FuGENE HD transfection 
reagent (Promega). Cells were seeded at the same time as the transfection protocol 
was performed, as this gave a higher rate of success than when transfecting adhered 
cells, optimised during my Masters project. A ratio of 1:1.5 plasmid DNA to FuGENE 
reagent was used. After 12 hours, medium was exchanged for normal growth 
medium and cells were cultured for a further 36 hours. Growth medium 
supplemented with 3µg/ml puromycin was then added to the cells and replaced every 
second day for 14 days. A polyclonal population of knockdown cells was then 
maintained under selective pressure for performing experiments. 
2.3.3 Site-directed mutagenesis of human MYO9A construct and expression in 
SH-SY5Y cells 
In order to analyse the effect of MYO9A-CMS patient mutations in vitro, site-directed 
mutagenesis was used on a human-MYO9A construct and SH-SY5Y cells used to 
express the resulting plasmids.  
A plasmid containing the human MYO9A open reading frame with a c-terminal 
Human influenza hemagglutinin (HA)-tag was obtained from VectorBuilder, as an 
E.Coli stock (Figure 2.1). A sterile inoculating loop was used to transfer bacteria from 
the stock to Luria broth (LB) agar plates containing 100µg/ml of Ampicillin (Sigma 
Aldrich) before incubating at 37°C overnight. A distinct colony was selected and 
cultured overnight with vigorous shaking at 37⁰C in 3ml LB medium, containing 
100µg/ml of Ampicillin. Purification of plasmid DNA was performed using a QIAprep 
Spin Miniprep Kit (Qiagen) according to manufacturer’s instructions. To confirm the 
presence of the expected MYO9A sequence, plasmid DNA was sent for Sanger 
sequencing (Eurofins Genomics, Germany), using MYO9A start, middle and end 
primers listed in Table 2-2 to sequence different regions of the insert. 
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Figure 2.1. Vector map of human MYO9A plasmid. Includes c-terminal HA-tag, 
cytomegalovirus promoter, puromycin resistance gene, ampicillin resistance gene 
and BamHI restriction sites.  
Following confirmation of the insert, CMS-patient mutations (R1517H, D1698G and 
R2283H) and a benign polymorphism (S1971L) were inserted into the sequence 
using a QuikChange XL Site-Directed Mutagenesis Kit according to manufacturer’s 
instructions (Agilent). Briefly, mutagenesis primers were obtained from Eurofins 
(Table 2-2) and a reaction mixture prepared as shown in Table 2-10 for each primer 
pair.  
Component Quantity per reaction (µl) 
10× reaction buffer 5  
Double stranded DNA template Volume for 10ng 
Oligonucleotide primer 1  Volume for 125ng 
Oligonucleotide primer 2 Volume for 125ng 
dNTP mix 1 
QuikSolution 3 
ddH20 To final volume of 50 
Pfu Turbo DNA polymerase 1 (2.5U/µl) 
Table 2-10. Components for QuikChange XL site-directed mutagenesis kit.  
The reaction mixes were subject to thermal cycling according to the steps in Table 
2-11, followed by cooling on ice for 2 mins. Dpn I restriction enzyme (10U/µl) was 
then added to each reaction and mixed gently before incubating for 1 hour at 37°C. 
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Step Temperature (⁰C) Time Cycles 
1 95 1 min 1 
2 95 50 secs 18 
60 50 secs  
68 1 min/kb of plasmid length = 
12 min 
 
3 68 7 1 
Table 2-11. Thermal cycling parameters for the QuikChange XL site-directed 
mutagenesis kit. 
XL10-Gold ultracompetent cells were used for transformations. XL10 cells were 
thawed on ice and 45µl added to a prechilled 14ml falcon tube, along with 2µl β-ME 
mix and incubated for 10 mins with regular mixing. Dpn I-treated DNA from each 
reaction was added to separate aliquots of ultracompetent cells, at 2µl per sample 
and gently mixed. Reactions were incubated on ice for 30 mins and then cells heat-
shocked at 42°C in a water bath for 30 secs. After incubating on ice for 2 mins, 0.5ml 
of preheated (42°C) NZY+ broth was added to each sample and incubated at 37°C for 
1 hour with shaking at 250 rotations per minute. Samples were then applied to LB-
ampicillin (100µg/ml) agar plates and incubated overnight at 37°C.  
The following day, colonies from each plate were selected as described above, 
incubated overnight in LB medium containing ampicillin, and subject to purification 
using a QIAprep Spin Miniprep Kit (Qiagen) according to manufacturer’s instructions. 
To confirm mutagenesis success, PCRs were performed on the plasmid DNA as 
described in Section 2.1.4, using primers from Table 2-2, before sending for Sanger 
sequencing (Eurofins Genomics, Germany).  
For expression of the human MYO9A constructs (wild-type and with mutations), 
transfections were performed using Lipofectamine 2000 reagent (ThermoFisher 
Scientific) in SH-SY5Y cells. Cells were seeded at the time of transfection (0.3x106 
cells/well of a 6-well plate), and the protocol performed as described in Section 2.2.7. 
A ratio of 1:3 plasmid DNA:Lipofectamine reagent was used. After 6 hours, the 
medium was changed for growth medium and cells cultured for 24-48 hours before 
lysing for western blot (Section 2.5), or fixing for immunofluorescence (Section 2.4.3).  
2.3.4 Conversion of fibroblasts to iNPCs 
A summary of this protocol is shown in Figure 2.2. Fibroblasts from a skin biopsy 
from suspected MYO9A CMS patient 1 (aged 3 at time of biopsy) were isolated by 
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EuroBioBank (http://www.eurobiobank.org/) and obtained, along with fibroblasts from 
a healthy control subject (age 27 at time of biopsy). Ethical approval obtained by the 
EuroBioBank. MYO9A CMS patient cells were cultured for 2 passages in fibroblast 
growth medium as described (section 2.2.1). Cells were then dissociated and 
counted using a haemocytometer, before seeding 75,000 cells/well of a 12-well plate. 
After 24 hours of culturing in growth medium, the conversion process was initiated. 
Control cells were converted under the same conditions by Emily McCarthy 
(Wellcome Trust Centre for Mitochondrial research, Newcastle, Prof. Rita Horvath). 
 
Figure 2.2. Summary of direct conversion protocol for fibroblasts to 
differentiated iNPCs.  
Direct conversions of fibroblasts into a proliferating neural progenitor cell population 
can be achieved by performing transductions to overexpress transcription factors 
(Oct4, K1f4, Sox2 and c-myc) using Sendai virus (Meyer et al., 2015). Virus 
containing each transcription factor were added to the cells with a multiplicity of 
infection of 3, in growth media and mixed gently. Cells were cultured overnight at 
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37⁰C in the presence of the viruses before application of neuroinduction media, as 
described in Table 2-12, and subsequent incubation at 39⁰C. 
Component Company Concentration  
DMEM/F-12 with 
GlutaMAX (1%) 
Gibco 1:1 with neurobasal 
Neurobasal Medium Gibco 1:1 with DMEM/F-12 
100x N-2 Supplement ThermoFisher 
Scientific  
1x 
50x B27 Supplement ThermoFisher 
Scientific 
1x 
Recombinant Human 
Leukemia Inhibitory Factor 
Peprotech 10ng/ml 
CHIR 99021 Peprotech 3µM 
SB431542 Stemcell technologies 2µM 
Table 2-12. Components of neuroinduction media for culturing cells during 
conversion from fibroblasts to iNPCs.  
Neuroinduction media was replaced every second day and stocks of media replaced 
every 5 days. Laminin-coated 6-well plates were prepared 6 days following 
transduction by diluting laminin (Gibco natural laminin mouse protein) to 50µg/ml in 
PBS and incubating overnight at 4⁰C. The laminin was then removed from the wells 
and wells allowed to air dry for 20 mins. Meanwhile, transduced cells were washed 
once in PBS and then split by incubating cells at 37⁰C for 5 mins in Accutase solution 
(Merck). The same volume of DMEM/F-12 was then added to each well and the 
sample centrifuged at 180g for 5 mins. The resulting pellet was resuspended in 1.5ml 
of neuroinduction media, containing 10µM of ROCK inhibitor (Y-27632, Millipore 
Sigma) and plated onto a laminin-coated well before incubating at 39⁰C. Medium was 
changed every second day and cells were moved to 37⁰C 14 days after initial 
infection. Colonies began to form around day 17 and were large enough to be 
selected by day 20. Laminin coating of 48-well plates was performed on day 19 post-
infection and cell colonies were selected the following day. Selection was performed 
using a fine pipette tip to scrape each colony from the plate, and then transferring the 
colony to a well of the 48-well plate containing neuroinduction medium with 10µM Y-
27632. Around 20 colonies were selected and grown for 4 days, until approximately 
90% confluent. Medium was changed every second day.  
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Following selection of individual colonies, those that had adhered and expanded 
were subject to RNA extraction, as described in section 2.1.2, and then cDNA 
generated for qRT-PCR (Section 2.1.3). Primers for a range of markers were used, 
as optimised by Prof. Rita Horvath’s research group at Newcastle University. These 
included primers against fibroblast markers; COL1A1 and COL3A1, stem cell 
markers; SOX1 and SOX2, and neuronal markers; NES and PAX6. House-keeping 
targets TBP and GAPDH were also included for normalisation of expression, 
sequences in Table 2-3. Colonies in which fibroblast marker expression was 
downregulated and both stem cell and neuronal markers were upregulated as 
compared to the initial fibroblast sample were deemed successfully converted into 
induced neuronal progenitor cells (iNPCs) and these were expanded for future 
experimental use and storage. Expansion was performed in neuroinduction media 
with 10µM Y-27632 at 37⁰C on laminin-coated plates, and freezing of iNPCs was 
achieved by detaching the cells as described above and resuspending the pellet in 
Recovery Cell Culture Freezing Medium (ThermoFisher Scientific).   
2.3.5 Differentiation of iNPCs to neurons 
Differentiation of iNPCs towards the neuronal lineage was performed on the most 
successfully converted iNPC colonies, as deemed by the qRT-PCR results. Cells 
were seeded onto laminin-coated plates, some containing coverslips if confocal 
imagining was required after differentiation. Neuroinduction medium was exchanged 
for neuro-differentiation medium when cells were around 70% confluent, the 
components of which are described in Table 2-13. 
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Component Company Concentration 
DMEM/F-12  Gibco  
100x N-2 Supplement ThermoFisher Scientific  1x 
50x B27 Supplement ThermoFisher Scientific 1x 
cAMP Millipore Sigma 300ng/ml 
Vitamin C Millipore Sigma 200µM 
BDNF Peprotech 10ng/ml 
GDNF Peprotech 10ng/ml 
Table 2-13. Components of neurodifferentiation medium for differentiation of 
INPCs toward neuronal lineage.  
Neuro-differentiation media was replaced every second day for three weeks, at which 
point cells had developed neurite outgrowths and organised into networks. They also 
expressed neuronal markers as confirmed by immunofluorescence imaging of Tuj1 
and MAP-2 (section 2.4.3, Table 2-14). 
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Antibody 
type 
Antibody Source Concentration 
for 
immunofluore-
scence 
Concentra-
tion for 
western 
blot 
Primary Mouse 
monoclonal anti-
neurofilament 
ThermoFisher 
Scientific 
1:100 1:1000 
Primary Rabbit polyclonal 
anti-TrkA  
Millipore 1:100  
Primary Rabbit polyclonal 
anti- ubiquitin 
Abcam 1:500  
Primary Rabbit polyclonal 
anti-SQSTM1/ 
P62  
Abcam 1:400  
Primary Rabbit polyclonal 
anti-β-tubulin 
Abcam 1:100 1:500 
Primary Mouse 
monoclonal anti-
β-actin 
Millipore 
Sigma 
 1:1000 
Primary Mouse 
monoclonal anti-
agrin (D-2) 
Santa Cruz 1:100  
Primary Rabbit polyclonal 
anti-
synaptophysin 
Ab-4 
ThermoFisher 
Scientific 
1:200  
Primary Mouse anti-SV2  Developmental 
Studies 
Hybridoma 
Bank 
1:200  
Primary Mouse anti-Tuj1 Abcam 1:200  
Primary Chicken anti-
MAP2 
Millipore 
Sigma 
1:250 
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Primary Mouse 
monoclonal anti-
HA (12CA5) 
Roche 1:100 1:100 
 
Primary 6H1 Mouse 
monoclonal 
MHC2x IgGM 
Developmental 
Studies 
Hybridoma 
Bank 
1:25  
Primary Mouse 
monoclonal BA-
F8 anti-MHC1 
IgG2b 
Developmental 
Studies 
Hybridoma 
Bank 
1:25  
Primary Sc-71 Mouse 
monoclonal 
MHC2a IgG1 
Developmental 
Studies 
Hybridoma 
Bank 
1:200  
Primary BF-F3 Mouse 
monoclonal 
MHC2b IgM 
Developmental 
Studies 
Hybridoma 
Bank 
1:200  
Primary Rabbit polyclonal 
anti-laminin IgG 
Millipore 
Sigma 
1:750  
Direct Oregon Green 
488 phalloidin  
Life 
Technologies 
1:1000  
Direct Alexa Fluor 594 
phalloidin 
Life 
Technologies 
1:1000  
Direct Alexa Fluor 488 
α-bungarotoxin 
conjugate 
Life 
Technologies 
1:1000  
Secondary Alexa Fluor 488 
IgG goat anti-
rabbit 
Life 
Technologies 
1:500  
Secondary Alexa Fluor 594 
IgG goat anti-
rabbit 
Life 
Technologies 
1:500  
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Secondary Alexa Fluor 594 
IgG goat anti-
mouse  
Life 
Technologies 
1:500  
Secondary Alexa Fluor 488 
IgG goat anti-
rabbit 
Life 
Technologies 
1:500  
Secondary Alexa Fluor 350 
IgG2b goat anti-
mouse 
Life 
Technologies 
1:500  
Secondary Alexa Fluor 594 
IgG1 goat anti-
mouse 
Life 
Technologies 
1:100 
 
 
Secondary Alexa Fluor 488 
IgM goat anti-
mouse 
Life 
Technologies 
1:500  
Secondary Goat anti-rabbit 
HRP conjugated 
Invitrogen  1:2000 
Secondary Goat anti-mouse 
HRP conjugated 
Invitrogen  1:2000 
Secondary DyLight 680 goat 
anti-mouse  
ThermoFisher 
Scientific 
 1:2000 
Secondary DyLight 680 goat 
anti-rabbit 
ThermoFisher 
Scientific 
 1:2000 
Secondary DyLight 800 goat 
anti-mouse  
ThermoFisher 
Scientific 
 1:2000 
Secondary DyLight 800 goat 
anti-rabbit  
ThermoFisher 
Scientific 
 1:2000 
Table 2-14. Antibodies used for immunofluorescence and immunoblotting 
studies, including concentrations.  
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2.3.6 FM-Dye endo/exocytosis 
To look at recycling dynamics in cells depleted for MYO9A, an FM-Dye assay was 
performed. NSC-34 control and MYO9A-depleted cells were seeded at 0.1 x 106 cells 
per well of 12 well plates containing coverslips and incubated in growth medium at 
37⁰C overnight. FM 1-43X (ThermoFisher Scientific) working stock (5μg/ml) was 
made up in ice cold Hank's Balanced Salt Solution (HBSS, Gibco) without 
magnesium or calcium.  
Dye was added to each well of control and knockdown cells in duplicate sequentially 
to achieve staining times of 1, 3, 6, 9, 12, 15 and 18 mins. After addition of dye to 
each well, cells were incubated at 37°C. After incubating each well for the 
appropriate time, cells were washed in ice-cold HBSS 3 times and fixed in 4% 
paraformaldehyde (PFA) in HBSS for 10 mins on ice. Coverslips were removed from 
wells and mounted onto slides with mounting medium containing DAPI (Vectashield). 
Imaging was then performed using a Nikon A1R confocal. Z-stacks were obtained 
throughout the cells volumes, and 4 separate fields of view were chosen at random 
for imaging for each cell type/time point. Fluorescence intensity was then measured 
using ImageJ for at least 36 cells per condition using the corrected total cell 
fluorescence (CTCF) value to correct for cell size. This is calculated by measuring 
the area, average fluorescence and integrated density of individual cells, and a mean 
background fluorescence value taken from 3 regions of each field of view. CTCF was 
then calculated using the following equation:  
CTCF=Integrated density-(area of selected cell x mean fluorescence of background) 
In iNPC cells the FM-Dye procedure was carried out using an alternative procedure, 
whereby high K+ was used to stimulate exocytosis. INPCs that had been 
differentiated for 3 weeks were used for this experiment. The staining solution 
described above was added to each well of control subject or MYO9A-patient 
neuronal cells and left for 1 min at 37°C. Some cells were fixed at this point. The rest 
of the cells were subject to a 10 min wash at room temperature with 2 changes of 
wash solution, before more cells were fixed. For the remaining cells, HBSS with 
50mM KCl was added for 5 or 25 mins, before fixation. Cells were then mounted, 
imaged and analysed as described for NSC-34 cells above.  
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2.3.7 TrkA receptor transfection 
For the two assays requiring expression of a paradigmatic receptor, Tropomyosin 
receptor kinase A (TrkA), transfections were performed in the same manner using 
Lipofectamine 2000 as described (O'Connor et al., 2018a). NSC-34 control and 
MYO9A-depleted cells were split as described in Section 2.2.1 and seeded either 
onto coverslips within 6-well plates (for the receptor internalisation assay, 0.3 x 106 
cells/well) or onto µ-Slide 8 well glass bottom chambered coverslips (Ibidi, for live-cell 
time-lapse imaging, 5x104 cells/well). Transfections were performed at the time of 
seeding cells as this was found to improve efficiency. TrkA-GFP tagged constructs 
(gift from Dr. Joachim Weis, Aachen) were transfected according to manufacturer’s 
instructions using Lipofectamine 2000 (ThermoFisher Scientific) at a ratio of 1:3 DNA 
to reagent. Briefly, plasmid DNA was added to opti-MEM reduced serum medium 
(Gibco) and Lipofectamine reagent combined with opti-MEM, then both incubated at 
room temperature for 5 mins. Lipofectamine solution was then combined with 
plasmid DNA solution and mixture incubated at room temperature for 20 mins before 
adding to cells. Cells were incubated overnight in the transfection reagent and then 
washed 3 times in PBS before continuing incubation in growth medium until required.  
2.3.8 TrkA receptor internalisation tracking 
Transfected cells were washed twice with pre-warmed PBS 24 hours after 
transfection. Cells were then serum starved in serum-free DMEM for 2 hours before 
application of growth medium containing 50ng/ml of nerve growth factor (NGF, 
Millipore Sigma) to stimulate internalisation of receptors. This process should be 
complete by around 15 mins (Cabrera et al., 2015), after which serum- and NGF-free 
medium was added to the cells to allow recycling of receptors back to the surface. 
Fixation of cells was performed at different time points within this procedure, 
including before NGF application and then 0, 10, 30, 60 and 180 mins following NGF 
addition. Cells were fixed in 1:1 4% PFA in PBS:growth medium at 37°C for 5 mins. 
Samples were then mounted in ProLong Diamond Antifade Mountant with DAPI 
(Molecular probes) for confocal imaging. For analysis, 50 cells per time point were 
imaged and the entire experiment repeated 4 times, giving a total of 200 cells per 
time point. Cells were individually assessed for the presence of surface or 
internalised TrkA receptors. Confirmation that the TrkA-GFP plasmid was producing 
TrkA protein, a set of transfected cells were also stained with an anti-TrkA antibody 
to look for colocalising signals (Table 2-14). 
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2.3.9 Protein levels of TrkA 
During the receptor internalisation assay described above, it is possible that 
receptors are being targeted for degradation rather than recycling back to the 
surface. To account for this, levels of TrkA protein were also assessed throughout 
the time period of the experiment. Cells were seeded onto 10 cm2 plates at a density 
of 4 x 106 cells/plate, and transfected as described in section 2.2.7. Cells were lysed 
before addition of NGF, and then following 0, 60 and 180 mins after application. 
Lysates were then subject to western blotting as described in section 2.5, using an 
antibody against TrkA (Table 2-14). This was performed 3 times.  
2.3.10 TrkA live-cell trafficking 
For tracking of TrkA receptor movements within the cell, time-lapse imaging was 
performed on control and MYO9A-depleted NSC-34 cells. One day following 
transfection, cells were either incubated overnight in serum-free medium or in serum-
free medium containing 3nM of ROCK inhibitor (InSolution Y-27632, Calbiochem). 
Control NSC-34 cells were also subject to other treatment conditions for assessing 
the contribution of a disturbed cytoskeleton to disruption of trafficking dynamics. 
Treatment of cells with Nocodazole (10µM, Millipore Sigma) was performed in growth 
medium for 5 hours before imaging cells, and Cytochalasin D (1µg/ml, Millipore 
Sigma) was also applied in growth medium and cells incubated for 1 hour before 
imaging.  
To visualise nuclei during imaging, NucRed Live 647 ReadyProbes reagent 
(Invitrogen) was applied to each well (2 drops per ml). Cells were imaged using a 
Nikon A1R laser scanning confocal microscope over a period of 10 mins per cell, with 
z-stacks obtained covering the height of the cell. Resulting image series were then 
analysed using IMARIS (x64 v8.4.0, Bitplane AG). TrkA-positive vesicles were 
automatically detected using thresholding which was manually edited to ensure 
appropriate vesicle selection. Following identification of vesicles, the IMARIS 
software tracked their movement over time and in 3D space to allow speed to be 
calculated for each point. Over 3 experimental repeats, 10 cells were analysed per 
condition.  
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2.4 Zebrafish  
2.4.1 Maintenance and strains  
Zebrafish were maintained in tanks with fresh water at 28.5°C under the care of 
facility staff, according to Home Office guidelines (under project number: 70/8038). 
Fish were housed with a continuous light-dark cycle (14 hours light, 10 hours dark). 
The strains of zebrafish used in this project are listed in Table 2-15. Euthanasia of 
fish was achieved by using a 1:1 ratio of fresh system water:4mg/ml tricaine 
methanesulfonate.  
Strain Genotype Function Source 
AB Wild-type  Zebrafish International 
Resource Center 
Golden slc24a5b1/+ Lack of pigmentation  Zebrafish International 
Resource Center 
Islet-1  Tg[isl1:GFP]  Express GFP in 
cranial motor neurons 
and Rohon beard 
sensory cells 
Zebrafish International 
Resource Center 
Table 2-15. Strains of zebrafish used, including the effect of each genotype. 
2.4.2 Breeding and embryo harvesting  
To breed zebrafish for injection of embryos or to generate new lines, males and 
females were separated the evening before. Breeding tanks with mesh grids to 
separate the fish were used, with 1 male in the bottom tank and 1 or 2 females in the 
top tank. Larger tanks were also used, holding up to 6 males and females.  
In the morning the water in the tanks was replaced and fish combined for mating. 
Approximately 20 mins after eggs were laid, they were collected and washed with E3 
medium (5mM NaCl, 0.17mM KCl, 0.33mM MgSO4, 0.33mM CaCl2 and 0.01% 
methylene blue). Embryos were taken for injection if required and then stored in E3 
medium at 28.5°C for up to 5 days post fertilisation (dpf). Embryos after this point 
were culled or moved into nursery tanks for development.  
2.4.3 Design and preparation of morpholinos 
MOs against the zebrafish MYO9A orthologues, Myo9aa and Myo9ab, were 
designed and optimised in my Masters project (O'Connor et al., 2016). These MOs 
were splice blocking and targeted exon 4 and exon 7 of myo9aa/ab respectively 
76 
 
(ZV9/danRer7 assembly) and were obtained from Gene Tools LLC (USA). The 
sequences for MOs used were: myo9aa: 5’-CAGCAGGATGAAGTCGTACCTGATT-
3’ and myo9ab 5’-TATGTTGAAGAGTGTTACCGTTGTC-3’. For a negative control, 
the standard control MO from Gene Tools was utilised, which targets a mutation in 
human beta-globin, to account for phenotypes associated with the injection process.  
To prepare MO stocks for injecting, the 300nmols of lyophilized powder received from 
Gene Tools LLC was dissolved in Danieau buffer to a concentration of 5mM, this was 
stored at -20°C. For a working stock solution, the 5mM stock was diluted to 1mM and 
aliquoted for use in injections. Prior to injecting, the MO working stock was 
supplemented with 0.05% Phenol red and heated to 65°C for 5 mins, cooled on ice 
for 1 min and then mixed by gentle vortexing.  
2.4.4 Microinjections of MOs and Cas9/gRNA 
To perform microinjections, embryos were taken at the one cell stage and all dead or 
abnormal embryos were removed. Embryos (20-30) were lined up in a petri dish 
against a microscope slide as shown in Figure 2.3. Glass needles were made from 
Bo-glass capillaries with filament (Hilgenberg, Germany) using a micropipette puller 
((Program P:500, Heat:800, Pull:150, Velocity:100 and Time:150), Flaming/Brown 
Micropipette Puller, Sutter Instrument Co. Novato, USA). Needles were loaded with 
5µl of required solution and placed onto the micromanipulator before attaching to a 
microinjector (FemtoJet Microinjector, Eppendorf, UK). To obtain the appropriate 
drop size, settings on the microinjector were kept constant (180hPa injection 
pressure, 0.1ms Injection time, 18hPa back pressure), and the needle was broken 
using forceps to change the diameter of the drop (measured using a graticule with 
0.01mm units). To calculate the amount of MO injected using this technique, the 
following calculation was used:  
Volume of a sphere=  𝑉𝑉 = 4
3
𝜋𝜋𝑟𝑟3 
𝑑𝑑 = Diameter of drop on graticule in mm  
𝑟𝑟 = Radius (half of diameter)  
1mm3 = 1μl, therefore 𝑉𝑉mm3=𝑉𝑉μl given per injection  
Morpholino molecular weight = MMw 
Morpholino working stock concentration = WS in mM 
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1M= MMw 
Therefore 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊 = 𝑀𝑀𝑀𝑀𝑀𝑀
�
1𝑀𝑀
𝑊𝑊𝑊𝑊
�
𝑔𝑔 𝑖𝑖𝑖𝑖 1𝐿𝐿 
Convert to 𝑖𝑖𝑔𝑔/𝑖𝑖𝑛𝑛  
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊 = �𝑛𝑛𝑛𝑛
𝑛𝑛𝑛𝑛
� 𝑥𝑥 𝑉𝑉𝑖𝑖𝑛𝑛 = amount injected in each drop 
After setting up the microinjector (Figure 2.3), the MOs were injected into the yolk sac 
directly behind the cell between the 1 and 4 cell stage. For generating ‘crispant fish’, 
which are the F0 mosaic fish generation, the sgRNA and Cas9 protein were injected 
directly into the cell at the single cell stage. 
 
Figure 2.3. Images demonstrating set-up for microinjection of zebrafish 
embryos. Embryos are positioned in a petridish underneath a light microscope and a 
micromanipulator used to control entry of a micropipette into the yolk sac or single-
cell of embryos. 0.05% phenol red solution can be used to confirm injection success. 
Images taken from video generated by Dr Alasdair Wood and Dr Juliane Müller 
(Newcastle University).  
Fish were then incubated in petri dishes of up to 50 fish containing E3 medium at 
28.5°C for a maximum of 5 days, with dead fish removed daily. For experiments 
requiring dechorionation, pronase (from Streptomyces griseus, Roche) was added to 
the zebrafish embryos at a final concentration of 1mg/ml in E3 medium. After 
approximately 5 mins the chorions were removed and the zebrafish were washed 
three times with E3 medium. Zebrafish were then left to acclimatise outside of the 
chorion for at least half an hour before further use.  
2.4.5 Genotyping crispants 
Crispant zebrafish genotyping was performed on 4 dpf fish. For genotyping, 5 control 
and 5 fish injected with each of the CRISPR/Cas9 sgRNAs were pooled and gDNA 
extracted as described in section 2.1.1. PCRs were performed using primers outlined 
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in Table 2-2, according to the HotStarTaq protocol described in section 2.1.4. PCR 
products were then ligated into the pGEM-T Easy vector (Promega), by first setting 
up the reaction shown in Table 2-16.  
Component Amount (µl) 
2x Rapid Ligation Buffer, T4 DNA 
Ligase 
5 
pGEM-T Easy Vector (50ng) 1 
PCR Product 1 
T4 DNA Ligase (3 Weiss units/µl) 1 
Nuclease free water  2 
Table 2-16. Ligation reaction mix for pGEM-T-Easy vector and zebrafish PCR 
product.  
Reactions were incubated overnight at 4°C before analysing the product on an 
agarose gel to confirm ligation success. Transformations using Top10 chemically 
competent cells (One Shot TOP10 Chemically Competent E.coli, Life Technologies) 
were then performed according manufacturer’s instructions. Briefly, 1µl of ligation 
reaction was added directly to a vial of One Shot cells and incubated on ice for 30 
mins. After 30 seconds in a 42⁰C water bath, samples were incubated on ice for 2 
mins and 250µl of warmed S.O.C medium was added. The vial was shaken 
vigorously for 1 hour at 37⁰C. Bacteria from these vials was then cultured overnight 
at 37⁰C on LB agar plates containing 100µg/ml of Ampicillin (Millipore Sigma).  
After the formation of individual colonies, 5 from each condition were selected and 
used for colony PCR. The PCR reaction was prepared using the HotStarTaq protocol 
as described, and a pipette tip was used to remove the colony from the agar plate 
and placed in the PCR reaction. Primers for this reaction were M113 standard 
primers, with annealing temperature set at 57°C and 35 cycles performed. After 
checking for PCR success on an agarose gel, products were sent for Sanger 
sequencing using a Eurofins ‘PlateSeq Kit for crude PCR products’ kit, with the M13 
uni (-21) standard primer (5’-TGTAAAACGACGGCCAGT-3’).  
Sequences were then analysed for the presence of deletions or insertions within the 
sgRNA target site to confirm the effectiveness of the CRISPR/Cas9 injections.  
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2.4.6 Generating genetic mutants using CRISPR/Cas9 
In this study the F0 mosaic ‘crispant’ zebrafish were used for experiments. In parallel, 
attempts were made to generate an adult mutant line. In order to produce the genetic 
mutant line, crispants injected with all 4 sgRNAs were grown to 3 months in nursery 
tanks, before being transferred into main tanks ready for breeding. The F0 fish were 
incrossed and the F1 generation raised to adulthood before being fin clipped to 
identify zebrafish with the same mutations. Males and females with the same 
deletions/insertions were incrossed and the F2 generation raised to adulthood, of 
which 25% should be homozygous for the identified deletion/insertion.  
2.4.7 Chorion movements 
In early development zebrafish begin to perform spontaneous movements within the 
chorion. These movements consist of tail turns that involve contraction and swivelling 
of the tail, and occur from around 18 hpf up until 27hpf. To quantify the number of 
spontaneous chorion movements performed by the zebrafish, embryos at 24 hpf 
were recorded using a Leica stereomicroscope mounted with a Chameleon digital 
camera (CMLN-13s2M). Recordings were made for one minute, and included over 40 
zebrafish per condition. The number of full twists performed by each fish was then 
manually counted from the recordings.  
2.4.8 Tactile stimulation assay 
At 48 hpf zebrafish are able to respond to tactile stimulation by swimming quickly 
away by at least one body length. In order to assess this response, zebrafish were 
first dechorionated at 48 hpf using the aforementioned method (Section 2.3.4) and 
allowed to acclimatise for around an hour. The tactile response assay was then 
performed as described in O’Connor et al (2018a). Briefly, the fish were placed in a 
petri dish (one fish at a time) containing fresh E3 medium on top of an illuminated 
stage and a Canon legria hfr76 camera was held using a clamp 7cm above the dish. 
A fine pipette was used to touch the zebrafish on the back of the head and the 
response recorded (camera records at 25 frames per second). Room temperature 
remained constant at 28°C throughout the experiment.  
The videos were imported into Fiji ImageJ as FFmpeg movies and then manually 
thresholded to allow visualisation of the zebrafish, before converting to a binary 
image. The Trackmate plugin was then used to measure the movement of the 
zebrafish, with manual editing of each frame to ensure that only the zebrafish was 
detected and the movement identified was accurate (Figure 2.4). Values for distance 
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travelled and average speed were exported, and from this data the initial acceleration 
could also be calculated.  
 
Figure 2.4. Trackmate tracking protocol.  Example images from video of the tactile 
response assay in a control 48 hpf zebrafish, showing the fish in a petridish, a tap on 
head with pipette tip and subsequent swimming away from stimulus. Fish outlined 
with red dashed circle. The output from the Trackmate tracking software (ImageJ) is 
also shown, with the thresholded zebrafish detected in a pink circle and tracked 
movement shown with a red line.  
2.4.9 Acetylcholinesterase assay 
To quantify the activity of AChE at different time points of development, a protocol 
was modified from Teixido et al (2013). Zebrafish tails (removed with a scalpel 
following euthanasia) were pooled at age 1, 2, 3, 4 and 5 dpf (10 per condition and 
time point). Homogenisation of tissue was performed in 0.5ml of ice cold sodium 
phosphate buffer (0.1M, pH7.2, with 0.1% v/v Triton x-100), using a Tissue Rupture. 
Samples were then centrifuged at 10000g for 15 mins at 4⁰C, before removing 
supernatants for the assay. A bicinchoninic acid assay was then used to quantify 
protein concentration and 10µg of each sample was made up to 30µl in the sodium 
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phosphate buffer (without Triton). The samples were then added to a 96-well plate in 
triplicate, along with buffer only blanks. A reaction mix was then added to each well, 
containing 50mM sodium phosphate buffer (without Triton), 60µl of 0.35mM 5,5′-
Dithiobis(2-nitrobenzoic acid, ThermoFisher Scientific) made up in sodium phosphate 
buffer with 0.1mM EDTA and 18µl of 0.53mM acetylthiocholine iodide (made up in 
distilled water, Millipore Sigma). A Varioskan LUX plate-reader (ThermoFisher 
Scientific) was then used to take spectrophotometric readings at 405nm continuously 
for 10 mins, maintaining a constant temperature of 22⁰C. Enzyme activity was then 
calculated and expressed as nmols of substrate hydrolysed per min per mg of 
protein.  
2.4.10 Treatment with NT1654 
The agrin compound NT1654 was used to treat control and Myo9aa/ab-depleted 
zebrafish. This compound is a 44kDa artificial agrin fragment developed by 
Neurotune (Switzerland). NT1654 was delivered to the embryos at the same time as 
MO or CRISPR/Cas9 injection, due to the size being incompatible with water-based 
diffusion delivery (Pelka et al., 2017). Embryos from the same pair of fish were split 
into each of the four categories (control, treated control, Myo9aa/ab-depleted, treated 
Myo9aa/ab-depleted) for each injection session to ensure fair comparisons for 
survival and development. As there was no previous data regarding NT1654 use in 
zebrafish, a range of doses were trialled from 0.15ng to 2.4ng per injection droplet 
and survival rates were assessed at 2 dpf. After selecting the lowest two doses as 
most appropriate, further fish were treated with these concentrations and subject to 
movement tests as described in Sections 2.3.7 and 2.3.8 to assess any effects on 
the control zebrafish. A final concentration of 0.15ng/injection droplet was then 
selected.  
2.4.11 Treatment with fasudil 
Fasudil (5mM, Millipore Sigma), a ROCK inhibitor, was used to treat the control and 
Myo9aa/ab-depleted zebrafish. The zebrafish were housed in 12-well plates, with ten 
or less fish per well, in E3 medium. A range of concentrations of fasudil were trialled 
to optimise the dose, from 1nM to 100µM, starting from 7 hpf and final assessments 
made at 48 hpf. Based on preliminary survival rate data and assessment of chorion 
movements as described in Section 2.3.7, a concentration of 10µM was used for the 
study.  
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Fish were split into 4 treatment groups including control, 10µM fasudil treated control, 
Myo9aa/ab-depleted and 10µM fasudil treated Myo9aa/ab-depleted. Treatment 
started at 7 hpf and was continued to 5 dpf, with solution changes daily. NMJ 
morphology was assessed at 24 hpf, 48 hpf and 5 dpf, as described in section 2.4.9. 
Chorion movements were also analysed at 24 hpf and the tactile stimulation assay 
performed at 48 hpf.  
2.5 Immunofluorescence and histology 
2.5.1 Dissection of mouse tissue  
Control and MYO9A KO mice were obtained from the laboratory of Prof. Martin 
Bähler in Münster, Germany (Table 2 17, Abouhamed et al., 2009). Mice were 
euthanised by cervical dislocation and the following tissues dissected; 
gastrocnemius, tibialis anterior, quadriceps, heart, liver, kidney, spleen, diaphragm, 
intercostal muscles, brain, spinal cord and sciatic nerve. 
Animal Gender Strain DOB Age 
Wild type 1 male Bl6/C57 19.07.16 8months 12 days 
Wild type 2 male Bl6/C57 02.11.16 4months 29 days 
Wild type 3 male Bl6/C57 02.11.16 4months 29 days 
Mutant 1 male Bl6/C57 10.05.16 10months 21 days 
Mutant 2 male Bl6/C57 13.05.16 10months 18 days 
Mutant 3 male Bl6/C57 10.05.16 10months 21 days 
Mutant 4 male Bl6/C57 30.05.16 10months 1 day 
Table 2-17. Wildtype and MYO9A KO (mutant) mice used in this study. 
2.5.2 Cryosection of mouse muscle 
Freshly dissected mouse tissue was submerged in OCT compound in a tissue mould, 
however, unfortunately isopentane and liquid nitrogen were unavailable for snap 
freezing. Therefore, samples were frozen slower than desired on dry ice. Samples 
were shipped to Newcastle University and stored at -80°C until required, at which 
point they were removed from moulds and mounted on cryostat grids. Sections 
between 7 and 50µm were cut and mounted on SuperFrost microscope slides 
(FisherScientific). 
2.5.3 Staining of cells 
To prepare cells for staining, they were seeded onto coverslips, coverslides or 8-well 
chamber glass bottom coverslips, and then treated as desired. Cells were fixed as 
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described in section 2.2.6 and washed 3 times in PBS. If permeabilisation was 
required, this was achieved using 0.1% Triton X-100 in PBS for 10 mins at room 
temperature. Following 3 washes in PBS, blocking was performed using 4% bovine 
serum albumin (BSA) in PBS with 0.1% Tween (PBST) at room temperature for 1 
hour. Primary antibodies (Table 2-14) were diluted in 1% BSA in PBST and 
incubated overnight at 4⁰C. Samples were washed 3 times in PBST and then 
incubated for one hour at room temperature with secondary antibodies diluted in 1% 
BSA in PBST, as listed in Table 2-14. Following a final 2 washes in PBST and 1 
wash in PBS, samples were mounted in ProLong Diamond Antifade Mountant with 
DAPI (Molecular Probes) or Vectashield fluorescent mounting medium with DAPI 
(Vector Laboratories). 
Cells were imaged using a Nikon A1R confocal microscope using 10x and 20x air 
objectives as well as 40x, 60x and 100x oil-immersion objectives. For a number of 
experiments the CTCF value was also calculated using ImageJ as described in 
section 2.2.6, to provide a means of quantifying differences in protein abundance 
between samples or over time.  
In cells stained with phalloidin and imaged at 40x or 60x objective, the presence or 
absence of stress fibre-like structures was manually assessed. A directionality plugin 
on ImageJ was also applied to the same images to determine the orientation of the 
actin filament network in the cells (http://imagej.net/Directionality; date last accessed 
November 5, 2017). 
2.5.4 Staining of whole zebrafish 
Zebrafish were stained at different developmental stages between 24 hpf and 5 dpf. 
All fish were dechorionated using Pronase if required and then euthanized using the 
described Tricaine method. Fish were fixed in 4% PFA in PBS overnight at 4⁰C. This 
was followed with a 5 min PBS wash and then a 5 min distilled water wash, before 
incubating in acetone at -20⁰C for 7 mins. Another wash in distilled water was 
performed, followed by PBST. Fish older than 48 hpf then had Collagenase A 
(Millipore Sigma, 1mg/ml) treatment for 30 mins, 60 mins or 90 mins for 3, 4 and 5 
dpf fish respectively. Collagenase was removed and fish washed 4 times in PBST. 
Fish of all ages were then blocked in 5% horse serum in PBST for 1 hour at room 
temperature. Primary antibodies (listed in Table 2-14) were diluted in 5% horse 
serum in PBST and applied to fish overnight at 4⁰C with constant agitation. Fish were 
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then washed 5 times in PBST for 20 mins each time before incubating at room 
temperature with secondary antibody for 2 hours, also diluted in 5% BSA in PBST 
(Table 2-14). Samples were washed 2 times in PBST before leaving to wash 
overnight at 4⁰C with constant agitation, followed by a final PBS wash. Fish were 
mounted in wells created by tape on microscope slides, in Vectashield fluorescent 
mounting medium (Vector Laboratories), then sealed to make airtight. Z-stack images 
encompassing the entire volume of the zebrafish tail were obtained using a 10x and 
20x air objective, as well as a 40x oil-immersion objective on a Nikon A1R confocal 
microscope. Some images for NMJ morphology assessments were also taken on a 
Zeiss LSM880 Airyscan laser scanning confocal microscope using a 63x water-
immersion objective.  
2.5.5 Staining of mouse muscle sections for MHC analysis 
To stain mouse sections, slides were defrosted and sectioned tissue circled with a 
PAP pen (Abcam). Slides were soaked for 10 mins in PBS and then fixed in 4% PFA 
in PBS for 5 mins. After washing 3 times with PBS, tissue was then permeabilised in 
0.1% Triton X-100 in PBS for 15 mins, then blocked in 1% normal goat serum in PBS 
at room temperature for 1 hour. Samples were incubated with primary antibody 
(Table 2-14) diluted in blocking solution for 1 hour at room temperature. One section 
was labelled with the following antibodies; anti-MHC1 IgG2b, anti-MHC2a IgG1, anti-
MHC2b IgM and anti-laminin IgG, while a serial section was labelled with anti-MHC2x 
IgGM and anti-laminin IgG. Slides were washed 3 times with PBS and then 
secondary antibodies (Table 2-14) were applied for 1 hour at room temperature, 
hidden from light. After washing 3 times in PBS, Vectashield was added for mounting 
with a coverslip. Imaging tiles were taken to cover the whole muscle section and this 
was performed using an Axio Imager Z1 fluorescent microscope at 10x and 20x 
objectives.  
2.5.6 Staining of whole mouse muscles 
Tissue was fixed in 4% PFA in PBS overnight at 4⁰C, before washing 3 times in PBS 
for storage and shipping back to the UK. Muscles were labelled with aBTx-
conjugated with Alexa Fluor 488 (Molecular Probes) for 30 mins at room temperature 
under constant agitation. Samples were washed for 1 hour in PBS at room 
temperature with 4 changes of PBS. Ideally the fixation step would have been 
performed at this point for 1 hour at room temperature but unfortunately this was not 
possible due to the requirement of transporting tissue back to the UK. Muscles were 
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then teased into small bundles and cleared of connective tissue using a dissecting 
microscope before being treated with ethanol for 10 mins at -20⁰C and then methanol 
in the same conditions. Permeabilisation was performed using 0.1% Triton in PBS at 
room temperature for 15 mins using constant agitation. A PBS wash followed for 2 
hours and then blocking was performed with 5% BSA in PBST for 2 hours at room 
temperature under constant agitation. Primary antibodies were then applied (anti-
neurofilament light chain and anti-synaptophysin, Table 2-14) in blocking buffer and 
samples incubated overnight at 4⁰C with constant agitation, and a further 2 hours at 
room temperature the following day. After washing 5 times for 20 mins each in PBST, 
secondary antibodies were applied (Table 2-14) in blocking buffer. An overnight PBS 
wash was then performed at 4⁰C and then muscles mounted in Vectashield on slides 
framed with tape to create a well. Muscles were then imaged using a Nikon A1R 
confocal microscope with Z-stack images taken to encompass each NMJ identified 
with 1-3µm step sizes, using a 60x oil-immersion objective.  
2.5.7 Haematoxylin and Eosin Staining  
Mouse muscle sections were defrosted at room temperature for 30 mins before 
incubating in Mayer's Hematoxylin (ThermoFisher Scientific) for 1 min. After washing 
in water until clear, slides were placed in 1% aqueous eosin solution (ThermoFisher 
Scientific) for 30 secs and washed again in water until clear. Samples were then 
dehydrated in a series of alcohol solutions; 70% ethanol for 1 min, 90% ethanol for 1 
min, 100% ethanol for 1 min, fresh 100% ethanol for 3 min, then slides were cleared 
with histoclear (NationalDiagnostics, USA) for 5 mins and then fresh histoclear for 2 
mins before partially drying and mounting with DPX mounting medium (Merck). 
Stained sections were imaged using the tiling feature on an Axio Imager Z1 
microscope at 20x objective.  
2.5.8 NMJ morph protocol 
This protocol, developed by Jones et al  (2016), was used to analyse mouse NMJs 
(stained with aBTx, synaptophysin and neurofilament) imaged using a confocal 
microscope to obtain z-stacks. Analysis was performed using FIJI (ImageJ). Briefly, a 
z-stack image was opened as a maximum intensity projection, then each channel 
colour (red for presynaptic and green for postsynaptic) was separately subject to 
manual thresholding. After removing noise, applying a despeckle process and then 
manually removing any remaining background artefacts the image was converted 
into binary.  
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With the presynaptic image the number of axonal inputs was counted when present, 
and the diameter of axons measured (average taken from minimum, maximum and 
edge of endplate diameters). After removing the axon from the image, the nerve 
terminal area and perimeter were measured. To assess branching of the nerve 
terminal, the binary image was skeletonized and the ‘BinaryConnectivity’ plugin used 
to obtain number of terminal branches, branch points and total branch length, giving 
rise to the average length of branches and a ‘complexity’ rating.  
For the postsynaptic image the same processes as described above were applied to 
obtain measurements for AChR perimeter and area. Endplate area (total area taken 
up by AChRs, including gaps), diameter and perimeter were also obtained and a 
‘compactness’ value calculated by dividing the area of the AChRs by the endplate 
area.  
To measure the overlap of the pre and postsynapse and the area of synaptic contact, 
the original images were used. The colour of the endplate image was inverted, and 
the images of the nerve terminal and endplate concatenated before producing an 
average intensity projection and making the image binary. This will show only the 
unoccupied AChRs. The area of these receptors removed from overall AChR area 
provides a value for synaptic contact, whereas division by AChR area gives a value 
for overlap.  
Finally, to calculate the number of AChR clusters, average cluster area and 
‘fragmentation’ of NMJs, the original aBTx maximum intensity projected image was 
segmented using the ‘segmented particles’ process. The number of clustered 
segmented particles was then manually counted and used to calculate the average 
area by dividing with the AChR area, and then ‘fragmentation’ obtained by 
subtracting the number of clusters from 1 and then dividing 1 by this value. Muscle 
fibre measurements were not obtained.  
2.5.9 NMJ morphology measurements in zebrafish 
In MO-injected fish, the morphology of the NMJs were assessed by observation of 
overall motor neuron length/branching/AChR staining. To generate a more robust 
means of assessment that allowed for quantification of morphological features of 
zebrafish NMJs that could be compared between genotypes and treatment 
conditions, a set of parameters were established for 24 hpf, 48 hpf and 5 dpf fish and 
used to assess the crispants (Figure 2.5).  
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Zebrafish were labelled with an SV2 antibody (motor neurons) and aBTx (AChRs). Z-
stacks were obtained on a confocal microscope through the entire depth of the 
zebrafish tail. Using Fiji (ImageJ), maximum intensity projections were produced and 
used for subsequent analysis. At 24 hpf, the size of the myotomes was measured, 
and the presence or absence of a central AChR cluster noted, referred to as the 
‘choice point’. The distance motor neuron axons had travelled past the choice point 
was also manually measured, along with total AChR area per myotome. In 48 hpf 
and 5 dpf fish, size of myotomes were also measured, along with number of 
presynaptic and postsynaptic clusters per myotome and per 100µm2. The average 
size and total area of clusters was also calculated and the number of large clusters 
with a size over 20µm2 recorded.  
Counts and measurements of clusters were performed by automatic thresholding and 
conversion of images to binary before using the ‘analyse particles’ tool in Fiji. The 
length of the myosepta, displaying AChR-positive staining, was manually measured, 
along with the innervation by motor neurons, giving a percentage of myoseptal 
innervation value. 
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Figure 2.5. NMJ morphology measurements.  A. Representative image of whole 
zebrafish at 72 hpf, with enlarged tail region demonstrating the orientation of the NMJ 
staining within the tail musculature. B. Example features measured at 24 hpf: 
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proportion of myotomes with a choice point cluster of AChRs (outlined with a white 
circle) and length of motor neuron extension past the choice point (white line). C. 
Total area, average area and number of clusters can be measured per myotome 
from maximum intensity projections. Following selection of the myotome and 
thresholding, the distinct clusters are selected and number and area are analysed. D. 
% innervation of myosepta as calculated from the amount of motor axon growth up 
the myosepta (red, yellow line) expressed as a percentage of myosepta length 
(length of aBTx +ve myosepta, green, yellow line). E. Size of myotome measured by 
outlining individual myotomes as highlighted in blue.  
2.5.10 Western blotting 
2.5.11 Lysate preparation 
To make protein lysates from cultured cells, cells were washed three times in PBS 
before scraping directly into ice-cold lysis buffer (RIPA buffer with protease inhibitor 
tablet (Roche)) to generate whole protein extracts. Samples were maintained at 4°C 
with constant agitation for 30 mins, centrifuged for 20 mins at 1750g at 4°C, then 
supernatant removed and stored at -80°C. To prepare lysates from zebrafish tissue, 
embryos were euthanised with Tricaine and washed 3 times in PBS. Mouse tissues 
that had been stored at -80°C were also used. For both sample types, ice cold lysis 
buffer was added and homogenisation performed using a TissueRuptor before 
incubating at 4°C with constant agitation for 2 hours. Samples were then centrifuged 
for 20 mins at 13000g before discarding the pellet. Samples were then subject to a 
bicinchoninic acid assay, using serial dilutions of BSA in RIPA buffer as protein 
standards. 
2.5.12 SDS-PAGE and western blotting 
To prepare samples for loading onto the gel, they were diluted in RIPA buffer to the 
same concentration, then 2x Laemmli buffer (Bio-Rad) was added before heating to 
95°C for 5 mins. Equal loading of samples was confirmed by Coomassie staining, in 
which Coomassie Brilliant Blue dye (ThermoFisher Scientific, 1g Coomassie, 400ml 
ETOH, 500ml water, 100ml acetic acid) was added to the gel for 30 mins at room 
temperature with constant agitation, then destained for 1 hour in destaining buffer 1 
(477.5ml water, 100ml acetic acid, 400ml ETOH and 22.5ml glycerine), followed by 
another destain in buffer 2 (827.5ml water, 50ml acetic acid, 100ml ETOH and 
22.5ml glycerine). The gel was then washed overnight in water before imaging using 
a LiCor Odyssey CLx Imaging System and protein bands per lane quantified using 
the CLx imaging software (Image Studio Lite).  
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For western blotting, adjusted samples were loaded onto hand-cast polyacrylamide 
gels (6 or 12%), or onto 4-12% Bis-Tris NuPAGE gels (1mm, 26 well, ThermoFisher 
Scientific), along with a protein ladder (SeeBlue Plus2 pre-stained protein standard or 
PageRuler Prestained Protein Ladder, ThermoFisher Scientific). Hand-cast gels were 
run in Tris-Glycine running buffer (3g Tris, 14.4g glycine, 990ml water, 10ml 10% 
sodium dodecyl sulfate (SDS)). Pre-made gels were run in NuPAGE MES SDS 
running buffer (ThermoFisher Scientific). Gels were run at 120V for 30 to 100 mins 
depending on protein size.  
After running, gels were transferred using wet transfer or dry transfer. For wet 
transfer a polyvinylidene difluoride-membrane (Millipore) was soaked in methanol for 
one minute before assembling the transfer stack. The stack was placed in a tank with 
transfer buffer (3g Tris, 14.4g glycine, 800ml water and 200ml methanol) and put in 
an ice box before running at 100V for 1 to 2.5 hours depending on protein size. For 
dry transfer an iBlot2 blotting system was used according to manufacturer’s 
instructions (ThermoFisher Scientific), using iBlot2 transfer stacks (Regular, midi 
size, polyvinylidene difluoride-membrane, ThermoFisher Scientific). For most proteins 
the protocol used was 20V for 1 min, 23V for 4 min then 25V for 2 mins, except for 
proteins of a molecular weight above 180kDa, for which a transfer of 20V at 10 mins 
was used. After transfer, membranes were blocked in 5% BSA in tris-buffered saline 
(TBS) with 0.1% Tween 20 (TBST) for 1 hour at room temperature with constant 
agitation.  
Blocking buffer was washed off using TBST and primary antibodies made up in TBST 
according to dilutions shown in Table 2-14. Membranes were incubated overnight at 
4°C with constant agitation. The following day membranes were washed 3 times in 
TBST for 5 mins each, before making up secondary antibodies in TBST according to 
dilutions listed in Table 2-14. Secondary antibody mixtures were applied for 1 hour at 
room temperature and then membranes washed 3 times in TBST before a final wash 
in TBS.  
Membranes incubated with a secondary antibody conjugated to HRP were visualised 
using enhanced chemiluminescent substrate (SuperSignal West Femto, Pierce) and 
imaged on an Amersham Imager 600. Those incubated with fluorescent secondary 
antibodies were imaged using the Odyssey CLx Imaging System. Analysis of band 
density was either performed using the CLx image analysis software (Image Studio 
Lite), or ImageJ FIJI.  
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2.6 Sample preparation for secretomics 
NSC-34 cells (three samples of both wild-type and MYO9A-depleted) were cultured 
to 80% confluence in 10cm dishes and washed 3 times with PBS. Serum-free growth 
medium was added for 4 hours, followed by the addition of growth medium 
supplemented with 10% FBS for 1 hour (pulse). Following 3 washes with PBS, 
serum-free medium was applied for 3 hours (chase) and then collected and 
centrifuged for 4 mins at 1750g. The supernatant was combined with 10× ice-cold 
ultrapure ethanol overnight at -80°C. Samples were then centrifuged at 18000g for 
30 mins at 4°C and the pellets dried under laminar hood flow before the addition of 
SDS lysis buffer (50 mM Tris–HCl pH 7.8, 150 mM NaCl, 1% SDS, 1 protease 
cOmplete mini tablet and one phosphatase inhibitor PhosSTOP tablet, Roche). 
Samples were subjected to quantitative mass spectrometry in Leibniz-Institut für 
Analytische Wissenschaften-ISAS e.V (ISAS), Dortmund by Vietxuan Phan.  
Criteria for defining a protein as regulated are: protein commonly quantified in each 
replicate, identified by at least one unique peptide, an analysis of variance 
(ANOVA) p-value of <0.05 and an average log 2 ratio of either lower than the down-
regulated cut-off (-4.44) or higher than the up-regulated cut-off (4.06). 
2.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (v5.04 and 
v8.0.2). Data sets were first tested for normal distribution and from these results 
either nonparametric (Mann-Whitney test) or parametric tests (unpaired t-test) were 
applied for comparisons of two data sets. For analysis of 3 or more datasets, one-
way ANOVA with Turkey post hoc test or Kruskal-Wallis with Dunn’s post hoc test 
were performed, depending on distribution of data. Outliers were identified and 
removed according to the ROUT method. Statistical significance was taken 
as p< 0.05. In vitro experiments were blinded for image analysis and in 
vivo experiments blinded prior to live recording and for image acquisition. 
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Chapter 3. Generation and characterisation of models of MYO9A-
deficiency 
3.1 Introduction 
Studying the contribution of a specific protein to the phenotype of a complex disorder 
affecting many different muscles of the body requires a combination of approaches. 
A number of cell and animal systems have been utilised in the study of CMS, 
including immortal cell-lines, patient cells, zebrafish, mice and patient motor point 
biopsies (O'Connor et al., 2018b, Webster, 2018, Slater et al., 2006).  
In vitro models are particularly useful for analysing molecular pathways and 
biochemical events. This is important for understanding the pathway on which the 
protein acts to disrupt the safety factor of the NMJ and to assess the pathogenicity of 
variants identified in patients. The majority of studies in the CMS field have utilised 
immortal cell-lines such as kidney-derived HEK 293 or fibroblast-derived COS-7 cells 
(Chapter 1, Section 1.4.1), with the aim of analysing the effect of specific patient 
mutations on protein localisation, binding, splicing or AChR channel kinetics. C2C12 
cells have proven useful for identifying mutations important for AChR clustering 
(Chapter 1, Section 1.4.1) and the only studies identified in which patient myoblasts 
were utilised revealed further information regarding the function of GFPT1 (Chen et 
al., 2015, Dusl et al., 2015).  
MYO9A had not previously been associated with normal function or a disease of the 
neuromuscular system prior to our finding that 3 patients with CMS exhibit variants in 
MYO9A that segregate with the disease (O'Connor et al., 2016). Based on a number 
of lines of evidence, including the presence of other unconventional myosins at the 
growth cone of nerves (Yu et al., 2015, Suter et al., 2000), the potential presence of 
MYO9A at the growth cone in a nerve cell-model (O'Connor et al., 2016), effects of 
MYO9A-loss on CNS neurons (Folci et al., 2016) and features of the human MYO9A-
CMS condition being compatible with a presynaptic disorder, in this study I 
hypothesised that MYO9A plays a role in the nerve terminal. Therefore, rather than 
utilise muscle or fibroblast-derived cells, a mouse-derived motor neuron cell line 
(NSC-34) was used. This model was complemented by derivation of iNPCs from 
patient-fibroblasts, the first time this has been performed for a CMS patient. This 
allowed for molecular features and pathways involved in MYO9A-CMS to be 
assessed.  
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It is apparent that not only the presence of proteins at the NMJ, but also their correct 
function and localisation at the synapse, is important for maintaining transmission. 
For example, the proteins mediating the close apposition of presynaptic active zones 
with postsynaptic AChRs are essential for maintaining the safety factor (Slater, 
2017). Therefore, the use of animal models in which the entire NMJ can be analysed 
in its native environment is a useful tool for CMS research. A large number of animal 
models have been generated for studying CMS subtypes, including mice, zebrafish, 
Drosophila and C.elegans (Table 3-1), some of which are discussed in O’Connor et 
al (2018b). Invertebrate models and small vertebrates such as zebrafish offer 
opportunities to study molecular and behavioral defects in well characterised systems 
over short time periods. For more complex behavioral assays, anatomical analysis 
and preclinical studies, mice are the model of choice for most CMS studies (Chapter 
1, Section 1.4.3).  
By exploring a range of techniques and taking advantage of the benefits of each 
model system, a greater understanding regarding a potential role for MYO9A in 
function and disease at the NMJ can be obtained.  
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Gene Models developed 
 Mouse Zebrafish C.elegans Drosophila 
DOK7     
MUSK      
LRP4     
AGRN     
COLQ     
GFPT1     
ALG2     
ALG14     
GMPPB     
DPAGT1     
Table 3-1. Animal models developed for the in vivo analysis of the ten currently 
recognised LG-CMS genes, including mice, zebrafish, Caenorhabditis elegans 
(C.elegans) and Drosophila. Table from O’Connor et al (2018b). 
3.2 Aim of chapter 
To generate a range of in vitro and in vivo models appropriate for studying the role of 
MYO9A at the NMJ, including patient-derived neuronal progenitor cells and 
knockdown zebrafish.  
3.3 MYO9A knockdown NSC-34 cells 
Expression of MYO9A was knocked down from NSC-34 cells using shRNA-mediated 
selective inactivation of MYO9A mRNA. Initially, two different MYO9A shRNAs were 
trialed for effectiveness, along with a non-targeting control shRNA complementary to 
the luciferase RNA sequence (O'Connor et al., 2016). This was performed in my 
MSci project (MSci thesis, University of Glasgow, 2015), however, confirmation of 
MYO9A knockdown and generation of new control knockdown cells (using a 
commercially available non-target shRNA) was performed during this PhD project.  
3.3.1 Confirmation of knockdown 
The selection of one MYO9A shRNA was performed previously, and this shRNA was 
used to generate a polyclonal population of stable knockdown NSC-34 cells. Control 
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knockdown cells were similarly generated, using a commercially available non-
targeting control shRNA.  
To confirm whether the MYO9A shRNA had the desired effect on Myo9a expression, 
and in the absence of a validated MYO9A antibody, qRT-PCR was used. Initially this 
experiment had been performed using the house-keeping gene encoding β-Actin, 
however, this was later found to be regulated in cells lacking MYO9A and thus the 
loss of expression was re-confirmed using an alternative gene: Pgk1. 
 Expression of Myo9a in the stable knockdown population was significantly reduced 
as compared to control knockdown cells (p=0.002, Mann Whitney test, Figure 3.1).  
 
Figure 3.1. qRT-PCR to assess effectiveness of shRNA-mediated knockdown of 
MYO9A from NSC-34 cells.  Expression of Myo9a in control and MYO9A KD 
(knockdown) cells, normalised to Pgk1 and results expressed for MYO9A KD cells 
relative to controls. Error bars represent mean of 3 repeats ± standard error of the 
mean (S.E.M). **p≤0.005, Mann Whitney test.  
3.3.2 MYO9A KD cell gross morphology 
Control and MYO9A KD cells were cultured and gross morphology assessed. At the 
light microscope level cells lacking MYO9A appeared larger and flatter, therefore 
cells were stained with phalloidin to detect filamentous (f)-actin and their morphology 
studied using confocal microscopy. Nuclear area and cell area of MYO9A KD cells 
was significantly larger than controls (p≤0.0001, Mann Whitney test, Figure 
3.2.A,B,E). Volume of nuclei was not significantly different (p=0.068, Mann Whitney 
test, Figure 3.2C,E), and height of cells at the tallest point was significantly reduced 
in MYO9A KDs (p≤0.0001, Mann Whitney test, Figure 3.2D,E). 
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Figure 3.2. Gross morphology of MYO9A KD NSC-34 cells. A. Area (control n=43 
and MYO9A KD n=45) and B. Volume of control (n=57) and MYO9A KD (n=90) cell 
nuclei. C. Area (n=28) and D. Height (n=24) of control and MYO9A KD cells. E. 
Representative images of control and MYO9A KD cells, nuclei stained with DAPI 
(blue) and f-actin, used to delineate cell area, stained with fluorophore-conjugated 
phalloidin (green). Axes of plane in view depicted in bottom left of each image. Scale 
bar = 20µm. Error bars represent mean ± S.E.M, ns=not significant, ****p<0.0001, 
Mann Whitney test.  
3.4 Patient-derived induced neuronal progenitor cells 
3.4.1 Induced neuronal progenitor cell conversion  
In order to better replicate the genetic environment of MYO9A-CMS, fibroblasts from 
a skin biopsy of MYO9A patient 1 (p.R1517H and p.R2283H) were obtained by the 
MRC Centre for Neuromuscular Diseases Biobank and made available for culture. 
The levels of MYO9A expression in patient fibroblasts compared to a control subject 
were analysed using qRT-PCR, revealing no significant differences between the 
levels of MYO9A RNA (p=0.519, paired t-test, Figure 3.3). Due to the lack of a 
validated commercially available MYO9A antibody, levels of protein expression were 
not quantified.  
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Figure 3.3. qRT-PCR to assess expression of MYO9A in control and MYO9A 
patient fibroblasts. Expression of MYO9A in control subject and MYO9A patient 
fibroblasts, normalised to TBP and expressed relative to control. Error bars represent 
mean of 3 repeats + S.E.M. ns=not significant, paired t-test. 
Based on previous data (O'Connor et al., 2016), we hypothesised that MYO9A would 
play a role in the nerve/nerve terminal, therefore we converted the fibroblasts into 
neuronal progenitor cells. This was achieved using a direct conversion method in 
which fibroblasts are infected with Sendai virus to induce expression of transcription 
factors: Oct4, Klf4, Sox2 and c-myc (Meyer et al., 2015). Fibroblasts were subject to 
the conversion protocol for up to 20 days, by which time distinct colonies of iNPCs 
had formed (Figure 3.4). Fibroblasts from a control subject were converted and 
confirmed as iNPCs by Emily McCarthy, an MRes student (Newcastle University), by 
using RNA expression of nerve/stem cell markers as described below.  
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Figure 3.4. Conversion of MYO9A-patient fibroblasts into induced neuronal 
progenitor cells.  MYO9A-CMS patient fibroblasts shown pre-infection, followed by 
varying time points post-infection. 20 colonies were isolated upon formation of 
multiple, distinct colonies and expanded for 7 days. Scale bar = 200µm. 
A number of colonies were selected and expanded separately. After 1 week, cells 
were harvested for RNA and qRT-PCR performed to analyse the expression of 
fibroblast markers (COL1A1, COL3A1), neuronal markers (NES, PAX6) and stem cell 
markers (SOX1, SOX2). Identification of colonies that have a decrease in fibroblast 
markers and increase in neuronal and stem cell markers as compared to the initial 
patient fibroblasts were deemed successful conversions and were maintained for 
differentiation to the neuronal cell lineage. In total, 20 colonies were assessed, a 
selection of failed and successful conversions are shown in Figure 3.5. For example, 
iNPC colonies 11 and 16 have a decrease in COL1A1 and COL3A1 expression, but 
an increase in SOX1, SOX2, PAX6 and NES expression as compared to the 
fibroblasts they are derived from, thus have successfully undergone the conversion 
process. 
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Figure 3.5. Relative expression ratio of induced neuronal progenitor cell 
colonies as compared to patient fibroblasts.  Gene expression of colonies as 
compared to the original patient fibroblasts (black line) were confirmed using qRT-
PCR against a selection of fibroblast, neuronal and stem cell markers. Results shown 
are normalised to TATA-binding protein and GAPDH, and relative to fibroblast cells. 
Error bars represent mean + S.E.M. from 3 repeats.  
3.4.2 Differentiation of induced neuronal progenitor cells towards neuronal 
lineage 
Following selection of successfully converted colonies, 3 were expanded and subject 
to 21 days of differentiation as described by Meyer et al (2015). Light microscope 
images at different time points of the differentiation process for control subject and 
MYO9A patient cells are shown in Figure 3.6. Cells re-arrange into colonies and form 
a network of connections across the culture plate.   
 
Figure 3.6. Differentiation of control and MYO9A patient INPCs over 21 days. 
Scale bar = 200µm. 
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To assess whether cells have differentiated into neurons, cells were then stained with 
antibodies against Tuj1 (neuron-specific class III beta-tubulin) and MAP2 (expressed 
in neurons), as shown in Figure 3.7. Both control and patient cells express the 
neuronal markers and thus have been successfully differentiated.  
 
Figure 3.7. Control and MYO9A patient INPCs following neuronal 
differentiation.  Cells were stained for 2 neuronal cell markers: Tuj1 (green) and 
MAP2 (red). Scale bar = 50µm. 
3.4.3 SH-SY5Y cells expressing MYO9A with patient mutations 
The levels of MYO9A RNA were not reduced in fibroblasts from one of the patients, 
therefore an attempt was made to express each of the patient MYO9A mutations in 
SH-SY5Y cells (a neuroblastoma cell-line derived from bone marrow). A vector 
containing the coding sequence of MYO9A and an HA-tag was obtained from 
VectorBuilder (https://en.vectorbuilder.com/). Mutagenesis was performed on the 
sequence to generate 4 further constructs. Of these, 3 had the patient mutations 
(R1517H, R2283H and D1698G) and 1 contained a predicted benign polymorphism 
in the same region of MYO9A (S1971L). Confirmation of the mutagenesis protocol 
was obtained by sequencing, as shown in Figure 3.8.  
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Figure 3.8. Sequencing of mutagenesis constructs. The wildtype MYO9A coding 
sequence was subject to mutagenesis to introduce the 3 patient mutations (R1517H, 
R2283H and D1698G), as well as a benign polymorphism (S1971L). Sequencing 
was performed to confirm the mutagenesis was successful (coloured arrows) and 
aligned with the wildtype sequence to show the base change (highlighted).  
SH-SY5Y cells were transiently transfected with each construct and cells harvested 
for western blot or fixed for imaging. Western blotting was performed with an anti-HA 
antibody, however, no band around the predicted molecular weight for MYO9A was 
identified (293 kDa, Uniprot). A number of non-specific bands were also present, 
including a strong band at 100 kDa (Figure 3.9). 
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Figure 3.9. SH-SY5Y cells expressing MYO9A-HA.  SH-SY5Y cells were 
transfected with a construct coding for wildtype MYO9A with an HA tag. Anti-HA 
antibody reveals lack of band at the predicted molecular weight for MYO9A (293 
kDa), and the presence of non-specific banding at lower molecular weights. 
Molecular weight marker positions are shown on the left.  
Immunofluorescent staining of SH-SY5Y cells expressing wildtype MYO9A and each 
of the introduced mutations was performed using an anti-HA antibody and phalloidin 
to label f-actin (Figure 3.10). Localisation of MYO9A was not as expected: either 
colocalising with f-actin, or at the tips of extending processes. The localisation or 
cellular compartment containing MYO9A was unclear, and some staining appeared 
to be outside of the cell, thus raising the question as to what was being detected by 
the anti-HA antibody. No gross differences in the localisation between wildtype, 
polymorphism and patient mutation forms of MYO9A were identified.   
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Figure 3.10. Immunofluorescent staining of SH-SY5Y cells expressing MYO9A. 
Cells transfected with a construct containing the coding sequence for wildtype 
MYO9A and patient/polymorphism variants (R1, R2, D1 and S1). Anti-HA antibody 
used to identify MYO9A (green) and phalloidin to detect f-actin (red). Scale bar = 
20µm.  
3.5 MO-mediated Myo9aa/ab knockdown zebrafish 
While much can be learnt from in vitro models of disease, CMS is a complex disorder 
affecting NMJ signal transmission, and where MYO9A in particular plays a role is not 
yet known. Therefore, we utilised zebrafish as an in vivo model to allow the study of 
movement, NMJ development and morphology. The MO model was first generated 
during my MSci project, however, I have performed comprehensive phenotyping and 
expanded on preliminary data during this doctoral project.  
3.5.1 Gross morphology of knockdown zebrafish 
Zebrafish have two orthologues to human MYO9A: myo9aa/ab and both have been 
shown to be expressed during development (O'Connor et al., 2016). Knockdown of 
Myo9aa/ab by co-injection of MOs in zebrafish produced a pronounced phenotype at 
48 hpf including varying degrees of tail curvature and some presence of cardiac 
oedema (Figure 3.11.A). Survival of fish was assessed daily and dead fish removed. 
By 48 hpf, twice as many Myo9aa/ab KD fish died as compared to controls (22% and 
11% respectively, Figure 3.11.B).  
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Abnormal phenotypes were already present at 24hpf, by which time the more 
severely affected embryos had stunted tail growth within the chorion and reduced 
head size, while mild/moderate zebrafish had shortened tails. The levels of severely 
affected fish were increased by 9% in the Myo9aa/ab KD fish, and the mild/moderate 
phenotype present in 45% more of the injected Myo9aa/ab KD population (Figure 
3.11.C). 
 
Figure 3.11. Gross morphology of Myo9aa/ab KD zebrafish.  A. Phenotype of 
zebrafish at 48 hpf, with examples of non-injected, mild, moderate and severely 
affected Myo9aa/ab KD fish shown. Presence of cardiac oedema indicated with black 
arrow. Scale bar = 200µm, images used in my MSci thesis (University of Glasgow, 
2015). B. Survival rate of zebrafish by 48 hpf following injection with a control MO or 
optimised quantity of Myo9aa/ab MO (n=100). C. Phenotype of fish at 24 hpf, defined 
as normal, mild/moderate or severe (n>50). MO = morpholino.  
3.6 CRISPR/Cas9-mediated myo9aa/ab knockout zebrafish 
There has been some concern within the scientific community regarding the reliability 
of MO-mediated knockdowns in zebrafish, largely due to a disparity between 
phenotypes observed in morphants and genetic mutants generated by techniques 
such as CRISPR/Cas9 (Kok et al., 2015). To address this issue, the generation of a 
genetic knockout for myo9aa/ab in zebrafish was carried out using CRISPR 
technology. 
3.6.1 Generation of crispants 
Four different sgRNAs, two against each gene, with predicted off-target effects of 
zero, were synthesised and injected into zebrafish at the one-cell stage along with 
the Cas9 protein.  
To confirm the success of the CRISPR/Cas9 injections at inducing 
deletions/insertions at the predicted genomic locations, sequencing was performed. 
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A wild-type sequence of myo9aa is shown in Figure 3.12, along with a deletion within 
the target region of myo9aa using one of the sgRNAs against exon 2. Successful 
deletions in myo9ab exon 1, and an insertion in myo9ab exon 12 are also shown, 
demonstrating the effectiveness of the selected sgRNAs and injection protocol.  
 
Figure 3.12. Genomic sequence of CRISPR-targeted myo9aa and myo9ab. The 
wild-type sequence for myo9aa is shown in the first panel, with the presence of a 
deletion in the target region of the sgRNA for exon 2 (highlighted yellow) shown in 
the top right. The bottom left panel shows a deletion induced by a sgRNA against 
exon 1 of myo9ab (pink), and in the bottom right panel an insertion can be observed 
(green) in exon 12 of myo9ab. The other highlighted regions show the location of the 
sequencing primers.   
3.6.2 Gross morphology of myo9aa/ab crispants 
Similar phenotypes were induced by each myo9aa/ab sgRNA, as well as in co-
injected fish, as shown in Figure 3.13A. The co-injected crispant groups, as outlined 
in the methods section, include: 3 sgRNAs (myo9aa2 + myo9ab1 + myo9ab12) or 4 
sgRNAs (myo9aa2 + myo9aa2b +myo9ab1 + myo9ab12). Tyrosinase (Tyr) is a 
protein involved in pigment formation in the fish, therefore a published sgRNA 
against tyr was included as an injected control (Jao et al., 2013). The lack of pigment 
confirms the success of CRISPR/Cas9/sgRNA delivery and action. Furthermore, fish 
injected with tyr sgRNA do not have a tail phenotype demonstrating that this is not a 
result of the CRISPR/Cas9 injection itself. 
Severity of the phenotype was ranked at 72 hpf from mild to severe by degree of tail 
curvature, as outlined in Figure 3.13B. The number of injected fish (3 and 4 sgRNA 
injected) with each phenotype, expressed as a proportion of controls, is shown in 
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Figure 3.13B. Fewer normal fish were identified for 3 and 4 sgRNAs as compared to 
controls. For the 3 sgRNA group, 3-fold more were identified as ‘mild’, whereas 
injecting 4 sgRNAs resulted in over twice the number of ‘moderate’ fish. 
 
Figure 3.13. Phenotypes of mosaic myo9aa/ab knockout zebrafish. A. 
Representative images of 48 hpf zebrafish injected with sgRNAs (numbers following 
the gene refer to exon targeted). Combinations of 3 and all 4 sgRNAs were also 
performed, along with a control against the tyrosinase gene (tyr) in which no pigment 
can be observed confirming knockdown success. Scale bar = 500µm. B. Images 
showing phenotypic classification of injected zebrafish at 72 hpf, ranging from normal 
to severe. Graph shows proportion of fish injected with 3 (n = 292) or all 4 (n = 160) 
sgRNAs as compared to controls (black line, n = 138). Error bars represent mean ± 
S.E.M.  
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3.7 MYO9A KO mouse 
A MYO9A KO mouse was generated by Prof. Bähler (University of Münster, 
Abouhamed et al., 2009). This mouse often exhibited hydrocephalus due to a buildup 
of fluid within the 3rd ventricle of the brain, and has shown defective kidney function, 
however, skeletal muscle performance and integrity of the neuromuscular synapse 
had not yet been assessed (Abouhamed et al., 2009, Thelen et al., 2015). To extend 
our analyses into a mammalian system, tissue from the MYO9A KO mouse was 
obtained. The genotype of the 4 mutant mice supplied was confirmed using gDNA 
extracted from tail tips. The wild-type allele was absent from all 4 mutant mice, as 
shown in Figure 3.14. A product of approximately 700 bp using primers against the 
mutant allele was present in all of the mutant animals and not in the wild-type, 
indicating the presence of a large deletion, as predicted product size is 2896 bp.  
 
Figure 3.14. Genotyping of Myo9a KO mouse.  PCR electrophoresis gel confirming 
genotype of MYO9A KO mice from gDNA extracted from tail tips. The presence of 
the wild-type allele (260 bp) is absent from all 4 mutant mice, indicated by the blue 
arrow. The mutant allele (approx. 700 bp) is present in all 4 mutant mice (red arrow), 
and not in the wild-type. Primers against Gapdh were also used to confirm quality of 
gDNA. WT = Wildtype, MT= mutant, ctrl = control. 
3.8 Discussion 
The aim of this chapter was to describe the generation of models of MYO9A-CMS or 
MYO9A loss that could help achieve the overarching goal of discovering whether 
MYO9A plays a role at the NMJ. To gain a comprehensive overview, a range of 
approaches were used as summarised in Table 3-2, including a knockdown cell-line, 
patient cells, zebrafish models and a MYO9A KO mouse.  
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Model  Advantages Disadvantages Chapter 
used 
MYO9A KD 
NSC-34 cells 
Unlimited supply of 
material, easy to work 
with, neuronal cell 
relevant for NMJ 
Knockout rather than patient 
mutation 
5, 6 
Patient 
mutation-
expressing 
SH-SY5Y 
cells 
Expression of patient 
mutation, neuronal cell 
Expression of patient mutations 
not confirmed, expression of 
endogenous MYO9A not 
removed, expression not on 
genetic background of patient 
- 
Patient 
iNPCs 
Cells from patient, 
patient genetic 
background, neuronal 
cells relevant for NMJ 
Limited supply of tissue, only one 
patient available 
4, 5 
Zebrafish 
Myo9aa/ab 
MO 
knockdown 
Rapid results, whole 
organism, study of intact 
NMJs rather than nerve 
or muscle cell, 
behavioural assessment  
MOs are transient, two 
orthologues of human gene, 
knockout rather than expression 
of patient mutations, mosaic 
knockdown 
4, 6 
Zebrafish 
myo9aa/ab 
crispant  
Not transient, rapid 
results, whole organism, 
study of intact NMJs, 
behavioural assessment 
Two orthologues of human gene, 
knockout rather than expression 
of patient mutations and mosaic 
knockdown 
4, 5, 6 
MYO9A-/- 
mouse 
Mammalian model, 
NMJs more similar to 
human, whole organism 
and ability to study intact 
NMJs 
Behavioural testing was not 
possible, knockout rather than 
expression of patient mutations 
and tissue preparation not optimal 
4, 5 
Table 3-2. Summary of models generated for study of MYO9A.  Table includes 
model generated, main advantages and disadvantages for studying the role of 
MYO9A at the NMJ and the chapter where each model is used.  
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3.8.1 MYO9A KD NSC-34 cells 
During my MSci project MYO9A was targeted for stable knockdown from NSC-34 
cells, and reduced levels of MYO9A expression confirmed by qRT-PCR due to the 
lack of a commercially available antibody that worked in western blot (O'Connor et 
al., 2016). Abundance of MYO9A was normalised to β-actin, however, in later 
experiments the levels of actin identified in western blot and immunofluorescence 
experiments differed between control and MYO9A KD cells. Therefore, the 
knockdown of MYO9A was reconfirmed in this study using an alternative 
housekeeping gene: Pgk1. This gene has been shown to be an appropriate 
reference gene for qRT-PCR in neuronal cells (Boda et al., 2009). 
NSC-34 cells were initially selected as an appropriate in vitro model to assess the 
effect of reduced MYO9A levels due to features such as ability to synthesise and 
release ACh, ability to generate action potentials, presence of important cytoskeletal 
proteins like neurofilament, as well as the capability of clustering AChRs on cultured 
myotubes (Cashman et al., 1992). This cell-line has been used to model various 
neurodegenerative diseases, including ALS (Liu et al., 2002, Rizzardini et al., 2005) 
and SMA (Acsadi et al., 2009), as well as looking at cellular processes associated 
with a myosin protein (myosin VI) (Sundaramoorthy et al., 2015). This is the first 
study to use these cells as an in vitro model for CMS and for the analysis of MYO9A-
loss on cell structure and function.   
Basic morphology assessment of MYO9A KD NSC-34 cells was performed in this 
chapter, with detailed analysis of pathways and mechanisms of action addressed in 
subsequent sections of this thesis. The actin cytoskeleton is a major component of 
cells and regulates cell size and shape (Rottner et al., 2017). MYO9A is an actin-
based molecular motor that can also act to cross-link actin filaments, as well as 
displaying indirect effects on the cytoskeleton as a regulator of RhoA activity (Hall, 
1998, Wallace et al., 2018, Saczko-Brack et al., 2016, Omelchenko and Hall, 2012, 
Chieregatti et al., 1998). Therefore, changes in MYO9A levels may impact on the 
ability of the actin cytoskeleton to maintain an extensive and complex three-
dimensional cell structure. Initial observations of MYO9A KD cells revealed an 
increase in cell area and a corresponding reduction in height. This likely reflects an 
overall flattening and spreading out of cells, rather than changes in volume. Similarly, 
nucleus area was increased in MYO9A KD cells and volume remained the same as 
control cell nuclei. Actin also attaches to the cell membrane and drives protrusions 
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such neurite extensions, which have been shown to be affected in cells lacking 
MYO9A (O'Connor et al., 2016). Other reports of MYO9A-depletion in cell models are 
conflicting, with loss from 16HBE (human bronchial epithelial) cells leading to 
rounding of cell bodies (Omelchenko and Hall, 2012) where as in caco-2 (human 
intestinal) cells there is flattening and thus a larger area of cells (Abouhamed et al., 
2009). This could be due to variations in RhoA activity in different cells types (Hall, 
1998), However, RhoA activity in nerves has been reported to be associated with cell 
rounding as opposed to fibroblasts for which RhoA activation causes cell spreading 
(Guilluy et al., 2011, Kranenburg et al., 1999, Ridley and Hall, 1992). It could also be 
due to effects of MYO9A on downstream pathways other than those mediated by 
RhoA.  
Alterations in nuclei area in MYO9A KD cells were also observed, which has been 
suggested to be due to perinuclear stress fibre formation compressing the nuclei 
(Vishavkarma et al., 2014). Another ubiquitously expressed CMS-related protein, 
MACF1, interacts with the actin cytoskeleton and has been shown to regulate the 
shape and position of nuclei in muscles and other cell types (Escobar-Aguirre et al., 
2017, Oury et al., 2019, Wang et al., 2015). Therefore, the effect observed due to 
MYO9A-loss may be influenced by altered actin dynamics but further investigation 
would be required.  
3.8.2 MYO9A-CMS patient cells 
The three reported MYO9A-CMS patients carry MYO9A missense mutations that are 
unlikely to cause loss of protein expression to the same extent as the knockdown 
cells. Therefore, to better replicate the patient condition, fibroblasts from one of the 
MYO9A-CMS patients were obtained. To quantify the level of MYO9A expression, 
qRT-PCR was performed revealing no significant difference between levels of 
MYO9A in the patient cells as compared to a healthy control subject. Due to the 
inability to quantify protein levels in the fibroblasts, the possibility remains that the 
mutations affect protein folding, stability or degradation. It could also be the case that 
fibroblasts do not express high levels of MYO9A, however, levels of MYO9A RNA 
were not quantified in iNPCs. An investigation of the Human Protein Atlas 
(https://www.proteinatlas.org, last accessed February 21, 2019, Uhlen et al., 2015) 
revealed levels of MYO9A in fibroblasts are among the lowest in all expressing 
tissues (whereas nerve and muscle tissues have higher levels of MYO9A) thus there 
may not be easily detectable changes in abundance. The levels of RNA often do not 
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predict protein quantity due to factors such as post-translational modifications and 
activation of protein degradation pathways. For example, levels of MYO9A RNA in 
skeletal muscle on the Human Protein Atlas are among the lowest, but protein levels 
are among the highest. In CMS caused by SLC18A3 p.Gly360Arg, levels of RNA are 
unchanged as compared to wild-type, however protein levels are undetectable in the 
patient (Aran et al., 2017). A larger sample size and an antibody for western blot 
would have provided better insight into this question, however, fibroblasts were not 
available from the other patients. In the future, a genetic modification technique such 
as CRISPR/Cas9 could be used to knockout MYO9A expression from the patient 
fibroblasts. Cells could then be converted into neurons and results compared with 
unmodified patient cells to see if results from the patient mutation were similar to loss 
of MYO9A. 
While fibroblasts have been used in many cases to investigate the molecular basis 
for neuropathic and myopathic diseases, they are more suited to analysis of events 
that occur in in all cell types such as mitochondrial biogenesis and function 
(Bartsakoulia et al., 2018, Chaouch et al., 2014, Perez et al., 2017). However, to 
compare with the knockout NSC-34 cells neurons would be a more appropriate 
system to allow features such as neurite growth and vesicle release to be assessed. 
The technique applied here involves converting fibroblasts into iNPCs, a proliferating 
neuronal stem cell population that are tripotent and can differentiate into neurons, 
oligodendrocytes and astrocytes (Meyer et al., 2015). To deliver the transcription 
factors, a non-integrating virus (Sendai) was used, thus avoiding issues such as 
random genome integration associated with lentiviral vectors (Fusaki et al., 2009). 
Successful generation of iNPCs was achieved in this project, determined by the up 
and downregulation of various stem cell, neuron and fibroblast markers. This was 
further confirmed by the ability of selected colonies to differentiate into neurons that 
express Tuj1 and MAP2, as described by Meyer et al (2015). 
3.8.3 SH-SY5Y cells with patient mutations 
In an attempt to address the qRT-PCR findings using a different method, and to 
understand more about the effect of each patient mutation on nerve cells, SH-SY5Y 
cells were used. Cells were transfected with a MYO9A construct containing each of 
the patient mutations, as well as a predicted benign polymorphism in the same tail 
region. However, the presence of MYO9A in these cells could not be confirmed by 
western blot against the HA-tag expressed by the vector. MYO9A is 298 kDa protein 
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and has been shown to be detectable by immunoblot using an anti-MYO9A antibody 
generated by the laboratory of Prof. Bähler (Münster, Chieregatti et al., 1998). In this 
case, however, a strong band was present at 100kDa, the origin of which is 
unknown. Use of an antibody against MYO9A in NSC-34 cells revealed an 
enrichment of the protein at growth cones of extending neurites (O'Connor et al., 
2016). Immunofluorescence results in the transfected SH-SY5Y cells were 
inconclusive, as the localisation of MYO9A was not as expected, either in the growth 
cones or associated with the actin network. The HA-positive staining appeared in 
some cases to be extracellular, raising the possibility that the culture was 
contaminated, however mycoplasma testing was negative. As the presence of 
MYO9A could not be confirmed, these cells were not used in subsequent 
experiments.  
3.8.4 Zebrafish models of MYO9A-deficiency 
The NMJ changes significantly during development and there is constant cross-talk 
between the pre and postsynaptic components, and other associated cell types such 
as Schwann cells. Therefore, to obtain a more holistic view of MYO9A function at the 
NMJ, an in vivo model was required. Zebrafish develop rapidly and are well suited for 
studies of the NMJ in first few days of life, due to their optical transparency and well 
documented time-points of NMJ development. In previous data collected in my MSci 
project, a MO-mediated knockdown approach was utilised to target Myo9aa/ab in 
zebrafish and their basic phenotype was assessed (O'Connor et al., 2016).  
The zebrafish depleted for Myo9aa/ab exhibited varying degrees of tail curvature, a 
feature present in other zebrafish models of CMS (Chaouch et al., 2014, Muller et al., 
2010, Kim et al., 2007). Curvature of tails can be associated with activation of p53-
mediated apoptosis, however, co-injection with a p53 MO did not rescue the tail 
phenotype, suggesting it is likely related to loss of MYO9A (Langheinrich et al., 2002, 
Robu et al., 2007, O'Connor et al., 2016). Large injection volumes have also been 
shown to affect morphology of zebrafish in development including causing tail 
curvature and reducing survival rates (Schubert et al., 2014). The injection volume 
used in this study of 4.2nl falls within the recommended range for limiting this effect. 
This is supported by analysis of survival rates, for which zebrafish injected with a 
control MO in this study had a survival rate of 89%, as compared with a report that 
zebrafish injected with water at a 4.2nl volume have a survival rate of 84% (Schubert 
et al., 2014).  
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A suggested control for zebrafish morphants is to compare results to a genetic 
knockdown using a technique such as CRISPR/Cas9 (Stainier et al., 2017). This has 
further benefits for analysis of NMJ development as MOs are diluted and degrade 
over the first few days, whereas genetic knockout allows assessment at later time 
points. Injection of 4 sgRNAs against myo9aa/ab along with the Cas9 protein 
successfully induced deletions and insertions at their target sites as expected, and 
gave rise to a curved tail phenotype as found in MOs.  
Ideally the sgRNA should target the 5’ end of the gene, thus increasing the likelihood 
of producing a truncated protein that is not functional, but not so near the start that an 
alternative start codon may allow protein production to continue. However, due to the 
numerous parameters that must be fulfilled to design an effective sgRNA (Sorlien et 
al., 2018), for myo9ab one sgRNA targeted exon 1 and the other exon 12. This was 
deemed acceptable as Myo9ab has 44 exons and thus even targeting exon 12 is 
likely to significantly impair protein function, especially the tail region which is where 
the patient mutations reside. This was supported by the presence of a curved tail 
phenotype in zebrafish injected with the myo9ab exon 12 sgRNA alone, however 
both were injected for experiments to increase the likelihood of knockdown. The 
sgRNA targets for myo9aa were in close proximity to each other in exon 2 (33 
bases), therefore co-injection was more likely to induce larger deletions if cutting 
occurs in both places at a similar time. Thus, injecting both myo9ab sgRNAs and 
either 1 or both myo9aa sgRNAs was trialed, revealing a more severe phenotype 
present in fish injected with all 4 sgRNAs. Co-injection of multiple (up to 5) sgRNAs 
has been performed elsewhere with no reported toxic effects (Ota et al., 2014), thus 
this method was used for the rest of the study.  
As a control for the CRISPR/Cas9 injections, a sgRNA against the pigment formation 
gene Tyr was used, as previously described (Jao et al., 2013). Injection successfully 
reduced pigment formation and did not induce the curved tail phenotype associated 
with the myo9aa/ab knockout. Full pigment depletion was often achieved, suggesting 
a high degree of efficiency. Mutagenesis rates in F0 fish using CRISPR/Cas9 of 75-
99% have been reported, thus despite the genetic mosaicism of the zebrafish 
crispants, they still offer a good model in which to screen for phenotypes. Crispants 
were initially used while adult knockout lines were generated, however, efforts to 
make single gene or double gene knockouts were not successful, with no 
homozygote F2 zebrafish identified.   
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3.8.5 MYO9A KO mouse 
Finally, to apply findings to a mammalian system, tissue from a MYO9A KO mouse 
generated by the laboratory of Prof. Bähler (University of Münster) was obtained 
(Abouhamed et al., 2009). As proteomic data has identified the presence of MYO9A 
in human myoblasts and myotubes, mouse muscle was taken for analysis (O'Connor 
et al., 2018b). Mouse muscle can offer many insights into pathology, through 
histological analysis of fibres, immunological staining of various markers including 
fibre type-specific labels and NMJ morphology. Genotype of the mice was confirmed 
and thus the model utilised for experiments.  
3.8.6 Conclusion 
Overall, generation of a variety of models to investigate MYO9A function in nerve 
cells and at the NMJ was achieved. Using a combination of in vitro and in vivo 
approaches in the following chapters, the contribution of this unconventional myosin 
protein to NMJ development, morphology and function will be explored and potential 
mechanisms of action investigated. 
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Chapter 4. Assessment of early NMJ development and adult NMJ 
morphology in models of MYO9A-depletion 
4.1 Introduction 
The overall aim of this project was to determine whether MYO9A plays a role at the 
NMJ, and therefore in the absence of correct function leads to impaired signal 
transmission that manifests as a CMS. The use of the models generated in the 
previous chapter form the basis of this investigation, with a range of in vitro and in 
vivo approaches applied. The use of zebrafish as a model for CMS will first be 
discussed, followed by a description of zebrafish development and the functional 
tests that can be used in the context of NMJ disruption, as well as the benefits 
associated with NMJ analysis in mouse models. 
MYO9A CMS patients present with symptoms early in life. The two Kurdish siblings, 
previously shown to have mutations in MYO9A, presented clinically with a prenatal 
onset including reduced foetal movements (O'Connor et al., 2016). They also had 4 
other siblings that had previously died due to symptoms associated with CMS 
(hypotonia, feeding difficulties, respiratory failure) within the first year of life 
(O'Connor et al., 2016). This suggests that MYO9A affects synaptic transmission 
early in development. Zebrafish are a well-suited model to study early development 
as they develop externally, with optical clarity allowing visualisation of NMJs. In 
addition, they perform a well characterised set of movements that appear 
sequentially such as twists of the tail while in the chorion, response to tactile 
stimulation after hatching and then free swimming in larval stages (Saint-Amant and 
Drapeau, 1998). Zebrafish have successfully been used to study other forms of CMS 
(Muller et al., 2010, Senderek et al., 2011), as well as myopathic and neurological 
disorders such as muscular dystrophies and spinal muscular atrophy (SMA) (Bassett 
et al., 2003, Boon et al., 2009, Gupta et al., 2012). 
The developmental stages of zebrafish from embryo to larvae are displayed in Figure 
4.1. Of particular interest here is the rapid appearance of the tail structure, which is a 
useful site in which to study neuron extension, AChR clustering and muscle 
morphology.  
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Figure 4.1. Early zebrafish development. Development of zebrafish embryos 
begins at the one cell stage, in which the cell and adjoining yolk sac are maintained 
within an egg (chorion). By 2 hpf the 64-cell stage is reached, and by only 14 hours 
the presence of 10 muscle somites can be observed in the tail (blue). Between 48 
and 72 hours post fertilisation the zebrafish hatch from the chorion and the total 
number of somites is present (30-34). Zebrafish are referred to as larvae by 72 hours. 
Image modified from Kimmel et al (1995). 
Innervation of the tail musculature commences during the embryonic stage at around 
18 hpf. This begins with the extension of axons from primary motor neurons that 
have their cell bodies in the ventral spinal cord. There are 3 primary neurons that 
innervate each muscle somite, the caudal, medial and rostral neurons. These 
neurons have specific, non-overlapping regions of innervation covering the 
myotomes (Figure 4.2). The first of the 3 primary neurons to send out an axon from 
the spinal cord is the caudal motorneuron. Within minutes of this axonal outgrowth 
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spontaneous muscle twitches can be observed while the zebrafish is still within the 
chorion, giving rise to spontaneous coiling movements (Saint-Amant and Drapeau, 
1998). These movements increase in frequency as the motorneurons continue to 
develop, peaking at 19 hpf and then slowly declining in frequency until ceasing at 27 
hpf. This is the time point at which secondary motorneurons begin to send out axons, 
which are thought to mediate muscle contractions for slower rhythmic swimming, 
rather than fast muscle twitches (Myers et al., 1986, Saint-Amant and Drapeau, 
1998). During primary motorneuron extension the axons from each of the 3 primary 
motor neurons travel along a common pathway to the horizontal myoseptum. At this 
point is a cluster of prepatterned AChRs that are present on muscle pioneer cells 
(cells that give rise to the earliest muscle cells in the zebrafish, Eisen et al., 1986, 
Felsenfeld et al., 1991). Here, the axons make a choice (thus this point is referred to 
as the ‘choice point’) regarding their route of innervation, with axons from each 
primary motor neuron subset diverging to give rise to the non-overlapping pattern of 
innervation observed in zebrafish muscle (Figure 4.2). The target choice of these 
axons can be achieved in the absence of muscle pioneer cells and the cluster of 
prepatterned AChRs that is formed on them, however, this absence influences 
formation of appropriate arborisations (Melancon et al., 1997). 
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Figure 4.2. Innervation pattern of primary motor neurons in the developing 
zebrafish tail.  Neuronal trajectories of caudal, medial and rostral primary motor 
neurons shown at 24 hpf, 48 hpf and 120 hpf. A merged image shows the resulting 
non-overlapping regions of innervation for each primary motor neuron. Red spots = 
AChRs, large red spot = choice point cluster situated at the horizontal myoseptum.  
Embryos begin to respond to touch from 21 hpf if manually removed from the 
chorion, but do not gain the ability to respond by swimming until the time of 
secondary motorneuron outgrowth at around 27 hpf. The swimming response 
increases in frequency until peaking at 36 hpf (Saint-Amant and Drapeau, 1998). As 
zebrafish naturally hatch from the chorion by 48 hpf, a useful test to assess the 
movement of the fish can be performed after this time point. This is the touch-evoked 
response assay in which a tap on the head or tail of the fish causes a rapid swim 
away from the stimulus (O'Connor et al., 2018a, Saint-Amant and Drapeau, 1998). At 
this time point it is a particularly useful test as it can be performed on a large number 
of animals and initial acceleration of the zebrafish is proportional to the force 
produced by the skeletal muscle, removing the need for securing zebrafish in a force 
transduction system (Sztal et al., 2016). From 3 dpf zebrafish begin to swim freely 
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and this behaviour matures over the following days to prepare for capture of prey 
when zebrafish begin to feed themselves at 6 dpf (Budick and O'Malley, 2000, Buss 
and Drapeau, 2001). In humans a 6-minute walk test is commonly used to assess 
functional ability in patients with disorders such as muscular dystrophy, and by 
analogy with this a 10-minute swim test has also been developed in the 6 dpf 
zebrafish (Sztal et al., 2016). While this is a useful test to indirectly analyse 
nerve/muscle performance, it cannot be performed on MO-mediated knockdowns 
due to the transient nature of the technique. Overall, there are a number of well-
defined NMJ and locomotive development features that can be tracked throughout 
zebrafish embryo and larval stages as summarised in Figure 4.3, providing a useful 
model in which to study the effects of MYO9A loss.  
 
Figure 4.3. Stages of zebrafish development and behavioural tests performed.  
Timeline shows the main points of zebrafish development important for this study 
including neuron extension, time that movements are obtained, tests performed at 
each stage and progression to adult zebrafish. Hpf = hours post fertilisation, dpf = 
days post fertilisation. 
The zebrafish motor system has a number of similarities to the human which make it 
a useful model to study the NMJ, including similarities of neuron subtypes, region 
specific innervation, preservation of the dystrophin associated glycoprotein 
components and similar contractile apparatus (Babin et al., 2014, Egashira et al., 
2018). However, it also has some key differences including the presence of gap 
junctions and innervation of muscle fibres by single primary motor neurons and 
multiple secondary motor neurons that coordinate different forms of swimming activity 
(Nguyen et al., 1999, Westerfield et al., 1986). Therefore, it is useful to also include 
analysis of mammalian NMJs which are evolutionarily closer to human.  
Mouse models have been used successfully to study the developing and mature 
NMJ in response to different genetic manipulations, including CMS models of 
disease (O'Connor et al., 2018b, Webster, 2018). Key features of NMJ morphology 
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can be quantified, including AChR area, nerve terminal size, fragmentation and more 
recently this has been extended by Jones et al (2016) to encompass 21 variables 
giving a comprehensive overview of the structure of NMJs. However, the contribution 
of any morphological defect toward function requires electrophysiological data and 
careful interpretation.   
Using a combination of approaches to assess the effect of MYO9A deficiency at the 
NMJ will help to elucidate any contribution of this unconventional myosin protein to 
cholinergic signal transmission. Furthermore, if characterisation of any models reveal 
consistent changes, this offers parameters that can be measured following drug 
screens.  
4.2 Aim of chapter 
To perform observations of NMJ development in zebrafish, coupled with assessment 
of patient nerve cells and morphology of adult NMJs in a MYO9A knockout mouse.  
Initially analysis of patient cell neurites was performed to determine whether the 
presence of MYO9A mutations affected neurite extension. This was followed by 
behavioural assessments of zebrafish depleted for Myo9aa/ab accompanied with 
analysis of NMJ morphology at different time points in development. Finally, mature 
NMJs in MYO9A KO mouse were assessed and compared to wild-type controls to 
determine presence of any structural abnormalities. 
4.3 Morphology of neurites in vitro 
Previous data demonstrated a neurite phenotype in the mouse-derived motor neuron 
NSC-34 cell-line lacking MYO9A (O'Connor et al., 2016). Neurites were significantly 
longer in KD cells, and had more primary, secondary and tertiary branches. To 
assess whether the patient cells also exhibited altered neurite outgrowths, 
differentiated MYO9A CMS patient iNPCs, generated from fibroblasts (Chapter 3, 
Section 3.4) were compared to controls in a scratch assay (Al-Ali et al., 2017). A 
region of cells was removed by scratching with a pipette tip and imaged at ‘Day 0’. 
Following 3 days of culture the same region was imaged to enable visualization of 
neurite extension over the scratched area (Figure 4.4A). Measurement of neurites 
revealed a significant increase in the length of those extending from the MYO9A-
CMS patient cells as compared to the control subject (p≤0.0001, Mann Whitney test). 
This suggests that patient cells also exhibited a neurite phenotype, as observed in 
the MYO9A KD NSC-34 cells.  
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Figure 4.4. Neurite extension in iNPCs following scratch assay. A. 
Representative images of differentiated control and MYO9A patient iNPCs 
immediately following a scratch to remove cells in the tissue culture dish, and 3 days 
after when neurites have started to bridge the gap. Enlarged regions of each image 
are shown in the lower panel. Scale bars = 200µm. B. Graph showing the length of 
neurites of control (n=86) and MYO9A patient (n=72) cells 3 days following the 
scratch. A total of 3 scratches was performed. Error bars = mean ± S.E.M, 
****p<0.0001, Mann Whitney test.  
4.4 Behavioral assessment of zebrafish models 
Zebrafish perform well characterised movements during development at distinct time 
points. These movements coincide with development of the NMJ, allowing any 
differences that impact on NMJ signalling to be identified if they manifest as changes 
in behaviour. As zebrafish have two MYO9A orthologues; myo9aa and myo9ab, 
sgRNAs targetting both genes were required. Preliminary experiments were 
performed to determine the most effective combination of sgRNAs using either: 
 3 sgRNAs - myo9aa2 + myo9ab1 + myo9ab12 sgRNAs 
4 sgRNAs - myo9aa2 + myo9aa2b +myo9ab1 + myo9ab12 sgRNAs 
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The preliminary tests performed to determine the combination of sgRNAs to be used 
for subsequent NMJ analysis consisted of 2 behavioural tests, in which myo9aa/ab 
depleted fish were compared with uninjected controls and Tyr sgRNA controls 
(targets a gene affecting pigmentation). To support results by using an alternative 
method of depletion and to expand on the observational analysis performed in 
O’Connor et al (2016), Myo9aa/ab MO-mediated knockdown zebrafish were also 
subject to behavioural assessments.  
4.4.1 Chorion movements 
Spontaneous movements begin in zebrafish embryos around 17 hpf, and as axon 
outgrowth progresses across the myotomal surface, the movements increase in 
frequency until ceasing at 27 hpf (Myers et al., 1986, Saint-Amant and Drapeau, 
1998). The spontaneous movements are characterised by a full rotation of the 
embryo within the chorion, driven by the tail. Results obtained from the Myo9aa/ab 
MO zebrafish revealed a significant reduction in chorion movements performed at 24 
hpf as compared to controls (O'Connor et al., 2016). To reconfirm these results, 
chorion movements were again assessed in Myo9aa/ab MO fish at 24 hpf (Figure 
4.5). Morphants performed significantly fewer chorion rotations as compared to 
controls (p=0.0031, Mann Whitney test), thus demonstrating the same trend as in our 
previous study.  
 
Figure 4.5. Movements performed by zebrafish within the chorion at 24 hpf.  
Full chorion movements performed in one minute by uninjected (control, n=58) and 
Myo9aa/ab MO-injected (n=43) zebrafish. MO=morpholino. Error bars = mean ± 
S.E.M. **p<0.01, Mann Whitney test. 
To determine whether depletion of Myo9aa/ab using CRISPR/Cas9 produces a 
similar lack of movement in early development, zebrafish injected with 3 (myo9aa2, 
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myo9ab1 and myo9ab12) or 4 sgRNAs (myo9aa2, myo9aa2b, myo9ab1 and 
myo9ab12) were subject to chorion movement analysis.  
Uninjected (control) and tyr (injected control) sgRNA injected zebrafish perform on 
average 2.4 and 3 rotations per minute, respectively (p=0.095, Mann Whitney test), 
demonstrating that the injection procedure and CRISPR-mediated knockdown of 
alternative genes doesn’t significantly affect chorion movements (Figure 4.6). 
Myo9aa/ab 3 sgRNA fish move on average 1.2 times per minute which is significantly 
lower than both controls (p≤0.0001, Mann Whitney test). Myo9aa/ab 4 sgRNA 
zebrafish perform significantly less rotations than 3 sgRNA-injected, as well as the 
controls, with only 0.3 turns per minute (p≤0.0001, Mann Whitney test (Figure 4.6). 
Therefore, the 4 sgRNA-injected fish show a more pronounced phenotype, and both 
MO and CRISPR/Cas9-mediated depletion of Myo9aa/ab affect chorion movements.  
 
Figure 4.6. Movements performed by zebrafish within the chorion at 24 hpf.  
Full chorion movements performed in one minute by uninjected (control, n=77), 3 
myo9aa/ab sgRNA (n=63) and 4 myo9aa/ab sgRNA (n=65) injected zebrafish. 
Tyrosinase (tyr) crispant injected control also included (n=68). KD = knockdown, error 
bars = mean ± S.E.M. ****p<0.0001, ns = not significant, Mann Whitney test.  
4.4.2 Tactile stimulation 
In the hours that follow the initial outgrowth of secondary motorneurons, the fish gain 
the ability to perform a touch-evoked swimming response in reaction to contact with a 
fine pipette tip on the back of the head, referred to here as the tactile stimulation 
assay (Saint-Amant and Drapeau, 1998, Kimmel et al., 1974). The evoked movement 
is an escape response which causes a characteristic c-bend movement performed by 
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the zebrafish, followed by a fast swim away from the stimulus (Saint-Amant and 
Drapeau, 1998). Initially in my MSci project this was analysed by simple observation 
of responses (O'Connor et al., 2016), however, the movements performed can be 
quantitatively analysed using ImageJ software with a TrackMate plugin as described 
in our recent manuscript (O'Connor et al., 2018a). Therefore, the tactile stimulation 
assay was performed in the Myo9aa/ab MO zebrafish and the distance travelled, 
average speed of swimming and initial acceleration were quantified (Figure 4.7).  
Myo9aa/ab MO zebrafish moved on average 15.5mm, which was significantly less 
than controls which travelled 34.6mm after stimulation (p=0.0001, Mann Whitney test, 
Figure 4.7A). Similarly, the controls were able to swim over twice as fast as the 
Myo9aa/ab MO fish, with an average speed of 19mm/s as opposed to 6.8mm/s, 
respectively (p<0.0001, Mann Whitney test, Figure 4.7B). Initial acceleration, 
indicative of force of muscle contraction, was also reduced in zebrafish depleted for 
Myo9aa/ab as compared to controls with averages of 2.9mm/s2 and 8.1mm/s2, 
respectively (p<0.0001, Mann Whitney test, Figure 4.7C).  
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Figure 4.7. Tactile stimulation response of MO-mediated Myo9aa/ab knockdown 
zebrafish.  Uninjected and Myo9aa/ab morphant zebrafish were subject to a tactile 
stimulation assay at 48 hpf. Distance travelled (A), average speed (B) and initial 
acceleration (C) of each fish was quantified. Error bars = mean ± S.E.M, control 
n=32, Myo9aa/ab morphant n=41. ***p≤0.001, ****p<0.0001, Mann Whitney test. MO 
= morpholino. 
This experiment was also performed using CRISPR/Cas9-mediated KD for two main 
reasons. Firstly, to determine whether CRISPR/Cas9 depletion of Myo9aa/ab 
produced a similar effect on movement as MO-mediated reduction, and secondly to 
assist in selecting an effective sgRNA combination for NMJ morphology assessments 
(Figure 4.8).  
There were no significant differences between control (uninjected) and control (tyr 
sgRNA) zebrafish for distance, speed or acceleration (p=0.619, p=0.102, p=0.380 
respectively, Mann Whitney test). MYO9A KD 3 sgRNA injected zebrafish travelled 
significantly less distance than uninjected and tyr controls (p=0.011, p=0.093 
respectively, Mann Whitney test). They also swam significantly slower than tyr 
controls (p=0.011, Mann Whitney test), but not uninjected controls (p=0.163, Mann 
Whitney test). Initial acceleration was similarly reduced in comparison to tyr controls 
but not uninjected zebrafish (p=0.201, p=0.100 respectively, Mann Whitney test). The 
movement response was more severely affected in 4 sgRNA injected zebrafish when 
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compared to uninjected and tyr injected controls, with significant decreases in 
distance travelled (p<0.0001, p=0.0001 respectively, Mann Whitney test), speed of 
movement (p<0.0001, Mann Whitney test) and initial acceleration (p=0.005, p=0.002 
respectively, Mann Whitney test).  
 
Figure 4.8. Tactile stimulation response of CRISPR/Cas9-mediated myo9aa/ab 
knockdown zebrafish.  Uninjected, Tyrosinase (tyr) sgRNA injected controls, 3 
myo9aa/ab sgRNA targeted and 4 myo9aa/ab sgRNA targeted fish were subject to a 
tactile stimulation assay at 48 hpf. The distance travelled (control n=13, tyr sgRNA 
n=15, 3 sgRNA n=17, 4 sgRNA n=20), average speed of movement (control n=18, 
tyr sgRNA n=12, 3 sgRNA n=15, 4 sgRNA n=20) and initial acceleration (control 
n=13, tyr sgRNA n=15, 3 sgRNA n=17, 4 sgRNA n=19) were quantified for each fish. 
Error bars = mean ± S.E.M. ns = not significant, *p≤0.05, **p≤0.01, ***p≤0.001, 
****p<0.0001, Unpaired t-test. 
Results obtained from the MO and CRISPR/Cas9-mediated Myo9aa/ab depletion 
experiments were more similar for the 3 rather than 4 sgRNA-injected fish. Distance 
travelled in MO fish was 15.5mm, compared to 12.5mm and 3.4mm performed by 3 
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and 4 sgRNA injected fish, respectively. Speed of swimming responses was 6.8mm/s 
in MO fish and 8.9mm/s in 3 sgRNA-injected fish, as opposed to just 2.5 mm/s in 4 
sgRNA-injected fish. Finally, acceleration was only 0.9mm/s2 for 4 sgRNA-injected 
fish, whereas 3 sgRNA and MO-injected fish produced values of 3mm/s2 and 
2.9mm/s2 respectively. Overall, both methods of depleting myo9aa/ab expression 
affected motor behaviours at 24 and 48 hpf, and as 4 sgRNA-injected fish had a 
more pronounced phenotype these were used for subsequent NMJ morphology 
experiments.  
4.5 Neuromuscular junctions and muscle fibres in zebrafish models 
Earlier analysis of NMJ morphology in 48 hpf Myo9aa/ab morphant zebrafish 
revealed defects in neuron outgrowth and branching, however, these results were not 
quantified (O'Connor et al., 2016). Based on these initial findings, and due to the 
observation that motor behaviours during development are affected by MYO9A 
orthologue deficiency, a quantitative approach to assessing NMJ morphology was 
used. Furthermore, as defects in movement could be due to involvement of cranial 
motor neurons or muscle architecture, these features were also assessed in the 
myo9aa/ab crispant zebrafish, however, no clear gross morphological differences 
had been identified in the morphant fish. As results in the previous section 
demonstrated a greater phenotypic severity in 4 sgRNA-injected zebrafish, these 
were selected for use for the rest of the study and are referred to as ‘myo9aa/ab 
crispants’.  
4.5.1 CNS and muscle gross morphology in zebrafish models 
Tg(islet1:GFP) zebrafish express GFP under the control of the islet1 promoter, which 
drives expression of fluorescence in the cranial motor neurons (as well as the Rohon 
Beard sensory cells, Higashijima et al., 2000). Visualisation of cranial motor neurons 
in control and myo9aa/ab crispants revealed no gross differences between 
localisation or network of neurons (Figure 4.9).  
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Figure 4.9. Cranial motor neurons in zebrafish.  For visualisation of cranial motor 
neurons, 48 hpf zebrafish expressing GFP under the Islet-1 promoter were analysed. 
Cranial nerves III, IV, Va, Vp, VII and X are labelled. Scale bar = 50µm, 15 zebrafish 
screened.  
Muscle fibres of 48 hpf fish were stained with fluorophore-conjugated phalloidin 
which binds to f-actin. In control muscle, somites are clearly delineated with 
horizontal and vertical myosepta, muscle fibres are organised in the appropriate 
orientation and no fibres cross over to alternate sides (Figure 4.10). Myo9aa/ab 
crispants have similarly well-structured somites, however, in some cases muscle 
fibres could be observed crossing the midline.  
 
Figure 4.10. Muscle fibre morphology in myo9aa/ab crispants.  Muscle fibres in 
control and myo9aa/ab crispant fish at 48 hpf were stained with fluorophore-
conjugated phalloidin to detect f-actin. The blue line delineates the vertical myosepta, 
green line is the horizontal myosepta and the white dashed line outlines a myotome 
(two of which make up a somite). White arrow indicates a muscle fibre crossing over 
into alternative myotome. Scale bar = 50µm, 15 control and 15 crispant zebrafish 
were qualitatively assessed.  
4.6 NMJ analysis at different time points 
A comprehensive morphological characterisation protocol was applied to study the 
NMJs of myo9aa/ab crispant fish at different time points during development. Time 
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points selected encompass different stages of NMJ maturation: 24 hpf (initial 
outgrowth of primary motorneurons, synaptogenesis occurring and spontaneous 
movement), 48 hpf (second and higher order branches of primary motorneurons 
present, secondary motorneuron outgrowth, response to tactile stimulation) and 5 dpf 
(innervation territories and coverage representative of adult patterns, larvae 
behaviours obtained including escape response and spontaneous swimming, 
maximal swimming rates achieved).  
At 24 hpf, zebrafish were fixed and stained with aBTx-conjugated with a fluorophore 
to detect AChRs and an antibody against SV2 for presynaptic motor neuron vesicles 
(Figure 4.11, Panzer et al., 2005). At this stage in development, zebrafish have a 
cluster of AChRs at the horizontal myoseptum and this represents a pathway ‘choice 
point’ for extending primary motor neurons. This is clearly visible in control zebrafish, 
but frequently absent in the myo9aa/ab crispants (Figure 4.11).  
 
Figure 4.11. NMJ morphology of myo9aa/ab crispant zebrafish at 24 hpf.  
Representative images of NMJs in control and myo9aa/ab crispant zebrafish at 24 
hpf. Acetylcholine receptors stained with aBTx (green), and motor neurons detected 
with an antibody against SV2 (red). White boxes demark areas enlarged in the right-
hand panel. Scale bar = 50µm.  
Various features of NMJs in early development were quantified as shown in Figure 
4.12. Measurement of the average area of the AChR clusters revealed a significant 
decrease in size for myo9aa/ab crispants as compared to controls (p= 0.0261, 
Unpaired t-test). There was no significant change in number of AChR clusters larger 
than 20µm2 at this time point, or in the total area of clusters (p=0.3264, p=0.1286 
respectively, Unpaired t-test). Proportion of myotomes with a choice point cluster was 
130 
 
significantly decreased in crispants as compared to controls, with almost 100% of 
controls exhibiting clusters as opposed to only 30% of crispants (p=0.0027, Unpaired 
t-test). The distance that neurons had extended past the choice point was also 
measured, revealing that motor neurons in crispants had travelled significantly less 
than controls, at 17µm and 43µm respectively (p=0.0157, Unpaired t-test). However, 
overall length of neuron outgrowths was not affected (p=0.3244, Unpaired t-test). 
Size of myotomes was significantly reduced from 5829µm2 in controls to 1890µm2 in 
crispants (p=0.0013, Unpaired t-test). Overall, both pre and postsynaptic NMJ 
features are affected in 24 hpf myo9aa/ab crispant fish as compared to controls. 
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Figure 4.12. Quantification of NMJ morphology in myo9aa/ab crispant zebrafish 
at 24 hpf. Various features of NMJ morphology in control (n=7) and myo9aa/ab 
crispants (n=6) were quantified: average and total area of acetylcholine receptor 
(aBTx) clusters and number over 20µm2, size of muscle myotomes, proportion of 
myotomes with a choice point cluster, number of neurons per myotome and the total 
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length these neurons had extended, as well as length past the choice point. Error 
bars = mean ± S.E.M. **p≤0.01, *p≤0.05, ns = not significant, Unpaired t-test. 
By 48 hpf motor neurons have extended down the middle of the myotome and 
started to innervate the vertical myoseptal region. The AChR choice point cluster has 
dispersed and the majority of prepatterned receptors have been contacted by 
extending motor axons. An example of a neuron that has not extended as far along 
the vertical myoseptal in the crispant fish as in the controls is shown in Figure 4.13, 
along with the presence of uninnervated AChRs.  
 
Figure 4.13. NMJ morphology of myo9aa/ab crispant zebrafish at 48 hpf. 
Representative images of NMJs in control and myo9aa/ab crispant zebrafish at 48 
hpf. Acetylcholine receptors stained with aBTx (green), and motor neurons detected 
with an antibody against SV2 (red). White boxes demark areas enlarged in the 
bottom panel. Scale bars = 50µm 
A number of presynaptic features were quantified in 48 hpf fish (Figure 4.14), 
including the number of SV2 clusters per myotome and per 100µm2. Both 
measurements revealed significantly less SV2 clusters in crispants as compared to 
controls (p=0.0031, p=0.0200 respectively, Unpaired t-test). There was no significant 
difference in the number of SV2 clusters over 20µm2 in size between controls and 
crispants (p=0.2193, Unpaired t-test), despite an increase in the average cluster size 
(p=0.0011, Unpaired t-test). Total cluster area was significantly reduced in crispant 
fish as opposed to controls (p<0.0001, Unpaired t-test). During development AChRs 
cluster along the vertical myosepta in preparation for innervation from extending 
primary motor axons. Therefore, the length of the vertical myosepta in which AChR 
clusters were present (detected by aBTx fluorescence) was measured, and 
compared to the distance that the motor axon had extended to give rise to % 
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innervation. This demonstrated a significant decrease in myoseptal innervation from 
80% in controls to 65% in crispants (p=0.0428, Unpaired t-test). 
 
Figure 4.14. Quantification of presynaptic NMJ morphology in myo9aa/ab 
crispant zebrafish at 48 hpf.  Various features of NMJ morphology in control (n=15) 
and myo9aa/ab crispant (n=20) were quantified: SV2 clusters per myotome, per 
100µm2 and over 20µm2 and % innervation of myosepta, as well as average SV2 
cluster area and total area. Error bars = mean ± S.E.M. *p≤0.05, **p≤0.01, 
****p<0.0001, ns = not significant, Unpaired t-test. 
Postsynaptic features of the NMJ were also assessed at 48 hpf, revealing a 
significant decrease in the number of AChR clusters per myotome and per 100µm2 
(p<0.0001, Unpaired t-test, Figure 4.15). There was no significant difference in the 
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number of AChR clusters over 20µm2 in size between controls and crispants 
(p=0.0584, Unpaired t-test), despite an increase in average cluster area in crispants 
(p=0.0006, Unpaired t-test). Total cluster area was significantly decreased in 
crispants as compared to controls (p<0.0001, Unpaired t-test). As opposed to results 
at 24 hpf, the size of myotomes were no longer significantly smaller in myo9aa/ab 
crispant fish as compared to controls (p=0.0762, Unpaired t-test). Overall, the 
number of pre and postsynaptic clusters were affected in crispant fish, as well as 
length of motor neuronal innervation of the myosepta, supporting qualitative results 
obtained previously in Myo9aa/ab morphant fish (O'Connor et al., 2016). 
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Figure 4.15. Quantification of postsynaptic NMJ morphology in myo9aa/ab 
crispant zebrafish at 48 hpf. Various features of NMJ morphology in control (n=15) 
and myo9aa/ab crispant (n=20) were quantified: AChR (aBTx) clusters per myotome, 
per 100µm2 and over 20µm2 as well as size of myotomes, average aBTx cluster area 
and total cluster area. Error bars = mean ± S.E.M. ***p≤0.001, ****p<0.0001, ns = not 
significant, Unpaired t-test. 
In zebrafish at 5 dpf, myotomes have a dense innervation from primary and 
secondary motor neurons which are in contact with AChRs. In myo9aa/ab crispant 
zebrafish there are examples of sparsely innervated myotomes as shown in Figure 
4.16, where branching is less complex than in controls.  
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Figure 4.16. NMJ morphology of myo9aa/ab crispant zebrafish at 5 dpf.  
Representative images of NMJs in control and myo9aa/ab crispant zebrafish at 5 dpf. 
Acetylcholine receptors stained with aBTx (green), and motor neurons detected with 
an antibody against SV2 (red). Scale bars = 50µm.  
A number of parameters quantified at 24 and 48 hpf were also measured at 5dpf 
(Figure 4.17). There was no significant difference in the number of presynaptic 
clusters per myotome in crispants, however number per 100µm2 was significantly 
increased in crispants as compared to controls (p=0.6482, p=0.0095 respectively, 
Unpaired t-test). The number of SV2-positive clusters over 20µm2 was not 
significantly affected, and neither was the average area of clusters (p=0.1995, 
p=0.1306 respectively, Unpaired t-test). However, there was a decrease in total SV2 
cluster area in crispant fish, reflected in the reduced myotomal staining in Figure 4.16 
(p=0.0465, Unpaired t-test). The percentage of myoseptal innervation is not 
significantly affected by depletion of Myo9aa/ab at this time point (p=0.1961, 
Unpaired t-test).  
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Figure 4.17. Quantification of presynaptic NMJ morphology in myo9aa/ab 
crispant zebrafish at 5 dpf.  Various features of presynaptic NMJ morphology in 
control (n=9) and myo9aa/ab crispant (n=7) were quantified: average and total area 
of SV2-positive clusters, clusters per myotome, per 100µm2 and over 20µm2, as well 
as % myoseptal innervation. Error bars = mean ± S.E.M. **p≤0.01, ns = not 
significant, Unpaired t-test.  
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Postsynaptic features of 5dpf zebrafish NMJs were also quantified, and as with 
presynaptic clusters, there was no significant decrease in the number of AChR 
clusters per myotome in crispant fish as compared to controls at this time point 
(p=0.0862, Unpaired t-test). Similarly, there was also a significant increase in number 
of clusters per 100µm2 in crispant fish, as found with SV2 clusters (p=0.0424, 
Unpaired t-test). The number of large clusters (>20µm2), as well as total and average 
area of AChR clusters however, were all significantly reduced in crispant fish as 
opposed to controls (p=0.0497, p=0.0002, p=0.0360 respectively, Unpaired t-test). As 
observed at 24 hpf, the size of myotomes in crispant fish were significantly smaller 
than controls (p=0.0004, Unpaired t-test). Overall, there is a general improvement in 
presynaptic features measured by 5 dpf, except for the total area of SV2 clusters 
which is decreased and the number of SV2-positive clusters per 100µm2 which is 
elevated in crispant fish and reflected also in the increased number of aBTx clusters. 
Conversely, postsynaptic AChR clusters are more affected at this time point, with 
area and number of large clusters reduced in crispants, along with the presence of 
smaller somites.  
139 
 
 
Figure 4.18. Quantification of postsynaptic NMJ morphology in myo9aa/ab 
crispant zebrafish at 5 dpf.Various features of NMJ morphology in control (n=9) 
and myo9aa/ab crispant (n=7) were quantified: Acetylcholine receptor (aBTx) clusters 
per myotome, per 100µm2 and over 20µm2 as well as size of myotomes, average and 
total area of aBTx clusters. Error bars = mean ± S.E.M. *≤0.05, ***p≤0.001, ns = not 
significant, Unpaired t-test 
 AChE is expressed in the CNS, muscle, primary motor and sensory neurons 
throughout the zebrafish embryo, first appearing around 12 hpf (Bertrand et al., 2001, 
Behra et al., 2002). Activity of AChE is important as it acts to stop the action of ACh 
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on AChRs in the synaptic cleft, and in zebrafish the levels of this enzyme have been 
found to correlate with developmental stage (Koenig et al., 2016). Therefore, this is a 
useful assay to help address whether the behavioural alterations and NMJ 
morphology differences are linked to developmental delay/less neuronal and muscle 
tissue in the crispant fish. AChE activity was calculated using the isolated tails of 
embryos during the first 5 days of development, to remove the impact of brain AChE 
from results (Figure 4.19). Expression of AChE is very low at 1 dpf, however, 
significantly less activity was detected in the myo9aa/ab crispants than in controls 
(p=0.012, Mann Whitney test). Activity was also significantly lower at 2 dpf and 5 dpf 
in crispant fish as compared to controls (p=0.012, p<0.0001 respectively, Mann 
Whitney test). There were no significant differences between detected activity at 3 
and 4 dpf (p=0.730 for both, Mann Whitney test). This suggests that crispant fish 
have less AChE activity 1,2 and 5 dpf than their control counterparts, and that this 
could be due to developmental delay, a reduction in neural/muscle tissue or impaired 
AChE activity.  
 
Figure 4.19. AChE activity in tails of myo9aa/ab crispant zebrafish during 
development. Activity of AChE quantified at day 1 – 5 post fertilisation in control and 
myo9aa/ab crispant fish tails. 10 fish tails pooled per reaction, 5 reactions performed 
for 1dpf, 2dpf, control 3dpf, myo9aa/ab crispant 4 dpf, 4 reactions for myo9aa/ab 
crispant 3 dpf, control 4 dpf and 2 reactions for 5 dpf. *p≤0.05, ****p<0.0001, ns = not 
significant, Mann Whitney test. Error bars = mean + S.E.M. Dpf = days post 
fertilization 
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4.6.1 Morphology of MYO9A KO mouse neuromuscular junctions and muscle 
fibres 
The MYO9A KO mouse has not previously been assessed for defects of the NMJ 
either through behavioural, histological, immunofluorescent or physiological 
techniques. Therefore, to complement the work performed in vitro in a mouse-derived 
motor neuron cell-line (O'Connor et al., 2016) and patient iNPCs, and in vivo in the 
zebrafish, analysis of NMJ and muscle architecture was performed in the mouse.  
4.6.2 Histological assessment of muscle 
Muscle from patients was not obtainable and thus the patient muscle phenotype is 
unknown. As some small, infrequent alterations to muscle fibre organization was 
observed in the zebrafish, features of muscle in the MYO9A KO mouse were 
visualized with haematoxylin and eosin staining. 
Quadriceps, gastrocnemius and tibialis anterior muscles from MYO9A KO and 
wildtype mice were analysed and representative images are shown in Figure 4.20. 
There was no identified fatty infiltration of muscle or fibrosis, neither was there a 
significant increase in the proportion of rounded muscle fibres (Quadriceps p=0.100, 
gastrocnemius p=0.229 and tibialis anterior p=0.800, Mann Whitney test). 
Percentage of fibres (300 per animal per muscle) that had internal nuclei was also 
quantified. In quadriceps only 1% of wildtype (n=3) muscle fibres had internal nuclei, 
whereas MYO9A KO had slightly more at 6% (n=3), however this was not significant 
(p=0.200, Mann Whitney test). In tibialis anterior and gastrocnemius muscles of 
wildtype animals, 1% had internal nuclei (n=1 tibialis anterior, n=2 gastrocnemius), 
this was slightly increased to 3% in both muscle types of MYO9A KO animals (n=2, 
not enough animals to perform statistics). 
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Figure 4.20. Histological features of MYO9A KO mouse muscle.  Quadriceps 
muscle from control and MYO9A KO mouse stained with haematoxylin and eosin. 
Enlarged regions (white boxes) show presence of internal nuclei (white arrows) in 
control and MYO9A KO mice. KO = knockout, scale bar = 500µm.  
The area of muscle fibres was also measured for comparison between wildtype and 
MYO9A KO mice. Results were pooled into wildtype and MYO9A KO for easier 
comparison (Figure 4.21A) and data for individual animals is also shown (Figure 
4.21B). In tibialis anterior muscles, wildtype animals had an average fibre area of 
3277 ± 1664µm2 (± standard deviation) whereas mutant muscle had a significantly 
smaller average fibre area of 2308 ± 986µm2 (p<0.0001, Mann Whitney test). 
Similarly, quadriceps muscle fibre area was also significantly reduced in MYO9A KO 
mice as compared to wildtype, from 3065 ± 1121µm2 to 2579 ± 1312µm2 (p<0.0001, 
Mann Whitney test). Muscle fibre area was also significantly reduced in 
gastrocnemius muscles of MYO9A KO mice, from 2428 ± 1172µm2 in controls to 
1721 ± 709µm2 in MYO9A KOs (p<0.0001, Mann Whitney test). Therefore, data 
demonstrates that mice lacking MYO9A have smaller muscle fibres than wildtypes. 
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Figure 4.21. Muscle fibre area in wildtype and MYO9A KO mice.  A. Frequency 
distributions of muscle fibre cross sectional area from pooled wildtype (black line) and 
MYO9A KO (mutant, grey line) mice. B. Muscle fibre area measurements split into 
individual wildtype (WT, black line) and MYO9A KO (MT, grey dashed line) animals 
for quadriceps (WT1,3, MT3,4 n=200, WT2 n=57, MT1 n=105 fibres), gastrocnemius 
(WT1,2,3MT1,3,4 n=200, MT2 n=65) and tibialis anterior (WT2, MT1,2,3,4 n=200, 
WT3 n=142) muscles. Graphs represent percentage of fibres within each size bin of 
500µm2. 
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4.6.3 Fibre typing of muscle 
Muscle fibre type composition can give an insight as to whether muscles have 
appropriate proportions of each muscle fibre type, therefore muscles were stained 
with antibodies against type I, IIa, IIb and IIx MyHC for analysis (Figure 4.23).  
 
Figure 4.22. Fibre type analysis of wildtype and MYO9A KO mice.  
Representative images of fibre type staining in wildtype (quadriceps) and MYO9A KO 
(gastrocnemius) mice. In the top panel fibres are labelled as follows: type I (blue), 
type II (red), type IIb (green) and laminin (green). In the bottom panel type IIx fibres 
and laminin are green. Scale bar = 500µm.  
Muscle fibre type quantification was performed by manually categorising each 
muscle fibre, however, staining for Type IIb and Type IIx fibres was often hard to 
identify. Nevertheless, there were no significant differences observed for the 
proportion of muscle fibre types between wildtype and mutant animals (p>0.05, Mann 
Whitney test, Figure 4.24).   
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Figure 4.23. Fibre type composition in MYO9A KO mice.  Fibre type analysis was 
performed manually on transverse sections of wildtype and MYO9A KO (mutant) 
gastrocnemius (wildtype n=3, mutant n=4), tibialis anterior (wildtype n=2, mutant n=4) 
and quadriceps (wildtype n=3, mutant n=3) muscles. None of the comparisons 
between wildtype and mutant animals were significant (p>0.05, Mann Whitney test). 
At least 300 fibres analysed per muscle per genotype, error bars = mean + S.E.M. 
4.6.4 NMJ morphology 
Numerous differences were detected in the analysis of zebrafish NMJs in the 
absence of MYO9A, therefore MYO9A KO mice were subject to a comprehensive 
investigation of NMJ morphology. Using the ‘NMJmorph’ protocol developed by 
Jones et al (2016), a range of presynaptic and postsynaptic features were assessed 
using whole muscles (tibialis anterior, gastrocnemius, diaphragm and intercostal) 
stained with aBTx to detect AChRs, and antibodies against neurofilament and 
synaptophysin for presynaptic axons and nerve terminals, respectively. 
Representative images are shown in Figure 4.24, highlighting the presence of NMJs 
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with abnormal structures within mutant animal muscles, however, many mutant NMJs 
were also normal in appearance.   
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Figure 4.24. Morphology of NMJs in wildtype and MYO9A KO mice.  
Representative images of NMJs in wildtype and MYO9A KO mice (mutant 1-4). 
Presynapse stained with antibody against synaptophysin (red), axon detected with an 
antibody against neurofilament light chain (red) and postsynaptic AChRs stained with 
aBTx (green). Scale bar = 25µm. 
The NMJ morph protocol provides a comprehensive overview of synaptic 
morphology, comprising of 21 variables that can be measured. Staining of axons with 
an antibody against neurofilament was largely unsuccessful in these samples, 
therefore in this study parameters including axon measurements have been 
removed. Measurements were performed on tibialis anterior and gastrocnemius 
muscles, as well as intercostal and diaphragm due to the involvement of a respiratory 
phenotype in patients (O'Connor et al., 2016). Approximately 30 NMJs per animal per 
muscle were assessed, exact numbers are provided in Tables 4-1 to 4-4.  
The tibialis anterior muscle was the most affected in the NMJ analysis, with a 
significant reduction in the majority of measured parameters when comparing 
mutants to wildtype. A summary of results is displayed in Figure 4.25, and full results, 
including statistics, are shown in Table 4-1. All presynaptic measurements were 
decreased in mutants, most to between 20 and 40% of wildtype values, including 
nerve terminal area and number/total length of axon branches. With regards to 
postsynaptic features, endplate area and average AChR cluster area were most 
affected in the mutants as compared to controls, whereas % compactness (how 
compact the endplate is) and fragmentation were relatively unaffected as compared 
to wildtypes. The final set of measurements cover both pre and postsynaptic 
features, demonstrating that the % overlap of the nerve and endplate was not 
affected and thus the two compartments still align with one another, however the 
average area of synaptic contact was reduced in mutants. When considering the 
mutants separately, it could be observed that mutant 2 appeared relatively spared, 
with a significant reduction in only nerve terminal perimeter, area, total length of 
branches and area of synaptic overlap. However, from the mice available 
observations suggest an overall reduction in NMJ size in the absence of MYO9A. 
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Figure 4.25. Radar plot of NMJ morphology measurements from tibialis anterior 
muscle.  Various features of NMJ morphology measured in mouse tibialis anterior 
muscle from wildtype (2 mice pooled) and mutant (MYO9A KO, 4 pooled) mice. 
Values are expressed as a proportion of wildtype. Blue shading = presynaptic 
features, red shading = postsynaptic features and purple shading = combined 
features. 
The other muscles analysed did not show consistently significant alterations in any of 
the parameters. Gastrocnemius was relatively unaffected by absence of MYO9A as 
shown in Table 4-2 and Figure 4.26. Of note is the reduction in nerve terminal area 
and number of branch points in pooled mutant animals as compared to controls, as 
found in tibialis anterior muscle. However, there was an increase in the area of 
synaptic contact and % pre and postsynaptic overlap in mutants. Considering the 
mutants separately, these values are only elevated in two mutants, whereas they are 
decreased in the other two, highlighting the variability of results present. Mutant 4 
had significantly larger postsynaptic features when compared to the wildtype animals, 
which was not the case for the other mutants. Overall, there was a general decrease 
in the presynaptic nerve terminal area and number of branch points, however, the 
data for this muscle had a higher level of inter-mutant variability.  
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Figure 4.26. Radar plot of NMJ morphology measurements from gastrocnemius 
muscle.  Various features of NMJ morphology measured in mouse gastrocnemius 
muscle from wildtype (2 mice pooled) and mutant (MYO9A KO, 4 pooled) mice. 
Values are expressed as a proportion of wildtype. Blue shading = presynaptic 
features, red shading = postsynaptic features and purple shading = combined 
features. 
As observed in tibialis anterior muscle, NMJs from mutant animals had an overall 
reduction in the size of presynaptic components in the intercostal muscles (Figure 
4.27, Table 4-3). In particular, nerve terminal area and number of branch points were 
reduced in all mutants as compared to control. However, it should be noted that 
mutant 1 and 3 had only 3 and 5 NMJs with presynaptic staining present, 
respectively. With regards to the postsynapse, AChR area, endplate area and 
average area of AChR clusters were all decreased in mice lacking MYO9A as 
compared to wildtypes. This was also observed in the tibialis anterior muscle. 
Analysis of mutants separately revealed a non-significant increase in these features 
for mutant 4, however this was accompanied by larger standard deviations and a 
corresponding significant decrease in % compactness, suggesting that endplates are 
more spread out in this animal (Table 4-3). The area of synaptic contact and % 
overlap were reduced by 30-50% in mutants as opposed to controls, likely as a 
reflection of reduced nerve terminal sizes, but also indicating there may be some 
misalignment of nerve terminals and muscle endplates. Overall for intercostal 
muscles, as observed in tibialis anterior muscle there is a trend toward smaller NMJs 
with an emphasis on decreased size of presynaptic components.  
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Figure 4.27. Radar plot of NMJ morphology measurements from intercostal 
muscle.  Various features of NMJ morphology measured in mouse intercostal 
muscles from wildtype (2 mice pooled) and mutant (MYO9A KO, 4 pooled) mice. 
Values are expressed as a proportion of wildtype. Blue shading = presynaptic 
features, red shading = postsynaptic features and purple shading = combined 
features. 
NMJ analysis of diaphragm muscle revealed a large decrease in size of presynaptic 
components for mutants as opposed to wildtype animals (Table 4-4, Figure 4.28). 
This is in corroboration with tibialis anterior and intercostal muscles. However, it 
should be noted that presynaptic staining for mutant 1 was not detectable and mutant 
3 had only 4 identifiable NMJs, thus the total NMJ number for presynaptic and 
combined component measurements was only 15. Taking this into account, while 
there is a considerable decrease in the % overlap and area of synaptic contact in 
mutants as compared to controls, more NMJs would be required to confirm these 
observations. The postsynapse is less affected in the diaphragm as opposed to 
intercostal and tibialis anterior muscles, with a small overall decrease in % 
compactness and average AChR areas. On the other hand, fragmentation is 
increased by 20% in mutants in contrast to controls, however none of the mutants 
have a significantly elevated level of fragmentation as compared to controls when 
considered separately. Therefore, for diaphragm muscle there is a reduction in size 
of presynaptic components and some postsynaptic features, however more animals 
would be required to expand these observations.  
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Figure 4.28. Radar plot of NMJ morphology measurements from diaphragm 
muscle. Various features of NMJ morphology measured in mouse diaphragm muscle 
from wildtype (2 mice pooled) and mutant (MYO9A KO, 4 pooled) mice. Values are 
expressed as a proportion of wildtype. Blue shading = presynaptic features, red 
shading = postsynaptic features and purple shading = combined features. 
 In summary, presynaptic components assessed in mutant animals were smaller than 
in controls for tibialis anterior, intercostal and diaphragm muscles, and less affected 
in gastrocnemius muscle. In tibialis anterior, intercostal and diaphragm muscles there 
was also a modest decrease in postsynaptic NMJ size, as well as the combined 
features of % overlap and area of synaptic contact, whereas the latter measurements 
were increased in gastrocnemius muscles of mutants compared to controls. This 
highlights a general trend toward smaller NMJ size in some muscles from MYO9A 
KO mice as compared to wildtype animals. 
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Tibialis Anterior WildType Mutant 1 Mutant 2 Mutant 3 Mutant 4 
Parameter Mean SD N Mean SD N P Value Mean SD N P Value Mean SD N P Value Mean SD N P Value 
Nerve Terminal Perimeter (µm) 347.47 128.46 37.00 216.67 75.84 21.00 **** 261.21 89.47 15.00 * 248.09 132.44 30.00 ** 206.09 64.34 29.00 **** 
Nerve Terminal Area (µm2) 385.91 134.25 38.00 272.20 70.13 22.00 *** 274.20 274.20 16.00 ** 219.99 106.02 31.00 **** 207.16 77.15 30.00 **** 
Number of Terminal Branches 32.43 19.53 38.00 19.95 14.15 22.00 * 26.80 14.64 16.00 ns 27.00 20.68 31.00 ns 22.00 11.20 30.00 ns 
Number of Branch Points 17.69 10.18 36.00 13.05 8.57 21.00 ns 14.33 6.66 15.00 ns 10.33 6.48 30.00 *** 8.38 3.13 29.00 **** 
Total Length of Branches (µm) 168.02 64.68 38.00 112.00 42.51 22.00 *** 127.02 45.81 16.00 * 113.95 59.07 31.00 *** 92.47 27.81 30.00 **** 
Average Length of Branches (µm) 6.75 3.49 38.00 7.58 3.78 22.00 ns 5.57 2.36 16.00 ns 7.57 16.65 31.00 ns 4.96 2.29 30.00 ns 
Complexity  4.82 0.60 37.00 4.23 0.68 22.00 ** 4.55 0.52 16.00 ns 4.23 0.73 31.00 *** 4.13 0.38 30.00 **** 
AChR Perimeter (µm) 299.28 99.71 52.00 183.89 64.02 31.00 **** 265.34 94.43 35.00 ns 229.70 116.43 31.00 * 205.19 87.84 30.00 *** 
AChR Area (µm2) 437.87 163.31 65.00 257.42 76.93 31.00 **** 372.92 125.63 35.00 ns 301.10 141.23 31.00 **** 277.07 122.20 30.00 **** 
Endplate Diameter (µm) 46.47 9.49 65.00 40.12 8.14 31.00 ** 44.00 8.15 35.00 ns 42.43 11.16 31.00 ns 37.58 8.96 30.00 **** 
Endplate Perimeter (µm) 124.50 25.13 65.00 105.80 21.50 31.00 ** 117.77 20.44 35.00 ns 109.49 28.22 31.00 * 105.70 27.12 30.00 ** 
Endplate Area (µm2) 846.47 343.23 65.00 513.71 206.61 31.00 *** 737.03 269.24 35.00 ns 606.82 324.75 31.00 ** 576.57 274.37 30.00 *** 
Compactness % 52.27 8.56 65.00 53.11 10.52 31.00 ns 52.46 10.21 35.00 ns 52.28 9.17 31.00 ns 49.99 9.67 30.00 ns 
Area of Synaptic Contact (µm2) 282.86 135.38 50.00 144.19 73.32 22.00 **** 183.38 101.14 16.00 ** 141.54 79.30 28.00 **** 171.74 88.45 30.00 *** 
Overlap (%) 59.48 20.11 38.00 56.16 29.64 22.00 ns 52.75 22.10 16.00 ns 49.53 18.28 28.00 ns 62.89 20.04 30.00 ns 
Average Area of AChR Clusters (µm2) 274.68 140.73 52.00 161.24 80.46 31.00 *** 229.56 133.36 35.00 ns 173.75 108.95 26.00 ** 195.80 115.26 30.00 * 
Fragmentation 0.32 0.31 65.00 0.36 0.29 31.00 ns 0.37 0.33 35.00 ns 0.37 0.35 26.00 ns 0.28 0.31 30.00 ns 
Table 4-1. NMJ measurements in tibialis anterior muscle.  Mean values for each parameter, standard deviation (SD) and 
number of NMJs assessed (N) are shown. P values for each mutant as compared to the wildtype results (data from 2 wildtypes 
pooled and averaged) are shown, as calculated using One-way ANOVA, ns=not significant, *p≤0.05, **p≤0.01, ***p≤0.001, 
****p<0.0001. AChR=acetylcholine receptor. 
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Gastrocnemius WildType Mutant 1 Mutant 2 Mutant 3 Mutant 4 
Parameter Mean SD N Mean SD N P Value Mean SD N P Value Mean SD N P Value Mean SD N P Value 
Nerve Terminal Perimeter (µm) 242.74 105.82 17.00 201.07 85.35 28.00 ns 215.05 95.48 26.00 ns 221.63 68.31 10.00 ns 277.38 86.97 27.00 ns 
Nerve Terminal Area (µm2) 275.87 111.93 17.00 194.86 65.68 28.00 * 218.14 94.08 26.00 ns 193.19 86.32 10.00 ns 302.48 95.00 28.00 ns 
Number of Terminal Branches 22.71 13.69 17.00 20.75 14.96 28.00 ns 20.73 12.35 26.00 ns 19.20 9.75 10.00 ns 29.39 19.52 28.00 ns 
Number of Branch Points 15.00 7.18 4.00 8.11 5.05 28.00 ns 8.38 4.43 26.00 ns 7.90 9.08 10.00 ns 11.84 5.54 28.00 ns 
Total Length of Branches (µm) 115.79 50.64 18.00 91.37 35.86 28.00 ns 99.31 42.69 25.00 ns 100.61 43.69 10.00 ns 128.37 39.74 28.00 ns 
Average Length of Branches (µm) 5.79 2.45 18.00 5.75 2.52 28.00 ns 5.54 2.01 25.00 ns 6.50 3.14 10.00 ns 5.75 2.64 28.00 ns 
Complexity  4.35 0.61 18.00 3.95 0.75 28.00 ns 4.13 0.96 26.00 ns 3.91 0.65 10.00 ns 4.48 0.56 28.00 ns 
AChR Perimeter (µm) 229.58 80.20 70.00 204.03 85.88 33.00 ns 210.91 97.95 31.00 ns 229.04 78.79 32.00 ns 274.90 80.67 32.00 * 
AChR Area (µm2) 318.46 102.06 70.00 250.49 107.94 33.00 * 265.25 116.45 31.00 ns 360.86 110.34 32.00 ns 392.52 117.19 32.00 ** 
Endplate Diameter (µm) 39.00 6.05 70.00 37.33 8.33 33.00 ns 36.98 9.09 31.00 ns 38.62 6.58 32.00 ns 48.08 18.17 32.00 *** 
Endplate Perimeter (µm) 108.92 16.98 70.00 101.03 23.06 33.00 ns 101.23 24.92 31.00 ns 110.34 15.98 32.00 ns 124.75 23.79 32.00 ** 
Endplate Area (µm2) 657.52 222.93 70.00 529.15 238.55 33.00 ns 558.58 277.04 31.00 ns 697.02 227.98 32.00 ns 836.65 297.02 32.00 ** 
Compactness % 49.64 10.01 70.00 48.59 8.76 33.00 ns 49.11 8.12 31.00 ns 52.61 8.56 32.00 ns 49.06 10.22 32.00 ns 
Area of Synaptic Contact (µm2) 112.77 105.55 16.00 103.09 85.97 28.00 ns 180.88 103.83 26.00 ns 96.38 72.36 9.00 ns 207.29 111.63 28.00 * 
Overlap (%) 35.11 42.30 18.00 45.88 30.48 28.00 ns 62.29 19.43 26.00 * 30.54 18.72 9.00 ns 53.88 26.05 28.00 ns 
Average Area of AChR Clusters (µm2) 214.59 117.18 70.00 165.40 107.22 32.00 ns 154.36 76.69 31.00 ns 292.71 150.57 32.00 * 293.68 149.56 32.00 * 
Fragmentation 0.33 0.30 70.00 0.32 0.31 32.00 ns 0.35 0.31 31.00 ns 0.20 0.30 32.00 ns 0.25 0.27 32.00 ns 
Table 4-2. NMJ measurements in gastrocnemius muscle.  Mean values for each parameter, standard deviation (SD) and 
number of NMJs assessed (N) are shown. P values for each mutant as compared to the wildtype results (data from 2 wildtypes 
pooled and averaged) are shown, as calculated using the one-way ANOVA, ns=not significant, *p≤0.05, **p≤0.01, ***p≤0.001, 
****p<0.0001. AChR=acetylcholine receptor. 
 
154 
 
Intercostal WildType Mutant 1 Mutant 2 Mutant 3 Mutant 4 
Parameter Mean SD N Mean SD N P Value Mean SD N P Value Mean SD N P Value Mean SD N P Value 
Nerve Terminal Perimeter (µm) 213.48 84.94 29.00 123.44 44.41 3.00 ns 158.22 63.40 23.00 * 146.38 64.01 5.00 ns 202.81 65.38 16.00 ns 
Nerve Terminal Area (µm2) 237.98 87.70 29.00 124.49 49.79 3.00 ns 167.54 84.39 23.00 * 122.64 34.67 5.00 ** 187.00 56.09 16.00 ns 
Number of Terminal Branches 23.93 13.90 29.00 13.00 7.35 3.00 ns 16.04 8.79 23.00 * 19.20 8.84 5.00 ns 24.94 11.58 16.00 ns 
Number of Branch Points 12.78 10.82 29.00 4.00 4.24 3.00 ns 6.91 3.63 23.00 * 3.60 1.96 5.00 ns 8.94 6.57 16.00 ns 
Total Length of Branches (µm) 102.22 36.85 29.00 56.47 24.40 3.00 ns 72.15 30.47 23.00 ** 59.70 26.94 5.00 * 89.43 33.41 16.00 ns 
Average Length of Branches (µm) 5.92 4.53 29.00 5.23 1.89 3.00 ns 5.93 4.21 23.00 ns 3.38 1.11 5.00 ns 3.86 1.12 16.00 ns 
Complexity  4.27 0.57 29.00 3.09 0.89 3.00 ** 3.71 0.58 23.00 ** 3.68 0.41 4.00 ns 4.10 0.70 16.00 ns 
AChR Perimeter (µm) 177.15 67.01 34.00 88.78 24.39 3.00 ns 147.92 55.05 30.00 ns 153.84 62.69 23.00 ns 197.57 66.42 30.00 ns 
AChR Area (µm2) 260.95 85.02 34.00 142.80 40.99 3.00 ns 183.61 77.66 30.00 *** 189.10 56.64 23.00 ** 276.13 87.28 30.00 ns 
Endplate Diameter (µm) 34.79 6.46 34.00 21.15 1.38 3.00 ns 40.25 26.99 28.00 ns 40.71 29.60 23.00 ns 36.07 5.99 30.00 ns 
Endplate Perimeter (µm) 95.66 17.12 34.00 62.40 7.08 3.00 ** 85.60 17.97 30.00 * 85.54 21.01 23.00 ns 103.62 19.02 30.00 ns 
Endplate Area (µm2) 487.37 174.76 34.00 236.01 60.43 3.00 ns 384.67 167.62 30.00 * 388.62 161.15 23.00 ns 583.48 211.86 30.00 ns 
Compactness % 54.84 8.73 34.00 60.17 2.91 3.00 ns 48.59 9.23 30.00 ** 51.06 7.93 23.00 ns 48.40 6.72 30.00 ** 
Area of Synaptic Contact (µm2) 113.25 146.65 29.00 37.81 7.32 3.00 ns 82.77 67.61 23.00 ns 16.37 63.10 5.00 ns 87.03 53.28 16.00 ns 
Overlap (%) 41.05 65.90 29.00 29.03 11.46 3.00 ns 37.13 21.82 23.00 ns 8.24 34.07 5.00 ns 40.22 23.20 16.00 ns 
Average Area of AChR Clusters (µm2) 176.41 99.41 34.00 77.65 18.69 3.00 ns 103.28 52.53 30.00 *** 126.09 39.89 23.00 ns 195.03 104.76 30.00 ns 
Fragmentation 0.32 0.31 34.00 0.39 0.28 3.00 ns 0.40 0.29 30.00 ns 0.27 0.29 23.00 ns 0.29 0.28 30.00 ns 
Table 4-3. NMJ measurements in intercostal muscles.  Mean values for each parameter, standard deviation (SD) and number of 
NMJs assessed (N) are shown. P values for each mutant as compared to the wildtype results (data from 2 wildtypes pooled and 
averaged) are shown, as calculated using the one-way ANOVA, ns=not significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001. 
AChR=acetylcholine receptor. 
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Diaphragm WildType Mutant 1 Mutant 2 Mutant 3 Mutant 4 
Parameter Mean SD N Mean SD N P Value Mean SD N P Value Mean SD N P Value Mean SD N P Value 
Nerve Terminal Perimeter (µm) 167.02 48.67 29.00 0.00 0.00 0.00  102.87 33.62 3.00 ns 123.66 11.64 4.00 ns 197.17 29.53 8.00 ns 
Nerve Terminal Area (µm2) 248.82 123.46 30.00 0.00 0.00 0.00  71.91 33.34 3.00 * 202.75 66.35 4.00 ns 163.00 42.45 8.00 ns 
Number of Terminal Branches 15.47 10.53 30.00 0.00 0.00 0.00  14.67 5.19 3.00 ns 6.25 2.95 4.00 ns 25.50 7.12 8.00 * 
Number of Branch Points 9.33 11.51 30.00 0.00 0.00 0.00  4.00 1.63 3.00 ns 4.00 1.00 4.00 ns 7.63 3.57 8.00 ns 
Total Length of Branches (µm) 86.00 54.75 30.00 0.00 0.00 0.00  42.62 16.63 3.00 ns 56.02 10.32 4.00 ns 82.23 15.89 8.00 ns 
Average Length of Branches (µm) 7.40 5.28 30.00 0.00 0.00 0.00  3.30 1.85 3.00 ns 11.83 6.60 4.00 ns 3.54 1.47 8.00 ns 
Complexity  3.81 0.70 30.00 0.00 0.00 0.00  3.25 0.26 3.00 ns 3.07 0.21 4.00 ns 4.14 0.28 8.00 ns 
AChR Perimeter (µm) 170.14 65.61 87.00 229.33 86.74 37.00 **** 183.84 57.37 25.00 ns 133.26 9.28 4.00 ns 170.47 50.45 26.00 ns 
AChR Area (µm2) 221.21 73.14 87.00 229.21 93.14 37.00 ns 161.49 39.95 25.00 ** 192.35 78.35 4.00 ns 217.71 74.55 26.00 ns 
Endplate Diameter (µm) 35.22 21.47 87.00 36.57 14.76 37.00 ns 31.37 4.58 25.00 ns 29.72 2.30 4.00 ns 36.59 25.32 26.00 ns 
Endplate Perimeter (µm) 101.35 78.06 87.00 98.89 18.56 37.00 ns 88.40 14.43 25.00 ns 81.46 6.35 4.00 ns 90.91 19.02 26.00 ns 
Endplate Area (µm2) 445.19 151.13 87.00 559.81 220.08 37.00 ** 428.38 130.24 25.00 ns 366.11 104.74 4.00 ns 454.95 142.60 26.00 ns 
Compactness % 52.35 17.39 87.00 42.30 10.11 37.00 ** 39.86 10.94 25.00 *** 51.23 9.86 4.00 ns 48.77 10.99 26.00 ns 
Area of Synaptic Contact (µm2) 112.67 125.03 30.00 0.00 0.00 0.00  51.00 84.00 3.00 ns 52.24 24.77 3.00 ns 5.30 73.35 8.00 ns 
Overlap (%) 43.62 50.03 30.00 0.00 0.00 0.00  29.60 46.84 3.00 ns 37.90 33.32 3.00 ns 4.09 39.26 8.00 ns 
Average Area of AChR Clusters (µm2) 146.40 93.08 87.00 116.11 88.29 37.00 ns 101.74 73.03 25.00 ns 151.33 109.05 4.00 ns 131.18 85.25 26.00 ns 
Fragmentation 0.34 0.32 87.00 0.49 0.36 37.00 ns 0.46 0.34 25.00 ns 0.31 0.32 4.00 ns 0.37 0.34 26.00 ns 
Table 4-4. NMJ measurements in diaphragm muscle. Mean values for each parameter, standard deviation (SD) and number of 
NMJs assessed (N) are shown. Scored out boxes represent measurements that were not obtained for that animal. P values for 
each mutant as compared to the wildtype results (data from 2 wildtypes pooled and averaged) are shown, as calculated using the 
one-way ANOVA, ns=not significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001. AChR=acetylcholine receptor 
.
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4.7 Discussion 
The main aim of this chapter was to determine whether loss of MYO9A, or presence 
of CMS patient mutations, affects the NMJ. This was assessed using an iNPC neurite 
extension assay, behaviour of zebrafish and zebrafish NMJ morphology, as well as 
assessment of mouse muscle and NMJ phenotypes. 
4.7.1 Neurite phenotype of patient iNPCs 
Previous data revealed an increase in neurite extension and branching in NSC-34 
cells depleted for MYO9A (O'Connor et al., 2016). Due to our finding that the MYO9A 
CMS patient fibroblasts did not exhibit a decrease in MYO9A expression at the RNA 
level, differentiated iNPCs were also subject to a neurite outgrowth assay to 
determine whether MYO9A mutations may cause a similar phenotype. Neurites in 
MYO9A patient iNPCs were significantly longer than those in control cells, thus 
corroborating results obtained from the MYO9A KD cell-line. A similar phenotype is 
also found in dissociated hippocampal neurons from mice lacking another 
unconventional myosin protein: MYO10, in which excessive extension of neurites is 
observed (Yu et al., 2015).  Furthermore, in hum-7 mutants (C.elegans MYO9A 
homologue) the rate of protrusion formation from epidermal cells in early 
development is increased as compared to wildtype animals (Wallace et al., 2018), 
suggesting a common effect of increased RhoA activity on cell extensions.   
4.7.2 Assessment of 24 hpf zebrafish movement and NMJ morphology 
Zebrafish perform a stereotyped set of locomotive behaviours during early embryonic 
and larval development stages. These movements can be easily observed in a large 
number of zebrafish and quantified to reveal abnormalities that may reflect underlying 
neuronal or muscle defects. The first movement performed is spontaneous twitching 
in the chorion. Wildtype zebrafish performed a full chorion rotation on average 2.4 
times per minute in this study, which is similar to results found elsewhere (Liu et al., 
2012). Myo9aa/ab morphant fish were shown to move 30% less than controls at this 
time point, and it was found that crispant fish injected with either the 3 or 4 sgRNA 
combinations also displayed reduced movement but to a greater degree (50% and 
88% respectively). Loss of an alternative RhoA modulating protein, Ephexin1, from 
mice also affects motor behaviours demonstrating the importance of RhoA pathway 
integrity in movement (Shi et al., 2010). The increased severity of the 4 sgRNA 
injection as compared to the 3 sgRNA could be due to the likelihood of larger 
deletions induced in myo9aa if both target regions are cut at the same time, thus 
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increasing the chance of disrupting Myo9aa expression. Injected controls receiving 
sgRNA against the tyr gene did not display a reduction in spontaneous movements, 
suggesting that the injection procedure or CRISPR/Cas9 activity itself does not cause 
developmental delay or absence of these movements. Furthermore, this behavior is 
not dependent on supraspinal input and is mediated at the level of the spinal cord 
(Downes and Granato, 2006). Previous results showed no effect on the distribution or 
quantity of Rohon Beard sensory cells in the spinal cord during development in the 
absence of Myo9aa/ab (O'Connor et al., 2016), therefore it is likely an effect of the 
motor system. The lack of movement observed at this early time point may also 
underlie the curved tail phenotype exhibited by the 48 hpf zebrafish. It has been 
shown that embryos raised in anaesthetic (therefore not performing chorion 
movements), have curved tails upon dechorionation, thus tail straightening may be 
activity dependent (Saint-Amant and Drapeau, 1998). 
In support of these behvioural phenotypes, a number of morphological features were 
found to be disrupted in 24 hpf myo9aa/ab crispants. The average area of AChR 
clusters was decreased by over 50% in crispants as compared to controls and half of 
crispant myotomes analysed did not have a choice point cluster present. As this is 
after the time period expected for prepatterned receptor clusters (primary neurons 
have already contacted the area), this is unlikely to be a defect in prepatterning but in 
the incorporation of synaptic AChRs. However, to verify this assumption, earlier time 
points should be assessed to determine whether prepatterned clusters are ever 
present. Furthermore, a RhoGDP/GTP nucleotide exchange factor (RhoGEF) protein 
Ephexin1 has been demonstrated to disperse pre-existing AChR clustering (prior to 
application of agrin) in C2C12 cells, thus MYO9A as a RhoGAP may also cause early 
AChR dispersion when absent (Shi et al., 2010).  
 The size of myotomes was reduced in the crispant zebrafish by 68%. A number of 
studies in mammals have found muscle fibre diameter to correlate with NMJ size (for 
example: Wærhaug and Lømo, 1994, Balice-Gordon et al., 1990, Nystrom, 1968, 
Slater et al., 1992). While muscle fibre diameter wasn’t measured here, as myotome 
size is reduced more than AChR cluster area it could be that reduced AChR area is a 
function of reduced muscle size, and Myo9aa/ab may play a role in muscle 
development. A zebrafish mlh mutant also shows evidence of reduced synapse size 
and smaller somites/muscle fibre diameter (Panzer et al., 2005). However, a recent 
study challenged the idea that muscle fibre diameter is a predictor for NMJ size due 
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to a lack of correlation between the two in mouse muscle (Jones et al., 2016). 
Therefore, further work will be required to determine whether effects on muscle mass 
or NMJ size are secondary defects to the primary pathology.  
Primary motor neurons had also extended further in wildtype fish than crispants at 
this early time point. As it has been shown that the presence of AChRs are not 
necessary for motorneuron outgrowth in the fish, this indicated that there may be a 
defect in axon extension (Westerfield et al., 1990). Other zebrafish models of CMS 
such as those lacking agrin or GFPT1 homologues also display truncated and 
abnormal extension of motor neurons during development, thus supporting this 
finding in the MYO9A-depleted zebrafish (Kim et al., 2007, Senderek et al., 2011). 
These results are conflicting with the in vitro observations that loss of MYO9A causes 
over-extension of neurites, which could be due to cross-talk with muscle fibres in vivo 
during outgrowth. In order to address this, it would be beneficial to analyse co-
cultures in which wildtype/MYO9A KD nerve cells are incubated with 
wildtype/MYO9A KD muscle cells to observe any effects on neurite extension. 
Overall, movements of myo9aa/ab crispant fish were impaired at 24 hpf and 
corresponding defects to NMJ morphology were observed. 
4.7.3 Assessment of 48 hpf movement and NMJ morphology 
As zebrafish development progressed and the ability to respond to tactile stimulation 
was obtained, it could be observed that fish lacking Myo9aa/ab were less able to 
perform the response. Corroborating this, ability of CMS zebrafish models to perform 
appropriate motor activities is impaired in 12 of the 13 studies identified in Table 1-1 
(Chapter 1, Section 1.4.2), thus highlighting that impairment of the NMJ in developing 
embryos due to loss of CMS-associated proteins can impact movement. Of particular 
interest was the reduction in initial acceleration in morphant and crispant fish, which 
indicates a reduced force of muscle contraction (Sztal et al., 2016). This could 
suggest less overall innervation of the myotomes (thus less muscle fibres contracting 
in response to stimulation), which was supported by the finding that there were less 
pre- and postsynaptic clusters present at this time point, and the progression of 
neuronal processes across the myotomes was delayed in crispants. The 
aforementioned mouse lacking the RhoA-modulating protein, Ephexin1, displays 
numerous effects on AChR clustering, as well as on formation of postsynaptic 
specialisations such as junctional folds (Shi et al., 2010). Therefore, the reduced 
acceleration in crispant fish could also be related to problems with muscle 
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fibre/endplate architecture which would need a more in depth analysis of muscle at 
the ultrastructural level. Another study in which acceleration was used as a readout 
measure for assessment of a muscle disorder in zebrafish identified reduced muscle 
mass as a cause for decreased force production (Sztal et al., 2018). In myo9aa/ab 
crispants at 48 hpf there is no change in myotome size as compared to controls, thus 
while muscle mass itself was not measured this implies that it is likely a disorder of 
transmission rather than amount of muscle tissue. Acceleration impairment could 
also represent reduced quantal content of presynaptic terminals, as reduced quantal 
contents have been observed in other CMS zebrafish models that exhibit movement 
defects (Wen et al., 2016). This is supported by the finding that there is reduced total 
SV2 cluster area, as area of the presynaptic NMJ has been shown to correlate with 
QC (Slater, 2015). To assess this electrophysiology recording of activity at individual 
synapses would be required, such as can be achieved by the paired neuron-muscle 
recordings performed by Wen et al (2010). 
4.7.4 Assessment of 5 dpf NMJ morphology, AChE activity and CNS 
involvement 
At 5dpf there was no longer a decrease in pre and postsynaptic cluster number per 
myotome, and per 100µm2 there was an increase. For the presynapse, this was 
accompanied by an increase in average cluster area, however the number of large 
clusters (over 20µm2) was not affected and results were variable, ranging from 0.7 to 
5.0µm2 as opposed to 0.8 to 1.4µm2 in controls. Due to the mosaic genotype of the 
crispant fish, and not being able to determine which cells were mutant or not, a high 
level of variability was to be expected. Furthermore, total SV2 cluster area was 
decreased, suggesting there is still impaired innervation of myotomes at this time 
point. Reflecting this result, clusters of AChRs remain significantly smaller at 5 dpf, 
and total cluster area is reduced. This highlights a potential mechanism of MYO9A-
loss affecting AChR clustering during development, such as effects on the agrin-
LRP4-MuSK pathway. Zebrafish lacking functional proteins involved in this pathway 
similarly display reduced AChR clustering (Kim et al., 2007, Muller et al., 2010, 
Remedio et al., 2016, Zhang and Granato, 2000).  
The level of AChE activity was quantified in myo9aa/ab crispant fish and compared to 
wildtype controls, revealing a significant reduction in activity at 24 hpf, 48 hpf and 5 
dpf. This could reflect developmental delay in the crispant fish as the levels of activity 
have been shown to correlate with developmental stage (Koenig et al., 2016). This 
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could also reflect a decrease in expression/action of AChE due to effects of 
Myo9aa/ab on the enzyme directly. There could also be an indirect effect on AChE 
through reduced nerve/muscle tissue quantity in crispants and corresponding to this 
there was a reduction in total AChR/SV2 cluster areas for the time points where 
reduced AChE activity was observed, which could reflect less NMJs (and thus less 
AChE expressed). However, whether smaller NMJs lead to less AChE activity or if 
the effect is converse is not clear, as in a zebrafish AChE mutant AChR clustering 
and neural input to the axial musculature is also reduced (Behra et al., 2002). 
Another theory is that reduced AChE activity could influence the amount of ACh 
present in the synaptic cleft and thus decrease the activation of AChRs, reflected in 
the abnormal movements observed at 24 and 48 hpf. Defective movements in the 
AChE mutant zebrafish have similarly been observed, although these fish completely 
lack enzymatic activity and are paralysed by 3 dpf (Behra et al., 2002). To ascertain 
whether the reduction in AChE activity in myo9aa/ab crispants is sufficient to impair 
the action of ACh on AChRs, and thus affect depolarisation of the muscle and 
resulting muscle contractions, it would necessary to perform electrophysiology in the 
zebrafish.  
The question also remains as to whether there is CNS involvement in any 
phenotypes observed, as previous studies of the MYO9A KO mouse revealed the 
variable presence of hydrocephalus but also an impairment in CNS glutamatergic 
signaling (Abouhamed et al., 2009, Folci et al., 2016). One of the MYO9A CMS 
patients also displayed signs of learning difficulties in early life (O'Connor et al., 
2016). While analysis of tg(islet1:GFP) zebrafish didn’t reveal any gross 
abnormalities, a more in depth characterisation of CNS morphology may be useful, 
including the cerebellum which is important for movement coordination.  
Overall, a number of effects on movement during early development of zebrafish 
lacking Myo9aa/ab were observed, and supported by a number of defects in NMJ 
morphology up to 5dpf. Whether these structural changes represent impairment to 
signal transmission will require further investigation.  
4.7.5 Analysis of NMJ morphology in the MYO9A KO mouse 
Analysis of NMJ and muscle morphology was performed in the MYO9A KO mouse 
revealing an overall decrease in NMJ size (for tibialis anterior, diaphragm and 
intercostal muscle). This included a decrease in presynaptic area, presynaptic branch 
number, number of branch points, branch length and terminal complexity. There was 
161 
 
also a tendency toward smaller postsynaptic features such as decreased AChR area, 
endplate area, average AChR cluster area, synaptic contact and % overlap of pre 
and postsynapse. Analysis of muscle fibre area was also reduced in mutants. The 
co-occurrence of reduced NMJ size and muscle fibre area could suggest that one is 
affected as a consequence of the other, however this cannot be determined from the 
data available and is confounded by the finding that muscle fibre area is also reduced 
in gastrocnemius muscle which does not exhibit consistent changes in NMJ area. 
Insight could be gained from measurement of fibre diameters and NMJ morphologies 
in conjunction, to see whether large NMJs ever appear on small fibres and vice 
versa. It must be noted that mutant and wildtype mice were not aged matched, with 
the mutants being approximately 6 months older. As both groups of mice were 
adults, and it has been shown that little difference is expected to occur in NMJ size 
until between 14 and 19 months, they were both included in the study (Cheng et al., 
2013). Aged matched mice are being analysed in a future project. Furthermore, in the 
zebrafish experiments using age-matched fish, similar reductions in number of pre 
and postsynaptic clusters were identified at 48 hpf in fish lacking Myo9aa/ab, as well 
as a decrease in total SV2 and AChR cluster area at all time points assessed.  
In the analysis of mouse NMJs, it was surprising that not all muscles were affected by 
MYO9A loss in the same way. For example, gastrocnemius NMJs displayed an 
increase in % overlap of pre and postsynaptic regions as well as an increase in 
synaptic contact, as opposed to a decrease in these features for the other muscles 
assessed. However, in other mouse models of CMS such as agrnnmf380/nmf380, a 
differential effect on NMJ degeneration was observed in diaphragm, tibialis anterior 
and soleus muscles, with the rate of degeneration varying between the three muscles 
(Bogdanik and Burgess, 2011). In the muscle-specific Gfpt1tm1d/tm1d mouse, 
quantification of AChR cluster area revealed a larger decrease in mutant animals for 
the tibialis anterior than intercostal muscles, again highlighting the variable 
susceptibility of muscles to disruption in NMJ-related genes (Issop et al., 2018). It 
would be interesting to investigate further, using an RNAseq or proteomic-based 
approach to identify differentially regulated pathways between each of the muscles. 
Furthermore, as tibialis anterior contains predominantly fast twitch muscle fibres, and 
gastrocnemius, diaphragm and intercostal muscles are mixed, assessment of a 
predominantly slow twitch muscle such as soleus should also be performed. This 
would assist in identifying any fibre-type specific changes to NMJ morphology, as 
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even in wildtype muscle it has been observed that NMJs have a fibre type-specific 
morphology (Ogata and Yamasaki, 1985). 
4.7.6 Summary 
Analysis of NMJs in zebrafish and mice lacking MYO9A, as well as in patient iNPC 
neurites, reveals some changes regarding morphology that may indicate a role for 
MYO9A at this synapse. Of particular interest was the discovery that at 24 hpf in 
zebrafish lacking Myo9aa/ab there is an impairment in AChR cluster formation and 
neuron growth, and the number of pre and postsynaptic clusters are reduced in 48 
hpf zebrafish, as well as less developed innervation patters, which is reflected in the 
defective movements recorded in morphants and crispants lacking Myo9aa/ab. 
Similarly, the tibialis anterior muscle in adult MYO9A KO mice had NMJs of a 
significantly reduced size, as well as less consistent decreases in size for other 
muscles assessed. Further investigations are required to try and separate the 
contribution of MYO9A to pre and postsynaptic phenotypes, however, this 
comprehensive phenotyping provides a basis on which to use modulating 
compounds or therapeutic targets in an attempt to understand more about the 
pathways or rescue the phenotype, respectively.  
To understand how MYO9A loss is affecting the NMJ and accompanying motor 
behaviours in the zebrafish, in the next chapter a potential mechanism of action will 
be explored and contribution of the RhoA pathway to phenotypes assessed.   
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Chapter 5. Investigation of cytoskeleton and vesicle trafficking in 
absence of MYO9A 
5.1 Introduction 
In the previous chapter, a role for MYO9A was identified in nerve cell morphology, as 
well as in the development of the zebrafish NMJ and in maintenance of adult mouse 
NMJs. How MYO9A is playing a role at the NMJ is as yet unknown. Due to the 
interaction of this unconventional myosin with actin and the RhoA pathway, it was 
hypothesised that MYO9A would affect the cytoskeleton and vesicle trafficking in 
nerve, and potentially also muscle cells, thus impacting on synaptic organisation.  
MYO9A is an actin-based molecular motor, with a RhoGTPase domain in the tail 
specific to the MYO9 subtype of unconventional myosins. MYO9A has previously 
been shown to regulate the actin cytoskeleton in a number of studies (Omelchenko 
and Hall, 2012, Saczko-Brack et al., 2016, Wallace et al., 2018). While the 
cytoskeleton is critically important for both pre and postsynaptic compartments of the 
NMJ, here the focus will be on the neuronal cytoskeleton as MYO9A has previously 
been shown to play a role in neurons (Folci et al., 2016, O'Connor et al., 2016). The 
neuronal cytoskeleton is a complex structure composed of a series of highly dynamic 
components, namely microtubules, actin filaments and intermediate filaments, as 
summarised in Figure 5.1. Throughout neuron migration, neurite extension, synapse 
formation and maintenance, the cytoskeleton undergoes constant changes in order 
to accommodate alterations in morphology, protrusion formation, attachment, 
trafficking of proteins and endo/exocytosing important signaling molecules or 
receptors. The cytoskeleton is even more critical in neurons as opposed to other cell 
types, due to the extensive distances that axons have to travel in the body. 
Therefore, the network of structural and motor proteins must not only maintain cell 
shape but also transport cargo to and from the cell body and nerve terminals.  
The microtubule network is the component primarily responsible for mediating this 
long-distance axonal transport, and is formed from multiple filaments of α- and β-
tubulin that interact to form tubular structures with polarity. A number of proteins 
associate with microtubules, including the molecular motors that transport cargo 
between nerve terminals and the soma, proteins that bind to stabilise or destabilise 
structures and those that provide links to other cytoskeletal components (Kirkpatrick 
and Brady, 1999).  
164 
 
Actin is also involved in cellular transport processes, as well structural stability of 
cells and tethering of surface proteins. F-actin is a polar structure composed of 
globular actin monomers bound to ATP. These filaments are highly dynamic, with 
constant turnover occurring as monomers are lost and gained, while overall filament 
length remains the same. Actin binding proteins are able to influence filament 
dynamics by capping the ends to affect turnover (Kirkpatrick and Brady, 1999, 
Rottner et al., 2017). Stress-fibres, parallel bundles of actin and myosin, are more 
stable than other filaments and act to manipulate cell shape and adhesion, influenced 
by the RhoA/ROCK pathway (Tojkander et al., 2012). Cross-linking proteins are also 
important in stabilising filaments, and can provide links to important components of 
the NMJ such α-actinin which may anchor AChRs to the actin network and rapsyn 
(Dobbins et al., 2008, Mitsui et al., 2000). F-actin utilises a range of motor proteins, 
such as the myosin superfamily, to facilitate transport within neurons. Myosins can 
have the ability to respond to important biochemical alterations such as elevated 
calcium, which in the case of unconventional myosin va causes the binding of 
syntaxin at active zones and subsequent docking of synaptic vesicles (Watanabe et 
al., 2005). 
Neurofilaments are members of the intermediate filament family and represent the 
third significant contributor to the neuronal cytoskeleton. These filaments are made 
up of light, medium and heavy chains and they lack polarity, thus providing 
predominantly structural support to cells. Peripheral neuropathies including Charcot-
Marie-Tooth disease have been shown to be linked to alterations in neurofilament 
expression (Zhai et al., 2007).  
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Figure 5.1. Schematic of major cytoskeletal components in neurons.  The three 
main cytoskeletal components of neurons are actin filaments, microtubules and 
neurofilaments. Microtubules are particularly important for long-distance axonal 
transport, neurofilaments for stability and various confirmations of actin are shown for 
stress-fibre formation, acto-myosin contractility, vesicle sequestration and cortical 
actin for cell morphology. Diagram taken from O’Connor et al (2018a). 
RhoGAPs and RhoGEFs are important proteins in the dynamic regulation of actin 
filaments through their interaction with small GTPases such as RhoA. Dysfunction of 
members of this family, such as FRABIN, have already been reported to impact 
functioning of the peripheral nervous system, in this case to cause Charcot-Marie-
Tooth disease type 4H (Delague et al., 2007). RhoA is of particular interest as 
MYO9A contains a RhoGAP domain and has been shown to negatively regulate this 
GTPase (Chieregatti et al., 1998). Rho activity can modulate actin dynamics and 
affect focal adhesion formation (Ridley and Hall, 1992), thus may provide a link 
between MYO9A defects and downstream impacts on the filaments to which they 
bind and traverse. A key effector of RhoA is ROCK, which acts on a number of other 
molecules. These include activation of LIM kinase which coordinates actin 
polymerisation, myosin regulatory light chain to promote contractility, and to influence 
binding of actin to the membrane and intermediate filament proteins such as desmin 
(Schwartz, 2004). A summary of the main actions of the RhoA/ROCK pathway are 
shown in Figure 5.2, including the action of the ROCK inhibitor compound: Y-27632, 
used in this chapter.  
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Disruption in any of a number of these cytoskeletal components and interacting 
pathways may lead to disruption in NMJ formation and signal transmission. 
Therefore, in this chapter the effect of mutations or loss of MYO9A expression on the 
cytoskeleton and RhoA pathway will be examined using the models generated in 
Chapter 3.  
 
Figure 5.2. Action of MYO9A on the RhoA/ROCK pathway. MYO9A has been 
shown to negatively regulate the activity of RhoA, an effector of ROCK (among other 
substrates). Through ROCK signalling, MYO9A may indirectly affect a number of 
different aspects of neuronal cytoskeleton modulation. Black arrows = activation, red 
arrows = inhibition. The site of action of two ROCK inhibitors used in this study (Y-
27632 and fasudil) is also shown. Figure adapted from: (O'Connor et al., 2018a, 
Schwartz, 2004). 
5.2 Aim of chapter 
The aim of this chapter was to determine whether MYO9A influences the structure or 
function of the NMJ through effects on the cytoskeleton and RhoA pathway. 
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5.3 Cytoskeletal defects in MYO9A-deficient NSC-34 cells 
Based on the aforementioned functions of MYO9A, to assess whether loss of 
MYO9A impacts the cytoskeleton in nerve cells, immunofluorescence was performed 
on MYO9A KD NSC-34 cells for 3 of the major cytoskeletal components: β-tubulin, 
neurofilament (light chain) and F-actin (Figure 5.3A). Observation of protein 
localisation showed an apparent decrease in perinuclear fluorescence intensity for β-
tubulin and neurofilament in MYO9A KD cells. F-actin-positive extensions from the 
MYO9A KD cells also have a different morphology to those observed in control cells, 
with a much denser staining pattern and the presence of stress-fibre like structures 
across the cell body.  
Quantification of fluorescence intensity revealed a significant decrease in the amount 
of β-tubulin in MYO9A KD cells as compared to controls (p<0.0001, Mann Whitney 
test, Figure 5.3B). There was also a decrease in the amount of fluorescently labelled 
neurofilament light chain detected (p<0.0001, Mann Whitney test). Conversely, there 
was a significant increase in the expression of F-actin in MYO9A KD cells (p=0.0016, 
Mann Whitney test).  
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Figure 5.3. Quantification of cytoskeletal protein immunofluorescence in 
MYO9A KD NSC-34 cells.  A. Control and MYO9A KD NSC-34 cells were stained for 
β-tubulin, neurofilament light chain and F(filamentous)-actin. Enlarged portions of the 
representative images are shown in the right hand panels. Scale bar = 10µm. B. 
Corrected total cell fluorescence quantified for each fluorophore in control and 
MYO9A KD NSC-34 cells: β-tubulin (control n=30, MYO9A KD n=28), neurofilament 
light chain (control n=130, MYO9A KD n=223) and F-actin (control n=41, MYO9A KD 
n=34), measurements corrected for cell-size. **p≤0.01, ****p<0.0001, Mann Whitney 
test. Error bars = mean ± S.E.M.  
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To confirm the results obtained using fluorescence quantification, western blots were 
performed for β-actin (ubiquitously expressed actin isoform) and β-tubulin (Figure 
5.4). The adjusted β-tubulin density was significantly decreased in MYO9A KD cells 
as compared to controls (p=0.0286, Mann Whitney test). β-actin on the other hand 
was significantly increased, as found in the fluorescence experiment (p=0.0286, 
Mann Whitney test). 
 
Figure 5.4. Western blot analysis of cytoskeletal proteins in cells depleted for 
MYO9A.  Western blots were performed for β-tubulin and β-actin in control and 
MYO9A KD NSC-34 cells and a Coomassie used for loading control. Adjusted 
densities (normalised to loading control) are shown for 4 repeats and MYO9A KD 
results are expressed as proportion of control. *p≤0.05, Mann Whitney test, error bars 
= mean ± S.E.M.  
Initial observations of the actin cytoskeleton in MYO9A KD cells revealed the 
presence of actin stress-fibre like structures. Examples of such structures stained 
with phalloidin are shown in Figure 5.5A. The number of MYO9A KD cells that had 
actin stress fibre-like bundles present was 67% higher than in control NSC-34 cells 
(p<0.0001, Mann Whitney test, Figure 5.5B). Using a directionality plugin available on 
ImageJ, the organisation of actin filaments in the cells was also assessed (Figure 
5.5C). The plugin determines the direction that most structures are orientated toward, 
and from this calculates a degree of dispersion (standard deviation) from this value. 
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There was significantly less organisation (more dispersion) of actin filaments in 
control cells as compared to MYO9A KD cells, suggesting that more filaments were 
arranged into parallel stress fibre-like structures that have a similar orientation in 
MYO9A KD cells (p<0.0001, Mann Whitney test).  
 
Figure 5.5. Assessment of actin stress fibre-like structures in cells depleted for 
MYO9A. A: Representative images showing presence of actin stress fibre-like 
structures in MYO9A KD cells. White box demarks enlarged region of image shown 
in right-hand panel. Scale bars = 20µm. B. Percentage of control (n=104) and 
MYO9A-depleted (n=65) NSC-34 cells that have actin stress fibre-like structures 
present. C: Orientation of actin positive fibres assessed using the ImageJ 
Directionality plugin. The dispersion of the fibre direction is shown (low dispersion = 
increased organisation). ****p<0.0001, Mann-Whitney test, Control n=75 MYO9A KD 
n=59, error bars represent mean ± S.E.M. 
5.4 Cytoskeleton in MYO9A CMS patient cells 
To determine whether the presence of MYO9A mutations associated with CMS also 
cause defects in the cytoskeleton, patient fibroblasts and iNPCs were subject to 
immunoblot analysis of β-tubulin, β-actin and neurofilament light chain (Figure 5.6A). 
Following normalisation of β-actin densities to loading control, there was a decrease 
in detected protein levels in MYO9A patient fibroblasts as compared to control 
fibroblasts (Figure 5.6B). Conversely, there was a slight increase in expression of β-
actin for differentiated MYO9A patient iNPCs. There were no significant differences 
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between the expression of β-tubulin between patient and control fibroblasts or 
differentiated iNPCs (Figure 5.6C). Neurofilament light chain levels were decreased 
in MYO9A patient fibroblasts, as found in immunofluorescence for MYO9A KD NSC-
34 cells, however in iNPCs there was a slight increase in average expression as 
compared to controls (Figure 5.6D). Therefore, the cytoskeleton quantification results 
do not consistently replicate those observed in NSC-34 cells, however more data 
would be required to confirm observations.  
 
Figure 5.6. Western blot analysis of cytoskeletal proteins in MYO9A patient 
CMS fibroblasts and iNPCs.  (A) Western blots were performed for (B) β-actin 
(n=2), (C) β-tubulin (n=3) and (D) neurofilament light chain (NF-L, n=2) in control and 
MYO9A patient fibroblasts and differentiated iNPCs, with Coomassie loading control. 
Adjusted densities (normalised to loading control) are shown for control and MYO9A 
CMS patient fibroblasts and iNPCs. ns=not significant, Mann Whitney test, error bars 
= mean ± S.E.M.  
5.5 Cytoskeleton in vivo 
The levels of cytoskeletal components in zebrafish and mice were also assessed in 
the absence of MYO9A to determine whether results reflect those obtained in vitro. In 
zebrafish, blots were performed on 48 hpf uninjected, myo9aa/ab crispants and tyr 
crispants (Figure 5.7). Following normalisation to loading control, as opposed to 
results obtained in NSC-34 cells, levels of β-tubulin were significantly increased in 
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zebrafish lacking Myo9aa/ab as compared to controls or tyr crispants (p=0.0027, 
p=0.0410 respectively, Unpaired t-test). Expression of β-actin, however, corroborates 
that found in the nerve cell-line, with a significant increase in Myo9aa/ab depleted 
fish as compared to controls and tyr crispants (p<0.0001, p=0.0002 respectively, 
Unpaired t-test). There was no significant difference in expression of β-tubulin or β-
actin between controls and tyr crispant fish (p=0.4705, p=0.3613 respectively, 
Unpaired t-test). Therefore, knockout of MYO9A causes similar effects on amount of 
β-actin in vitro and in vivo, whereas β-tubulin quantities differ.  
 
Figure 5.7. Western blot analysis of cytoskeletal proteins in myo9aa/ab crispant 
zebrafish.  Western blots were performed for β-tubulin (n=3) and β-actin (n=3) in 
control, myo9aa/ab crispant and tyr crispant zebrafish, with a Coomassie loading 
control. Mouse kidney was included as a positive control. Adjusted densities 
(normalised to loading control) are shown. NS=not significant, *p≤0.05, **p≤0.01, 
***p≤0.001, ****p<0.0001, Mann Whitney test, error bars = mean ± S.E.M.   
Wildtype and MYO9A KO mice were also subject to immunoblot analysis for 
cytoskeletal proteins using gastrocnemius, quadriceps and heart tissues, as well as 
kidney and tibialis anterior muscle for β-tubulin (Figure 5.8). Levels of β-tubulin after 
normalisation to loading control were significantly decreased in mutant 
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gastrocnemius as compared to wildtype (p<0.0001, Mann Whitney test). Levels were 
also reduced in quadriceps muscle but this was not significant (p=0.1268, Mann 
Whitney test), and there was no consistent change in tibialis anterior muscle 
(p=0.9338, Mann Whitney test). Heart and kidney expression of β-tubulin appeared 
unaffected by absence of MYO9A. Levels of neurofilament or β-actin were not 
significantly different between wildtype and mutant animals for any tissue measured. 
Therefore, results obtained in the MYO9A KO mouse for the gastrocnemius muscle 
reflect those observed in the NSC-34 cells depleted for MYO9A, however, there is a 
lack of consistent changes for the other cytoskeletal components/tissues.  
  
174 
 
 
Figure 5.8. Western blot analysis of cytoskeletal proteins in MYO9A KO mice.  
Western blots were performed for β-tubulin in heart, kidney, gastrocnemius 
(Gastroc), tibialis anterior (TA) and quadriceps (Quad) muscles of wildtype (WT) and 
MYO9A KO (MT) mice, with a Coomassie loading control. β-actin and neurofilament 
(light chain) were also subject to western blot analysis in Gastroc, Quad and Heart 
tissues. Adjusted densities (normalised to loading control) are shown. ****p<0.0001, 
Mann Whitney test, unlabelled pairs are not significant. Error bars = mean ± S.E.M. 
Data from 2 wildtype and 3 mutants pooled for analysis.  
5.6 Effects of ROCK inhibitor treatment on cytoskeleton 
RhoA mediates the action of a large range of intracellular pathways, including 
activation of ROCK and subsequent signalling cascades affecting components of the 
cytoskeleton such as microtubules and actin (Liu et al., 2015). As cytoskeletal protein 
quantities were found to be altered in NCS-34 cells lacking MYO9A, to determine 
whether this was due to the action of MYO9A on the RhoA pathway a ROCK inhibitor 
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(Y-27632) was applied to the cells and the assays repeated. In both control and 
MYO9A KD cells application of Y-27632 caused neurite extension (Figure 5.9A), as 
reported in the literature, thus providing evidence of effective treatment conditions 
(Chen et al., 2013, Gu et al., 2013). 
Quantification of fluorescence intensity was performed (Figure 5.9B), revealing that 
while Y-27632 increased the level of β-tubulin in MYO9A KD cells, it was not 
significantly improved from the level in untreated cells (p=0.0590, Mann Whitney 
test). The expression of β-tubulin following treatment also remained significantly 
different to that in controls (p<0.0001, Mann Whitney test). Y-27632 application 
significantly decreased the level of β-tubulin in controls cells as compared to 
untreated (p=0.0044, Mann Whitney test).  
Expression of F-actin was significantly reduced in MYO9A KD cells by application of 
Y-27632 (p=0.0007, Mann Whitney test), to a level that was no longer significantly 
different to control cells (p=0.4836, Mann Whitney test). Treatment of control cells did 
not significantly affect the level of actin present (p=0.3903, Mann Whitney test). 
Neurofilament levels were decreased in MYO9A KD cells when compared to controls, 
however, Y-27632 treatment significantly decreased this further (p=0.0416, Mann 
Whitney test). Levels of neurofilament were also significantly decreased in control 
treated cells as compared to untreated controls (p<0.0001, Mann Whitney test). 
Therefore, application of Y-27632 and thus blockade of ROCK signalling significantly 
improved levels of F-actin in the MYO9A KD cells but not neurofilament or β-tubulin.  
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Figure 5.9. Analysis of cytoskeleton in presence of Y-27632. A. 
Immunofluorescent staining of control and MYO9A-depleted NSC-34 cells with and 
without over-night treatment of ROCK inhibitor: Y-27632 (10µM). β-tubulin, 
neurofilament light chain and F-actin were assessed. Scale bars = 20µm. (B) Graphs 
showing the corrected total cell fluorescence for levels of β-tubulin (n > 26), 
neurofilament (n > 87) and F-actin (n > 33) in each cell/treatment condition. p ≤ 0.05, 
**p≤ 0.01, ***p≤ 0.001, ****p< 0.0001, ns = not significant, Mann Whitney test. 
MKD = MYO9A-depleted, error bars = mean ± S.E.M. 
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Western blot analysis of cells treated with Y-27632 was also performed to confirm 
fluorescence data (Figure 5.10). Neurofilament levels were decreased in cells lacking 
MYO9A, and this was increased by application of Y-27632 but not to the same level 
as in controls. Similarly, treatment also increased levels of neurofilament in control 
cells. While these trends don’t reflect results observed in immunofluorescence, not 
enough data was obtained to perform statistics.  
β-tubulin levels remained unchanged by Y-27632 treatment in MYO9A KD cells 
(p=0.4857, Mann Whitney test), thus expression was still significantly reduced when 
compared to controls as found in fluorescence analysis (p=0.0294, Mann Whitney 
test). Inhibitor treatment significantly decreased β-tubulin expression in control cells, 
as also observed using fluorescence quantification (p=0.0294, Mann Whitney test). 
Reflecting results obtained in the immunofluorescence analysis, application of Y-
27632 in MYO9A KD cells was able to reduce the expression of β-actin. However, 
this still remained higher than in untreated control cells. Control cells treated with the 
inhibitor displayed a slightly elevated expression of β-actin. Overall, western blot 
analysis revealed similar effects of Y-27632 treatment on cells for β-actin and β-
tubulin expression, but not for neurofilament. A summary of all western blot results is 
shown in Table 5-1.  
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Figure 5.10. Western blot analysis of cytoskeletal proteins in the presence of Y-
27632.  Control and MYO9A KD (MKD) NSC-34 cells were untreated or subject to Y-
27632 treatment overnight before western blot analysis of β-tubulin (n=4), 
neurofilament light chain (n=2) and β-actin (n=2) quantities. Coomassie used as 
loading control. Graphs depict the adjusted densities (normalised to loading control). 
*p≤0.05, ns=not significant, Mann Whitney test for β-tubulin blots. Error bars = mean 
± S.E.M. 
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Table 5-1. Summary of western blot results for MYO9A KD NSC-34 cells, patient 
fibroblasts and iNPCs and MYO9A KO mouse tissue lysates.  Results are shown 
as compared to the relevant untreated control for each group. Trend of change is 
indicated by arrows, with no change highlighted by: ↔. Statistically significant results 
are described elsewhere but are labelled with appropriate number of asterisks. Red = 
downregulated, blue = no change, green = upregulated.  
5.7 Vesicle trafficking 
Due to the observed effects of MYO9A-depletion on the cytoskeleton, it was 
hypothesised that this may lead to a downstream impact on vesicle trafficking, a 
process highly dependent on the appropriate structure of the cytoskeleton. If vesicle 
trafficking were impaired, this may provide insight into how MYO9A could cause 
impaired function of the NMJ, as transport of proteins to the NMJ, out of the terminal 
and into the cleft and also uptake of proteins from muscle or Schwann cells are 
crucial for proper function. 
5.7.1 FM-dye in NSC-34 cells and iNPCs 
In order to test whether there is a global defect in endo/exocytosis from NSC-34 cells 
depleted for MYO9A, an FM-dye assay was performed using FM 1-43. FM-dyes 
become brightly fluorescent when taken up into the membrane of endocytosing 
vesicles, therefore dye was applied to the cells for different time periods to measure 
its uptake and release over time (Figure 5.11A). Quantification of fluorescence 
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intensity was performed at times 1, 3, 6, 9 ,12, 15 and 18 mins, to allow time for 
vesicle internalisation and subsequent spontaneous release (Figure 5.11B, Bertrand 
et al., 2006, Zefirov et al., 2006). No significant differences in fluorescence intensity 
were identified at 1 or 3 mins (p=0.6478, p=0.3235 respectively, Unpaired t-test). At 6 
mins, control cells had taken up significantly more dye than MYO9A KD cells 
(p=0.0220, Unpaired t-test), whereas by 9 mins, control cells exocytosed significantly 
more dye than MYO9A KDs (p=0.0014, Unpaired t-test). A significant increase in 
uptake then occurred in MYO9A KD cells from 12 – 18 mins as compared to controls 
(p< 0.0001, p=0.0037, p< 0.0001 respectively, Unpaired t-test).  
  
181 
 
 
Figure 5.11. Global endo/exocytosis analysis using FM-Dye in MYO9A-depleted 
cells.  A: Control and MYO9A KD NSC-34 cells were exposed to FM 1-43 dye for 
between 1 and 18 mins before fixation for quantification at different time points. 
Uptake of dye into membrane of endocytosing vesicles creates a fluorescent signal 
(red). Scale bar = 10µm. B: Graph displaying the corrected total internal FM-Dye cell 
fluorescence at different time points, *p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001, 
Unpaired t-test. Error bars = mean ± S.E.M, 1-9 mins n>100, 12-18 mins n>36. 
While evidence of disrupted cytoskeleton was not obtained from preliminary western 
blot analysis in patient fibroblast or iNPCs, samples were limited and thus results not 
conclusive. In order to determine whether the differentiated iNPCs had similar 
defects in endo/exocytosis as the MYO9A KD NSC-34 cells, a FM-dye assay was 
also performed. In this assay cells were incubated with FM 1-43 for 1 minute to allow 
loading of cells. This was followed by fixation, or by washing for 10 mins then fixation, 
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or subsequent treatment with a high KCl solution to stimulate vesicle release for 5 or 
25 mins before fixation (Figure 5.12A, Iwabuchi et al., 2014). Initial uptake of dye was 
significantly higher in control subject cells compared to MYO9A patient cells, as 
identified by increased fluorescence intensity (p<0.0001, Mann Whitney test, Figure 
5.12B). By 10 mins, uptake had increased in MYO9A iNPCs and was significantly 
lower in controls (p<0.0001, Mann Whitney test), however, this difference was no 
longer significant by 15 mins (p=0.3202, Mann Whitney test). After 25 mins of high 
KCl treatment, control iNPCs exocytosed the majority of detectable FM 1-43 dye, as 
expected, however MYO9A KD cells retained the dye within cells and had 
significantly higher levels of FM 1-43 fluorescence (p< 0.0001, Mann Whitney test).  
 
Figure 5.12. Global endo/exocytosis analysis using FM-Dye in MYO9A CMS 
patient iNPC cells.  A: Control and MYO9A CMS patient differentiated iNPC cells 
were exposed to FM 1-43 dye (green) for 1 minute and then either fixed, washed for 
10 mins and fixed, or subject to a further 5 or 25 mins in high KCl solution. Scale bar 
= 20µm. B: Graph displaying the corrected total FM-Dye cell fluorescence at different 
time points, ****p<0.0001, ns = not significant, Mann Whitney test. Error bars = mean 
± S.E.M, n>147 per time point.  
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5.7.2 TrkA receptor dynamics 
Following the finding that global endo/exocytosis was impaired in patient and MYO9A 
KD cells using FM 1-43 dye assays, the internalisation and recycling back to the 
surface of a paradigmatic receptor was assessed in the NSC-34 cell model. The TrkA 
receptor was chosen due to the ability to stimulate its internalisation using application 
of its high affinity ligand: NGF. Transfection of a TrkA-GFP construct was performed 
in both control and MYO9A KD NSC-34 cells and production of the TrkA protein was 
confirmed by staining cells with an anti-TrkA antibody (Figure 5.13). 
 
Figure 5.13. Confirmation of TrkA protein production by TrkA-GFP plasmid.  
Control NSC-34 cells were transfected with a TrkA-GFP (green) plasmid and stained 
with an anti-TrkA antibody (red) to confirm the antibody colocalises with the GFP-
positive signal. Scale bar = 50µm.  
After 24 hours the proportion of cells with receptors on the surface or internalised 
was determined. Example images of receptor position classification are shown in 
Figure 5.14A. Cells were classified before application of NGF, and then immediately 
following application and at 10, 30, 60 and 180 minute time points thereafter (Figure 
5.14B). An initial decrease in the number of cells expressing surface receptors 
occurred following application of NGF, as expected, with no significant difference 
between control and MYO9A KD cells (p=0.3429, Mann Whitney test). In control cells 
almost all receptors had returned to the surface by 60 mins post-NGF application, 
which was complete by 180 mins. However, MYO9A KD cells had significantly fewer 
cells with surface receptors at these time points, and did not reach the same level of 
surface as expression as preNGF within the 180-minute time frame (p=0.0286, 
p=0.0284, Mann Whitney test).  
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Figure 5.14. Internalisation of paradigmatic receptor in control and MYO9A KD 
NSC-34 cells.  A. Control and MYO9A KD NSC-34 cells were transfected with a 
TrkA-GFP construct (green). Representative images for classification of surface and 
internalised TrkA-GFP receptors. Scale bars = 10µm. B. Graph depicting the change 
in TrkA receptor localisation over-time following NGF application to induce 
internalisation. Values have been normalised to pre-NGF levels to allow direct 
comparison at each time point and error bars represent the mean ± S.E.M from 4 
repeats, NGF = nerve growth factor, *p≤0.05, ns = not significant, Mann Whitney test, 
n=200. 
A reduction in the number of receptors returning to the surface in MYO9A KD cells 
could be indicative of disrupted trafficking processes, however it could also be 
explained by increased degradation of receptors within the cell. To explore this 
option, the level of TrkA expression over the time period of the experiment was also 
measured using western blotting. As shown in Figure 5.15, the expression of TrkA 
decreased over 180 mins in both control and MYO9A KD cells, with no significant 
difference between the two expression levels (p=0.6428, p=1.000, p=0.700, time 0, 
60 and 180 mins respectively, Mann Whitney test). Thus increased protein 
degradation does not appear to account for the reduced surface expression of TrkA 
receptors in cells depleted for MYO9A.  
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Figure 5.15. Expression of TrkA in control and MYO9A KD cells  at time 0, 60 
and 180 min, following application of nerve growth factor. Results shown are relative 
to control cells at time 0 min. Example blots are shown under the graph with 
Coomassie loading controls. Error bars represent mean ± S.E.M from 3 repeats. ns = 
not significant, Mann Whitney test. 
5.7.3 TrkA trafficking and Y-27632 treatment 
Following the observation that there is not increased degradation of TkrA receptors in 
MYO9A KD cells as compared to controls, a basic tracking experiment was 
performed to determine whether trafficking of receptors is impaired. Control and 
MYO9A KD NSC-34 cells were transiently transfected with TrkA-GFP and 24 hours 
later were subject to live-cell imaging over 10 minute periods (Figure 5.16). The 
speed of GFP-positive receptors was tracked using IMARIS software (x64 v8.4.0).  
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Figure 5.16. IMARIS-based tracking of TrkA-positive vesicles over time.  TrkA-
GFP clusters were imaged over periods of 10 mins in individual cells and IMARIS 
used to select and track the movement of individual clusters. Coloured spots 
represent the cluster/vesicles and the pathways moved are shown as coloured lines. 
Enlarged region in white box.  
In cells depleted for MYO9A, receptors moved significantly slower than in controls 
(p<0.0001, Mann Whitney test, Figure 5.17A). As it was demonstrated that cells have 
a disrupted cytoskeleton and that expression of some cytoskeletal proteins can be 
rescued by the application of Y-27632, this was tested to see if blocking the ROCK 
pathway would improve the speed of intracellular receptor movement. In control cells, 
overnight treatment with 3nM Y-27632 caused a significant reduction in the speed of 
TrkA movement (p<0.0001, Mann Whitney test), however, in MYO9A KD cells it 
caused a significant improvement in speed, although not to the same level as 
untreated controls (p<0.0001, Mann Whitney test). As it was hypothesised that 
transport machinery would be disrupted due to the impact of MYO9A on the 
cytoskeleton, the result of independent disruption of the cytoskeleton on intracellular 
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transport was also tested (Figure 5.17A,B). Treatment of control cells with 1µg/ml 
Cytochalasin-D for 1 hour (disrupts actin cytoskeleton) or 10µM Nocodozole for 5 
hours (affects β-tubulin network) caused a significant decrease in the speed of GFP-
positive receptor movements within the cells (p<0.0001, Mann Whitney test).  
 
Figure 5.17. Trafficking of TrkA receptors in MYO9A KD NSC-34 cells in 
presence of Y-27632.  A. Speed of internalised TrkA-GFP-positive receptors tracked 
in live cells imaged over 10 mins. Control and MYO9A KD NSC-34 cells were either 
untreated or treated with a ROCK inhibitor (Y-27632). Controls cells were also 
subject to Cytochalasin D (1µg/ml) or Nocodozole (10µM) to disrupt the actin and β-
tubulin networks, respectively. Absolute values are shown and error bars represent 
mean ± S.E.M, ****p<0.0001, Mann Whitney test, n=10 cells per condition. B. 
Representative images of cytoskeletal disruption, identified with fluorescent labelling 
of β-actin or β-tubulin, are shown for control NSC-34 cells, scale bars = 25µm. 
5.8 Rho kinase inhibitor therapy in myo9aa/ab crispant zebrafish 
In this chapter, evidence has been provided for a beneficial effect of inhibiting the 
ROCK pathway in vitro using the inhibitor Y-27632. Application of this drug to NSC-
34 cells depleted for MYO9A revealed a partial restoration of cytoskeletal disruption 
and defects in the intracellular trafficking of a paradigmatic protein. As Y-27632 was 
used in an experimental setting, a clinically approved ROCK inhibitor (fasudil) was 
trialled for effectiveness in the zebrafish crispant model (Okumura et al., 2017). The 
effects of fasudil on survival rate, motor behaviour and NMJ morphology were 
assessed, providing insight into whether suppression of an over-active RhoA/ROCK 
system would be beneficial in vivo as well as in the cell model.  
5.8.1 Dose-finding experiments for fasudil in zebrafish 
Fasudil has been approved for use in humans, and has previously been applied to 
zebrafish and other animals (Philip et al., 2017, Gunther et al., 2017, Shibuya et al., 
188 
 
1992). Concentrations in zebrafish that were trialled previously range from 0.01–
75μM and an EC50 of 3.85μM was reported, however, the exact treatment regimen 
and how it was administered was not clear (Philip et al., 2017). Therefore, for this 
study concentrations from 1nM to 100μM were tested and fasudil was administered 
in zebrafish E3 medium, as oral administration of the drug is effective in murine 
systems (Gunther et al., 2017). Wildtype and myo9aa/ab crispant fish were treated 
from 7 hpf until 48 hpf and their survival rates recorded for each concentration 
(Figure 5.18A). Survival rates were variable throughout the concentration ranges, 
however, 75% of controls survive without treatment, and this decreases to 66% at 
100μM fasudil. Crispant fish have a survival rate of 66%, which increases to a 
maximum of 92% with treatment at concentrations of 1μM and 10μM fasudil. 
These preliminary positive effects on survival in crispant fish were further supported 
by functional analysis: the effect on motor behaviours during development. In order to 
find an appropriate dose to use for detailed NMJ analysis, a concentration that 
improves the movement of the fish was desired. Therefore, crispant fish were subject 
to chorion movement analysis at 24 hpf, following fasudil treatment from 7hpf at the 
aforementioned concentrations. Untreated crispants performed on average 0.88 
chorion movements per minute (Figure 5.18B), and this improved as concentration 
was increased, reaching 4.4 movements per minute at 100µM fasudil. While this was 
the largest number of chorion movements, at this concentration the survival of 
crispant fish had started to decline. Therefore, based on the positive improvements 
obtained from 10µM fasudil for both survival and movement, this concentration was 
selected for the subsequent study.  
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Figure 5.18. Dose-finding experiments for fasudil treatment in zebrafish.  A. 
Control and myo9aa/ab crispant zebrafish were treated with fasudil from 7 hpf at 
concentrations from 1nM to 100µM. Survival rates were assessed at 48 hpf and are 
expressed as a proportion of treated fish per concentration (12 fish per 
concentration). B. Fasudil-treated myo9aa/ab crispant fish were subject to chorion 
movement analysis at 24 hpf at varying concentrations of drug from 1nM to 100µM (6 
fish per concentration).  
Utilising the selected concentration of 10µM fasudil, the survival analysis was 
repeated on a larger number of fish that were also used for downstream analysis of 
movement and NMJ morphology (Figure 5.19). In this experiment, 98% of control fish 
survived to 48 hpf, which decreased to 88% with treatment, however this was not 
significant (p=0.6634, Kruskal-Wallis test). Crispant fish had a significantly lower 
survival rate than controls of 63% (p=0.0024, Kruskal-Wallis test), which was 
significantly increased to 91% with fasudil application (p=0.0009, Kruskal-Wallis test). 
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Figure 5.19. Survival rates for fasudil-treated control and myo9aa/ab crispant 
zebrafish.  Control (n=4) and myo9aa/ab crispant (n=6) fish were treated with 10µM 
fasudil (control n=19, crispant n=30) at 7 hpf and survival assessed at 48 hpf. Results 
expressed as percentage of fish survived per condition. **p≤0.01, ***p≤0.001, ns=not 
significant, Kruskal-Wallis test.  
5.8.2 Behavioral analysis 
As performed for assessment of Myo9aa/ab depletion, motor behaviors following 
application of fasudil were also tested to determine whether inhibiting the ROCK 
pathway leads to functional improvements in vivo.  
At 24 hpf the chorion movement assay was repeated with 10µM fasudil on control 
and crispant fish (Figure 5.20). As previously described, there was a significant 
decrease in the chorion movements performed by myo9aa/ab crispants as compared 
to controls (p=0.0004, Kruskal-Wallis test). Application of fasudil significantly 
decreased chorion movements in control fish, but improved them in crispants, 
however, this was not significant (p<0.0001, p>0.9999 respectively, Kruskal-Wallis 
test). 
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Figure 5.20. Movements performed by fasudil-treated zebrafish within the 
chorion at 24 hpf.  Full chorion movements performed in one minute by control 
(n=34), myo9aa/ab crispant (39), fasudil-treated control (n=45) and fasudil-treated 
crispant (n=56) zebrafish at 24 hpf. Error bars = mean ± S.E.M. **p≤0.01, ***p≤0.001, 
****p<0.0001, ns = not significant, Kruskal-Wallis test.  
The response of zebrafish to tactile stimulation at 48 hpf was also recorded and 
compared after fasudil treatment to determine if modulation of RhoA/ROCK effect the 
ability of fish to rapidly swim following a stimulus (Figure 5.21). Fasudil was able to 
significantly improve the distance the crispant fish could swim, how fast they swam 
and also the acceleration observed at the onset of movement (p<0.0001, p=0.0005, 
p=0.0025 respectively, Kruskal-Wallis test), to a level comparable with controls. No 
significant differences in the movement of control fish treated with fasudil were 
observed for any parameter. Overall, treatment of myo9aa/ab crispant fish with 10µM 
fasudil was able to significantly improve survival rates and motor behaviours.  
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Figure 5.21. Tactile stimulation response of fasudil-treated myo9aa/ab crispant 
zebrafish.  Control (n=13), myo9aa/ab crispant (20), fasudil-treated control (n=17) 
and fasudil-treated crispant (n=15) zebrafish were subject to a tactile stimulation 
assay at 48 hpf. Distance travelled after stimulus applied, average speed of 
movement and initial acceleration were quantified for each zebrafish. Error bars = 
mean ± S.E.M. **p≤0.01, ***p≤0.001, ****p<0.0001, ns = not significant, Kruskal-
Wallis test.  
5.8.3 NMJ analysis 
As positive improvements in both survival and motor behaviours were observed 
following fasudil treatment, whether these changes were reflected at the level of the 
developing NMJ was also assessed. As representative images for control and 
myo9aa/ab crispants have already been shown in Chapter 4, Section 4.5.2, here only 
those from fasudil-treated fish are shown (Figure 5.22). Important features are 
present in the treated crispant fish that had been identified as defective in the 
untreated crispants, such as the presence of the ‘choice point’ AChR cluster at 24hpf, 
myoseptal innervation at 48 hpf and clusters of pre/postsynaptic staining over the 
myotomal surface at 5dpf.  
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Figure 5.22. NMJ morphology of fasudil-treated zebrafish.  NMJs were visualised 
in control and myo9aa/ab crispant zebrafish at 24 hpf, 48 hpf and 5 dpf using an 
antibody against SV2 (red, presynaptic vesicles) and fluorophore-conjugated aBTx 
(green, postsynaptic AChRs). Scale bar = 50µm. 
As improvements were observed in crispant zebrafish movements at 24 hpf, analysis 
of NMJ morphology was performed to identify if any of these parameters could be 
linked to such changes, results are summarised in Table 5-2. Due to variability in 
data and lower N numbers, the majority of differences observed were not significant 
(Figure 5.23). The average and total area of AChRs was decreased in myo9aa/ab 
crispant fish as compared to controls, and this rose after fasudil treatment. The same 
trend was also observed in the number of large AChR clusters over 20μM2, as well 
as for the length of motor neuron outgrowths from the spinal cord. The proportion of 
myotomes exhibiting a ‘choice point’ cluster of AChRs was significantly decreased in 
crispant fish as compared to controls and treated controls (p=0.0100, p=0.0147 
respectively, Kruskal-Wallis test). While the mean number of myotomes with a cluster 
increased after fasudil treatment, and there were no longer fish exhibiting no 
myotomal clustering, this improvement was not significant (p=0.2775, Kruskal-Wallis 
test). The size of myotomes in the crispant fish were increased following ROCK 
inhibitor treatment, and this was comparable to the size of control myotomes but was 
not a significant improvement from untreated crispant fish (p=0.0966, Kruskal-Wallis 
test). A similar trend also occurred for length of motor neuron extension past the 
choice point, for which a significant decrease in length was present in crispants but 
not in treated crispants, despite the improvement between untreated and treated 
crispants not demonstrating significance (p=0.3696, Kruskal-Wallis test). 
 
Table 5-2. Summary of NMJ morphology results obtained in 24 hpf zebrafish 
treated with fasudil. Red = significantly less than untreated controls and blue = 
statistically unchanged from controls as compared to controls. 
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Figure 5.23. Quantification of fasudil-treated myo9aa/ab crispant zebrafish NMJ 
morphology at 24 hpf. Various features of NMJ morphology in control (n=15), 
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myo9aa/ab crispants (n=16), myo9aa/ab crispants + fasudil (n=9) and control + 
fasudil fish (n=10) were quantified: average and total area of acetylcholine receptor 
(aBTx) clusters and number over 20µm2, size of muscle myotomes, proportion of 
myotomes with a cluster, the length these neurons had extended past the choice 
point and their overall outgrowth. Error bars = mean ± S.E.M. **p≤0.01, *p≤0.05, no 
comparison bar = not significant, Kruskal-Wallis test.  
 Improvements in distance travelled, average speed, and to a lesser extent 
acceleration, were all improved in fasudil-treated crispant fish at 48 hpf, thus NMJ 
analysis was repeated at this time point (Figure 5.24), and results are summarised in 
Table 5-3. There were no significant differences in the number of presynaptic clusters 
per myotome following fasudil treatment in crispants, however there was a significant 
reduction in the number of clusters for treated control zebrafish (p=0.1700, p<0.0001 
respectively, one-way ANOVA). When accounting for myotome size by analysing 
number of clusters per 100μm2, there was a further significant decrease in number of 
clusters in myo9aa/ab crispants following treatment (p=0.0113, one-way ANOVA). No 
significant differences were observed for the number of presynaptic clusters over 
20μm2, nor was any change found in the % of myoseptal innervation, although slight 
increases in both parameters were observed in treated crispants as compared to 
untreated crispants. Quantification of total and average SV2 cluster area similarly 
revealed no significant differences from 10µM fasudil application. 
 
Table 5-3. Summary of NMJ morphology results obtained in 48 hpf zebrafish 
treated with fasudil.  Red = significantly less than untreated controls, blue = 
statistically unchanged from controls and green = significantly increased as 
compared to controls. 
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Figure 5.24. Quantification of fasudil-treated myo9aa/ab crispant zebrafish 
presynaptic NMJ morphology at 48 hpf.  Various features of presynaptic NMJ 
morphology in control (n=15), myo9aa/ab crispants (n=20), control + fasudil (n=10) 
and myo9aa/ab crispants + fasudil (n=10) were quantified: number of SV2 
(presynaptic) clusters per myotome, per 100µm2 and over 20µm2, as well as the 
average and total area of SV2 clusters (expressed as per myotome rather than per 
fish) and % of myosepta innervation. Error bars = mean ± S.E.M. *p≤0.05, **p≤0.01, 
***p*<0.0001, ns = not significant, one-way ANOVA.  
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Analysis of postsynaptic NMJ features revealed no significant improvements in the 
number of AChR clusters per myotome or per 100µm2 in the crispant fish treated with 
fasudil (Figure 5.25). Size of myotomes and number of large AChR clusters over 
20µm2 in area were not affected by Myo9aa/ab depletion, and fasudil application did 
not cause any significant alterations to these parameters. Average area of aBTx 
clusters was significantly increased in crispant fish (p=0.0005, one-way ANOVA), 
which was not rescued by fasudil application. Fasudil significantly increased average 
aBTx area in control fish (p=0.0044, one-way ANOVA). Conversely, total aBTx area 
was significantly reduced by fasudil application in control fish, and did not rescue the 
decrease present in crispant fish (p<0.0001, p=0.0716 respectively, one-way 
ANOVA).  
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Figure 5.25. Quantification of fasudil-treated myo9aa/ab crispant zebrafish 
postsynaptic NMJ morphology at 48 hpf.  Various features of postsynaptic NMJ 
morphology in control (n=15), myo9aa/ab crispants (n=20), control + fasudil (n=10) 
and myo9aa/ab crispants + fasudil (n=10) were quantified: number of aBTx 
(postsynaptic) clusters per myotome, per 100µm2 and over 20µm2, myotome size, as 
well as average and total aBTx area (expressed as per myotome rather than per 
fish). Error bars = mean ± S.E.M. *p≤0.05, **p≤0.01, ***p≤0.001****p<0.0001, ns = 
not significant, one-way ANOVA. 
200 
 
The final analysis performed on fasudil treated fish was at 5dpf, for which motor 
movement data was not obtained, therefore providing insights into any longer-acting 
changes induced by blocking the ROCK pathway (Figure 5.26, Figure 5.27). A 
summary of results is shown in Table 5-4. With regards to presynaptic morphological 
features of the NMJ, the area of presynaptic clusters was increased in crispant fish 
following treatment, as compared to untreated crispants and controls (p<0.0001, one-
way ANOVA). A significant increase in area was also observed in treated control fish 
(p=0.0145, one-way ANOVA). The total area of SV2 clusters also increased in 
crispants and controls treated with fasudil, as compared to untreated controls 
(p=0.0023, p=0.0072 respectively, one-way ANOVA). The number of large clusters 
(over 20µm2), was similarly increased following treatment in both control and crispant 
subgroups as compared to controls (p=0.0257, p=0.0010 respectively, one-way 
ANOVA). Following treatment with fasudil, the number of presynaptic clusters per 
myotome were significantly reduced in crispants as compared to controls and 
untreated crispants (p<0.0001, one-way ANOVA), however no significant change 
was observed in treated controls. The number of clusters per 100µm2 had been 
increased by depletion of Myo9aa/ab, and this was significantly reduced by fasudil, 
although to a level still significantly different to controls (p=0.0019, p<0.0001, 
p=0.0042, one-way ANOVA). Percentage of myoseptal innervation was not 
significantly affected by treatment or depletion of Myo9aa/ab.  
 
Table 5-4. Summary of NMJ morphology results obtained in 5 dpf zebrafish 
treated with fasudil.  Red = significantly less than untreated controls, blue = 
statistically unchanged from controls and green = significantly increased as 
compared to controls. 
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Figure 5.26. Quantification of fasudil-treated myo9aa/ab crispant zebrafish 
presynaptic NMJ morphology at 5 dpf.  Various features of presynaptic NMJ 
morphology in control (n=10), myo9aa/ab crispants (n=7), control + fasudil (n=5) and 
myo9aa/ab crispants + fasudil (n=10) were quantified: average and total area of SV2 
(presynaptic) clusters (expressed as per myotome rather than per fish), number of 
clusters per myotome, per 100µm2 and over 20µm2, as well as the length of 
myoseptal innervation and % of myoseptal innervation. Error bars = mean ± S.E.M. 
*p≤0.05, **p≤0.01, ***p≤0.01, ****p<0.0001, ns = not significant, one-way ANOVA. 
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As postsynaptic effects of ROCK inhibitor treatment were not assessed in vitro, they 
were also analysed in the zebrafish at 5 dpf (Figure 5.27). The area of postsynaptic 
receptors was significantly increased in treated crispant fish as compared to controls, 
as well as in treated controls (p=0.0112, p=0.0028 respectively, one-way ANOVA). 
Total aBTx cluster area was not significantly affected in controls treated with fasudil, 
however, treatment decreased total cluster size further in crispant fish as compared 
to controls (p=0.0679, p<0.0001 respectively, one-way ANOVA). The number of 
larger AChR clusters was only significantly elevated in control zebrafish treated with 
fasudil, but a slight non-significant elevation was also present in crispants (p=0.0220, 
p=0.8949 respectively, one-way ANOVA). No significant differences were observed 
in the number of AChRs per myotome or per 100µm2, although a similar trend was 
observed for both parameters as treatment with fasudil decreased the number of 
clusters present for control and crispant zebrafish. Crispant fish had smaller 
myotomes at this time point as compared to controls, and this was slightly improved 
by application of the ROCK inhibitor (p=0.0006, p=0.0016 respectively, one-way 
ANOVA). 
Overall, there were numerous changes in NMJ morphology induced by 10µM fasudil 
during development. The most promising improvements were observed in treated 
crispant fish at 24 hpf where length of neuron outgrowths, the presence of choice 
point clusters on myotomes and size of myotomes were rescued. At 5 dpf, a small 
number of differences in pre and postsynaptic features were observed in treated 
crispant fish, however, none were fully rescued.   
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Figure 5.27. Quantification of fasudil-treated myo9aa/ab crispant zebrafish 
postsynaptic NMJ morphology at 5 dpf.  Various features of postsynaptic NMJ 
morphology in control (n=10), myo9aa/ab crispants (n=7), control + fasudil (n=5) and 
myo9aa/ab crispants + fasudil (n=10) were quantified: average and total area of 
aBTx (postsynaptic) clusters (expressed as per myotome rather than per fish), 
number of clusters per myotome, per 100µm2 and over 20µm2, as well as myotome 
size and myoseptal length. Error bars = mean ± S.E.M. *p≤0.05, **p≤0.01, ***p≤0.01, 
****p<0.0001, ns = not significant, one-way ANOVA. 
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5.9 Discussion 
The aim of this chapter was to determine how defective function of MYO9A may 
contribute to impairment of the NMJ. Unconventional myosin proteins are involved in 
a diverse range of cellular functions, but primarily they are actin binding molecules 
that can traverse actin filaments in cells. Association of such proteins with CMS has 
not previously been reported, however, defects in other proteins associated with the 
cytoskeleton have been found to cause CMS. These include plectin, an intermediate 
filament binding protein that also interacts with actin and microtubules (Selcen et al., 
2011). Recently, mutations in MACF1 have also been attributed to CMS, which again 
has binding sites for microtubules and actin, and plays a role in maintenance of 
postsynaptic components at the NMJ (Oury et al., 2019). Therefore, the effect of 
MYO9A on the cytoskeleton and role this may have at the NMJ was investigated in 
vitro and expanded in zebrafish.  
5.9.1 Effect of MYO9A loss or patient mutations on cytoskeleton  
Analysis of actin, β-tubulin and neurofilament quantities revealed that loss of MYO9A 
can affect the abundances of important cytoskeletal components. Strikingly, there 
was a large increase in the presence of actin in NSC-34 cells lacking MYO9A, found 
in both immunofluorescence and immunoblotting experiments. There was also a 
significant increase in actin levels for MYO9A KD fish, however, this finding was not 
reflected in the mouse tissue or patient fibroblasts and only a small increase in 
expression was found in patient iNPCs. Further western blots would be required to 
confirm this observation, but it may be that MYO9A is affecting actin abundance 
specifically in the nerve, thus mouse muscle lysates in which NMJs aren’t enriched, 
and patient fibroblasts, do not offer the best tissue for this assessment. While there is 
a small increase in actin in the patient iNPCs carrying MYO9A missense mutations, it 
appears that complete loss of MYO9A in our models affects actin levels more 
significantly. This might be due to loss of the head/neck regions of MYO9A, important 
for the cross-linking of actin filaments, which are not the same regions holding the 
mutations for this patient (Saczko-Brack et al., 2016). Loss of this cross-linking ability 
may cause excessive actin to build-up within cells to compensate, or may disrupt 
actin cycling dynamics and affect it’s break down. Another study demonstrated 
necessity for the motor (head) domain for targetting of MYO9A to actin bundles, 
again highlighting why different effects may be observed in the full knockout 
cell/zebrafish model as compared to patient cells (Omelchenko and Hall, 2012).  
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MYO9A KD cells were subject to phalloidin staining to allow visualisation of actin 
cytoskeleton morphology. Actin is important for extending neurites and is enriched at 
growth cones, where MYO9A was previously shown to be present (O'Connor et al., 
2016), and where other unconventional myosins are located (Suter et al., 2000, Yu et 
al., 2015). In the MYO9A KD NSC-34 cells, actin accumulation was still present in 
neurite-like protrusions from the cells, and the cells were able to send out extensive 
projections, however the organisation of actin in these regions appeared disordered. 
Similarly, in hum-7 (C.elegans MYO9A/MYO9B orthologue) mutants, F-actin still 
correctly localises to the ventral surface of cells for extension of protrusions important 
for cell migration (Wallace et al., 2018). Phalloidin staining also revealed the 
presence of stress-like fibres in the cells, and these were significantly increased in 
MYO9A KD cells. It should be noted that confirmation of these parallel actin-positive 
bundles as stress-fibres would require co-staining for the focal adhesion marker, 
paxillin. Nevertheless, supporting our observation a screen of proteins that show 
deregulated expression in association with increased actin expression and stress-
fibre formation identified MYO9A downregulation (Tavares et al., 2017). Furthermore, 
overexpression of Myr 7 (MYO9A rat homolog) in HeLa cells was found to cause loss 
of stress fibres and rounding up of cells, and similar effects were observed for 
overexpression of the MYO9B homologue (Muller et al., 1997, Chieregatti et al., 
1998).  
MYO9A is also a negative regulator of the RhoA pathway and the KO models likely 
effect the RhoGAP domain to a greater extent than the patient mutations. Removal of 
negative regulation of RhoA could lead to an increase in RhoA activity and thus 
upregulation of the downstream ROCK pathway. The ROCK pathway can affect the 
actin, neurofilament and tubulin cytoskeleton through a number of interacting 
molecules, as highlighted in Figure 5.2. For example, in a SMA mouse model, an 
increase in RhoA activity was observed in the spinal cord and linked to altered actin 
cytoskeleton dynamics (Bowerman et al., 2010). In a previous study involving 
MYO9A, loss of this unconventional myosin was shown to affect bronchial cell 
migration and ability of cells to form contacts thus leading to cell scattering and this 
was attributed to local effects on the RhoA pathway and actin organisation 
(Omelchenko and Hall, 2012).  
The action of MYO9A on the RhoA pathway was tested by applying a ROCK inhibitor 
(Y-27632) to the MYO9A KD cells. This revealed a significant decrease in the 
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expression of actin to a level similar to control KD cells, thus indicating that at least 
part of the effect of MYO9A-loss on the cytoskeleton is mediated by the RhoA 
GTPase domain in the tail region in this study. Although it should be noted that Y-
27632 is not a selective inhibitor of ROCK and also inhibits other kinases with similar 
potency (Davies et al., 2000).  
Cytoskeletal analysis also revealed a decrease in the level of neurofilament in the 
MYO9A KD NSC-34 cells, but no consistent changes in patient cells or mouse 
tissues. NSC-34 cells expressing mutant SOD1, as a model of the 
neurodegenerative disease ALS, have also been shown to exhibit lower levels of 
neurofilament. Whether this phenotype was a protective or injurious occurrence 
remains unclear (Menzies et al., 2002). There have been no previous reports of 
MYO9A and neurofilament interactions, however ROCK has been shown to 
phosphorylate neurofilament, and phosphorylation of neurofilament light chain 
inhibits fibril formation (Hisanaga et al., 1990, Hashimoto et al., 1998). Activation of 
the RhoA/ROCK pathway has also been shown to reduce microtubule and 
neurofilament network assembly, however, the reason for reduced overall expression 
of these proteins in the knockdown cells remains unclear (Hirose et al., 1998), and 
addition of the ROCK inhibitor only slightly increased the amount of neurofilament 
light chain in MYO9A KD cells. Reduced perinuclear staining of neurofilament light 
chain and β-tubulin can be observed in NSC-34 cells depleted for MYO9A. While 
localisation of MYO9A in this region has not been reported, Myr 5 (MYO9B rat 
homologue) has been shown to be localised in the perinuclear region and thus 
depletion may affect local levels of neurofilament and tubulin through interactions 
with RhoA (Muller et al., 1997). This would require further investigation and would be 
assisted by the generation of a cell-line expressing MYO9A with a fluorescent tag. A 
reduction in β-tubulin network formation has been reported in other cell models of 
motor neuron-related diseases such as in mutant SOD1 NSC-34 cells (Wen et al., 
2010). In absence of MYO9A, β-tubulin was partially rescued by Y-27632 treatment 
but not to a significant level. An increase in β-tubulin has previously been reported in 
podocyte cells treated with Y-27632 therefore further improvement may be observed 
if cells were subject to a dose-response assay (Gao et al., 2004). Mice lacking 
MYO9A similarly showed a decrease in β-tubulin levels in gastrocnemius and 
quadriceps muscles, however, in zebrafish a significant upregulation was observed. 
As tissue from the whole zebrafish were included in lysates, a tissue specific analysis 
of tubulin expression may provide a better overview of any potential disruptions due 
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to MYO9A loss. There were no changes in the level of cytoskeletal components in 
patient iNPCs, however, it should be noted that in order to generate the cells they 
were treated for a prolonged time period with Y-27632 as part of the conversion 
protocol (Meyer et al., 2015). This treatment may have affected later results as it 
could have alleviated some of the phenotype observed from MYO9A disruption, as 
found in the NSC-34 cells.  
Overall, an effect of MYO9A-loss on the actin cytoskeleton was most prominent, and 
could be partially attributed to the interaction of MYO9A with the RhoA pathway. 
Some changes to the neurofilament and β-tubulin networks were also observed, 
although not consistently throughout models, and some improvements to levels of 
these cytoskeletal components could be achieved with ROCK inhibitor treatment.  
5.9.2 A role for MYO9A in intracellular transport and release mechanisms 
As disruption of the cytoskeleton was observed, it was hypothesised that this may 
impact on trafficking within cells and endo/exocytosis, both of which are crucial for 
the proper functioning of the NMJ. To address this question, FM 1-43 dye assays 
were performed in MYO9A KD cells and patient iNPCs. In the knockdown cells, a 
slower uptake of dye was observed. Defective endocytosis was also detected in 
mouse kidney cells lacking MYO9A, for which it was hypothesised that loss of 
MYO9A and subsequent increase in Rho activity may increase membrane tension 
and stall actin dynamics to prevent vesicle internalisation (Thelen et al., 2015). 
MYO9A has been shown to indirectly regulate activity of mDia1, which plays a role in 
endosomal trafficking and thus may provide another downstream pathway in which 
loss of this unconventional myosin acts (Thelen et al., 2015). Furthermore, other 
unconventional myosins such as myosin Va are also implicated in endocytotic 
mechanisms (Hasson, 2003). In iNPCs, endocytosis of dye was also slower in 
patients than in controls. Addition of high KCl solution to stimulate release of vesicles 
was successful in controls, however, did not stimulate release in the patient cells 
during the time-frame assessed. Similarly, exocytosis was impaired in NSC-34 cells 
depleted for MYO9A, highlighting that both patient mutations and MYO9A KD can 
impair release mechanisms. This may have significant effects at the NMJ as release 
of proteins such as ACh and agrin from nerve terminals are essential for maintaining 
the structure and function of the synapse.  
Defects in global endo/exocytosis were explored in more detail by employing the use 
of a GFP-tagged paradigmatic growth factor receptor, TrkA. This receptor was 
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chosen due to its established internalisation from the cell surface in response to 
NGF, and the recycling back to the surface of the majority of the internalised 
population (Chen et al., 2005). However, the use of TrkA is also relevant for synaptic 
transmission as it has been shown to modulate ACh release from basal forebrain 
neurons (Auld et al., 2001). Impaired TrkA signaling has also been linked to disturbed 
neurotransmission and loss of presynaptic and vesicle trafficking proteins in neurons 
(Latina et al., 2017). Studies have previously been performed using TrkA-GFP 
dynamics to analyse receptor recycling and internalisation, including the ability to 
track movements using live-cell confocal microscopy (Chen et al., 2013, Freund-
Michel and Frossard, 2008, Jullien et al., 2003). A similar assay has also been 
performed by Roos et al. in which the epidermal growth factor receptor was used as 
a paradigmatic receptor for analysis of the cytoskeleton and vesicular transport 
integrity in the neurodegenerative disorder: Marinesco-Sjögren syndrome (2016).  
Defective recycling was identified in MYO9A-depleted NSC-34 cells as compared to 
controls, and this was shown to not be due to increased receptor degradation, thus 
indicating a likely defect in transport mechanisms. This was supported by live-cell 
imaging of transfected cells demonstrating slower intracellular movements of TrkA-
GFP in MYO9A KD cells. Treatment of cells with Y-27632 was able to significantly 
improve the speed of receptor movements, therefore both the cytoskeletal and 
transport defects can at least be partly attributed to effects of MYO9A-loss on the 
Rho pathway. Others have reported improvements to cell morphology and the 
cytoskeleton in different cell types lacking MYO9A when treated with Y-27632, 
although contribution to functional defects such as endocytosis have not previously 
been investigated (Abouhamed et al., 2009, Omelchenko and Hall, 2012). ROCK 
inhibitor treatment has also proven successful in rescuing phenotypes observed due 
to depletion of MYO9B in immune cells and cortical neurons (Hanley et al., 2010, 
Long et al., 2013). In the future, receptors or surface proteins with direct relevance 
for NMJ functioning, such as AChRs, MUSK and LRP4, could be assessed for similar 
defects in recycling/trafficking dynamics using a muscle-cell knockdown model of 
MYO9A to provide further insights regarding a role for MYO9A at the NMJ. These 
results collectively implicate a role for MYO9A in regulating intracellular transport and 
endo/exocytosis in vitro, and some aspects such as movement of intracellular 
receptors was improved by blocking the ROCK pathway.   
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5.9.3 Fasudil treatment of zebrafish 
To provide further evidence regarding the effect of ROCK inhibition on MYO9A-
depletion and to explore a potential therapeutic strategy, the myo9aa/ab crispant 
zebrafish model was also treated with a ROCK inhibiting drug. The ROCK inhibitor 
fasudil was selected for this study as it has already been approved for clinical use in 
humans, and has previously been used in zebrafish (Shibuya et al., 1992, Suzuki et 
al., 2007, Philip et al., 2017, Zhou et al., 2018).  
Survival of fish treated with increasing concentrations of fasudil varied during the 
dose optimisation study, which could be due to inconsistent uptake of drug by each 
fish during incubation as the drug was given in the water and plates containing the 
fish were not subject to constant agitation. In the future, more accurate dosing could 
be provided by injecting the drug or if the full CRISPR/Cas9-mediated KO line were 
generated adults can also be treated by oral gavage (Collymore et al., 2013). 
Chorion movements were improved in crispant fish in a fasudil dose-dependent 
manner and survival was also improved, providing support for the mode-of-action of 
MYO9A-loss leading to increased RhoA pathway activity. The selected fasudil dose 
of 10µM did not significantly affect survival in control fish, however, there was a 
detrimental effect to 24 hpf movements. This was to be expected due to the 
widespread action of the RhoA pathway and thus subsequent impact of reducing its 
action during development. By 48 hpf, the control zebrafish no longer responded 
negatively with regards to movement in the presence of fasudil, thus perhaps the 
dose is less toxic as the fish grow larger, as concentration remained constant 
throughout the time period of analysis. However, it remained sufficient to significantly 
improve the response of crispant fish to the tactile stimulation assay. Similarly, in a 
mouse model of ALS, administration of fasudil after symptom onset was able to 
improve motor behaviours (Gunther et al., 2017). Overall, movement and survival of 
zebrafish lacking Myo9aa/ab in development could be improved by application of 
fasudil to decrease the activity of the ROCK pathway. 
Reflecting the changes in movement, NMJ morphology of the crispant fish was 
similarly improved in some aspects during the time points assessed. Length of motor 
axon outgrowths past the choice point at 24 hpf were significantly increased by 
fasudil treatment, corroborating with numerous reports that ROCK inhibition can 
extend neurites in vitro (Govek et al., 2005). The proportion of myotomes expressing 
a choice point cluster was rescued, which could be linked to the improved neuronal 
210 
 
outgrowth as this time point was beyond that for which prepatterned receptors should 
be present. This is supported by roles for other RhoA/ROCK modulating proteins, 
such as Ephexin1, in mediating both prepatterned AChR clustering as well as AChR 
cluster maturation (Shi et al., 2010). Size of myotomes in the fish were also improved 
by fasudil treatment, correlating with results demonstrating a positive effect of fasudil 
application on muscle fibre size in a SMA mouse model (Bowerman et al., 2012).  
Surprisingly, despite the improvements to movement observed in 48 hpf crispant fish, 
no overt rescue of the NMJ parameters assessed was obtained. Fasudil treatment 
was associated with a further decrease in the number of SV2 and aBTx clusters per 
100µm2 and total area of these clusters, along with a further increase in the average 
size of SV2 clusters. This suggests that blocking the ROCK pathway caused fewer, 
larger pre and postsynaptic clusters to form, which could be related to the defects in 
cytoskeletal arrangement observed in vitro. Testing of a range of doses may have 
better revealed improvements, as well as increasing numbers of animals to account 
for the variability in data observed due to the mosaicism of the fish. Nevertheless, the 
movement benefits due to fasudil treatment suggest there may be modest 
improvements in release/functionality at the NMJ that are not detectable by the 
morphological changes measured here.  
 At 5 dpf the average and total areas of SV2 and AChR clusters and number of large 
SV2 clusters was increased beyond the level observed in controls, while the number 
of pre and postsynaptic clusters overall decreased. This reflects the results from 48 
hpf, with an accumulation of larger pre and postsynaptic regions detected. Analysis 
of the effects of fasudil in a SMA mouse model revealed that treatment led to an 
increase in endplate size but had no effect on presynaptic terminal size (Bowerman 
et al., 2012). To investigate this further, colocalisation analysis would provide insight 
into whether these larger clusters correctly oppose AChRs, thus still forming 
synapses. Furthermore, whether this phenotype manifests as functional changes to 
overall NMJ signalling capacity remains to be determined as neither behavioural 
testing or electrophysiology have been performed. Size of myotomes is no longer 
improved by fasudil treatment at this time point. This could suggest different 
mechanisms contributing to muscle development between embryonic and larval 
developmental stages, or that the dose of the drug should be increased as the fish 
grow larger (as concentrations up to 3x higher have been used in zebrafish 
previously, Zhou et al., 2018). To confirm the effectiveness of doses given, levels of 
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downstream targets of ROCK could be measured, such as phosphorylated cofilin as 
performed elsewhere (Bowerman et al., 2012).  
Overall, the fasudil treatment ameliorated many of the behavioural deficits observed 
in zebrafish lacking Myo9aa/ab and this was corroborated by several improvements 
in NMJ morphology, especially at the earlier stages of development. It is likely that 
such a treatment would require fine-tuning to optimise the precise dose at each time 
point, and more detailed longitudinal investigations required to assess for functional 
changes, as in the aforementioned SMA mice, consistent improvements in NMJ 
morphology were not observed until 6 months of treatment (Bowerman et al., 2012).  
5.9.4 Conclusion 
In this chapter a role for MYO9A in organisation and expression of proteins important 
for the cytoskeleton was demonstrated, including actin, β-tubulin and neurofilament 
light chain. The extent of defects in the presence of patient mutations required further 
investigation, however, global endo/exocytosis were shown to be impaired in patient 
iNPCs, as well as in NSC-34 cells lacking MYO9A. The effects of MYO9A-loss on the 
cytoskeleton and on intracellular transport could be partly alleviated by blockade of 
the ROCK-pathway using Y-27632. Treatment of myo9aa/ab crispant fish with fasudil 
also demonstrated some benefits to movement and NMJ development, thus 
highlighting the involvement of the RhoA/ROCK pathway in the downstream 
pathophysiology of MYO9A-deficiency.  
MYO9A-loss causes defects to the cytoskeleton and therefore disrupts intracellular 
trafficking mediated by the RhoA pathway. It was demonstrated that this is at least 
partially the mode of action of MYO9A-depletion in nerve cells, although other factors 
may contribute to the overall pathophysiology of MYO9A-CMS. These impaired 
functions may affect secretion and uptake of factors important for NMJ maturation 
and function, as well for structure of pre/postsynaptic components. The predicted 
effect on secretion will be explored in the following chapter.  
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Chapter 6. Deficient agrin secretion as a therapeutic target for 
MYO9A-related CMS 
6.1 Introduction 
In the previous chapter defects to the cytoskeleton, intracellular trafficking and 
endo/exocytosis were identified in vitro using MYO9A KD NSC-34 cells and patient 
iNPCs. The ability to partially modulate these phenotypes was achieved through the 
use of ROCK inhibitor drugs, both in the nerve cell model as well as in Myo9aa/ab-
deficient zebrafish. While this offers preliminary support for a role of MYO9A at the 
NMJ and a potential therapeutic strategy to investigate, there may be other pathways 
contributing to the pathological picture of MYO9A-CMS that could be targeted for 
treatments.  
Based on the impact of MYO9A loss on endo/exocytotic mechanisms, it was 
hypothesised that it may affect secretion of proteins important for the NMJ. Release 
of growth factors and guidance cues from muscle are important during motor axon 
extension from the spinal cord to target muscle. Axon growth cones must detect and 
respond to such environmental stimuli and also release factors attractive to Schwann 
cells for co-migration. Nerve cells synthesise agrin and it is transported to the nerve 
terminal for secretion into the synaptic cleft upon reaching the target muscle cell. 
Agrin acts on its receptor, LRP4, which interacts with MuSK and stimulates a 
downstream cascade of events culminating in postsynaptic differentiation and 
appropriate positioning of AChRs at the endplate, as outlined in (Figure 6.1, Tintignac 
et al., 2015, Wu et al., 2010). Agrin is also important for synaptic maintenance, as 
depletion from motor neurons in adult mice with normal NMJs causes loss of AChRs, 
components of the postsynaptic compartment and basal lamina, as well as reduction 
in size of presynaptic nerve terminals (Samuel et al., 2012).   
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Figure 6.1. Schematic diagram for action of agrin at NMJ.  (1) Agrin is 
synthesised in the cell body of the motor neuron and transported to the nerve 
terminal, where it is exocytosed (2) into the synaptic cleft. (3) Agrin binds to LRP4 
receptors (also the site of action of NT1654, used in this chapter) which stimulates 
phosphorylation of MuSK and subsequently recruits Dok7 (4). Interaction with Dok7 
initiates a number of downstream signalling pathways, including recruitment of 
Rapsyn to anchor AChRs in clusters at the endplate (5). Figure adapted from Wu et 
al (2010).  
Therefore, defective secretion or uptake of factors at the NMJ during development, 
maintenance or mature function could impact signal transmission through a variety of 
mechanisms. To determine whether secretory defects underpin the pathology of 
MYO9A loss at the NMJ, proteomics was performed on the secreted proteins from 
MYO9A KD NSC-34 cells by collecting cell culture media. Proteomics has been 
performed on micro-dissected NMJs from mice and human, revealing the protein 
signature of NMJ-enriched muscle and confirming ability of proteomics to detect 
proteins associated with nerve-muscle signalling such as agrin, growth factors, axon 
guidance cues and neurotrophic molecules (Jones et al., 2017). Other studies have 
analysed the proteomes of nerves, muscle or synaptic fractions from CNS tissue and 
cultured neural progenitor cells (for example: Cipriani et al., 2018, Phan et al., 2019, 
Gershoni-Emek et al., 2016, Ibebunjo et al., 2013, Mendes-Pinheiro et al., 2018, 
Henningsen et al., 2010, Schira et al., 2018), however, the use of secretomics to 
identify molecular mechanisms and potential drug targets at the NMJ using cultured 
nerve cells has not been performed previously. 
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6.2 Aims of chapter 
• To identify proteins with altered secretory profiles from MYO9A-deficient NSC-
34 cells. 
• To test a novel therapeutic strategy based on agrin for MYO9A-deficiency 
using zebrafish. 
6.3 Secretomic analysis of MYO9A-deficient NSC-34 cells 
In the previous chapter, a dysregulation of intracellular trafficking and endo/exocytotic 
functions was identified in cells lacking MYO9A. It was hypothesised that this may 
cause impairment in the secretion of factors important for NMJ development or 
function which would provide further insight into the pathophysiology of MYO9A-
CMS. To investigate this hypothesis, proteomics was performed on secreted proteins 
(secretomics) from control and MYO9A KD NSC-34 cells, by Vietxuan Phan (ISAS, 
Dortmund). This method involves culturing cells to sub-confluence before washing to 
remove traces of serum that confound proteomic measurements and culturing cells in 
serum-free media for 3 hours. The medium is then collected and prepared for 
analysis of secreted proteins.  
6.3.1 Analysis of secretomic data 
Secretomic data was generated from 3 control and 3 MYO9A KD NSC-34 cell 
secretion samples and was returned for analysis. Using an unbiased, label-free 
proteomic approach 1532 proteins were detected in the samples. Of these proteins, 
those detected by more than one unique peptide, with a fold change greater than 
4.06 or lower than -4.44, as well as having significantly different expression between 
control and KD samples (p<0.05, p-ANOVA), were considered dysregulated (n=76). 
As shown in the volcano plot, 46 of the identified proteins were found to be 
upregulated in the secretome of MYO9A KD cells as compared to controls, and 30 
were downregulated (Figure 6.2).  
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Figure 6.2. Volcano plot of MYO9A KD NSC-34 cell secretome.  Secreted proteins 
from control and MYO9A KD NSC-34 cells were subject to proteomic analysis. 
Proteins with significantly reduced expression in MYO9A KD cells are shown in red, 
and upregulated proteins shown in green (p<0.05, P-Anova, upregulated>4.06 Log2, 
downregulated<-4.44 Log2). Volcano plot generated by Vietxuan Phan (ISAS, 
Dortmund). Agrin data point indicated on graph. 
A list of up and downregulated proteins is provided in Table 6-1. Of these 76 
proteins, 67 have previously been reported as secreted from a search of Uniprot, 
Pubmed, LOCATE and MGI databases (Figure 6.3). The remaining 9 proteins have 
not previously been identified as secreted and include: PDLI1, GAS1, INF2, IGEB, 
DPYL5, VAT1L, AKA12, EF1A2 and H4. PDLI1 is predicted to play a role in actin 
stress fibre formation, GAS1 suppresses cell growth, INF2 severs actin filaments, 
IGEB is related to the immune system, DPYL5 is predicted to play a role in neuron 
differentiation and axon growth, the function of VAT1L is unknown but it is expressed 
in the CNS and peripheral nerves, AKA12 localises kinase receptors, EF1A2 is 
involved in protein synthesis and H4 contributes to the nucleosome (Uniprot 
https://www.uniprot.org/, last accessed 12/03/2019). Reported disease involvement is 
also highlighted in the table, with some relevant to the nervous/muscle systems such 
as ALS (SODE), Charcot-Marie-Tooth disease (NDRG1, INF2), Congenital Muscular 
dystrophy (CO6A1) and CMS (AGRN). The finding that Agrin (AGRN) secretion was 
downregulated was of particular importance, as is it is not only an important mediator 
of NMJ development and structure but also mutations in AGRN itself can cause CMS 
(Huze et al., 2009, Gautam et al., 1996, McMahan, 1990).
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Protein 
Accession 
number 
Localisation Function Disease involvement 
Direction 
of 
regulation 
Fold of 
regulation 
MIME  Q62000 secreted Bone formation and axonogensis  ↑ 8.84108552 
PPIC  P30412 secreted Protein folding  ↑ 8.129945779 
HMOX1  P14901 secreted Cytoprotection Heme oxygenase 1 deficiency ↑ 6.962838522 
LPP  Q8BFW7 secreted Cell shape and motility  ↑ 6.490882985 
MYOF  Q69ZN7 secreted Plasmalemma repair and endocytic recycling  ↑ 6.405636168 
PDLI1  O70400 cytoskeleton Cytoskeleton  ↑ 6.373342417 
GAS1  Q01721 cell 
membrane 
Cell growth suppressor  
↑ 
6.178146105 
SODE  O09164 secreted Destroys free radicals Amyotrophic Lateral Sclerosis 1 
 
↑ 
6.099830689 
CO4A1  P02463 secreted Interact with laminins, proteoglycans and 
entactin/nidogen 
Brain small vessel disease, Hereditary angiopathy 
with nephropathy aneurysms and muscle cramps, 
Porencephaly 1, Intracerebral haemorrhage, 
Schizencephaly  
↑ 
6.046721552 
MMP2  P33434 secreted Angiogenesis and tissue repair Multicentric osteolysis, nodulosis, and arthropathy ↑ 5.849368216 
SRPX2  Q8R054 secreted Promotes synapse formation Rolandic epilepsy with speech dyspraxia and mental 
retardation X-linked  
↑ 
5.70959609 
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SH3K1  Q8R550 secreted Endocytosis, lysosomal degradation, cellular 
stress responses, apoptosis and cytoskeletal 
organization 
 
↑ 
5.698131221 
NDRG1  Q62433 secreted Cell growth, differentiation, apoptosis, cell 
trafficking, myelin sheath, vesicular recycling 
and regulating microtubule dynamics 
Charcot Marie Tooth disease type 4D 
↑ 
5.678838973 
CAPG  P24452 secreted Blocks the barbed ends of actin filaments  ↑ 5.677222105 
CO6A1  Q04857 secreted Cell-binding protein. Bethlem myopathy 1 and Ullrich congenital muscular 
dystrophy 1  
↑ 
5.587756594 
ENOB  P21550 secreted Striated muscle development and 
regeneration 
Glycogen storage disease 13  
↑ 
5.556672165 
ANGP1  O08538 secreted Angiogenesis, endothelial cell survival, 
proliferation, migration, reorganization of the 
actin cytoskeleton 
 
↑ 
5.543351694 
S10A4  P07091 secreted   ↑ 5.524298487 
PRELP  Q9JK53 secreted Anchor basement membrane to connective 
tissue 
 
↑ 
5.508115793 
OSTP  P10923 secreted Part of bone mineralized matrix  ↑ 5.366001405 
IBP6  P47880 secreted Negative regulation of Wnt and cell 
proliferation 
 
↑ 
5.353125727 
SC65  Q8K2B0 secreted Cross-linking of collagen  ↑ 5.34165765 
EMIL2  Q8K482 secreted Anchoring smooth muscle cells to elastic 
fibres 
 
↑ 
5.327777219 
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CO3A1  P08121 secreted Cortical development, inhibits neuronal 
migration and activates the RhoA pathway 
 
↑ 
5.198026478 
PLTP  P55065 secreted Transfer of lipid molecules  ↑ 5.181661752 
LAMA4  P97927 secreted Attachment, migration and organization of 
cells into tissues during embryonic 
development 
 
↑ 
5.148926308 
VIME  P20152 secreted Intermediate filament, regulates microtubule 
dynamics 
Cataracts 
↑ 
4.949931945 
SPB6  Q60854 secreted Regulation of serine proteinases Autosomal recessive deafness ↑ 4.938047641 
RL22L  Q9D7S7 secreted Structural constituent of ribosome  ↑ 4.726654112 
S10AA  P08207 secreted Positive regulation of stress fibre assembly  ↑ 4.673247388 
CO5A2  Q3U962 secreted Connective tissue component Ehlers-Danlos syndrome, classic type  ↑ 4.661757006 
ANXA3  O35639 secreted Inhibitor of phospholipase A2  ↑ 4.62943553 
GSTA4  P24472  Conjugation of reduced glutathione to 
electrophiles 
 
↑ 
4.585769672 
CO1A2  Q01149 secreted Rho protein signal transduction Ehlers-Danlos syndrome 7B, Osteogenesis 
imperfecta 1 and Osteogenesis imperfecta 2 
↑ 
4.572424063 
CADH2  P15116 secreted Calcium-dependent cell adhesion proteins  ↑ 4.51399316 
HTRA1  Q9R118 secreted Serine protease Age-related macular degeneration 7, autosomal 
recessive cerebral arteriopathy 
↑ 
4.483872692 
AEBP1  Q640N1 secreted Enhanced adipocyte proliferation, reduced 
differentiation, binds calmodulin and is 
involved in protein processing 
 
↑ 
4.47579898 
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PEDF  P97298 secreted Neurotrophic protein; induces extensive 
neuronal differentiation, negative regulator of 
neuronal death 
Osteogenesis imperfecta 6  
↑ 
4.423969538 
LTBP2  O08999 secreted Structural role in elastic-fibre organisation Congenital glaucoma 3 D, Microspherophakia and/or 
megalocornea and Weill-Marchesani syndrome 3  
↑ 
4.33299379 
LYOX  P28301 secreted Oxidative deamination of peptidyl lysine 
residues in precursors to fibrous collagen 
and elastin  
Familial thoracic aortic aneurysm 10  
↑ 
4.291993841 
INF2  Q0GNC1 cytoplasm Severs actin filaments and accelerates their 
polymerization and depolymerisation 
Focal segmental glomerulosclerosis 5, Charcot-
Marie-Tooth disease, dominant, intermediate type, E  
↑ 
4.273975547 
LAMB1  P02469 secreted Organization of cells into tissues during 
embryonic development and architecture of 
cerebral cortex. 
Lissencephaly 5  
↑ 
4.191424881 
NID1  P10493 secreted Cell to extracellular matrix interactions  ↑ 4.186691014 
NQO1  Q64669 secreted Negative regulation of apoptosis  ↑ 4.186185145 
FKB10  Q61576  Accelerate protein folding Osteogenesis imperfecta 11, Bruck syndrome 1 ↑ 4.111759089 
GMDS  Q8K0C9 secreted Catalyses the conversion of GDP-D-
mannose to GDP-4-dehydro-6-deoxy-D-
mannose 
 
↑ 
4.079698454 
IGEB  P03975 cytoplasm   ↓ -4.44442495 
DOPO  Q64237 secreted Converts dopamine to noradrenaline Cardiac Regulation ↓ -4.449643808 
IGSF8  Q8R366 secreted May regulate neurite outgrowth in the adult 
brain 
 
↓ 
-4.518081271 
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MRP  P28667 secreted Regulates actin cytoskeleton and neuronal 
migration 
 
↓ 
-4.520508705 
LAT1  Q9Z127 secreted Involved in cellular amino acid uptake and 
neurogenesis in the brain 
 
↓ 
-4.533051028 
UCHL1  Q9R0P9 secreted Processing of ubiquitin precursors and of 
ubiquitinated proteins 
Alzheimer's Disease 
↓ 
-4.538729128 
BGLR  P12265 secreted Degradation of dermatan and keratan 
sulfates 
 
↓ 
-4.542954696 
COTL1  Q9CQI6 secreted Binds to F-actin in a calcium-independent 
manner 
Parkinson's Disease 
↓ 
-4.549514023 
H4  P62806 nucleus Core component of nucleosome  ↓ -4.549850244 
DPYL5  Q9EQF6 cytoplasm Neuronal differentiation and axon growth  ↓ -4.586679792 
SCG2  Q03517 secreted Secretory granule protein Parkinson's Disease ↓ -4.768512141 
SCG3  P47867 secreted Secretory granule protein Parkinson's Disease ↓ -5.120730002 
VAT1L  Q80TB8 cytoplasm Secretory granule protein Parkinson's Disease ↓ -5.205433024 
AKA12  Q9WTQ5 cytoplasm   ↓ -5.215792684 
AGRIN  A2ASQ1 secreted Formation and the maintenance of the 
neuromuscular junction 
Congenital Myasthenic Syndrome 
↓ 
-5.357776055 
GNA13  P27601 secreted Transmembrane signalling  ↓ -5.395246419 
TICN2  Q9ER58 secreted May participate in neurogenesis  ↓ -5.636804699 
APLP1  Q03157 secreted Postsynaptic function and regulation of 
neurite outgrowth 
 
↓ 
-5.790748164 
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H2AY  Q9QZQ8 secreted Represses transcription  ↓ -5.833594691 
SCG1  P16014 secreted Mediates the subcellular compartmentation 
of protein kinase A and C 
 
↓ 
-5.861864664 
MUC18  Q8R2Y2 secreted Cell adhesion  ↓ -5.952142061 
CLUS  Q06890 secreted Prevents aggregation of non-native proteins  ↓ -5.993152807 
PCSK1  Q9QXV0 secreted Neuroendocrine secretory pathway  ↓ -6.222680148 
ELN  P54320 secreted Structural protein  ↓ -6.64445921 
DKK1  O54908 secreted Antagonizes Wnt signalling  ↓ -7.281956859 
AAAT  P51912 secreted Amino acid transporter  ↓ -7.381076859 
LDHB  P16125 secreted Involved in synthesis of (S)-lactate from 
pyruvate. 
 
↓ 
-7.627742699 
EF1A2  P62631 nucleus Promotes binding of aminoacyl-tRNA to 
ribosomes during protein synthesis 
 
↓ 
-7.628200738 
ITA6  Q61739 secreted Receptor for laminin on platelets  ↓ -7.644407161 
CGL  Q8VCN5 secreted Catalyses the last step in the trans-
sulfuration pathway 
 
↓ 
-7.926937788 
Table 6-1.  Proteins identified in secretome analysis of MYO9A KD NSC-34 cells.  Unbiased, label-free proteomics was 
performed on secreted proteins from control and MYO9A KD NSC-34 cells. Protein name, Uniprot accession number and fold-
change of expression as compared to control cells are shown. Localisation data from Uniprot, Pubmed, LOCATE and MGI and 
disease involvement data from Uniprot also included. 
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Figure 6.3. Schematic diagram of secretomic protein localisation.  Localisation, 
as identified using Uniprot, MGI, Pubmed and LOCATE, of proteins shown to have 
dysregulated secretion in MYO9A KD NSC-34 cells as compared to controls. 
Proteins with upregulated secretion are shown in purple, downregulated are red.  
Pathway analysis was performed on the dysregulated proteins to identify any 
enriched pathways within the dataset that may be particularly affected by loss of 
MYO9A (Reactome pathways, STRING database v.11, Szklarczyk et al., 2019). For 
the proteins with increased secretion from KD cells, the top 11 pathways are shown 
(Figure 6.4A). Extracellular matrix organisation is the most over-represented 
pathway, with 13 of the 46 proteins displaying involvement in this process. A number 
of the other pathways contain the same proteins as this first group and are related to 
collagen dynamics. Of particular relevance to this project, signal transduction, 
developmental biology and axon guidance pathways are also enriched. Association 
analysis using the STRING database revealed a large cluster of proteins with 
predicted interactions (Figure 6.4B). Nodes (proteins) with colour represent those 
that were included in the enriched pathways and it can also be observed that the 
majority of these fall within the large cluster.  
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Figure 6.4. Pathway analysis and protein interaction network of upregulated 
proteins.  A. Pathway analysis was performed for upregulated proteins from 
secretomic data in MYO9A KD and control NSC-34 cells, using STRING software. 
The top 11 enriched pathways are shown with the number of proteins identified in 
each. B. STRING interaction network displaying upregulated proteins. Connections 
represent evidence linking proteins either through co-expression, experimental data 
and co-occurrence in publications. Coloured nodes indicate presence of protein in 
enriched pathways shown in the graph.  
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Pathway analysis was also performed for the proteins found to be less secreted from 
MYO9A KD NS-34 cells. Only 8 pathways were found to be enriched using 
Reactome pathways on the STRING database (Figure 6.5A). Presence of proteins 
involved in protein modification and breakdown appear to be downregulated in the 
MYO9A KD cell data, including pathways such as heparan sulphate 
glycosaminoglycan degradation, metabolism of amino acids and post-translational 
protein phosphorylation. While the enrichment of pathways linked to haemostasis 
and platelet activation were unexpected, further analysis of the proteins implicated in 
these pathways revealed they often have other relevant functions. These include a 
downregulation of clusterin which prevents build-up of non-native proteins, such as 
blood plasma proteins, but also amyloid fibrils and the secreted isoform protects cells 
from apoptosis (Uniprot, P10909). GNA13 encodes a RhoA activating protein, and 
SLC7A5 is implicated in neuronal proliferation (Uniprot, Q14344, Q01650). 
Association analysis using STRING revealed no distinct clusters of proteins 
downregulated from secretome of MYO9A KD cells, however, STRING predicts that 
the network has significantly more interactions than would be expected to occur at 
random (Figure 6.5B). 
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Figure 6.5. Pathway analysis and protein interaction network of downregulated 
proteins.  A. Pathway analysis was performed for downregulated proteins from 
secretomic data in MYO9A KD and control NSC-34 cells, using STRING software. 8 
enriched pathways are shown with the number of proteins identified in each. B. 
STRING interaction network displaying downregulated proteins. Connections 
represent evidence linking proteins either through co-expression, experimental data 
and co-occurrence in publications. Coloured nodes indicate presence of protein in 
enriched pathways shown in the graph. Agrin highlighted in orange. 
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6.3.2 Confirmation of secretomic findings 
The finding that Agrin secretion was downregulated from NSC-34 cells lacking 
MYO9A was particularly interesting for this project. Agrin was identified with 8 unique 
peptides, the identification of one of these peptides in the proteomic screen is shown 
in Figure 6.6. The absence of this peptide over 3 repeats can be seen in the 3D 
montage of agrin peaks. Overall there was 5.4-fold less Agrin in the secretome of the 
KD cells than controls (p=0.0008, pANOVA).  
 
Figure 6.6. 3D montage of agrin peptide peaks.  Agrin, as detected using the 
peptide: LYVGGLPEEQVATVLDR, was identified as dysregulated in the secretomic 
profile of control and MYO9A KD NSC-34 cells. An Absence of agrin can be 
observed in the MYO9A KD cells. Image generated by Vietxuan Phan, ISAS, 
Dortmund. 
While detection of a protein by 8 unique peptides, over 3 repeats, is very robust data, 
this finding was also confirmed using immunofluorescence. Control and MYO9A KD 
cells were stained with an antibody against agrin and the fluorescence intensity 
quantified. A large increase in the intracellular presence of agrin can be seen in the 
MYO9A KD cells as compared to controls (Figure 6.7A). This was confirmed by 
measurement of the corrected total agrin fluorescence for each cell, in which a 
significant increase in intracellular agrin was identified in KD cells (p<0.0001, Mann 
Whitney test, Figure 6.7B). In the previous chapter, defects to the cytoskeleton and 
intracellular trafficking were improved by application of a ROCK inhibitor (Y-27632). It 
was hypothesised that this significant build-up of intracellular agrin, coupled with the 
lack of secreted agrin from the MYO9A KD cells could be due to impaired trafficking 
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or release of the protein from the nerves. Therefore, cells were treated with Y-27632 
and then subject to agrin staining, revealing a significant reduction in the level of 
intracellular agrin in MYO9A-depleted cells (p<0.0001, Mann Whitney test), which 
was still significantly different to that observed in controls (p<0.0001, Mann Whitney 
test). Inhibition of ROCK also lead to a significant increase in intracellular agrin in 
treated control cells as compared to untreated (p<0.0001, Mann Whitney test).  
 
Figure 6.7. Expression of agrin in MYO9A KD cells.  A. Immunofluorescent 
imaging of agrin in control and MYO9A KD NSC-34 cells. Scale bar = 20µm. B. 
Corrected total agrin fluorescence for control (n=126), MYO9A KD (n=99) and Y-
27632-treated cells (control n=92, MYO9A KD n=99). **p<0.01, ****p<0.0001, Mann 
Whitney test. Error bars = mean ± S.E.M from 3 repeats. 
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This large increase in intracellular accumulation of agrin was hypothesised to 
increase the amount of agrin targeted for protein degradation, as secretion appeared 
impaired. Therefore, to investigate this the co-occurrence of agrin with proteins 
associated with degradation (P62 and ubiquitin) were investigated using 
immunofluorescence. IMARIS software was used to subtract background 
fluorescence from the images and then z-stack images were subject to thresholding 
to include the brightest 2% of pixels for each channel (Alexa Fluor 488 and 594). This 
allowed unbiased image analysis that eliminates the issue of differences in exposure 
time/image brightness between channels (Lorenzen et al., 2010). Colocalisation 
analysis was performed using Mander’s coefficient, as this technique measures co-
occurrence independently of the proportion of a signal (Dunn et al., 2011). This 
revealed a significant increase in the proportion of agrin that colocalised with P62 in 
MYO9A KD cells as compared with control (p=0.0022, Unpaired t-test, Figure 6.8A). 
The amount of the intracellular P62 population co-occurring with agrin was also 
significantly increased in cells lacking MYO9A (p=0.0037, Unpaired t-test). 
Representative images demonstrating an increase in pixels containing both green 
(agrin) and red (p62) for MYO9A KD NSC-34 cells as compared to controls are 
shown in Figure 6.8B. Similarly, there was a significant increase in the amount of 
agrin co-occurring with ubiquitin in cells depleted for MYO9A (p=0. 0081, Unpaired t-
test) and of the colocalisation of ubiquitin with agrin (p=0.0136, Unpaired t-test, 
Figure 6.8C). Example images as generated during analysis are shown in Figure 
6.8B, including agrin (green) and ubiquitin (red).  
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Figure 6.8. Colocalisation analysis of agrin with P62 and ubiquitin.  A. Mander’s 
coefficient co-localisation analysis of agrin and p62 in control (n = 6 fields of view) 
and MYO9A-depleted cells (n = 9 fields of view). M1 = proportion of agrin that co-
localises with p62 and M2 = proportion of p62 that co-localises with agrin. B. 
Representative images of immunofluorescent staining in control and MYO9A KD 
cells for co-localisation analysis using IMARIS. Images have been subject to 
thresholding and 3D image projection. White staining represents pixels in which there 
is co-occurrence of the proteins analysed. Scale bars = 20µm. C. Co-localisation 
analysis of agrin and ubiquitin in control (n = 5 fields of view) and MYO9A KD cells (n 
= 10 fields of view). M1 = proportion of agrin that co-localises with ubiquitin and M2 = 
proportion of ubiquitin that co-localises with agrin. *p≤0.05, **p≤0.01, Mann Whitney 
test. Error bars represent mean ± S.E.M. 
6.4 Agrin replacement therapy in Myo9aa/ab knockdown zebrafish 
The decrease in secreted agrin from NSC-34 cells lacking MYO9A was an important 
finding in this study, and may provide a link between the molecular changes 
observed using the in vitro models to potential dysfunction of the NMJ. Agrin is 
secreted from the nerve terminal and acts on its receptor, LRP4, on the muscle 
membrane to stimulate downstream events mediating AChR clustering at the 
endplate (Kim et al., 2008). If agrin is still being synthesised by nerve cells lacking 
MYO9A, but is not being released sufficiently, this could impact on the structure of 
the NMJ and the ability of the muscle to respond to ACh released during synaptic 
transmission, thus leading to fatigable weakness. To test this hypothesis, the 
morphant and crispant zebrafish models of MYO9A-deficiency were utilised. As the 
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defect may be with the secretory process from the nerve, insertion of a plasmid to 
drive agrin expression would not overcome this problem. Therefore, a compound 
generated by Neurotune AG was used (Hettwer et al., 2014). This compound, 
NT1654, is a 44kDa fragment of the c-terminal of mouse agrin (Figure 6.9). It 
contains an 8 amino acid insert (at the z site), crucial for the ability of agrin to 
stimulate AChR clustering. NT1654 is also soluble and resistant to neurotrypsin 
breakdown, thus can be applied systemically and maintain action at the NMJ without 
inactivation due to trypsin-mediated cleavage. Treating the zebrafish with this 
compound would bypass the identified issues with secretion, as NT1654 would be 
present in the synaptic cleft without requiring release from the nerve terminal. 
Therefore, control and MYO9A-deficient zebrafish were subject to agrin-replacement 
therapy and effects on NMJ morphology and motor behaviours assessed.  
 
Figure 6.9. Schematic of NT1654.  Domains of neural agrin included in the NT1654 
compound, including LG2, EG4 and LG3. The β-cleavage site has been removed to 
prevent breakdown by neurotrypsin and the 8 amino-acid insert at the z-site is 
present for AchR clustering activity. Figure adapted from(Hettwer et al., 2014). 
6.4.1 Dose-finding experiments for NT1654 treatment in zebrafish 
NT1654 has not previously been used in zebrafish, therefore a dose-finding 
experiment was first performed in wildtype fish. Concentrations were trialled from 
890pM (0.15ng/4.2nl drop size) to 14.3nM (2.5ng/4.2nl), as in vitro analysis of the 
AChR clustering ability of NT1654 on C2C12 myotubes revealed the ability of the 
compound to induce clusters between 450pM and 108nM (Hettwer et al., 2014). The 
molecular weight of NT1654 is 44kDa, therefore it was too large to add to the water 
of zebrafish and had to be injected into the embryo at the one-cell stage, as 
performed with MO and sgRNA injections. After 48 hours of development, survival of 
embryos was assessed, revealing that uninjected zebrafish had a 75% survival rate, 
while 0.15ng of compound reduced this to 59%. The decline continued in a dose-
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dependent manner and amounts over 1.2ng per drop injected reduced survival rates 
to almost 0% (Figure 6.10).  
 
Figure 6.10. Survival rates of zebrafish treated with NT1654.  Wildtype zebrafish 
were injected with different concentrations of NT1654 at the 1-cell stage and survival 
tracked over 48 hours (0-2.4ng per drop injected). Fish that survived to 48 hpf are 
shown in white, proportion that died are in grey, n=200 per concentration.  
As co-injection of NT1654 with MO or sgRNA/Cas9 is likely to cause increased 
toxicity in the zebrafish, partly due to injecting larger amounts of foreign material, the 
lowest two doses assessed for effects on survival were used in the next experiment. 
As it has been reported that muscles with appropriate innervation are unaffected by 
NT1654 treatment (Hettwer et al., 2014), here the effect of treatment on motor 
behaviours in developing zebrafish was tested. As shown in Figure 6.11A, 
movements performed within the chorion per minute were significantly reduced in fish 
treated with 0.15ng and 0.3ng of NT1654, as compared with controls (p=0.0007, 
p<0.0001 respectively, Mann Whitney test). At 48 hpf, the tactile stimulation assay 
revealed a significant increase in the distance travelled after application of 0.15ng 
and 0.3ng NT1654 (p=0.0284, p=0.0039 respectively, Mann Whitney test, Figure 
6.11B). Similarly, this was also reflected in an increase of average speed of 
movements in response to the stimulus, with speed increasing significantly for both 
concentrations (0.15ng p=0.0043, 0.3ng p=0.0196, Mann Whitney test, Figure 
6.11C). As toxicity was lower for 0.15ng treatment with NT1654, and effect on 
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movement in wildtype fish was also less than in 0.3ng-treated, the lower dose was 
chosen for the subsequent study.  
 
Figure 6.11. Effect of NT1654 on movements during zebrafish development.  A. 
Movements within chorion at 24 hpf by wildtype zebrafish treated with 0ng (n=242), 
0.15ng (n=78) and 0.3ng (n=42) NT1654. B. Distance travelled and C. average 
speed of movement in response to tactile stimulation at 48 hpf of wildtype zebrafish 
treated with 0ng (n=17), 0.15ng (n=12) and 0.3ng (n=10) NT1654. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, Mann Whitney test, error bars = mean ± S.E.M.  
6.4.2 Effect of NT1654 on gross morphology and behavioural phenotypes in 
Myo9aa/ab-depleted zebrafish.  
The lowest dose trialled was used for the subsequent study in an attempt to reduce 
the number of dying zebrafish in early development, as injection of MO and sgRNA to 
deplete Myo9aa/ab also cause a degree of toxicity. Control (uninjected) and 
Myo9aa/ab morphant zebrafish were treated with 0.15ng NT1654 at the one-cell 
stage (NT1654 co-injected with Myo9aa and Myo9ab MOs), as described in 
O’Connor et al. (2018a). After 48 hpf, survival rates were assessed, revealing 11% of 
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control and 23% of morphant fish had died (p=0.0661, one-way ANOVA, Figure 
6.12). Application of NT1654 to control fish caused 29% more to die over 2 days 
(p<0.0001, one-way ANOVA), and in MO/NT1654 co-injected fish 48% more fish died 
than in MO-injected alone (p<0.0001, one-way ANOVA).  
 
Figure 6.12. Survival rates of Myo9aa/ab morphant zebrafish treated with 
NT1654.  Control and Myo9aa/ab morphant fish were treated with 0.15ng NT1654 
and survival at 48 hpf assessed. Control n=354, control + NT1654 n=239, Myo9aa/ab 
morphant n=319, Myo9aa/ab morphant n=329. ****p<0.0001, ns=not significant, one-
way ANOVA. Error bars = mean ± S.E.M. 
In order to assess whether application of this concentration of NT1654 was having 
any observable improvements to the phenotype of Myo9aa/ab-depleted zebrafish 
(Figure 6.13A), fish were classified according to their gross phenotype at 24 hpf 
(Figure 6.13B). Phenotypes were classed as ‘normal’, ‘mild/moderate’ and ‘severe’, 
based on tail lengths, head morphology and overall appearance. In control fish, 93% 
were normal in phenotype, with 4% mild/moderate and 3% severe. Fish depleted for 
Myo9aa/ab were 40% normal, 49% mild/moderate and 11% severe, whereas those 
treated with NT1654 exhibited a 32% improvement in number of normal appearing 
fish and only 28% were now classed as abnormal.  
234 
 
 
Figure 6.13. Phenotypes of NT1654-treated zebrafish.  A. Representative images 
of control and Myo9aa/ab morphant fish (72 hpf) treated with NT1654. B. Control 
(n=99), Myo9aa/ab morphant (n=85) and Myo9aa/ab morphant + NT1654-treated 
(n=50) fish were manually assessed and categorised according to phenotype at 24 
hpf. Phenotypes were classed as normal, mild/moderate and severe. 
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After finding that 0.15ng NT1654 treatment was able to ameliorate some of the gross 
morphological defects observed in the morphant zebrafish, the effect on motor 
behaviours was assessed. As shown in Figure 6.14, at 24 hpf a reduction of 
Myo9aa/ab expression caused a significant reduction in the movements performed in 
the chorion (p=0.0009, Unpaired t-test). The movement impairment was significantly 
improved by treatment with NT1654, to a level no longer significantly different to 
controls (p=0.0079, p=0.6435 respectively, Unpaired t-test). 
 
Figure 6.14. Effect of NT1654 on chorion movements of Myo9aa/ab morphant 
fish.  At 24 hpf, control (n=58), Myo9aa/ab morphant (n=43) and Myo9aa/ab 
morphant + NT1654-treated (n=44) zebrafish were subject chorion movement 
analysis. Number of full chorion twists performed per minute was assessed. **p≤0.01, 
***p≤0.001, ns = not significant, Unpaired t-test.  
At 48 hpf, the response of zebrafish depleted for Myo9aa/ab to the tactile stimulation 
assay was impaired, as described in Chapter 4, Section 4.4.2. To determine whether 
0.15ng NT1654 treatment also improved movement at this later time-point, control 
and Myo9aa/ab morphant fish were tested at 48 hpf. In Figure 6.15, a significant 
reduction in distance travelled by morphant fish can be observed as compared to 
controls (p=0.0004, Kruskal-Wallis test). Distance swam in response to tactile 
stimulation was significantly improved by treatment with NT1654, restoring the 
response to a level comparable with controls (p=0.0265 and p=0.8769 respectively, 
Kruskal-Wallis test). No significant difference in the distance travelled was observed 
in control NT1654-treated fish, as opposed to observations in the dose trial 
experiment (p=0.3802, Kruskal-Wallis test).  
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The average speed of the swimming response elicited followed the same trend as 
the distance travelled, with a significant decrease in the speed of morphant fish as 
compared to control which was increased by application of NT1654 (p<0.0001, 
Kruskal-Wallis test). Again, control fish treated with NT1654 did not exhibit a 
significant change in speed and treated morphants were no longer significantly 
different to controls (p>0.9999, Kruskal-Wallis test).  
Initial acceleration of zebrafish, indicative of force of muscle contraction, was also 
significantly impaired in morphant fish (p<0.0001, Kruskal-Wallis test). Significant 
improvements were observed following NT1654-treatment in the morphant fish 
(p=0.0037, Kruskal-Wallis test), to a level comparable with untreated controls. There 
was no significant effect of NT1654 treatment on the acceleration of control fish 
(p>0.9999, Kruskal-Wallis test).  
 
Figure 6.15. Effect of NT1654 on movements of Myo9aa/ab morphant fish at 48 
hpf.  Distance travelled, average speed and initial acceleration of control, Myo9aa/ab 
morphant and NT1654-treated zebrafish tactile stimulation responses at 48 hpf as 
calculated using TrackMate (ImageJ). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001, ns=not significant, Kruskal-Wallis test, error bars represent mean ± 
S.E.M. Control n=32, NT1654 n=18, Myo9aa/ab morphant (KD) n=41, Myo9aa/ab 
morphant + NT1654 n=46.  
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While the MO-mediated approach reduces the expression of Myo9aa/ab at the RNA 
level, the NT1654 treatment was repeated using crispant fish which are genetically 
mosaic for deletions in myo9aa/ab. This was performed to account for the non-
specific effects that can be associated with MO-injections that may confound results 
(Schulte-Merker and Stainier, 2014), and also to remove any potential sampling bias 
due to higher death rate in co-injected MO+NT1654 fish.  
Assessment of survival rates was performed for control (uninjected), tyr crispant 
(injected control) and myo9aa/ab crispant, as well as tyr and myo9aa/ab treated with 
NT1654 at the time of CRISPR/Cas9 delivery. Results obtained revealed no 
significant differences in survival rates for any condition (Kruskal-Wallis test, Figure 
6.16).  
 
Figure 6.16. Survival rates of myo9aa/ab crispant zebrafish treated with 
NT1654. Control, tyr and myo9aa/ab crispant fish were treated with 0.15ng NT1654 
and survival at 48 hpf assessed. Control n=238, tyr n=53, tyr + NT1654 n=195, 
myo9aa/ab n=141 and myo9aa/ab n=223. No significant differences between any 
condition, Kruskal-Wallis test. Error bars = mean ± S.E.M. 
 As survival rates for co-injected crispant and NT1654 fish were not affected, the 
movement tests that were performed in morphant fish were repeated in crispants to 
confirm results. At 24 hpf the movements performed in the chorion were significantly 
reduced by decreasing myo9aa/ab expression, and this was significantly improved by 
treating with NT1654 (p<0.0001, Kruskal-Wallis test, Figure 6.17). The improvement 
in number of movements per minute was still significantly lower than that performed 
in controls (p=0.0232, Kruskal-Wallis test).  
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In the tactile response assay, distance travelled was significantly reduced after 
stimulus in myo9aa/ab crispants as opposed to controls, and again this was rescued 
by NT1654 treatment, to a level similar to controls (p<0.0001, p<0.0001, p>0.9999 
respectively, Kruskal-Wallis test).  
Average speed of crispant fish was decreased significantly as compared with 
controls (p=0.0002, Kruskal-Wallis test). Application of NT1654 able to rescue this 
decrease to a level comparable with controls (p<0.0001, p>0.9999 respectively, 
Kruskal-Wallis test). Acceleration was also significantly decreased in crispants as 
compared to controls (p=0404, Kruskal-Wallis test). The ability of crispant fish to 
accelerate effectively was improved by treatment, to a level not significantly different 
from controls (p=0.0002, p=0.8746 respectively, Kruskal-Wallis test). 
Therefore, the restorative effect of NT1654 treatment on movement of zebrafish 
lacking Myo9aa/ab at 24 hpf and 48 hpf was observed when depletion of Myo9aa/ab 
was performed using either MO or CRISPR/Cas9 techniques.  
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Figure 6.17. Effect of NT1654 on movements of myo9aa/ab crispant fish in 
development.  Chorion movements per minute at 24 hpf, as well as distance 
travelled, average speed and initial acceleration of control, myo9aa/ab crispant and 
0.15ng NT1654-treated crispant zebrafish in response to tactile stimulation at 48 hpf 
are shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, ns=not significant, 
Kruskal-Wallis test, error bars represent mean ± S.E.M. Control n=32, NT1654 n=18, 
myo9aa/ab crispant n=41, myo9aa/ab crispant + NT1654 n=46. Chorion movements: 
control n=77, crispant n=65 and NT1654 crispant n=129, 48 hpf movements: control 
n=18, crispant n=20 and NT1654 crispant n=22. 
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6.4.3 NMJ analysis after NT1654 application 
In Chapter 4, defects to the morphology of the developing NMJ were described in 
zebrafish, namely an impairment in AChR cluster formation and motor neuron 
outgrowth in 24hpf crispants, reduced pre and postsynaptic clusters at 48 hpf and 
less developed innervation patterns which were reflected by the defective 
movements observed. As motor behaviours show vast improvement after application 
of the exogenous agrin fragment, whether NT1654 treatment also improved 
morphology of the developing neuromuscular system was investigated. A screen of 
MO-injected fish was performed without in-depth morphological analysis (Figure 
6.18), which revealed an improvement in the appearance of AChR clusters and 
motor neuron innervation patterns by 48 hpf after NT1654 treatment (O'Connor et al., 
2018a). In the images shown, extension of motor neurons down the myotome and 
back up the myosepta was observed in the treated morphants but not in the 
untreated. Furthermore, as expected for the function of NT1654 in clustering AChRs, 
more prominent AChR staining was present in treated fish as indicated with an 
arrow-head.  
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Figure 6.18. Immunofluorescent staining of 48 hpf Myo9aa/ab morphant 
zebrafish treated with NT1654. Control and Myo9aa/ab morphant (KD) zebrafish 
were treated with NT1654 and NMJs visualised using an antibody against SV2 (pre-
synaptic vesicles, red) and fluorophore-conjugated aBTx (post-synaptic AChRs, 
green). Example of a shortened motor axon in Myo9aa/ab morphant shown with 
white arrow. Prominent AChR fluorescence shown with white arrow head. Enlarged 
regions of images in bottom panel demarcated with white boxes. Scale bars = 50µm. 
To expand on the promising observations made in the treated morphant fish, 
quantitative analysis of NMJs in NT1654-treated crispants was performed at 24 hpf, 
48 hpf and 5 dpf. At 24 hpf, the presence of longer motor neurons could be identified, 
as well as increased presence of the AChR ‘choice point’ cluster at the horizontal 
myoseptum (Figure 6.19). 
242 
 
 
Figure 6.19. NMJ morphology of 24 hpf myo9aa/ab crispant zebrafish treated 
with NT1654.  Representative images of NMJs in NT1654-treated control and 
myo9aa/ab crispant zebrafish at 24 hpf. Acetylcholine receptors stained with aBTx 
(green), and motor neurons detected with an antibody against SV2 (red). White 
boxes demark areas enlarged in the right-hand panel. Scale bar = 50µm.  
Quantification of various features of motor neuron/AChR morphology was also 
performed at 24 hpf, and compared to data presented in Chapter 4 for control and 
myo9aa/ab crispants (Figure 6.20). A summary of the results are shown in Table 6-2. 
A significant increase was found in the area of AChR clusters in NT1654-treated 
crispants as compared to untreated crispants and controls (p=0.0004, p=0.0028 
respectively, one-way ANOVA), corroborating with the observation that there was 
increased AChR staining at cluster points in Figure 6.19. Total area of AChR clusters 
was also significantly increased in treated crispant fish as compared to untreated 
crispants (p<0.0001, one-way ANOVA) and controls (p=0.0025, one-way ANOVA). 
The number of AChR clusters over 20µm2 in size was significantly increased after 
NT1654 treatment, to a level also significantly higher than in control fish (p=0.0017, 
243 
 
p=0.0078 respectively, one-way ANOVA). Reflecting both of these parameters, the 
proportion of myotomes with a choice point cluster present was also improved, to a 
similar amount as in controls (p=0.0007, p=0.9649 respectively, one-way ANOVA). 
Size of myotomes was unaffected by application of NT1654, although the presence 
of smaller myotomes observed in the crispants were absent in the treated fish and 
most fish had myotomes of very similar sizes after treatment. With regards to 
presynaptic features, the length of motor neuron outgrowths past the choice point 
were not significantly affected by NT1654 treatment, however treatment again 
reduced variability. The number of neurons expressed as a proportion of somite 
number at 24 hpf was decreased in myo9aa/ab crispants (p=0.0489, one-way 
ANOVA), and this was significantly increased by application of NT1654 to a level 
comparable with controls (p=0.0002, one-way ANOVA). Therefore, at 24 hpf 
treatment of myo9aa/ab crispant fish with NT1654 was able to rescue the proportion 
of myotomes expressing a choice point cluster of AChRs and with a neuron 
outgrowth, as well as increase the total area covered by AChRs in general and the 
average cluster size.  
Control zebrafish were also treated with NT1654 and NMJ morphology quantified. 
However, overall at 24 hpf control fish were relatively unaffected by injection of 
NT1654 and no significant differences were detected for any parameter.  
 
Table 6-2. Summary of NMJ morphology results obtained in 24 hpf zebrafish 
treated with NT1654.  Red = significantly less than untreated controls, blue = 
statistically unchanged from controls and green = significantly increased as 
compared to controls. 
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Figure 6.20. Quantification of NT1654-treated myo9aa/ab crispant zebrafish 
NMJ morphology at 24 hpf.  Various features of NMJ morphology in control (n=7), 
myo9aa/ab crispants (n=6), myo9aa/ab crispants + NT1654 (n=6) and control + 
NT1654 fish (n=4) were quantified: average and total area of acetylcholine receptor 
(aBTx) clusters and number over 20µm2, size of muscle myotomes, proportion of 
myotomes with a cluster, number of neurons per myotome and the length these 
neurons had extended past the choice point. Error bars = mean ± S.E.M. *p≤0.05, 
**p≤0.01, ***p≤0.001, ns = not significant, one-way ANOVA.  
The effect of NT1654 on 48 hpf NMJs was also assessed, as improvements were 
found in crispant fish responding to tactile stimulation at this time point. 
Immunofluorescent imaging revealed a decrease in the presence of pre and 
postsynaptic clusters across the surface of the myotomes in crispants, which 
appeared restored in NT1654-treated controls (Figure 6.21). In myo9aa/ab crispants 
the innervation pattern over the surface of the myotome appeared improved after 
NT1654 treatment as shown in the enlarged image panel, and motor neurons 
extended further up the myosepta.  
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Figure 6.21. NMJ morphology of NT1654-treated myo9aa/ab crispant zebrafish 
at 48 hpf.  Representative images of NMJs in untreated or NT1654-treated control 
and myo9aa/ab crispant zebrafish at 48 hpf. AChRs stained with aBTx (green), and 
motor neurons detected with an antibody against SV2 (red). White boxes demark 
areas enlarged in the right-hand panel. Scale bars = 50µm. 
The effect of NT1654 treatment on control and myo9aa/ab crispant fish NMJ 
morphology was also quantified at 48 hpf (Figure 6.22), and a summary shown in 
Table 6-3. The number of SV2 (presynaptic) clusters per myotome was significantly 
improved in crispant fish to a level similar to controls (p=0.0346, Kruskal-Wallis test). 
The number of clusters per 100µm2 however, was not significantly changed although 
there were on average 3.7 clusters in controls, 3.1 in NT1654-treated controls and 
2.5 in crispants, which was increased to 4.5 following NT1654 treatment. The number 
of large clusters, over 20µm2, was not altered by application of the agrin compound 
to crispants or controls, and neither was the percentage of myoseptal innervation. 
The average area of SV2 clusters was significantly elevated in fish lacking 
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Myo9aa/ab as compared to controls (p=0.0020, Kruskal-Wallis test). The average 
SV2 cluster area was significantly reduced in crispants treated with NT1654 
(p=0.0187, Kruskal-Wallis test), to a level similar to wildtype controls. On the other 
hand, total area of SV2 clusters was significantly reduced in crispants (p<0.0001, 
Kruskal-Wallis test), and this was elevated in NT1654 treated fish to a level 
analogous to controls (p=0.0024, Kruskal-Wallis test). Total SV2 cluster area was the 
only measured presynaptic parameter that was significantly altered in wildtype fish 
treated with NT1654, with a reduction in area observed (p=0.0141, Kruskal-Wallis 
test).  
 
Table 6-3. Summary of NMJ morphology results obtained in 48 hpf zebrafish 
treated with NT1654.  Red = significantly less than untreated controls, blue = 
statistically unchanged from controls and green = significantly increased as 
compared to controls. 
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Figure 6.22. Quantification of NT1654-treated myo9aa/ab crispant zebrafish 
presynaptic NMJ morphology at 48 hpf.  Various features of presynaptic NMJ 
morphology in control (n=15), myo9aa/ab crispants (n=20), control + NT1654 (n=8) 
and myo9aa/ab crispants + NT1654 (n=8) were quantified: number of SV2 
(presynaptic) clusters per myotome, per 100µm2 and over 20µm2, as well as the % of 
myosepta with innervation, average and total SV2 cluster area (expressed as per 
myotome rather than per fish). Error bars = mean ± S.E.M. *p≤0.05, ns = not 
significant, Kruskal-Wallis test.  
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Postsynaptic features of the NMJ were also assessed, revealing that while 
application of NT1654 to zebrafish depleted for Myo9aa/ab did not significantly 
improve the number of AChR (aBTx) clusters per myotome when compared to 
untreated crispants, it did increase the proportion enough that it was no longer 
significantly different to that observed in controls (p=0.2101, Kruskal-Wallis test, 
Figure 6.23). The number of clusters per 100µm2 was significantly reduced in 
crispant fish as compared to controls (p=0.0004, Kruskal-Wallis test). While this value 
was not significantly elevated by NT1654-treatment (p=0.1501, Kruskal-Wallis test), 
cluster number was improved to a level similar to that in controls (p>0.9999, Kruskal-
Wallis test). No significant changes were observed in myotome size in any condition, 
and neither were the proportion of large AChR clusters present. Average aBTx 
cluster area was significantly elevated in crispant fish as compared to controls 
(p=0.0009, Kruskal-Wallis test). The increase in average aBTx area was returned to 
a level similar to controls after NT1654 treatment (p=0.0001, Kruskal-Wallis test). The 
total area of aBTx clusters was decreased in crispants lacking Myo9aa/ab as 
compared to controls (p<0.0001, Kruskal-Wallis test). NT1654 application did not 
significantly improve this phenotype (p>0.9999, Kruskal-Wallis test), however, the 
total area was less significantly different to controls (p=0.0006, Kruskal-Wallis test). 
NT1654 did not affect postsynaptic NMJ morphology in control fish treated with the 
compound, except in the case of total AChR area for which a significant reduction in 
cluster area was observed (p<0.0001, Kruskal-Wallis test).  
Overall, the application of NT1654 to myo9aa/ab crispant fish was able to rescue the 
number of SV2 clusters per myotome, average and total area of SV2 clusters, aBTx 
clusters per 100µm2 and average area of aBTx clusters, demonstrating both pre and 
postsynaptic improvements to NMJ morphology at 48hpf.  
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Figure 6.23. Quantification of NT1654-treated myo9aa/ab crispant zebrafish 
postsynaptic NMJ morphology at 48 hpf.  Various features of postsynaptic NMJ 
morphology in control (n=15), myo9aa/ab crispants (n=20), control + NT1654 (n=8) 
and myo9aa/ab crispants + NT1654 (n=14) were quantified: number of aBTx 
(postsynaptic) clusters per myotome, per 100µm2 and over 20µm2, as well as 
myotome size, average and total aBTx cluster area (expressed as per myotome 
rather than per fish). Error bars = mean ± S.E.M. ***p≤0.001, ns = not significant, 
Kruskal-Wallis test.  
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To assess NMJ morphology at a later time-point in order to observe any longer acting 
effects of NT1654 treatment, the crispants were also subject to staining and analysis 
at 5dpf (beyond the time for which MO-mediated KDs could be analysed). Crispants 
had less pre and postsynaptic clusters present across the myotome which was 
improved in the NT1654-treated fish (Figure 6.24). 
 
Figure 6.24. NMJ morphology of NT1654-treated myo9aa/ab crispant zebrafish 
at 5dpf pf.  Representative images of NMJs in untreated and NT1654-treated control 
and myo9aa/ab crispant zebrafish at 5 dpf. AChRs stained with aBTx (green), and 
motor neurons detected with an antibody against SV2 (red). White boxes demark 
areas enlarged in the bottom panel. Scale bars = 50µm. 
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Quantification of NMJ features in 5dpf fish was performed on control, myo9aa/ab 
crispants and NT1654-treated crispants (Figure 6.25), and a summary of results 
shown in Table 6-4. Average area of presynaptic (SV2-positive) clusters was not 
significantly affected in any condition, and neither was the number of clusters per 
myotome. The number of clusters per 100µm2, however, was significantly improved 
by application of NT1654 to the crispants, bringing the number of clusters down to a 
level comparable with controls (p=0.0035, one-way ANOVA). While the mean 
number of large presynaptic clusters decreased in crispants from 1.2 to 0.4 and 
increased after NT1654 to 1.1, these differences were not statistically significant. The 
total area of SV2-positive clusters was significantly elevated in crispant fish treated 
with NT1654 as compared to untreated crispants (p=0.0020, one-way ANOVA), 
however, this remained statistically similar to the total area in control fish (p=0.7580, 
one-way ANOVA). The percentage of myoseptal innervation was not significantly 
altered between any of the groups.  
 
Table 6-4. Summary of NMJ morphology results obtained in 5 dpf zebrafish 
treated with NT1654.  Red = significantly less than untreated controls, blue = 
statistically unchanged from controls and green = significantly increased as 
compared to controls. 
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Figure 6.25. Quantification of NT1654-treated myo9aa/ab crispant zebrafish 
presynaptic NMJ morphology at 5 dpf.  Various features of presynaptic NMJ 
morphology in control (n=10), myo9aa/ab crispants (n=7) and myo9aa/ab crispants + 
NT1654 (n=8) were quantified: average and total area of SV2 (presynaptic) clusters 
(expressed as per myotome rather than per fish), number of clusters per myotome, 
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per 100µm2 and over 20µm2, as well as the length of myoseptal innervation and % of 
myoseptal innervation. Error bars = mean ± S.E.M. **p≤0.01, ns = not significant, 
one-way ANOVA. 
Postsynaptic NMJ analysis in 5dpf fish revealed a significant decrease in the average 
area of AChR clusters in NT1654-treated crispants as compared to control fish 
(p=0.0421, one-way ANOVA, Figure 6.26). Considering the total area of AChR 
clusters, loss of Myo9aa/ab led to a significant reduction in area (p=0.0010, one-way 
ANOVA), and this was significantly improved by addition of NT1654, to a level similar 
to controls (p=0.0119, one-way ANOVA). The number of clusters per myotome in 
crispant fish was also significantly increased by NT1654 treatment, as compared to 
both crispants and controls (p=0.0141, p=0.0214 respectively, one-way ANOVA). 
While size of myotomes was reduced in fish lacking Myo9aa/ab (p=0.0006, one-way 
ANOVA), this was improved by application of NT1654, to a level comparable with 
controls (p=0.0459, p=0.5702 respectively, one-way ANOVA). To determine whether 
total AChR area is altered in relation to somite size, the percentage change between 
each treatment condition was calculated. This revealed that while somite size is on 
average 37% decreased in crispants as compared to controls, the total AChR cluster 
area is 41% decreased. The increase in somite size following NT1654 treatment is 
40%, and for total AChR area is 44%, thus there may be a link between the two 
measurements. However, when considering the earlier time points measured, these 
changes are not consistent. For example, at 48hpf somite size is only 13% reduced 
in crispant fish as compared to controls, however, total postsynaptic cluster area is 
decreased by 67%. Following NT1654 treatment average somite size is unchanged, 
whereas total AChR area per somite increases by 15%. The number of postsynaptic 
clusters per 100µm2 was significantly elevated by NT1654 treatment of crispant fish, 
as compared to untreated controls (p=0.0120, one-way ANOVA). Finally, the 
proportion of large receptor clusters over 20µm2 in size was decreased from 1.2 per 
myotome in controls to 0.1 in crispants, which was increased to 1.1 by NT1654-
treatment, although these changes were not statistically significant. 
Overall, at 5dpf there was a restoration of SV2 cluster number per 100µm2, total 
AChR cluster area and size of myotomes in NT1654 treated crispants as compared 
to the untreated fish depleted for Myo9aa/ab.   
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Figure 6.26. Quantification of NT1654-treated myo9aa/ab crispant zebrafish 
postsynaptic NMJ morphology at 5 dpf.  Various features of postsynaptic NMJ 
morphology in control (n=10), myo9aa/ab crispants (n=7) and myo9aa/ab crispants + 
NT1654 (n=8) were quantified: average and total area of aBTx (postsynaptic) clusters 
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(expressed as per myotome rather than per fish), number of clusters per myotome, 
per 100µm2 and over 20µm2, as well as myotome size and myoseptal length. Error 
bars = mean ± S.E.M. *p≤0.05, ***p≤0.001, ns = not significant, one-way ANOVA. 
6.5 Discussion 
In this chapter, the effect of MYO9A-depletion on secretion of proteins from nerves 
was investigated based on the observation that loss of this unconventional myosin 
protein impacted on trafficking and uptake/release mechanisms. To address this, a 
secretomic approach was used to quantify the abundances of proteins secreted from 
control and MYO9A KD NCS-34 cells. While a number of proteins were identified as 
dysregulated, perhaps the most important finding was the downregulated secretion of 
agrin from NSC-34 cells lacking MYO9A. As agrin has a critical role at the NMJ as a 
protein secreted from the nerve terminal that acts to modulate AChR clustering at the 
postsynapse, application of a novel agrin compound to zebrafish was tested in an 
attempt to rescue some features associated with Myo9aa/ab-loss.  
6.5.1 Analysis of MYO9A KD NSC-34 cell secretomic profile 
In the secretomic analysis of NSC-34 cells depleted for MYO9A, 76 proteins of 1532 
detected were identified as dysregulated. There were 46 proteins with upregulated 
secretion, and 30 downregulated. Whether these findings represent 
increased/decreased expression or effects on secretion is not known, however this 
could be investigated by performing RNAseq on the cells to look at the expression of 
identified proteins. Investigation into reported localisation of the dysregulated proteins 
revealed that 9 of the 76 proteins were not previously identified as secreted. Included 
in this subset are those related to the cytoskeleton and neuron extension such as 
PDL1, INF2 and DPYL5 (Brot et al., 2014, Chen et al., 2009, Schnepp et al., 2005, 
Sia et al., 2013), with VAT1L also displaying peripheral nerve expression (Thul et al., 
2017, https://www.proteinatlas.org/ENSG00000171724-VAT1L/tissue). Furthermore, 
INF2, a Charcot-Marie-Tooth associated protein, is involved in the acceleration of 
actin cycling (Boyer et al., 2011, Chhabra and Higgs, 2006) and thus its increase 
may be associated with the increase in actin expression in cells lacking MYO9A. 
Dysregulation of other proteins involved in diseases affecting the nerve and muscle, 
such as ALS, congenital muscular dystrophy and CMS, were also identified and thus 
provide a link between MYO9A-related pathology and other disorders causing motor 
deficits, suggesting converging pathways and molecular mechanism between many 
of these diseases.  
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A number of the proteins that have been reported as secreted previously may also be 
important for the pathophysiology of MYO9A CMS, including the neuronal ubiquitin 
hydrolase, UCHL1. The UCHL1 KO mouse exhibits defective accumulation of 
vesicles at nerve terminals and have signal transmission defects at the NMJ (Chen et 
al., 2010). Mutations in UCHL1 are also associated with a motor neuropathy 
(Bilguvar et al., 2013). Alterations in the secretion of proteins may also reflect the 
activation of protective pathways, for example upregulation of pigment epithelium-
derived factor (PEDF), which is a neurotrophic factor (Houenou et al., 1999, Taniwaki 
et al., 1995).  
Pathway analysis performed on the secreted proteins was automated, using the 
STRING database, rather than manually curated, thus removing bias. However, this 
method may have missed numerous secondary pathways that could be relevant to 
the pathology of MYO9A-loss. An example of this was the surprising enrichment of 
haemostasis-related pathways in the downregulated proteins from KD cells. 
However, investigation of the proteins reported in this pathway revealed a number of 
secondary functions including preventing protein aggregation, RhoA activation and 
neuronal proliferation, which are likely more relevant that haemostatic processes. 
Another unexpected finding was the upregulation of extracellular matrix proteins, 
mainly collagens, in the secretome of MYO9A KD cells. As there has been no 
reported interaction between MYO9A and collagens, it could be that this is a stress 
response of the cells as collagen secretion has been shown to be upregulated after 
nerve injury (Koopmans et al., 2009). Proteomic profiling of sciatic nerves from 
SH3TC2-deficient mice also displayed increased collagens, which was hypothesised 
to be a protective action to maintain degenerating NMJs (Cipriani et al., 2018). The 
extracellular matrix is linked to the cytoskeleton via integrin signalling (also 
upregulated), thus providing an association between the defective cytoskeleton and 
extracellular matrix (Wu and Reddy, 2012). Furthermore, in our data there was 
dysregulated secretion of laminins, such as LAMA4, which is associated with 
mislocalisation of synaptic specialisations at the NMJ as reported in the Lama4 KO 
mice, and mutations in another laminin subunit gene (LAMA5) can cause CMS 
(Patton et al., 2001, Maselli et al., 2018). To determine if a similar synaptic 
phenotype occurs in absence of MYO9A as in Lama4, it would be interesting to 
perform electron microscopy of NMJs in MYO9A KO mice. In zebrafish, loss of 
Lamb1a, another identified laminin in the secretomics, affects muscle cell elongation 
during development (Snow et al., 2008). This could be linked to the small somite size 
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observed in Myo9aa/ab-depleted zebrafish. There was also an enrichment of 
proteins involved in axon guidance, signal transduction and developmental biology 
pathways in the secretomic dataset, thus providing support for a role for MYO9A at 
the NMJ.  
6.5.2 Decreased secretion of agrin 
The downregulation of agrin secretion from cells lacking MYO9A was considered one 
of the most important findings from the secretomic analysis. Agrin is secreted from 
nerves and acts on the Lrp4/Musk complex on the postsynaptic membrane in order 
to stimulate AChR clustering at the endplate (Maselli et al., 2012, Nicole et al., 2014, 
McMahan, 1990). CMS can also be caused by mutations in AGRN (Huze et al., 
2009, Karakaya et al., 2017, Nicole et al., 2014). The decrease in agrin secretion was 
associated with an increase in intracellular staining of agrin, supporting evidence 
obtained that exocytosis was affected in cells lacking MYO9A and in patient iNPCs. 
In the future, secretomics of iNPCs from patients and controls would be beneficial to 
confirm whether downregulation of agrin also occurs in the presence of patient 
mutations. 
 Thus far 9 CMS patients with mutations in AGRN have been reported, whereas 
there are only 3 MYO9A patients. Analysis of phenotypic overlaps reveal presence of 
proximal and distal muscle weakness with respiratory involvement (Huze et al., 2009, 
Karakaya et al., 2017, Nicole et al., 2014, O'Connor et al., 2016). However, not all 
phenotypes are found in both subtypes, including the presence of hypotonia, delayed 
motor milestones and ocular/bulbar involvement in MYO9A-CMS patients, 
highlighting that there are further factors influencing MYO9A pathophysiology. 
Nevertheless, a treatment such as NT1654 to ameliorate at least an agrin-mediated 
aspect of the disease may provide valuable improvement of symptoms and of NMJ 
signalling. Replacement of agrin has also shown benefit in a mouse model of severe 
SMA, in which a reduction in agrin was also identified, thus demonstrating the wider 
ranging appeal for such a treatment (Kim et al., 2017). In the SMA mouse, agrin was 
rescued by expression of a motor neuron-specific transgene, however, if secretion is 
impaired in the case of MYO9A this would not be of therapeutic benefit. One of the 
most promising features of the NT1654 treatment lies in the ability to administer the 
drug systemically, removing the need for complex gene therapy in patients. 
Therefore, the exogenous agrin fragment can act directly on the postsynapse without 
relying on transport and release machinery in the nerve.  
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6.5.3 Agrin-replacement therapy as a therapeutic strategy for MYO9A-CMS 
NT1654 treatment was tested in zebrafish to determine whether agrin replacement 
showed any therapeutic promise in vivo. Zebrafish express agrin from 2hpf (maternal 
transcripts) with a large increase by 24 hpf. Localisation to the brain, spinal cord and 
motor neurons has been shown (Kim et al., 2007). Zebrafish agrin has a 54% 
homology with mouse neural agrin, increasing to 60% when considering only the 
domains included within the NT1654 compound (Laminin G-like 2, EGF-like 4 and 
Laminin G-like 3). As the compound had not previously been tested in zebrafish, only 
in mice and cells, a range of concentrations were trialed using wildtype fish. The 
range tested fell within those shown to induce AChR clusters in vitro on C2C12 cells 
(450pM to 108nM) and a concentration of 890pM was selected for use based on 
minimising toxicity and effects on movement in controls (Hettwer et al., 2014). As 
survival of zebrafish co-injected with MO and NT1654 was considerably reduced, in 
the future a lower dose of NT1654 could be trialed in an effort to determine whether 
beneficial NMJ effects can still be obtained without impacting survival. However, co-
injection of Cas9/sgRNA with NT1654 did not affect survival rates, and thus it is likely 
that the toxicity was related to the combined delivery of the compound with 
morpholinos.    
Zebrafish depleted for Myo9aa/ab have curved tails, and in crispant fish tails curve 
dorsally or ventrally. Tails of fish lacking agrin have also been shown to curve in the 
same way and they exhibit abnormal swimming patterns (Kim et al., 2007). The 
rescue of this phenotype was obtained in many of the NT1654-treated morphant fish, 
thus corroborating a role for agrin in developing zebrafish morphology. 
Application of NT1654 also improved the motor behaviours of the morphant and 
crispant fish. At 24 hpf fish lacking Myo9aa/ab (mediated by either editing technique) 
displayed reduced chorion movements and they had impaired responses to tactile 
stimulation by 48 hpf. Mice lacking agrin (Agrnnmf380/nmf380) similarly display poor 
motor control phenotypes, thus reflecting the importance of agrin in performing tasks 
relying on NMJ integrity (Bogdanik and Burgess, 2011). Highlighting this point, the 
chorion movements were improved in both morphants and crispants lacking 
Myo9aa/ab when treated with NT1654. At 48 hpf consistent improvements were seen 
for all parameters measured as part of the tactile response assay (distance travelled, 
velocity and initial acceleration), for both crispants and morphants treated with 
NT1654. Of particular interest was the improvement in acceleration, which at this 
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time point has been shown to be indicative of muscle contraction force (Sztal et al., 
2016). In a sarcopenia mouse model in which a reduced grip strength was observed, 
treatment with NT1654 was able to ameliorate the grip strength deficits (Hettwer et 
al., 2014). Similarly, in a mouse model of SMA, NT1654 significantly improved the 
ability of mice to perform a range of behavioural tests including the hind-limb 
suspension test (Boido et al., 2018), thus reflecting observations obtained in the fish. 
No significant differences to the movement of control fish treated with NT1654 were 
observed, again supported by findings in mice that no detrimental effects were 
observed on healthy muscles (Hettwer et al., 2014). In the future, it would be 
beneficial to identify Myo9aa/ab-depleted zebrafish with movement defects during 
development and then to administer the NT1654 and monitor any subsequent 
changes in behaviour. This would require an alternative delivery method, for example 
pericardial injection of the drug which can be performed from around 3dpf (Smith et 
al., 2015).  
In the sarcopenia mouse model on which NT1654 was initially tested, vast 
improvements to NMJ morphology and muscle fibre composition were observed in 
soleus and diaphragm muscles, after onset of the sarcopenic phenotype (Hettwer et 
al., 2014). Myo9aa/ab-deficient zebrafish treated with NT1654 from the one-cell 
stage exhibited increases in the number of large AChR clusters and overall area of 
clusters, as well as the number of neurons extending from each somitic region and 
somites with a choice point cluster at 24 hpf. The increases in the presence of large 
AChR clusters and overall AChR fluorescence was expected, based on the 
interaction of NT1654 with the LRP4-MuSK signalling pathway (Hettwer et al., 2014). 
In agrin deficient zebrafish, the converse effect is observed, in which a decrease in 
myotomal AChR clusters can be observed during development (Kim et al., 2007). In 
the agrin-deficient fish, prepatterned AChR clusters and the presence of the choice 
point cluster occur normally, highlighting that these processes are not agrin-
dependent in the fish, as in mice (Lin et al., 2001). However, at 24hpf the myo9aa/ab 
crispant fish display reduced choice point clusters, which is improved by NT1654 
application. There are a number of potential explanations for this observation which 
require further investigation. For example, the choice point clusters assessed in this 
study are present after the motor neuron has already contacted that area in the 
majority of cases, therefore no longer represent prepatterned clusters and may be 
those incorporated in an agrin-dependent manner. To determine whether this is the 
case fish could be analysed at earlier time points of development when prepatterned 
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receptors are present, before the outgrowth of motor axons. Another option is that 
this represents an unexplored role of MYO9A in the muscle, potentially affecting 
AChR insertion at this early time point, which is then restored by NT1654 application. 
The effect of NT1654 on neurons extending from the spinal cord was unexpected, 
however application of agrin to in vitro cultures of PC12 cells and chick retinal 
neurons has been shown to mediate FGF2-induced neurite extension (Kim et al., 
2003). Furthermore, in the opposite scenario removal of agrin from zebrafish has 
been shown to cause truncated primary motor axons during development, as well as 
erratic trajectories of these axons across the myotome, corroborating our findings 
(Kim et al., 2007). Similar effects of abnormal axonal extensions are also observed in 
the diaphragm muscle of a murine model of agrin deficiency (AGZ) (Gautam et al., 
1996).  
The identified increase in total aBTx fluorescence at 24hpf was also observed at 
48hpf and 5dpf. This response to NT1654 was expected due to the demonstrated 
ability of this compound in previous studies to increase AChR density at NMJs and to 
induce AChR clustering in vitro (Li et al., 2018, Hettwer et al., 2014). Furthermore, 
agrin-deficient zebrafish show the converse, with reduced AChR clustering across 
the myotomes (Kim et al., 2007). This also supports evidence from the secretomic 
data which highlighted a lack of agrin secretion from the MYO9A KD NSC-34 cells, 
rather than defective functioning of the agrin pathway. Replacement of agrin, by the 
exogenous application of NT1654, was able to increase total AChRs on the myotome 
in the crispant fish, and thus the pathway between agrin and AChR clustering 
appears functional.  
There was also a decrease in the average size of aBTx clusters at 48hpf and 5dpf in 
crispant fish treated with NT1654, which may represent a removal of extra-synaptic 
receptors next to the NMJs or condensation of diffuse endplate clusters into mature 
synaptic form. Conversely, in Agrin-deficient mice (AGZ) there are smaller AChR 
clusters and increased scattered receptors (Gautam et al., 1996, Lin et al., 2001). As 
individual NMJs are difficult to identify at this stage in zebrafish development, to 
determine whether the reduced cluster sizes quantified apply to size of NMJs, older 
fish could be examined in the future. Furthermore, the contribution of such changes 
in cluster size to synaptic function should be analysed using electrophysiology, as in 
mammalian systems it has been reported that a loss or blockade of 80% of AChRs at 
the NMJ would be required to reduce the mEPP amplitude by half, highlighting the 
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high safety factor of the NMJ (Pennefather and Quastel, 1981). The presynaptic SV2 
clusters were similarly reduced in size at 48hpf in NT1654 treated crispants. This 
could highlight a return to normal function as terminals in zebrafish decrease in size 
during early development (Drapeau et al., 2001). Thus the significantly larger SV2 
clusters observed in untreated crispants may signify a delay in NMJ maturation, 
corroborating with the reduced AChE activity observed in Chapter 4, Section 4.5.2. 
These effects on nerve terminal size are further supported by observations from a 
conditional agrin KO mouse, in which atrophy and swelling of nerve terminals has 
been reported (Samuel et al., 2012). 
Agrin has been shown to induce ectopic, fully differentiated postsynaptic 
compartments anywhere on the muscle, including insertion of AChRs (Tintignac et 
al., 2015). While there is an increase in cluster number per 100µm2 at 48 hpf in 
NT1654-treated crispants, this is only to the level observed in controls. However, at 
5dpf, there is a further increase in cluster number which may represent ectopic 
AChRs. Colocalisation analysis should be performed in the future to determine 
whether clusters are correctly opposed with presynaptic terminals or not. From the 
data available, there is in fact a decrease in SV2 cluster number per 100µm2 by 5dpf 
highlighting that there may be non-synaptic AChR clusters present due to the 
NT1654 application, although no clear lack of SV2 staining overlying aBTx clusters 
can be visualised in the immunofluorescence images.  
At 5dpf myo9aa/ab crispant fish had significantly smaller muscle myotomes in the tail, 
and this was improved by NT1654 treatment. In the sarcopenia mouse, as well as in 
a rat model of autoimmune myasthenia gravis, NT1654 was able to restore the body 
weights of animals to the same level as controls (Hettwer et al., 2014, Li et al., 2018). 
Furthermore, in the myasthenia gravis rat and the SMA mouse model, a rescue of 
muscle atrophy was also achieved, thus supporting the observations in zebrafish 
(Boido et al., 2018, Li et al., 2018).  
Agrin deficient zebrafish exhibit CNS defects, including truncated branchiomotor 
axons. However, in analysis of Myo9aa/ab-deficient zebrafish no gross morphological 
differences were observed in cranial motor neurons. Detailed analysis of CNS 
morphology could be performed in the future, including staining of all axons using a 
zn-5 antibody. MYO9A KO mice have been reported to display CNS defects, 
although these were related to structure of ventricles and insertion of receptors at the 
postsynaptic density in dendrites of excitatory neurons and not in axon extension 
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(Abouhamed et al., 2009, Folci et al., 2016). Sensory neurons were also impaired in 
agrin deficient zebrafish, however this has not been observed in MYO9A KO mice, as 
well as in the zebrafish models, and patients have not reported any sensory 
abnormalities.  
6.5.4 Conclusion 
In this chapter, proteomic profiling of secreted proteins from MYO9A KD NSC-34 
cells was performed. Analysis of this data revealed a number of secreted proteins 
with dysregulated quantities in MYO9A KD cells as compared to controls, and their 
potential relation to pathology discussed. While many avenues to explore remain, of 
particular interest was the finding of downregulated agrin secretion from MYO9A-
deficient cells. This provided a novel therapeutic strategy that could be used as a 
starting point for the development of a non-invasive treatment for any condition in 
which agrin is decreased or dysfunctional at the NMJ, including MYO9A-CMS.  
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Chapter 7. General discussion and future directions 
The NMJ plays a critical role in generation of movement by the skeletal system, by 
transmitting signals from motor axons to muscles to induce contraction. This highly 
specialised synapse is present in animals from humans to small invertebrates, 
allowing a range of motor activities to be performed with precision and in response to 
rapidly changing stimuli. The safety factor of the NMJ, present due to the numerous 
specialisations that occur during development, maintains synaptic activity unless 
dysfunction impairs it enough to lead to failure of reliable NMJ signalling and disease. 
Defects in genes encoding proteins involved in maintaining this safety factor, thus 
causing CMS, are becoming increasingly identified using genetic techniques such as 
whole exome or genome sequencing. However, such studies are impeded by the 
rarity of the genetic subtypes of CMS and the absence of large cohorts of patients 
with the same mutations, or even mutations in the same gene. This renders the study 
of the pathophysiology of such genetic alterations difficult, and access to human 
material to aide this process is not always possible. In this study, investigations were 
based on a previous identification of missense mutations in MYO9A in 3 patients with 
CMS from 2 unrelated families (O'Connor et al., 2016). To overcome the problem of 
lack of patient muscle biopsies, or previous studies of MYO9A at the NMJ, a range of 
in vitro and in vivo models were successfully generated to investigate the role for this 
unconventional myosin protein at the NMJ.  
The initial hypothesis was that defects in MYO9A cause a presynaptic CMS, due to 
interactions with the cytoskeleton and RhoA pathway within motor neurons. To 
address this, the main aim of this project was to determine whether MYO9A 
contributes to the development and integrity of the NMJ.  
The main findings of this study were a role for MYO9A in extension of neurites in 
patient iNPCs, as well as morphology of developing zebrafish and adult mouse 
NMJs. An effect of MYO9A-loss was also found on the nerve cell cytoskeleton, 
intracellular transport and endo/exocytosis. These features of MYO9A-
pathophysiology could be partially ameliorated by inhibition of the ROCK pathway, 
and similarly a ROCK inhibitor was able to improve some early developmental 
defects in zebrafish NMJs. Furthermore, lack of agrin secretion from nerve cells 
lacking MYO9A was identified, and application of an artificial agrin fragment rescued 
some features of NMJ morphology disruption in zebrafish. Overall, the initial 
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hypothesis has been addressed, demonstrating a role for MYO9A at the NMJ and 
linking this with cytoskeletal and RhoA dynamics.  
7.1 Hypothesis for MYO9A-CMS pathomechanism  
Based on investigations carried out in this project, it is further hypothesised that 
MYO9A-CMS is caused by reduced agrin secretion from the nerve terminal. This is 
consistent with the known roles of agrin in NMJ development and maintenance 
(Butikofer et al., 2011, Samuel et al., 2012, Tintignac et al., 2015, Wu et al., 2010). 
Furthermore, mutations in AGRN itself can also cause CMS (Huze et al., 2009, 
Karakaya et al., 2017, Nicole et al., 2014). The evidence supporting this hypothesis, 
and areas identified that require clarification and further investigation will be 
highlighted in this discussion.  
7.2 Reduced agrin secretion 
The main evidence supporting the proposed pathomechanism for MYO9A-CMS 
arose from the finding that NSC-34 cells depleted for MYO9A secrete 5.4-fold less 
agrin than their control KO counterparts. While numerous other proteins of potential 
importance to the phenotype were also identified as dysregulated in the proteomic 
profile, agrin is a key player in NMJ development and in stability of the synapse 
throughout life (Tintignac et al., 2015). Immunofluorescence analysis of intracellular 
agrin revealed a corresponding build-up of this proteoglycan within cells lacking 
MYO9A, supporting the idea that secretion, rather than agrin expression, is impaired.  
The identification of 76 proteins with altered abundances in the media from MYO9A 
KD NSC-34 cells also highlights a general effect on release processes, rather than a 
specific loss of agrin secretion. This was supported by an impairment in uptake and 
release of the FM 1-43 dye from the medium of cultured MYO9A-deficient NSC-34 
cells and MYO9A-CMS patient differentiated iNPCs.  
A reduction of agrin release may drastically impair the development of the NMJ, and 
could coincide with the early onset of phenotypes observed in the MYO9A-CMS 
patients. Agrin KO mice do not survive after birth due to an inability to inflate their 
lungs, and analysis of NMJs reveals a marked reduction in AChR cluster area and 
presynaptic nerve branching and differentiation (Gautam et al., 1996). Conversely, 
CMS patients with AGRN mutations have not been reported to present with 
symptoms in the neonatal or early postnatal periods, but can exhibit a progressive 
worsening of symptoms and often have respiratory involvement (Huze et al., 2009, 
Karakaya et al., 2017, Nicole et al., 2014). Agrin is cleaved by a neuron-derived 
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serine protease; neurotrypsin, which removes the c-terminal portion of the protein 
important for the clustering of synaptic AChRs (Reif et al., 2007). Overexpression of 
neurotrypsin in mice causes a reduction in agrin activity at the NMJ due to increased 
cleavage, and causes numerous phenotypes associated with sarcopenia in aging, 
including fragmentation of the NMJ (Butikofer et al., 2011). MYO9A KO mice and 
zebrafish also show disrupted NMJs. Therefore, if there were a reduction in agrin 
secretion in the absence of MYO9A, it would be consistent with a negative effect on 
the NMJ as observed in other conditions in which agrin is depleted. 
To support this data, obtaining evidence for impaired agrin secretion in vivo is an 
important objective. This could be achieved by culturing motor neurons from MYO9A 
KO mice and performing secretomic analysis (Gingras et al., 2007), or through the 
visualisation of agrin in vivo at nerve terminals using a fluorescently-tagged 
construct, such as that used in rats by Bezekova et al (2001). Confirming the 
downregulation of agrin secretion should also be performed using the patient iNPCs 
and as only cells from one patient are available, fibroblasts that have the other 
patient’s mutations introduced and then subsequently converted to iNPCs would be 
beneficial. Although, to date the secretion of agrin from iNPCs differentiated toward 
the neuronal lineage has not be demonstrated, if agrin were secreted this would 
provide support that not only loss of MYO9A, but the identified missense mutations, 
can also lead to impaired secretion.  
7.3 Increased RhoA activity impedes agrin secretion 
Previous studies of MYO9A function have not reported an association between this 
unconventional myosin and agrin. Based on findings in this project, it is hypothesised 
that the decreased agrin secretion observed in cells lacking MYO9A is due to the 
corresponding increase in RhoA activity. This is demonstrated by the decrease in 
intracellular build-up of agrin in MYO9A-KO cells treated with the ROCK inhibitor Y-
27632, which decreases downstream RhoA pathway activity. Furthermore, effects on 
intracellular movement of the TrkA receptor were also improved following Y-27632 
treatment.  
As many RhoGAPs are expressed in neurons and therefore influence RhoA activity 
(Govek et al., 2005), it is likely that MYO9A affects local RhoA activity rather than 
having a global effect within the cell. MYO9A co-localises with f-actin and we have 
previously identified expression at the growth cones of neurons, where other 
unconventional myosins have also been reported (Raines et al., 2012, Suter et al., 
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2000, O'Connor et al., 2016). This may indicate that MYO9A-loss affects RhoA 
activity and actin dynamics in the nerve terminal of motor neurons, thus affecting 
secretion of proteins such as agrin. In order to address this, in the future MYO9A KO 
cells could be treated with the ROCK inhibitor and subject to secretomics to 
determine whether this rescues secretion of agrin. Additionally, evidence regarding 
impaired endo/exocytosis should be obtained in vivo which could be performed using 
FM 1-43 dye assays in zebrafish to assess efficiency of uptake and release at the 
NMJ (Li et al., 2003).  
While a number of studies have identified RhoA as an important mediator of 
postsynaptic differentiation through its effects on agrin-induced AChR clustering, 
there is limited research into roles at the presynapse. The C. elegans homolog of 
RhoA, RHO-1, has been shown to increase the levels of diacyglycerol, an UNC-13 
interacting protein, at the plasma membrane (McMullan et al., 2006, Momboisse et 
al., 2011). This action recruits UNC-13 (also a CMS-related protein) to the membrane 
where it is involved in vesicle exocytosis (Momboisse et al., 2011, Lackner et al., 
1999, Xu et al., 2017). In PC12 cells, RhoA has also been shown to inhibit 
exocytosis, related to the formation of peripheral actin filament dynamics (Bader et 
al., 2004). Therefore, if similar processes also occur in human nerve terminals, RhoA 
over-activity may affect the local actin cytoskeleton and recruitment of UNC-13, 
impairing release of vesicles including those containing agrin. Further research would 
be required to investigate this hypothesis, such as detailed structural analysis of the 
actin cytoskeleton in nerve terminals of cells lacking MYO9A, and examination of 
UNC-13 localisation to determine whether appropriate levels are present at the active 
zone.  
7.4 Treatment with NT1654 improves NMJ morphology in zebrafish lacking 
Myo9aa/ab 
The development of the NMJ and associated motor behaviours were assessed in 
zebrafish depleted for Myo9aa/ab using both MO and CRISPR/Cas9-mediated 
techniques. Use of both techniques revealed impaired movement of zebrafish at 24 
and 48 hpf, similar to those reported for zebrafish lacking agrin (Kim et al., 2007), 
thus providing support for reduced agrin secretion contributing to the 
pathomechanism of MYO9A-CMS. As impaired movements in zebrafish are not 
restricted to MYO9A or agrin knockdown and are present in a number of other 
zebrafish models of CMS, further evidence was obtained by the improvement of 
these behaviours by the application of NT1654 (a modified form of agrin). To support 
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this observation, in the future other zebrafish models of CMS in which agrin 
dysfunction is not implicated could be treated with NT1654, to ascertain whether the 
compound provides a general improvement to motor behaviours rather than a 
specific effect due to reduced agrin. 
Agrin secretion from the motor neuron during NMJ synaptogenesis is a critical step, 
without which AChR clusters do not form correctly (Gautam et al., 1996). In the 
myo9aa/ab crispant fish, there are fewer, larger AChR and SV2 clusters, but an 
overall decrease in pre/postsynaptic staining at 48hpf. This corroborates with 
observations of reduced myotomal AChR clustering in agrin-deficient zebrafish (Kim 
et al., 2007). By 5dpf, zebrafish lacking Myo9aa/ab exhibit decreased AChR and SV2 
cluster sizes, as well as an increase in cluster number as compared to wildtype fish. 
This reflects observations in the AGRN KO mouse, which exhibited a number of 
small AChR clusters opposing nerve terminals during development in utero, as well 
as an increase in presence of un-innervated clusters (Gautam et al., 1996). As it is 
difficult to interpret cluster size in zebrafish in a comparable way to NMJs in human or 
mouse due to the lack of distinct NMJ clusters at this period of development and at 
the resolution obtained, it would be beneficial to also analyse the adult homozygous 
myo9aa/ab KO zebrafish. Furthermore, observations of developing NMJs could be 
performed using zebrafish with fluorescent motor neurons and AChRs in a time-lapse 
experiment (Epley et al., 2008, Flanagan-Steet et al., 2005), to determine whether 
clusters decrease in size over-time, or if there is a lack of growth of clusters between 
48hpf and 5dpf and the insertion of new clusters at distinct points to increase cluster 
number. Nevertheless, reduced MYO9A affects the formation of appropriately 
distributed and proportioned NMJs across the tail musculature of zebrafish to at least 
5dpf. 
In support of the hypothesis that MYO9A-CMS is based on a reduction in agrin 
secretion, a number of the defects in NMJ morphology can be rescued by NT1654 
treatment. For example, an increase in total AChR cluster area was observed at all 
time points assessed, presence of a choice point cluster of AChRs at 24hpf was 
improved, number of SV2-positive clusters was rescued at 5dpf, as well as an 
improvement in myotome size. Many of these improvements corroborate with 
reported benefits of this compound in a mouse model of sarcopenia, induced by 
increased cleavage of agrin at the NMJ (Hettwer et al., 2014). The use of this 
exogenous agrin fragment bypasses the proposed impairment of secretion. However, 
269 
 
to confirm that mechanisms related to secretion rather than expression were the 
cause of reduced agrin in the MYO9A KD cell secretome, the myo9aa/ab crispants 
could be injected with an agrin construct to drive expression in motor neurons. This 
would determine whether similar improvements could be obtained, or whether no 
effect would be observed due to lack of ability to secrete the agrin. A further 
confirmatory study that would provide insight into the zebrafish phenotype would be 
electron microscope imaging of the NMJs in developing fish. This could be used to 
assess for both appropriately formed pre/postsynaptic apparatus, and a build-up of 
dense core vesicles that may contain agrin, reflecting observations in MYO9A KO 
NSC-34 cells at the light microscope level. While improvements in movement were 
obtained in the zebrafish, the contribution of morphological alterations at the NMJ to 
function is widely debated (Slater, 2008, Willadt et al., 2016). This is partly due to the 
safety factor of the NMJ, for example it has been suggested that a decrease of 80% 
of functional AChRs would be required at the murine NMJ to reduce the amplitude of 
an mEPP by 50% (Pennefather and Quastel, 1981). Therefore, it would also be 
beneficial to analyse both aspects in conjunction as performed in zebrafish by the 
laboratory of Prof. Paul Brehm (Ono et al., 2001, Wen et al., 2016). In the future, 
using a full myo9aa/ab CRISPR-mediated knockout model, fish could be subject to 
electrophysiological recording of postsynaptic activity in individual muscle cells in 
response to stimulation of presynaptic motor neurons in a paired patch clamp 
configuration (Wen and Brehm, 2010). This powerful technique would address 
whether important aspects of synaptic transmission such as QC are affected in the 
mutant fish and could be coupled with subsequent NMJ morphology analysis before 
and after NT1654 treatment.  
Analysis of mature NMJ morphology was performed using MYO9A KO mice, and this 
revealed further features compatible with a reduction in agrin secretion. For example, 
there was a decrease in AChR/endplate area in all but one mutant for the tibialis 
anterior muscle, and in certain mutants for gastrocnemius, intercostal and diaphragm 
muscles (correlating with the decreased cluster size observed in 5dpf fish). This was 
accompanied by a decrease in presynaptic nerve terminal area and reduced 
branching complexity in all but gastrocnemius muscle, similarly the zebrafish lacking 
MYO9A homologs showed abnormal motor neuron outgrowth during development. 
These features are consistent with observations of the conditional agrin KO mouse, 
whereby loss of agrin from adult NMJs revealed a decrease in AChR cluster area 
and atrophy of nerve terminals (Samuel et al., 2012). There was also a reduction in 
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myofibre cross-sectional area in MYO9A KO mouse as compared to controls. This 
reflects the phenotype of neurotrypsin overexpressing mice, in which there is a 
reduction in neural agrin activity at the NMJ. These mice have smaller muscle fibres, 
as well as a reduction in total fibre number, among other features not assessed in 
this study such as fibre-type grouping (Butikofer et al., 2011). Therefore, these 
characteristics are all compatible with a reduction in agrin from the nerve in the 
absence of MYO9A. It was unfortunate that treatment of the mice with NT1654 was 
not possible, as this would have confirmed whether the NMJ phenotype of the mice 
could similarly be improved by application of an exogenous agrin fragment. In the 
future, MYO9A KO mice could also be crossed with neurotrypsin KO mice (Reif et al., 
2007, Stephan et al., 2008), to ascertain whether preventing the cleavage of the 
agrin that is secreted is sufficient to improve the NMJ phenotype. Furthermore, 
analysis of gene expression for components of the agrin-LRP4-MuSK pathway could 
be performed as it would be expected that components may be downregulated in the 
MYO9A KO mouse and zebrafish, especially the activated, phosphorylated form of 
MuSK (Glass et al., 1996, Zong and Jin, 2013). 
7.5 Other pathways of potential importance to MYO9A-deficient phenotype 
While the main hypothesis for the mode of action for MYO9A loss is a reduction in 
agrin secretion from the nerve, a number of other scenarios may also contribute to 
impaired NMJ signalling. For example, both the in vitro and in vivo models studied 
exhibit effects on nerve and presynaptic nerve terminal morphology. This could be 
related to cytoskeletal disruption due to RhoA over-activity, as application of Y-27632 
was able to ameliorate some cytoskeletal defects in NSC-34 cells, and therefore 
improve intracellular trafficking. Furthermore, treatment of zebrafish with the ROCK 
inhibitor, fasudil, was found to provide some improvements to the NMJ, including 
neurite extension, somite size and choice point AChR clustering in early 
development. However, it is possible that the improvements observed due to fasudil 
in vivo were acting upstream of agrin release, and thus not due to distinct effects of 
MYO9A on the cytoskeleton (outlined in Figure 1.1). MYO9A has also been shown to 
act directly on the cytoskeleton, through cross-linking of actin-filaments (Saczko-
Brack et al., 2016). Loss of this action, as in the case of the KO models used in this 
project, may have implications for vesicle transport within nerves, as well as structure 
of the nerve terminal. However, patient mutations are not in the myosin motor domain 
which is the region crucial for the actin binding ability of this protein and the patient 
iNPCs still exhibited neurite extension defects and impaired FM dye uptake/release. 
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Investigation of such features would require ultrastructural analysis of actin filament 
morphology in both MYO9A KO mouse or zebrafish NMJs, as well as differentiated 
patient iNPCs. It is likely that disruption of intracellular trafficking or nerve cell 
morphology due to direct actin interaction or mediated via the RhoA pathway would 
similarly reduce agrin secretion, rather than these mechanisms being separate.  
It is also possible that MYO9A plays a role in the muscle, where its downstream 
target RhoA has been shown to be important for agrin-mediated AChR clustering 
(Weston et al., 2003). Conversion of fibroblasts to myoblasts and subsequent 
differentiation into myotubes would allow clustering of AChRs in the presence of 
MYO9A-CMS patient mutations to be analysed in vitro. Furthermore, generation of 
tissue-specific MYO9A KO mice such as nerve and muscle KOs would allow the 
contribution of this unconventional myosin to the NMJ and other phenotypes that 
have been associated with MYO9A-loss to be elucidated, as performed recently for 
another ubiquitously expressed CMS gene: GFPT1 (Issop et al., 2018).  
7.6 Conclusion 
In conclusion, evidence has been presented supporting a role for MYO9A at the 
NMJ, and its absence or dysfunction being compatible with causing CMS. The 
proposed working model for MYO9A-CMS is shown in Figure 7.1. While many 
avenues for exploration of the precise function of MYO9A at the NMJ remain open, 
an action on RhoA and the cytoskeleton have been demonstrated, with a 
downstream effect on agrin secretion. This is supported by a role in NMJ 
development in zebrafish, with impaired clustering of AChRs and motor neuron 
extension. Mature NMJs in mice also show disruption in the absence of MYO9A with 
smaller NMJs present and reduced myofibre areas. The identification of MYO9A as a 
protein important for NMJ morphology and motor behaviours supports the 
identification of MYO9A as a CMS gene and broadens the involvement of 
ubiquitously expressed proteins implicated in the disease. In the future, other genes 
within the unconventional myosin family or within the RhoA pathway may be 
considered as potential candidates for neuromuscular disease or in roles for NMJ 
function. A novel therapeutic strategy based on application of NT1654, an agrin 
fragment, was also tested in this study and phenotypic improvements obtained from 
treatment. This may provide support for future use of this compound in clinical trial for 
patients in which reduced presence of agrin at the NMJ is implicated, including 
MYO9A-CMS.  
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Figure 7.1. Proposed pathway of action for MYO9A-dysfunction at the NMJ.  
The pathway begins with loss or dysfunction of MYO9A and the predicted effect of 
this on a number of downstream processes, culminating in impaired neuromuscular 
transmission and CMS. The points of action for fasudil/Y-27632, NT1654 and 3,4-
DAP/Pyridostigmine as used with some efficacy in the patients are shown. Green 
arrow = positive action, red arrow = inhibits action. 
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